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Background: Idiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease that generally affects people
over 60 years old. The main symptoms are shortness of breath and cough, and as the disease progresses
there is a considerable impact on day-to-day life. Few treatments are currently available.
Objectives: To conduct a systematic review of clinical effectiveness and an analysis of cost-effectiveness of
treatments for IPF based on an economic model informed by systematic reviews of cost-effectiveness and
quality of life.
Data sources: Eleven electronic bibliographic databases, including MEDLINE, EMBASE, Web of Science, and
The Cochrane Library and the Centre for Reviews and Dissemination databases, were searched from database
inception to July 2013. Reference lists of relevant publications were also checked and experts consulted.
Methods: Two reviewers independently screened references for the systematic reviews, extracted and
checked data from the included studies and appraised their risk of bias. An advisory group was consulted
about the choice of interventions until consensus was reached about eligibility. A narrative review with
meta-analysis was undertaken, and a network meta-analysis (NMA) was performed. A decision-analytic
Markov model was developed to estimate cost-effectiveness of pharmacological treatments for IPF.
Parameter values were obtained from NMA and systematic reviews. Univariate and probabilistic sensitivity
analyses were undertaken. The model perspective is NHS and Personal Social Services, and discount rate is
3.5% for costs and health benefits.
Results: Fourteen studies were included in the review of clinical effectiveness, of which one evaluated
azathioprine, three N-acetylcysteine (NAC) (alone or in combination), four pirfenidone, one BIBF 1120,
one sildenafil, one thalidomide, two pulmonary rehabilitation, and one a disease management
programme. Study quality was generally good, with a low risk of bias. The current evidence suggests
that some treatments appear to be clinically effective. The model base-case results show increased survival
for five pharmacological treatments, compared with best supportive care, at increased cost. General
recommendations cannot be made of their cost-effectiveness owing to limitations in the evidence base.
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Limitations: Few direct comparisons of treatments were identified. An indirect comparison through a
NMA was performed; however, caution is recommended in the interpretation of these results. In relation
to the economic model, there is an assumption that pharmacological treatments have a constant effect on
the relative rate of per cent predicted forced vital capacity decline.
Conclusions: Few interventions have any statistically significant effect on IPF and a lack of studies on
palliative care approaches was identified. Research is required into the effects of symptom control
interventions, in particular pulmonary rehabilitation and thalidomide. Other research priorities include a
well-conducted randomised controlled trial on inhaled NAC therapy and an updated evidence synthesis
once the results of ongoing studies are reported.
Study registration: This study is registered as PROSPERO CRD42012002116.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Idiopathic pulmonary fibrosis (IPF) is a serious lung condition of unknown cause that scars and stiffensthe lung tissue; it generally affects people over 60 years old. The main symptoms are shortness of
breath and a cough, and as the disease progresses there is a considerable impact on day-to-day life.
Few treatments are available. We evaluated the benefits and harms of available treatments by considering
the most up-to-date, high-quality evidence, using a systematic approach. Searches for evidence from
11 databases were made and evidence was reviewed by two authors, using predefined criteria, to
consider its relevance. All included studies were assessed for their quality, and data from each study were
extracted into a standardised template. A narrative review and statistical methods to combine study data
were applied. A statistical model was developed to compare the cost-effectiveness of pharmacological
interventions for the treatment of IPF. Standard methods were used.
Fourteen studies were included in the review of clinical effectiveness. These evaluated six drugs and three
non-pharmacological interventions. Results were mixed. There are few treatments which have a significant
benefit. Harms from these treatments were not significant in most cases. Treatments are unlikely to
be considered cost-effective. There were few studies on interventions in symptom management and
palliative care. Further research is required in a number of areas including the effects of symptom control
interventions and an inhaled therapy. A number of ongoing studies are yet to report and these may
provide further evidence for the best approach to take for treating IPF.
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Scientific summary
Background
Idiopathic pulmonary fibrosis (IPF) is a serious lung disease, the exact cause of which is not known.
It generally affects people over 60 years of age and the main symptoms are shortness of breath and a
cough, which can have a considerable impact on day-to-day life. IPF was once thought to progress at
a steady, predictable rate, but it is now known that this is often not the case. Many people with IPF
deteriorate rapidly, while others have periods of relative stability. In general, people with IPF survive for
between 2 and 5 years. Evidence shows that the number of people with IPF is increasing, although the
reasons for this are unclear. IPF is a difficult condition to manage, particularly in the later stages. Few
treatments are available for IPF and none offers a cure. Treatments aim to reduce symptoms and improve
survival. The type of treatment offered can vary and with a number of new treatments emerging it is
timely to establish which are effective and provide the best value for money to the NHS.
Objectives
To evaluate the clinical effectiveness and cost-effectiveness of the different treatment strategies used within
the NHS for IPF through systematic reviews of the evidence for clinical effectiveness, cost-effectiveness and
quality of life (QoL), and economic modelling relevant to the UK setting to estimate the cost-effectiveness of
the different treatments.
Methods
Search strategies were developed and applied to 11 electronic bibliographic databases (including
The Cochrane Library, MEDLINE and EMBASE) from database inception to July 2013. Bibliographies
of retrieved papers were screened and experts contacted to identify any additional published and
unpublished references.
Titles and abstracts (where available) were screened for potential eligibility by two reviewers independently
using inclusion criteria that were defined a priori. Screening of the full text of retrieved papers was performed
by one reviewer and checked by a second. For the systematic review of clinical effectiveness, studies were
eligible for inclusion if the participants had a confirmed diagnosis of IPF and the interventions under study
were currently used to manage symptoms or modify IPF. Randomised controlled trials (RCTs) and controlled
clinical trials were eligible for inclusion. Data extraction and assessment of methodological quality were
undertaken by one reviewer and checked by a second. Differences in opinion were resolved through
discussion at each stage or consultation with a third reviewer if necessary. Data were synthesised through a
narrative review with tabulation of the results of included studies. Where appropriate, the studies were
combined in a meta-analysis and heterogeneity was assessed. A network meta-analysis (NMA) focusing on
pharmacological treatments for IPF and assessing forced vital capacity (FVC) end points was undertaken on
10 studies. The FVC end point was measured on two continuous scales and the NMA used the standardised
mean difference approach.
Systematic literature searches were undertaken to identify full economic evaluations of interventions
to manage IPF, and to assess the health-related quality of life (HRQoL) of people with IPF. Studies
reporting HRQoL in people with IPF were eligible for inclusion if they used either generic preference-based
measures or the St George’s Hospital Respiratory Questionnaire, a disease-specific instrument used in IPF.
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Data were extracted in a standardised form by a health economist and checked by a systematic reviewer,
with any differences resolved through discussion.
A cost–utility decision-analytic model was developed to compare the cost-effectiveness of pharmacological
interventions for the treatment of IPF. The model incorporates three survival curves, which are used to
inform the probabilities of transition from three health states: unprogressed IPF, progressed IPF and lung
transplant. Treatment effects are obtained from NMA. Utility values are applied to the health states to
estimate total quality-adjusted life-years (QALYs). Costs are included for treatments, treatment monitoring,
acute exacerbations, lung transplant and adverse events. The outcome of the economic evaluation is
reported as cost per QALY gained.
Results
Eight hundred and fourteen references were identified by searches for clinical effectiveness. Fourteen
studies were included, of which one evaluated azathioprine, three N-acetylcysteine (NAC) (alone or in
combination), four pirfenidone, one BIBF 1120 (nintedanib), one sildenafil, one thalidomide, two
pulmonary rehabilitation, and one a disease management programme. Study quality was generally
good with a low risk of bias; however, where there were areas of greater risk of bias, these have
been highlighted.
In patients with mild to moderate IPF, 10 studies evaluating five pharmacological interventions
(azathioprine, BIBF 1120, NAC, pirfenidone and thalidomide) were included. In a small RCT, treatment
with azathioprine and prednisolone led to an improvement in survival compared with placebo and
prednisolone when an age-adjusted analysis was used. There was no effect on lung function. This trial had
an unclear risk of bias and it is possible that the trial included participants who would have been diagnosed
with non-specific interstitial pneumonia, which may in part explain the treatment effect. Follow-up was
12 months. BIBF 1120 300mg/day was more favourable than placebo on some measures of lung function,
rates of acute exacerbations and the number of deaths; however, the primary outcome of annual rate
of decline in FVC was not statistically significantly different between groups in this 54-month study.
Treatment with NAC was evaluated in three studies: in combination with azathioprine and prednisolone in
two and as a single agent in an inhaled format in one. Follow-up was approximately 12 months in these
studies. Study results were mixed, with no benefit from triple therapy on FVC compared with placebo
in one study; however, there was a benefit on vital capacity when compared with double therapy in
another study. Inhaled single-therapy NAC did not have a statistically significant effect compared with a
control. Secondary outcomes were reported, similarly with mixed results across the three studies. The two
studies with triple-therapy interventions had a low risk of bias; however, the study using nebulised NAC
had an unclear risk of bias. Pirfenidone was studied in four RCTs, and meta-analysis of FVC shows that
pirfenidone appears to demonstrate an effect when compared with placebo treatment. However, caution
is required in interpreting these data as the outcomes pooled were different, and as a consequence a
standardised mean difference analysis was undertaken; in addition, the timing of assessment of these
outcomes varied (from 48 weeks to 72 weeks). Results for secondary outcomes were generally seen to
be less favourable to pirfenidone. In a small crossover study, thalidomide appeared to improve cough,
cough-related quality life and respiratory-related QoL, compared with treatment with placebo.
One study assessed sildenafil for those with moderate to severe IPF; the participants in this study also
had evidence of pulmonary hypertension. Results on the primary outcome, a 20% improvement on the
6-minute walk test, were not statistically significant between the sildenafil and placebo groups. Results for
secondary outcomes were mixed, with some favourable to sildenafil and others favouring placebo. This
study followed participants for 12 weeks.
Adverse events from the pharmacological interventions were generally mild to moderate and were
reasonably well balanced between the treatments and the placebo arms across the studies, with the
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exception of thalidomide. Severe adverse events appeared to be more common in one study in those
treated with triple therapy.
Three studies evaluated non-pharmacological treatments for populations with IPF. Two compared
pulmonary rehabilitation with a control; the other compared a disease-management approach with a
control. Results are uncertain with regard to pulmonary rehabilitation as differences favouring the
intervention were seen for some outcomes but not others. The included studies had an uncertain risk
of bias and outcomes were assessed at 10 and 12 weeks in the two trials, respectively, immediately
after the cessation of the intervention. The third study reported limited evidence on the effects of a
disease-management programme in IPF: there were no statistically significant differences in dyspnoea, and
QoL results were mixed. This study has an uncertain risk of bias and follow-up was at 6 weeks, immediately
after the programme had completed.
The fixed-effects NMA found only BIBF 1120 and pirfenidone to have a statistically significant improvement
in FVC over placebo. A head-to-head comparison of BIBF 1120 versus pirfenidone showed a trend
favouring BIBF, but this was not statistically significant. Caution is required in the interpretation of the
results of the NMA.
One full economic evaluation of treatment for patients with IPF was identified. This examined the benefits
of a testing strategy prior to treatment with NAC triple therapy but did not examine the cost-effectiveness
of IPF treatment. The systematic review of QoL studies included 23 studies; results varied, but generally
appeared to show that IPF has an adverse effect on HRQoL compared with population norms, and that
HRQoL is likely be diminish as IPF becomes more severe.
The model base-case results show increased survival for five of the treatments compared with best supportive
care (BSC), at increased cost. Only one treatment, inhaled NAC, is cost-effective at a willingness-to-pay (WTP)
threshold of £30,000, but its treatment effect does not achieve statistical significance in either the single
primary study or the NMA. The treatment effect of inhaled NAC compared with BSC is associated with an
expected value of partial perfect information of £15.8M at a WTP threshold of £20,000.
Discussion and limitations
This evidence synthesis reports the clinical effectiveness and cost-effectiveness of a range of interventions
which are currently used, or proposed to be used, to manage IPF in the UK. No previous systematic reviews
have included all potentially relevant treatments for IPF, and there have been only limited economic
evaluations in this area. The results of this report complement recent national guidance in the UK. The
current evidence suggests that there are few treatments that have any effect on surrogate outcomes which
can be linked through evidence to patient-related outcomes such as mortality. There is a scarcity of studies
on interventions in symptom management and palliative care in IPF.
This evidence synthesis has been undertaken following the principles for conducting systematic reviews and
economic evaluations. Limitations to this evidence synthesis include there being few direct comparisons
of treatments identified. An indirect comparison through a NMA was performed; however, caution is
recommended in the interpretation of these results. In relation to the economic model, there is an
assumption that pharmacological treatments have a constant effect on the relative rate of FVC
percentage decline.
Research is required into the effects of symptom control interventions, in particular pulmonary
rehabilitation and thalidomide. Other research priorities include a well-conducted RCT on inhaled NAC
therapy and an updated evidence synthesis once the results of ongoing studies are reported.
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Conclusions
This evidence synthesis has identified limited evidence of the effectiveness of a number of available
treatments for IPF. Pirfenidone and BIBF 1120 appear to be clinically effective; however, general
recommendations cannot be made in terms of their cost-effectiveness owing to limitations in the
evidence base. Further research is required in a number of areas as outlined above.
Study registration
This study is registered as PROSPERO CRD42012002116.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Description of underlying health problem
Idiopathic pulmonary fibrosis (IPF) is a debilitating respiratory condition for which there is no cure. It is
characterised by diffuse scarring (fibrosis) and mild inflammation of the lung tissue, leading to a gradual
worsening of lung capacity. IPF is classed as an idiopathic interstitial pneumonia (IIP), which is a group of
interstitial lung diseases (ILDs) also known as diffuse parenchymal lung disease.1 IPF is the most common
type of IIP, accounting for over 50% of this category of lung disease.2
Initially believed to develop as a result of a chronic inflammatory process, the mechanism that results in IPF is now
more widely thought to be due to fibrotic processes involving the epithelial alveolar cells.3 The disease is thought
to arise as a result of recurrent injury to epithelial alveolar cells. Many different cells types have been implicated
in the development of IPF, including fibroblasts, myofibroblasts, alveolar macrophages and endothelial cells. IPF is
a disease characterised by aberrant wound healing in which excessive (and perhaps abnormal) extracellular
matrix is deposited in the lung, thereby distorting the architecture and disrupting function. This lung injury and
scarring eventually leads to a decline in lung function, which culminates in respiratory failure and death.4
Shortness of breath on exercise and a chronic dry cough are the prominent symptoms.1
The natural history of IPF is not fully understood. It is a progressive chronic condition and was once
thought to progress at a steady, predictable rate. However, this is often not the case, with many people
deteriorating rapidly and others having periods of relative stability in their condition.2,5 In some individuals,
unexpected deterioration can occur with a sudden worsening of symptoms and resultant hypoxaemia
(decreased partial pressure of oxygen in blood).2,5 These episodes are usually without clinically apparent
infection or other identifiable cause. Known as ‘acute exacerbations’, these are thought to occur in about
10–15% of cases and are often fatal episodes.6
Distinguishing IPF from other IIPs can be difficult as presentation can be similar. International consensus
statements published in 20007 and 20028 provided guidelines for the definition of IPF following the
identification of a new subgroup of ILD, non-specific interstitial pneumonia (NSIP), which had a
substantially better survival.1 Prior to the identification of this group, some 20–35% of people diagnosed
as IPF would have had NSIP,8 although in older populations the relative likelihood of NSIP may be lower.
These guidelines also recognised that the term cryptogenic fibrosing alveolitis (CFA) was synonymous
with IPF.8 Prior to this, in the UK, the term CFA corresponded to a characteristic clinical presentation seen
in IPF but common also to other IIPs.9 In 2011, a joint statement from the American Thoracic Society (ATS),
the European Respiratory Society (ERS), the Japanese Respiratory Society and the Latin-American Thoracic
Society (hereafter referred to as the ATS/ERS 2011 guideline for ease of reference) provided updated
guidance for the diagnosis of IPF (see Diagnosis).10 No changes to the definition of IPF were made in the
2011 guideline (see below for discussion of diagnostic criteria).
Idiopathic pulmonary fibrosis is known to affect males more than females and in particular affects those in
middle age. The disease is uncommon in people < 50 years of age,2,11 and there is a peak prevalence
in the eighth decade. Factors associated with the condition, for which there is no known cause, include
cigarette smoking, environmental exposure, and possibly infective agents such as influenza, Epstein–Barr
virus and hepatitis C.7 Older age, male gender and smoking are all associated with shorter survival times
(see Prognosis and progression).12
DOI: 10.3310/hta19200 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 20
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
Epidemiology
The epidemiology of IPF is uncertain. Most estimates in the literature are based on populations aged
> 55 years and the number of incident cases of IPF appears to be increasing, although the reasons for
this are unclear.11,13 One particular difficulty with estimating the descriptive epidemiology of IPF is due to
the use of different case definitions for IPF. Many studies may not use the currently used definition of IPF
(based on ATS/ERS 2011 guidelines) and, as such, estimates may include people with other ILDs.
Large-scale population-based assessments of the epidemiology of IPF are limited; however, four published
studies have been identified which provide estimates of the incidence and/or prevalence of IPF. Two of
these are based on populations in the UK and two on populations in the USA.
Incidence of idiopathic pulmonary fibrosis
In the UK, two studies have been published using data from The Health Improvement Network (THIN),
which is a longitudinal primary care database recorded by general practitioners as part of routine
clinical primary care. In the first of these studies, Gribbin and colleagues11 used data from 1991 to
November 2004 from 255 general practices, which the authors state represented approximately 25% of
general practices that were using the particular primary care software at that time. The study identified
920 people over the age of 40 years who had received their first diagnosis of IPF during the period of
study. The study reports that participants with a clinical diagnosis of IPF were included but no definition
was provided. The mean age at presentation was 71 years and 62% were male. As seen in Table 1, the
overall crude incidence rate was 4.6 [95% confidence interval (CI) 4.3 to 4.9] per 100,000 person-years.
Table 1 also shows that the incidence rates were generally higher in men than in women, and incidence
also increased with increasing age.
In the most recent study using data from THIN’s database, Navaratnam and colleagues13 estimated
incidence rates of IPF from all information available in the database up until July 2009 and including
446 practices. The definition of a diagnosis of IPF was not provided and although authors note that the
diagnosis in the data sets has been validated, they also note that it is possible that some cases of other
fibrotic lung diseases may be included. Crude annual incidence rates were calculated stratified by sex and
age in 5-year age bands over the age of 55 years (see Table 1). After the exclusion of individuals with a
variety of comorbidities, the study identified 2074 incident cases during the period of study. This equated
to a crude overall incidence rate of 7.44 per 100,000 person-years (95% CI 7.12 to 7.77). As in the
Gribbin study,11 the authors found that the majority of incident cases were in men (63%) and that
incidence also generally increased with age.
Fernández Pérez and colleagues14 undertook a population-based historical cohort study in Olmsted County,
MN, USA, between 1997 and 2005. The study used the ATS/ERS 20028 consensus statement for the case
definition of IPF, with incidence rates calculated as of the date the patient met the criteria. Two sets of criteria
were used: a narrow criterion based on evidence of usual interstitial pneumonia (UIP) on surgical lung biopsy
or a definite pattern on high-resolution computed tomography (HRCT), and a broad criterion based on surgical
lung biopsy or a definite or possible pattern on HRCT. The age- and sex-adjusted incidence rate of IPF among
residents aged ≥ 50 years using the narrow IPF criterion was 8.8 per 100,000 person-years (95% CI 5.28 to
12.38 per 100,000 person-years). Using the broader criterion, the rates were estimated to be 17.43 cases per
100,000 person-years (95% CI 12.42 to 22.44 cases per 100,000 person-years). Incidence rates were directly
adjusted for age, or age and sex, using the population structure of white persons in the USA in the year 2000.
The incidence rates were seen to be higher in men than in women and also generally higher in the older
age categories.
In a registry study using data from a large US health-care claims database (approximately 3 million people
in 20 states), Raghu and colleagues15 also estimated incidence of IPF using a narrow and broad base
criteria. The broad criteria included all people aged ≥ 18 years, who were eligible for health benefits, and
had had at least one medical appointment with an International Classification of Diseases (ICD) code for
IPF and no medical appointments with an ICD code for any other ILD. To meet the narrow case definition,
the person was required to satisfy the broad criteria and have had at least one surgical lung biopsy.
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TABLE 1 Estimated incidence rates of IPF from four population-based registry studies
UK-based
Gribbin et al. 200611
Population-based cohort study
Population: from 255 general practices 1991 until November 2004
Incidence of IPF (95% CI) per 100,000 person-years
Crude rate 4.6 (4.3 to 4.9)
Men 5.69 (5.24 to 6.18)
Women 3.44 (3.10 to 3.82)
Age (years)
< 55 0.54 (0.43 to 0.67)
55–64.9 7.30 (6.27 to 8.50)
65–74.9 17.06 (15.20 to 19.14)
75–84.9 25.37 (22.67 to 28.40)
≥ 85 22.37 (18.04 to 27.74)
Navaratnam et al. 201113
Population-based cohort study
Population: from 446 general practices until July 2009
Incidence of IPF (95% CI) per 100,000 person-years
Crude rate 7.44 (7.12 to 7.77)
Men 9.46 (8.96 to 9.98)
Women 5.46 (5.07 to 5.86)
Age (years)
≤ 54 0.86 (0.75 to 1.00)
55–59 10.48 (9.06 to 12.13)
60–64 20.76 (18.34 to 23.50)
65–69 36.45 (32.99 to 40.27)
70–74 47.57 (43.26 to 52.32)
75–79 47.38 (42.76 to 52.49)
80–84 60.05 (52.47 to 68.73)
> 85 34.82 (27.55 to 44.01)
USA-based
Fernández Pérez et al. 201014 Broad definitiona Narrow definitiona
Population-based cohort study
Population: 128,000 residents; 596 people initially thought to have IPF were screened from Olmsted County, MN, USA,
between 1997 and 2005
continued
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TABLE 1 Estimated incidence rates of IPF from four population-based registry studies (continued )
USA-based
Fernández Pérez et al. 201014 Broad definitiona Narrow definitiona
Incidence of IPF (95% CI) per 100,000 person-years
Age- and sex-adjusted, aged ≥ 50 years 17.43 (12.42 to 22.44) 8.8 (5.28 to 12.38)
Men, age-adjusted 24.02 (14.84 to 33.20) 13.38 (6.51 to 20.24)
Women, age-adjusted 13.43 (7.50 to 19.37) 6.08 (2.08 to 10.08)
Age, men (years)
50–59 1.64 1.64
60–69 21.39 10.69
70–79 42.88 21.44
≥ 80 66.02 41.26
Age, women (years)
50–59 1.55 1.55
60–69 12.44 4.98
70–79 36.79 16.72
> 80 11.78 3.93
Raghu et al. 200615 Broad definitionb Narrow definitionb
Population-based cohort study
Population: from US health plan covering 20 states and approximately 3 million people, between 1996 and 2000
Incidence of IPF per 100,000
Age- and sex-adjusted 16.3 6.8
Age, men (years)
18–34 2.8 0.9
35–44 1.1 0.0
45–54 11.4 6.2
55–64 35.1 12.2
65–74 49.1 21.3
≥ 75 97.6 38.5
Age, women (years)
18–34 0.0 0.0
35–44 5.4 4.5
45–54 10.9 5.4
55–64 22.6 9.9
65–74 36.0 16.6
≥ 75 62.2 19.5
a Broad: usual interstitial pneumonia (UIP) on surgical lung biopsy or a definite or possible pattern on high-resolution
computed tomography; narrow: UIP on surgical lung biopsy or a definite pattern on high-resolution computed
tomography.
b Broad: aged ≥ 18 years, eligible for health benefits, ≥ 1 medical appointment with an International Classification of
Diseases (ICD) code for IPF and none with an ICD code for any other ILD; narrow: all of the broad criteria and
≥ one surgical lung biopsy.
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Data analysed were between 1996 and 2000 inclusive. Incidence rates were estimated by combining
age- and sex-specific rates from the study with population weights from the US census. In this study,
overall incidence rates for those diagnosed in 2000 were estimated to be 16.3 per 100,000 persons using
the broad case definition, and 6.8 per 100,000 persons using the narrow case definition. The study
demonstrated increasing incidence by age (see Table 1). Similar to other studies, incidence rates were also
generally higher in men than in women.
Overall, the estimates suggest an incidence rate in the region of approximately 4.6 to 8.8 per 100,000,
although this depends on the definitions of IPF used.11,13–15
In the two UK-based studies, analyses confirmed that the incidence of IPF had increased over the two time
periods studied. In the Gribbin and colleagues11 study, after adjusting for age and sex, the annual increase
in incidence of IPF was estimated to be 11% (rate ratio 1.11, 95% CI 1.09 to 1.13; p< 0.0001). In the
Navartnam and colleagues13 study, after adjustment for age, sex and health authority, the estimated
annual increase in incidence was 5% (rate ratio 1.05, 95% CI 1.03 to 1.06).
Prevalence
The two studies undertaken in the USA also reported estimated prevalence rates. Age- and sex-adjusted
prevalence rates among people aged ≥ 50 years in the study undertaken in Olmsted county14 was 27.9
(95% CI 10.4 to 45.4) cases per 100,000 people using the narrow criteria for IPF. For the broad criteria, the
estimated prevalence was 63 (95% CI 36.4 to 89.6) cases per 100,000. In the Raghu study,15 using data from
a health-care claims database, the prevalence of IPF was estimated to be 42.7 per 100,000 persons using the
broad definition, and 14.0 per 100,00 persons using the narrow definition. The prevalence was also seen to
increase with age and was generally higher in men than in women in this study. Overall estimates suggest
prevalence of between 14 and 30 per 100,000 persons when using a narrow definition for IPF.14,15
Mortality
Mortality rates were presented from the two UK studies using data from THIN’s primary care database.11,13
In the Navaratnam and colleagues13 study, data were also analysed from routine mortality data from the
Office for National Statistics (ONS) derived from death certificates in England and Wales between 1968 and
2008 and applied to the 2008 population. In the database cohort, the crude mortality rate was 228.8 per
1000 person-years (95% CI 193.8 to 216.7 per 1000 person-years). From the routine mortality data, the
overall mortality rate standardised to the 2008 UK population over this period of time was 2.54 per 100,000
person-years (95% CI 2.52 to 2.56 per 100,000 person-years). In the Gribbin study,11 the crude mortality rate
for people with IPF in THIN’s database cohort was 180 per 1000 person-years (95% CI 164 to 198 per
1000 person-years). In both studies mortality rates were higher in men and in older populations.
Prognosis and progression
The prognosis for individuals with IPF is poor.2 Mean survival with IPF is generally estimated to be between
2 and 5 years from diagnosis.1,16 In the study by Navaratnam and colleagues,13 median survival was
estimated to be 3.03 years, with an estimated 5-year survival of 37%. The Gribbin and colleagues11 study
showed the 3- and 5-year survival to be 57% and 43%, respectively.
The prognosis for an individual patient remains difficult to define and can be highly variable.17 Pulmonary
assessments can be useful to predict the course of the disease and which patients have a higher likelihood
of death within the next year.16 A decline in per cent predicted forced vital capacity (FVC) of at least 10%
in a 6-month period is associated with a nearly fivefold increase in the risk of mortality.18 From a single
time point other pulmonary function tests, such as the diffusing capacity of the lung for carbon monoxide
(DLCO), and exercise tests such as the 6-minute walk test (6MWT), have also been shown to be useful
prognostic determinants in some studies.18
Acute exacerbations of IPF are also known to have an impact on the prognosis of IPF. These periods
of rapid deterioration of IPF without infection, pulmonary embolism or heart failure have an impact
on the overall survival of patients with IPF, with mortality possibly being as high as 75%.1,17,19
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Although the evidence on the incidence and risk factors of acute exacerbation of IPF is limited, and varies
between studies, the incidence is thought to be in the region of 10–15%.1,6,17,19 Risk factors for acute
exacerbations include a low FVC, DLCO total lung capacity (TLC), and never having smoked.17
The presence of other comorbidities may also have an impact on the prognosis of IPF. Some evidence
supports the view that coexisting emphysema leads to a poorer prognosis.12,20 Although the coexistence of
emphysema leads to a preserved lung volume, it also leads to an impaired diffusion capacity, and results
of studies suggest that the fibrosis is the dominant prognostic factor.20 Rates of coexisting emphysema may
be as high as 30% in IPF.12 Pulmonary hypertension has also been shown to be an important determinant
of disease outcomes in IPF.1,21 Pulmonary hypertension is characterised by increased pressure in the
pulmonary arteries, and most patients with end-stage disease have this.
While there is no optimal marker for disease severity, recent evidence supports the view that the per cent
predicted FVC can be useful to categorise people into three severity groups: mild, moderate and severe.
Caution is required in using these cut-offs because they do not take into account other patient factors
such as the existence of comorbidities; however, a crude categorisation is normal FVC (> 80% predicted),
mild (≥ 70%), moderate (55–69%), and severe (< 55%).22,23
Impact of idiopathic pulmonary fibrosis
Presentation of an individual with IPF is often as a result of a gradual onset of shortness of breath on exertion.
This non-specific symptom can be wrongly attributed to the ageing process, emphysema, heart disease or a
respiratory tract infection, and therefore diagnosis can often be made some time after initial presentation.1,5 In
others, IPF is an incidental finding on a routine chest examination. Key symptoms of IPF include breathlessness
(dyspnoea), a non-productive (dry) cough, which can be paroxysmal (spasmodic) in nature, reduced exercise
tolerance and anxiety. In a retrospective review of 45 case notes of deceased patients, > 90% suffered
from breathlessness and 60% from cough.24 Other, less frequently documented symptoms were fatigue,
depression/anxiety and chest pain.24 Clark and colleagues25 described a high prevalence of nocturnal
hypoxaemia with decreased energy levels and impaired daytime social and physical functioning.
Symptoms become progressively worse over time.1 The irritating dry cough associated with IPF has a
significant impact on a patient’s life, leading to a reduced quality of life (QoL).4 Finger clubbing is found in
approximately 50% of patients.1 A progressive worsening of these symptoms, and deterioration in lung
function, increasingly limits normal physical activity, and the individual becomes more debilitated and
disabled.3,18 The result of this is often an incremental shift to becoming housebound, dependent on others
for completion of normal activities, and dependent on oxygen therapy.2 This leads to death from
respiratory failure or a complicating comorbidity.2
Breathlessness is one of the main distressing symptoms; however, no treatments aiming to modify the
disease process have been shown to improve breathlessness in IPF.26 Therefore, symptomatic treatment
is essential. Some IPF patients may need only short-burst oxygen initially for episodic breathlessness,
but many will need long-term oxygen therapy and ambulatory oxygen to maximise their QoL.27 IPF is
recognised as a clinical indication for referral for home oxygen.27 If breathlessness continues to burden a
patient, opioids and benzodiazepines, often in combination, can be prescribed as for other patients with
breathlessness in advanced disease.28
In a retrospective review of ILD patients, Bajwah and colleagues24 noted that, beyond symptoms, there was
a lack of documentation of spiritual needs and little documentation of assessment for depression and
anxiety, or documentation of preferred place of care or preferred place of death. The authors commented
that it is likely that these issues occur in these patients.24
Many patients with IPF are admitted to hospital and hospices, although accurate data are scarce. Many
studies have small sample sizes and data available predominantly relate to hospitals. One recent study
undertaken in the USA followed 168 patients over a 76-week period and found that 23% of these were
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hospitalised for respiratory-related illnesses on a total of 57 occasions.29 The mean number of days stay in
hospital was 15 days, with the most common reason for hospitalisation being suspected infection. Data
from the UK suggest that in 2008–9 there were 9500 finished consultant episodes for people categorised
as ‘other interstitial pulmonary diseases with fibrosis’, with around 600 hospital admissions.30 The mean
length of stay for these people was 9 days.
Idiopathic pulmonary fibrosis is a difficult condition to manage, particularly in the later stages. Early and
accurate diagnosis is important to maximise the potential for a better outcome.
Diagnosis
The 2011 ATS/ERS consensus statement for IPF10 states that ‘IPF should be considered in all adult patients
with unexplained slowly progressing exertional dyspnoea, and commonly presents with cough, bibasilar
inspiratory crackles, and finger clubbing’ (p. 792). Treatments for IPF predominantly aim to reduce the
decline in lung function and therefore early diagnosis is important to improve prognosis. Despite this, in
many cases, a diagnosis is made at the point where lung function abnormalities are more severe, with the
individual often having had asymptomatic disease progression for some years before.2 One reason for this
is that the diagnosis of IPF is a challenge because there are no specific abnormalities on laboratory tests.
Tests which suggest an inflammatory response in an individual, such as erythrocyte sedimentation rate,
and rheumatoid factor, may be abnormal, but these are not specific to IPF. For the general practitioner,
the tests available, and the symptoms shown by the patient, could be indicative of a number of other
conditions. Guidelines for the diagnosis of IPF have, however, recently been produced in the UK by the
National Institute for Health and Care Excellence (NICE).31
The gold-standard diagnosis of IPF requires precision and a multidisciplinary approach involving ILD
specialists, radiologists and pathologists.1,2,31 Correlation of the clinical, radiological and histopathological
features increases the accuracy of an IPF diagnosis and is often made on an individual basis. Clinical
symptoms, findings on HRCT, and results of lung biopsy are taken in context with one another, especially
as results on each factor can sometimes be discordant. Although surgical lung biopsy is recommended to
confirm all suspected cases of IPF, in some settings surgical lung biopsy may not be required and the
diagnosis is made on clinical and HRCT findings alone.1 This is especially likely when the risks of a surgical
procedure are weighed up with the potential delay in diagnosis while awaiting a surgical lung biopsy.2
If surgical lung biopsy is used, biopsies from two locations are usually taken.
High-resolution computed tomography allows a detailed examination of the pulmonary parenchyma, and
estimates of diagnostic accuracy are thought to be high (specificity exceeding 90%). The primary role of
HRCT is to discriminate between typical IPF and other HRCT appearances, which may be indicative of other
ILDs but may also represent IPF with atypical HRCT appearances.1
In the recent guidelines,10,31 the recommendation for diagnosis requires exclusion of other known causes of
ILD (e.g. domestic and occupational environmental exposures, connective tissue disorders and drug toxicity);
the presence of a UIP pattern on HRCT in patients not undergoing surgical lung biopsy; and specific
combinations of HRCT and surgical lung biopsy pattern in patients undergoing surgical lung biopsy.10
The ATS/ERS consensus guideline provides details of the criteria for UIP based on HRCT and histopathology
(from surgical lung biopsy) in tabular form. The details for a definite UIP pattern on HRCT include
subpleural, basal predominance; reticular abnormality; honeycombing with or without traction
bronchiectasis. Findings for a judgement of ‘possible UIP pattern’ and an ‘inconsistent with UIP pattern’ are
also presented. Histopathological criteria for UIP pattern include evidence of marked fibrosis; presence
of patchy involvement of lung parenchyma by fibrosis; and presence of fibroblast foci. Findings for a
judgement of ‘probably UIP pattern’, ‘possible UIP pattern’ and ‘inconsistent with UIP pattern’ are also
presented. In addition, the guideline presents the specific combinations of HRCT and surgical lung biopsy
patterns expected to make a diagnosis of IPF, using the criteria set out for each method as summarised
above. These criteria are presented in Table 2.
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Current service provision
As discussed above, IPF is often misdiagnosed because the early manifestations of the disease are
non-specific. This can lead to significant delays between symptom presentation and the correct
diagnosis in a disease where diagnosing IPF at an early stage is important to maximise the potential
for treatment.32,33 In addition, the incorrect diagnosis can lead to initiation of ineffective or potentially
harmful treatments and delay the opportunity for possible lung transplant (discussed in Lung transplant,
below).33 In some cases, the delay to diagnosis may be patient related, where individuals can be reluctant
to acknowledge the symptoms that they have and to seek help.34
Evidence suggests that longer delays in accessing specialist care in IPF are associated with a higher risk of
death.34 A US-based cohort study of 418 adults referred to a tertiary centre found that a median delay
from symptoms to initial evaluation at the centre was 2.2 years.34 Longer delay was associated with an
increased risk of death, independent of age, sex and baseline FVC per cent predicted, with an adjusted
hazard ratio (HR) per doubling of delay to access of 1.3 (95% CI 1.03 to 1.6). Results of a survey of
1251 IPF patients and 197 caregivers conducted in the USA found that 55% reported at least a 1-year
delay between initial presentation and diagnosis, with some 38% having been seen by three or more
physicians.35 Incorrect diagnoses included bronchitis, asthma, chronic obstructive pulmonary disease
(COPD), emphysema and heart disease. The study also found that 64% of responders agreed that there
was a lack of information and/or resources on IPF when they were diagnosed. Only half felt generally,
or well, informed about the treatment options available to them.
A European qualitative study of 45 IPF patients from five European countries found that the median
reported time from initial presentation with symptoms to diagnosis of IPF was 1.5 years.36 This ranged from
< 1 week to 12 years, and in 58% of cases the delay was > 1 year. Similar to the larger US-based survey,
a proportion of patients had consulted more than three physicians; in this study the rate was 55%. The
study also investigated feelings of satisfaction with medical care and information about IPF, and found this
was highest in those who received care at centres of excellence.
While these figures are based on studies which have small samples, and may not have participants who
are generalisable to those seen in the UK, the results suggest that a large proportion of patients
experience delays in obtaining a diagnosis, and it is not anticipated that these are significantly different
from what is experienced in the UK.
TABLE 2 Combination of HRCT and surgical lung biopsy for the diagnosis of IPF
HRCT pattern
UIP Possible UIP Inconsistent with UIP
Surgical lung biopsy pattern (if performed)
UIP, probable UIP,
possible UIP,
nonclassifiable
fibrosisa
Not UIP UIP, probable UIP Possible UIP,
nonclassifiable
fibrosisa
Not UIP UIP Probable UIP,
possible UIP,
nonclassifiable
fibrosis,a not UIP
Diagnosis of IPF
Yes No Yes Probableb No Possibleb No
a Some biopsies may reveal a pattern of fibrosis that does not meet the criteria for UIP pattern and the other IIPs.
b Multidisciplinary discussion should include discussions of the potential for sampling error and a re-evaluation of
adequacy of technique of HRCT.
Represented from American Thoracic Society.10
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The 2013 clinical guideline produced by NICE31 outlines the key clinical features to be used in primary care
to identify and assess possible IPF. The guideline recognises the fact that the initial assessment of these
individuals needs to be improved, to reduce the risk of delays in diagnosis and initiation of treatments,
including monitoring and best supportive care (BSC). The clinical features may include age > 45 years,
persistent breathlessness on exertion, persistent cough, bilateral inspiratory crackles and finger clubbing.
Spirometry may or may not be impaired. In cases of suspected IPF, people can then be referred to
secondary care for diagnosis and clinical management. The guideline states that the diagnosis should
be multidisciplinary at each stage of the diagnostic care pathway to include a consultant respiratory
physician, consultant radiologist and ILD specialist nurse. All patients should be given BSC from the point
of diagnosis, which includes information and support, symptom relief, management of comorbidities,
withdrawal of ineffective therapies and end-of-life care. In addition, individuals should be assessed
for pulmonary rehabilitation, if appropriate, and have a clinical nurse specialist available to them.
The guideline also recommends that lung transplantation in those without contraindications should be
considered between 3 and 6 months after diagnosis (or sooner if indicated clinically), with referral to
regional transplant units for assessment if appropriate.
Pulmonary rehabilitation
Individuals with ILD experience many of the same symptoms as those with COPD, commonly shortness
of breath, fatigue and reduced exercise tolerance. It would, therefore, seem a priority to address these
symptoms. Pulmonary rehabilitation is an established evidence-based intervention for individuals with
COPD, with the precise aims of reducing the physical and emotional impact of the disease on the
individual.37 It is well documented that rehabilitation improves exercise capacity, dyspnoea and QoL.37
The delivery of rehabilitation to individuals with COPD is advocated in national guidelines; however, until
the 2013 NICE guidelines this had not been extended to IPF.31 Many individuals are, therefore, currently
not offered pulmonary rehabilitation. Further details about the intervention itself can be found in
Description of technologies under assessment.
The referral to rehabilitation can be instigated by primary or secondary care physicians; in most cases,
this would be after a detailed assessment and optimisation of treatment from a physician with a special
interest in IPF. Prior to commencing a course of rehabilitation, medical management should be optimised;
this may include the provision of supplemental oxygen. The most advantageous time to refer is unclear in
the evidence, although it is anticipated that a prompt referral is more likely to be beneficial before an
individual is too disabled by the disease.
Lung transplant
Lung transplantation is the only treatment that has been shown to improve survival in patients with IPF.
The 5-year survival of IPF patients post transplant is in the region of 40–50%, which compares with
an overall 52% 5-year survival rate.38 As indicated in the NICE guidelines,31 treating clinicians should
carefully consider whether or not their patient might be eligible and refer potentially suitable patients
to a recognised transplant centre for a full evaluation. IPF is the most common ILD referred for lung
transplantation throughout the world. Data from the International Society for Heart and Lung
Transplantation (ISHLT) collected from 1 January 2011 to 30 June 2012 show IPF to be the third
most common diagnosis leading to lung transplant throughout Europe, representing 17% of all lung
transplants.38 Data from the NHS Blood and Transplant service reveals that 17% (numbering between
23 and 33 patients per year) of all lung transplants in the UK between April 2009 and March 2013
were for fibrosing lung disease (NHS Blood and Transplant, 26 February 2013, personal communication).
It is anticipated that the majority of patients in this category had IPF. This differs significantly from the
current experience in the USA, where IPF is now the most common indication for lung transplantation
(35% of transplants).39 In the USA, the allocation of organs is governed by the United Network for Organ
Sharing (UNOS) system which calculates a lung allocation score (LAS). This calculates a post-transplant
survival score and a waitlist survival score to give an overall LAS. Patients with a higher score are prioritised
on the basis of urgency.
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As IPF is a disease of older adults, many patients may not be considered for lung transplantation on the
basis of their age. Most centres use age > 65 years as a relative, but not an absolute, contraindication to
lung transplant. Data from ISHLT from 2011 to the first half of 2012 reveals that, worldwide, 15.4% of
patients who received a transplant were > 65 years of age.38 However, again, there was a considerable
difference between European and American practice, with 4.4% of European recipients being > 65 years,
compared with 25.3% of North American recipients. Recent data from the USA suggest that
post-transplant mortality is no higher in patients > 70 years when compared with those in the 60- to
69-year-old age group.40
People considered for transplant referral should be free of malignancy for at least 2 years and have no
evidence of significant coronary artery disease, heart failure or any significant disease in a vital organ.
They should be not be infected with human immunodeficiency virus (HIV), chronic hepatitis B or C
infection or be dependent on tobacco and other substances. Similarly, a lack of social support and
significant psychological problems are contraindications to lung transplant. Poor nutritional status
and being significantly overweight [body mass index (BMI) > 30 kg/m2] or underweight is another
important contraindication.41
Data from the UNOS show that overall mortality post lung transplant is 22% higher in patients with a BMI
> 30 kg/m2.42 Low-dose prednisolone use (< 0.3mg/kg/day) is not considered a contraindication.
In patients who have no contraindications to lung transplant, the following specific criteria have been
proposed to guide a timely referral in IPF:41
1. radiological or pathological evidence of UIP
2. diffusion capacity/transfer factor for carbon monoxide < 40% predicted
3. a reduction of 10% in the FVC over a 6-month follow-up period
4. a reduction in oxygen saturation below 88% on 6MWT
5. the presence of honeycombing on a HRCT scan (fibrosis score > 2).43
However, as more patients with IPF than any other condition die on lung transplant waiting lists, the
clinician should have a low threshold to refer a deteriorating patient even if they do not yet meet
the above criteria.44 Similarly, many experts would advocate early referral for a deteriorating patient even
if the radiological and/or pathological findings are not entirely consistent with a UIP pattern, as evidence
of deterioration is a powerful marker of a poor prognosis.
Traditionally, single-lung transplant has been preferred over double-lung transplant in IPF, with the latter
being preferred for patients with cystic fibrosis or conditions associated with chronic infections. Some
centres have suggested that long-term survival may be better post double-lung transplant,38,45 while others
report little difference.46,47 This remains a point of considerable debate and given the lack of availability of
organs for donation it is likely that single-lung transplant will continue to be widely used. Exceptions to this
may be in younger patients or those with a nidus of infection in the native lung.
Palliative care
As stated, patients with IPF have a poor prognosis, although determining individual prognosis is more
difficult than in, for instance, lung cancer, and treatment options are limited.27,48 Lee and colleagues49
describe three ‘pillars’ of care: disease-centred management, symptom-centred management, and
education and self-management.
American Thoracic Society guidelines suggest that palliative care principles should be initiated when a
patient with respiratory disease becomes symptomatic.48 This may be particularly helpful in IPF as diagnosis
can be variable and there may be rapid and unexpected deterioration resulting in death.27 The guideline
of the British Thoracic Society recommends that BSC should be considered a specific and important
treatment strategy in all patients with IPF.50 The recent NICE guideline31 states that BSC should be initiated
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at the point of diagnosis. Best supportive, or palliative, care is a proactive approach to symptomatic
treatment and may include oxygen therapy, pulmonary rehabilitation, opiates, antireflux therapy, the
withdrawal of steroids and other immunosuppressants, early recognition of terminal decline and liaison
with palliative care specialists.50 This should also allow patients with IPF the opportunity to consider their
expectations, goals and preferences, but there is a reluctance of professionals to broach these difficult
topics.27 This might be one explanation as to why the majority of IPF patients in a recent study had no
palliative care input in their last year of life, despite these recommendations regarding the early integration
of palliative care.24
The NICE 2013 guideline suggests that if a patient with IPF has breathlessness on exertion, ambulatory
oxygen should be considered.31 Where there is breathlessness at rest, consideration should also be given to
benzodiazepines and/or opioid therapy.
Description of technologies under assessment
There is no universally accepted best treatment for IPF, with several treatment options available to clinicians.
Disease-modifying treatments include immunosuppressants, antifibrotics and antioxidants, alone or in
combination. Symptomatic treatments available include oxygen therapy, opioids, corticosteroids, antireflux
therapy and pulmonary rehabilitation. Other treatments may be used to treat specific symptoms such as
intractable cough or pulmonary hypertension. Finally, in some cases, lung transplantation is considered.
Disease-modifying treatments
Cyclophosphamide and azathioprine are immunosuppressant treatments which may also suppress
inflammation and have been used in some patients with IPF. Both cyclophosphamide and azathioprine are
used, in some cases in combination with the corticosteroid prednisolone. The ATS/ERS 2011 consensus
guidance suggests that these are not used routinely in IPF.10 The NICE guideline states that where the
combination of azathioprine and prednisolone is already being used, there should be consideration of
gradual withdrawal of these treatments.31 In the UK, the use of cyclophosphamide and prednisolone is
mostly restricted to the treatment of acute exacerbations, although not widely used.
N-acetylcysteine (NAC) is a precursor to the antioxidant glutathione, which may be reduced in the lungs of
patients with IPF. It is an antioxidant therapy that does not have specific marketing authorisation for use in
IPF, and it is readily available in health-food shops and over the internet. It can be used alone or, as has
been done in the past, in combination with prednisolone and azathioprine (referred to as triple therapy).
The ATS/ERS 2011 consensus guidance10 suggests that NAC (alone or in triple therapy) is not used in the
majority of patients but it may be a reasonable choice in a minority. The 2013 NICE guideline31 suggests
that it may be used alone after discussion of the risks of the treatment, and that if used in combination
with azathioprine and prednisolone, these latter two treatments should be gradually withdrawn.
Pirfenidone is an orally bioavailable synthetic molecule with antifibrotic and anti-inflammatory properties.
The mechanism of action at the molecular level is not fully understood; however, pirfenidone has marketing
authorisation for use in mild to moderate IPF in Europe. Pirfenidone was not included in the scope of the NICE
2013 clinical guideline;31 however, it has been assessed by NICE under the technology appraisals programme.
Final guidance to the NHS issued in 201323 states that pirfenidone is recommended as an option where an
individual patient has a FVC between 50% and 80% predicted. This is the case only if the manufacturer of
pirfenidone provides the treatment at a previously agreed (undisclosed) discount price.
Symptomatic treatments
Prednisolone is a corticosteroid which can be used to reduce inflammation. Most widely used in the past
before the nature of IPF was fully understood and the diagnosis more specific, prednisolone is now used
predominantly for symptom control, including for acute exacerbations.10
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Pulmonary rehabilitation is conventionally offered as a package of supervised exercise and education over a
6- to 8-week period by a multidisciplinary team. The ATS/ERS 2011 consensus guidance10 suggests that
this is used in the majority of patients but this may not be a reasonable choice for some. In the UK, the
clinical guideline from NICE31 recommends that individuals should be assessed for pulmonary rehabilitation
where appropriate.
Most experience with pulmonary rehabilitation comes from treating COPD, although the adoption of
pulmonary rehabilitation in the UK for IPF is becoming more widespread. The process of rehabilitation
commences with a detailed assessment; it is most likely that a detailed study of lung function will
have already characterised the patient. The rehabilitation assessment should include an evaluation
of health-related quality of life (HRQoL), levels of anxiety and depression, and exercise capacity as a
minimum. Additional measures that might be considered could be measures of peripheral muscle
strength, self-efficacy and physical activity, but these are not widely reported for IPF. HRQoL measures are
those commonly employed for individuals with COPD, for example the St George’s Hospital Respiratory
Questionnaire (SGRQ)51 or the chronic respiratory disease questionnaire.52 The exercise test is usually
conducted outside the laboratory and in the UK is commonly the 6MWT53 or the incremental shuttle
walking test.54 During and immediately after an exercise test it is important to record levels of oxygen
saturation, and, in discussion with the patient, make a decision about the use of supplemental
oxygen while exercising. Repeat testing with oxygen might be expected to correct the desaturation to
some degree and/or improve the level of perceived breathlessness.
The usual format of rehabilitation is one of educational and supervised exercise. The groups are not
specifically designed for individuals with IPF and, therefore, the education sessions may not all be entirely
appropriate. Generally, the educational topics include medicines management, disease pathology, chest
clearance techniques, breathing control, healthy eating, travelling with a lung disease, inhaler techniques,
relaxation, stress management and energy conservation. The exercise programme is a combination of
strength and aerobic exercises, prescribed and progressed on an individual basis. Bouts of purposeful
exercise should also be completed at home, to accumulate five sessions per week of aerobic activity. On
completion of a course of rehabilitation, it is recommended that a repeat assessment be conducted to
reinforce the benefits of rehabilitation.
Maintaining the benefit of rehabilitation is challenging; however, there are opportunities to continue with
regular supervised exercise in the community with exercise specialists trained to manage participants
with chronic respiratory disease.
Oxygen therapy can either be used as a long-term therapy or be taken as a supplement after exertion. The
ATS/ERS 2011 consensus guideline10 suggests that long-term oxygen therapy is used in patients with IPF
and clinically significant resting hypoxaemia, and the NICE 2013 guideline31 also refers to the use of
oxygen for breathlessness on exertion as discussed above.
Palliative care/BSC should be considered from the outset as an adjunct to disease-focused care. This may
include corticosteroids, oxygen therapy, treatments for other symptoms such as cough, advanced directives
and end-of-life care issues including hospice care.
Treatments for specific symptoms
Sildenafil is a phosphodiesterase-5 inhibitor with marketing authorisation for use in pulmonary
hypertension and it has been used as a treatment for IPF. There are currently no recommendations from
the ATS/ERS consensus committee of the 2011 guidance10 and in the NICE guideline sildenafil was not
recommended as a treatment for modifying IPF owing to uncertainty around both benefits and harms.31
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Bosentan is a dual endothelin receptor A and B antagonist that has marketing authorisation for pulmonary
hypertension. Endothelin is a vasoconstrictor and growth factor that is involved in the pathogenesis of
pulmonary hypertension. The 2011 ATS/ERS10 consensus guidance suggests that these are not used based
on the potential risks and costs of therapy. The NICE clinical guideline concurs with this.31
Thalidomide is a potent immunomodulatory, anti-inflammatory and antiangiogenic drug, and may be a
potential therapy in IPF for cough.55 Thalidomide does not have a UK marketing authorisation for IPF;
however, the NICE clinical guideline31 states that thalidomide may be considered in a patient with
intractable cough.
Treatments undergoing assessment in UK participants
BIBF 1120 or nintedanib is an intracellular inhibitor of tyrosine kinases and is currently under evaluation in
phase III randomised controlled trials (RCTs) as a potential therapy for IPF. It has received orphan status
from the European Medicines Agency in 2013 (orphan status provides some favourable marketing
incentives to manufacturers).56
Overall aims and objectives of assessment
This project will evaluate the clinical effectiveness and cost-effectiveness of the different treatment
strategies used within the NHS for IPF. It will review systematically the evidence on those interventions that
are currently available and used to treat IPF. It will construct a new economic model relevant to the UK
setting to estimate the cost-effectiveness of the different treatments. Deficiencies in current knowledge will
be identified and recommendations for future research generated.
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Chapter 2 Methods for the systematic review of
clinical effectiveness and cost-effectiveness
The a priori methods for systematically reviewing the evidence of clinical effectiveness andcost-effectiveness are described in the research protocol, which was sent to our expert advisory
group for comment. Although helpful comments were received relating to the general content of the
research protocol, there were none that identified specific problems with the methodology of the review.
The methods outlined in the protocol are briefly summarised below.
Identification of studies
A comprehensive search strategy was developed, tested and refined by an experienced information
scientist. Separate searches were conducted to identify studies of clinical effectiveness, cost-effectiveness,
QoL and epidemiology. Sources of information and search terms are provided in Appendix 1. The most
recent searches were undertaken in July 2013.
Literature was sourced from 11 electronic databases, the bibliographies of articles, and grey literature
sources, and our expert advisory group were contacted to identify any additional studies. All databases were
searched from inception with no language restrictions. The following electronic databases were searched:
MEDLINE (Ovid); MEDLINE In Process & Other Non-Indexed Citations; EMBASE; The Cochrane Library
including Central Register of Controlled Trials and Cochrane Database of Systematic Reviews; Centre for
Reviews and Dissemination (CRD) including Health Technology Assessment Database, Database of Abstracts
of Reviews of Effects and NHS Economic Evaluation Database; Web of Science (Science Citation Index
Expanded) and Conference Proceedings Citation Index; and Bioscience Information Service Previews.
A comprehensive database of relevant published and unpublished articles was constructed using Reference
Manager software (Thomson ResearchSoft, San Francisco, CA, USA). Research-in-progress databases
(UK Clinical Research Network website, Current Controlled Trials and Clinical trials.gov, World Health
Organization-International Clinical Trials Registry Platform) were searched for any ongoing studies
of relevance.
In addition, professional society websites and conferences were searched for recent abstracts and ongoing
studies (see Appendix 1).
Study selection and data extraction
Studies were selected for inclusion in the systematic review of clinical effectiveness through a two-stage
process using predefined and explicit criteria (see Inclusion and exclusion criteria). Titles and abstracts from
the literature search results were independently screened by two reviewers to identify all citations that
possibly met the inclusion criteria. Full papers of relevant studies were retrieved and assessed by one
reviewer and checked by a second reviewer using a standardised eligibility form. As far as possible, full
papers or abstracts describing the same study were linked together, with the article reporting key
outcomes designated as the primary publication.
A two-stage approach was used to establish the relevance of each individual treatment for inclusion in the
evidence synthesis. The advisory group individually and independently commented on the relevance of
each treatment. The outcomes from this exercise were tabulated and those with complete consensus were
either included or excluded as appropriate. Where consensus on any particular intervention was not
reached, these were sent to the advisory group for a second time. At this stage, either consensus was
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confirmed or a decision was taken to include treatments where at least one expert had indicated that the
treatment was used in their clinical practice.
Titles and abstracts identified by the search strategy for the systematic review of cost-effectiveness and
HRQoL were assessed for potential eligibility by two reviewers using predetermined inclusion criteria
(see Inclusion and exclusion criteria). Full papers were formally assessed for inclusion by one health
economist with respect to their potential relevance to the research question and this was checked by
one reviewer.
Data were extracted by one reviewer using a standard data extraction form (see Appendix 2) and checked
by a second reviewer. At each stage, any disagreements between reviewers were resolved by consensus or,
if necessary, by arbitration by a third reviewer.
Critical appraisal strategy
The methodological quality and the quality of reporting of the included clinical effectiveness studies were
assessed using criteria based on those recommended by the CRD57 and the Cochrane Collaboration58
(see Appendix 2). The risk of bias within each study was summarised according to the risk of selection bias.
Quality criteria were applied by one reviewer and checked by a second reviewer, with any differences in
opinion resolved by consensus or by arbitration by a third reviewer.
Quality assessment for the systematic review of cost-effectiveness was based on a checklist for economic
evaluation publications59 and guidelines for good practice in decision-analytic modelling in health
technology assessment.60
Inclusion and exclusion criteria
Participants
l People with a confirmed diagnosis of IPF.
As there have been changes in the diagnostic criteria for IPF, particular attention was paid to the
inclusion criteria used by studies to ensure that the results were not influenced by mixed populations with
differing prognoses. Studies of mixed populations were included only if the study reported outcomes for
those with IPF separately.
Where the definition of IPF was uncertain, this was checked by our advisory group. Any studies remaining
uncertain would have been included but discussed separately; no such instances occurred.
The presence of pulmonary hypertension in participants in included studies was not a reason for exclusion.
Any included studies with known participants with pulmonary hypertension are discussed as appropriate
in the results.
Interventions
l Any available and currently used (in the NHS) interventions which aim to manage symptoms or modify
IPF were eligible.
As described above, clinical experts and the expert advisory group for the review were asked to identify the
current treatments used in the UK to ensure that the key treatments in use were included in the review.
For discussion of the included interventions see Chapter 3.
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Comparators
l Any of the included interventions.
l BSC.
l Placebo interventions.
Outcomes
l Measures of survival.
l Measures of symptoms (breathlessness, cough).
l QoL/HRQoL.
l Lung function/capacity.
l Exercise performance.
l Adverse events.
l Costs and cost-effectiveness.
Patient-assessed subjective outcome measures were included if assessed by validated tools (for descriptions
see Chapter 3 and Appendix 3).
A variety of surrogate end points have been used in trials of interventions for IPF. Appendix 3 describes the
key outcomes used, including evidence of the relationship between these and the final patient outcome.
Design
l RCTs.
l Where no RCTs were identified for a particular intervention, controlled clinical trials (CCTs) with a
concurrent control group were eligible.
l Economic evaluations (i.e. costs and consequences), including cost-effectiveness, cost–utility or
cost–benefit analyses.
Studies published as abstracts or conference presentations were included only if sufficient details were
presented to allow an appraisal of the methodology and the assessment of results to be undertaken.
Systematic reviews identified by the search were used as a source for identifying primary studies and are
summarised in Chapter 3 (see Existing systematic reviews).
Method of data synthesis
Studies of clinical effectiveness and cost-effectiveness were synthesised through a narrative review with
tabulation of results of included studies.
Where data were of sufficient quality and homogeneity, meta-analyses of the clinical effectiveness studies
were performed to estimate the mean difference (for continuous data) and risk ratio (RR) (for dichotomous
data) with 95% CIs. The random-effects method was used where statistical heterogeneity was observed. The
standardised mean difference was used to combine per cent predicted FVC/VC and mean change in FVC/vital
capacity (VC) in a meta-analysis. The standardised mean difference converts all outcomes to a common scale.
It is the difference in means between the treatment arms divided by the pooled standard deviation (SD) of
outcomes from all participants in each trial. Meta-analysis was performed by using Cochrane Review Manager
5 (RevMan, The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) and statistical
heterogeneity was assessed using chi-squared test and the I2 statistic.58 Where SDs were not presented in the
published papers, these were calculated from the available statistics (CIs, standard errors or p-values).
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In addition, a network meta-analysis (NMA) was undertaken to allow ranking of the effectiveness of the
range of treatments being evaluated. NMA is an extension of traditional, pairwise meta-analysis where a
statistical analysis of the network of trial evidence is used to produce comparable estimates of benefits
and harms for a range of treatments. The NMA was conducted using current guidance on good practice
(for further details see Chapter 3, Network meta-analysis).
The methods for the economic model are described in Chapter 4 (see Methods for economic analysis).
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Chapter 3 Clinical effectiveness
Research identified and included
Searches identified a total of 905 references after deduplication, and full texts of 64 references were
retrieved after screening titles and abstracts. Initial screening of the full texts identified 47 publications of
possible relevance. The interventions and comparators used in these 47 studies were tabulated and sent
to the advisory group to determine their relevance. The final list of included interventions can be seen
in Table 3. One new treatment, BIBF 1120 (nintedanib), was included as it will possibly be used in future
practice. After this exercise, 13 RCTs and one CCT61 were included (two of the RCTs were reported in
one publication).62
One non-English (Polish) publication was considered to be eligible for inclusion.61 The publication
contained an English translation of the abstract and results tables. A translation of the methods was
requested from the author; however, no response was received. The methods were translated using
Google Translate (http://translate.google.com) and results were extracted from the tables but not the text
to avoid error.
The number of references excluded at each stage of the systematic review is shown in Figure 1. References
that were retrieved as full papers but subsequently excluded are listed in Appendix 4, with reasons for
exclusion. Seventeen references were excluded owing to participants (eight studies), study design
(seven studies) or irrelevant outcomes (three studies), with one study being excluded for more than one
reason. Thirty-one studies were eligible in the first full-paper screen but were then excluded as the
interventions were not considered relevant by the advisory group. The level of agreement between
reviewers for screening was high, although this was not formally assessed.
Searches identified 25 relevant ongoing studies, a summary of which can be seen later in this chapter
(see Ongoing randomised controlled trials). One conference abstract was also identified but the abstract
did not present sufficient information for the study to be formally assessed for inclusion. This study was
a CCT of a 12-week pulmonary rehabilitation compared with a control group (undefined).64 No full
publication for this study has been identified on updated searches.
Four RCTs evaluated the use of pirfenidone,62,65,66 three the use of NAC (alone or in combination),67–69
one azathioprine,70 one BIBF 1120,71 one sildenafil (in severe IPF),72 one thalidomide,55 one a pulmonary
rehabilitation programme,73 and one a disease management programme.74 In addition, one CCT of
pulmonary rehabilitation was included.61 No studies of bosentan, cyclophosphamide and prednisolone,
methyprednisolone (alone or in combination with prednisolone) or co-trimoxazole (Septrin®, Aspen) were
included because studies of these interventions had ineligible comparator treatments. No studies of
palliative care interventions were identified that met the inclusion criteria.
Description of included studies
Eleven of the included RCTs investigated the use of pharmacological interventions for IPF. One was a
single-centre randomised crossover trial,55 and the rest were multicentre trials, with the number of centres
ranging from two70 to 110.62 The majority of centres were in either the USA or European countries,
although some included countries such as Mexico and Republic of Korea, and three studies were
undertaken solely in Japan.65,66,69 Sample sizes ranged from 2455 to 435,62 although all except two trials55,70
had sample sizes of 100 or more participants. Nine of the 11 trials investigating pharmaceutical agents
received some funding from the drug manufacturer. Across the 11 trials, participants would likely be
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TABLE 3 Status of interventions identified at the initial screening stage
Treatment Decision
Ambrisentan Exclude
Azathioprine and prednisolonea Include
BIBF 1120 (nintedanib) Include as possible future use
Bosentan Include if pulmonary hypertension present
Bromhexine hydrochloride Exclude
Colchicine Exclude
Colchicine and prednisolone Exclude
Colchicine and d-penicillamine Exclude
Colchicine and cyclophosphamide Exclude
Cyclophosphamide and prednisolone Include if used for acute exacerbations
Ciclosporin Exclude
Disease management programmes Include
Etanercept Exclude
Everolimus Exclude
Iloprost Exclude
Imatinib Exclude
Interferon-γ–1b Exclude
Interferon-γ–1b and prednisolone Exclude
Macitentan Exclude
Methylprednisolone Include if used for acute exacerbations
NAC Include
NAC (inhaled) Include
NAC, azathioprine, prednisolone Include
Pirfenidone Include
Pulmonary rehabilitation Include
Prednisone (prednisolone) Include
Prednisone and d-pencillamine Exclude
Prednisone, d-pencillamine, colchicine Exclude
Prednisone and warfarin Exclude
Prednisone and methylprednisolone Include if used for acute exacerbations
Septrin Include
Sildenafil Include if pulmonary hypertension present or in severe IPF
Thalidomide Include if for cough
a Although this is no longer indicated in IPF, it is still in use.
Bold used to denote included treatments.
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classified as mild to moderate in 10, with one study looking at participants in the more severe stages of
IPF.72 In the three studies investigating non-pharmacological interventions, one RCT was undertaken in
Japan and investigated a pulmonary rehabilitation programme,73 one CCT was undertaken in Poland
and investigated inspiratory muscle training in addition to pulmonary rehabilitation,61 and the other RCT
investigated a disease management programme in the USA.74 These trials were single-centre studies and
funding was from public or charitable funds where data were available. The sample size was 30 in both of
the pulmonary rehabilitation programme studies,61,73 and 21 in the disease management programme trial.74
The populations in these trials were at the more moderate to severe end of the spectrum of IPF. Further
detail of the characteristics of these studies and their participants can be found in subsections below and
in Table 4, which summarises the key attributes of the fourteen included studies, and Table 5, which
summarises the key participant characteristics.
The following sections are subdivided into pharmacological and non-pharmacological agents, and
individual interventions are discussed in alphabetical order within severity categories.
Identified on searching
(after duplicate removal)
(n = 905)
Titles and abstracts inspected
Full papers retrieved
(n = 64)
Full papers inspected
Potentially eligible
(n = 47)
Interventions sent to advisory
group
Included (n = 15 publications)a
(14 trials)
(n = 1 protocol)b
Excluded
(n = 841)
Excluded
(n = 17)
Excluded
(n = 31)
FIGURE 1 Flow chart for the identification of studies. a, two RCTs were reported in one publication; two further
trials each had two linked publication; b, one trial was published as a protocol only:63 see Ongoing randomised
controlled trials.
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TABLE 4 Summary of included studies
Study Intervention details Key eligibility criteriaa Outcomes
Pharmacological agents
Azathioprine
Raghu et al. 199170
Country: USA
Design: RCT
Number of centres:
two
Funding: Grant from
Virginia Mason
Research Centre,
Seattle, WA, USA
1. Prednisone and placebo, n=13
2. Prednisone and azathioprine,
n=14
Dose details: prednisolone
decreased from 1.5mg/kg/day
(not to exceed 100mg/day) for
2 weeks, decrease of 20mg/day
until a dose of 40mg/day was
reached for 2 weeks, decrease of
5 or 10mg/day every 2 weeks
according to patient tolerance.
Maintenance dose of ≤20mg/day
Azathioprine 3mg/kg/day (not to
exceed 200mg/day) to the nearest
25-mg dose increment for the
duration
Duration of treatment: assume
112 months
Inclusion criteria: a diagnosis of
IPF supported by lung biopsy.
Previously untreated and available
for routine follow-up. Fulfilled
criteria for progressive clinical
disease [one or more of
(1) progressive dyspnoea from
day of onset, (2) progressive
roentgenographic parenchymal
abnormality, (3) ≥ 10% decrease
in FVC or TLC compared with
previous values, (4) ≥ 20%
reduction in DLCO compared with
previous values]
Excluded: collagen vascular disease,
hypersensitivity pneumonitis,
pneumoconiosis, drug-induced
diffuse pulmonary injury, or
irradiation fibrosis
Primary outcomes: not
stated as primary or
secondary – measurable
change in lung function
(FVC, DLCO, PA – aO2) at
12 months; survival
Length of follow-up:
12 months
BIBF 1120
Richeldi et al. 201171
Country: 25 countries
including Italy, Mexico,
Germany, USA,
Republic of Korea, UK,
France
Design: RCT
(dose-finding phase II
study)
Number of centres: 92
Funding: supported by
Boehringer Ingelheim
1. BIBF 1120 50mg/day, n= 86
2. BIBF 1120 50mg twice per
day (100mg/day), n= 86
3. BIBF 1120 100mg twice per
day (200mg/day), n= 86
4. BIBF 1120 150mg twice per
day (300mg/day), n= 85
5. Placebo, n= 85
Dose details: a group-wise dose
escalation was used with
stepwise increases in dose for
serial cohorts
Duration of treatment:
52 weeks
Inclusion criteria: ≥ 40 years, IPF
consistent with the ATS/ERS
2000 criteria, diagnosis < 5 years,
HRCT < 1 year, FVC that was
≥ 50% predicted, DLCO 30–79%
predicted, and PaO2 when
breathing ambient air ≥ 55mmHg
at altitudes up to 1500m, or
≥ 50mmHg at altitudes above
1500m
Excluded: medical conditions or
concomitant medications that might
interfere with the performance of
the study, other diseases that might
interfere with testing procedures
(stated), continuous oxygen
supplementation, predisposition
to bleeding or thrombosis,
concomitant anticoagulation
medication, elevated liver enzymes,
likelihood of lung transplantation
during the study or life expectancy
<2.5 years for a disease other
than IPF
Primary outcomes:
annual rate of decline
in FVC
Secondary outcomes:
per cent predicted FVC;
DLCO; SpO2; TLC; 6MWT,
SGRQ, decrease in FVC
of > 10% or > 200ml;
SpO2 decrease of > 4%;
acute exacerbations;
survival; death from a
respiratory cause;
adverse events
Length of follow-up:
54 weeks
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TABLE 4 Summary of included studies (continued )
Study Intervention details Key eligibility criteriaa Outcomes
NAC (alone or in combination)
Demedts et al. 200567
Country: Belgium,
France, Germany, Italy,
Spain, the Netherlands
Design: RCT
Number of centres: 36
Funding: sponsored by
the Zambon group
1. NAC, prednisolone,
azathioprine, n= 92
(80 analysed)
2. Placebo, prednisolone,
azathioprine, n= 90
(75 analysed)
Dose details: NAC at 600mg
three times per day.
Azathioprine at 2mg/kg
per day. Prednisone dose
decreases from 0.5mg/kg
body weight per day;
0.4mg/kg per day at month 2;
0.3mg/kg at month 3; until
10mg per day in months 4–6
and then maintained until
month 12
Duration of treatment: not
stated, assume 12 months
Inclusion criteria: 18–75 years,
histological or radiologic pattern
typical of UIP. HRCT suggestive
or consistent with a probable
diagnosis of UIP. Open or
thoracoscopic lung biopsy in those
aged < 50 years. In the absence of
lung biopsy, a transbronchial
biopsy was advocated to exclude
alternative diagnoses. Duration
> 3 months, bibasilar inspiratory
crackles, dyspnoea score at least 2
on a scale of 0 (minimum) to 20
(maximum), VC ≤ 80% predicted
or TLC < 90% predicted, and
single-breath DLCO < 80%
predicted
Excluded: contraindication/
intolerance to study treatments.
Prednisone at least 0.5mg/kg/day or
azathioprine at least 2mg/kg/day
during the month before inclusion,
treatment with NAC of >600mg/day
for >3 months in the previous
3 years. Concomitant or pre-existing
diseases, or treatments that interfere
with IPF
Primary outcomes:
absolute changes in VC
and DLCO at 12 months
Secondary outcomes:
per cent predicted VC,
per cent predicted DLCO,
alveolar volume change
and per cent predicted,
CRP score, dyspnoea
score, maximum exercise
indexes, HRCT outcomes,
SGRQ, adverse events,
withdrawals, and
mortality
Length of follow-up:
12 months
Raghu et al. IPFCRN
201268
Country: USA
Design: RCT
(PANTHER study)
Number of centres: 25
Funding: grants from
the NHLBI; the Cowlin
Family fund. NAC and
placebo donated by
Zambon
1. NAC and placebo (data
not presented in article as
‘ongoing’ data collection),
n= 81
2. NAC/prednisolone/
azathioprine, n= 77
3. Placebo, n= 78
Dose details: NAC at 600mg
orally three times per day.
Prednisone decreased from
0.5mg/kg of ideal body weight
to 0.15mg/kg during 25 weeks.
Azathioprine (maximum
150mg/day) based on ideal
weight, concurrent use of
allopurinol, and thiopurine
methyltransferase activity
Duration of treatment: up to
60 weeks
Inclusion criteria: IPF aged between
35–85 years with mild to moderate
lung-function impairment (FVC
≥50% and DLCO ≥30% of
predicted values), modified criteria
of the ATS/ERS (2011) for diagnosis
of IPF, received diagnosis on
the basis of HRCT or biopsy
≤48 months before enrolment
Excluded: FEV1–FVC ratio <0.65;
PaO2 on room air <55mmHg;
residual volume > 120% predicted;
evidence of active infection;
significant bronchodilator response;
post-bronchodilator FVC differing
by > 11%; listed for lung
transplantation; history of cardiac
disease or hypertension; HIV or
hepatitis C; liver cirrhosis and
chronic active hepatitis
Primary outcomes:
change in FVC at
60 weeks
Secondary outcomes:
rate of death, time until
death, frequency of
acute exacerbation,
frequency of maintained
FVC response, time to
disease progression,
clinical and physiological
measures including
DLCO, 6MWT, CPI,
UCSDSBQ, SGRQ,
SF-36, EQ-5D. Adverse
events
Length of follow-up:
60 weeks in the planned
analysis. The study was
stopped early. The mean
follow-up was 32 weeks
continued
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TABLE 4 Summary of included studies (continued )
Study Intervention details Key eligibility criteriaa Outcomes
Homma et al. 201269
Country: Japan
Design: RCT
Number of centres: 27
Funding: grant from
Ministry of Health,
Labour and Welfare
1. NAC inhaled, n= 51
(38 analysed)
2. Control, n= 49
(38 analysed)
Dose details: NAC inhalation of
352.4mg diluted with saline to a
total volume of 4ml twice a day,
using microair nebulisers and
vibration mesh technology
Control: states ‘no treatment or
placebo’
Duration of treatment:
48 weeks
Inclusion criteria: well-defined IPF
(by ATS/ERS guidance and
Japanese criteria). Histological
evidence of UIP was not
mandatory, but HRCT evidence
was required as were presence of
other typical clinical features. Aged
between 50 and 79 years, severity
of disease classified as stage I
(partial O2 concentration
≥ 80mmHg at rest), or stage II
(partial O2 concentration
70–80mmHg at rest), a lowest
arterial oxygen saturation of
> 90% during the 6MWT
Excluded: an improvement in
symptoms during the preceding
3 months; use of NAC,
immunosuppressive agents,
oral prednisolone or pirfenidone;
clinical suspicion of IIP other
than IPF
Primary outcomes:
absolute change in FVC
at 48 weeks
Secondary outcomes:
changes in lowest
arterial O2 saturation,
6MWT distance, PFT
parameters (VC, per
cent predicted VC, TLC,
per cent predicted TLC,
DLCO, predicted DLCO),
serum markers of
pneumocyte injury;
disease progression as
determined by HRCT;
subjective changes in
symptoms such as
dyspnoea, adverse
events
Length of follow-up:
48 weeks
Pirfenidone
Noble et al. 201162
Capacity study 006
Country: Australia,
Belgium, Canada,
France, Germany,
Ireland, Italy, Mexico,
Poland, Spain,
Switzerland, UK, USA
Design: RCT
Number of centres:
110 centres
Funding: InterMune
1. Pirfenidone 2403mg/day,
n= 171
2. Placebo, n= 173
Dose details: the dose was
increased to the full dose over
2 weeks
Duration of treatment:
72 weeks
Inclusion criteria: aged 40–80 years,
diagnosis of IPF in the previous
48 months, no evidence of
improvement in measures of disease
severity over the preceding year.
Predicted FVC of ≥ 50%, predicted
DLCO of ≥ 35%, either predicted
FVC or DLCO ≤ 90%, 6MWT
distance of ≥150m
Excluded: obstructive airway
disease, connective tissue disease,
alternative explanation for ILD,
those on a waiting list for a lung
transplant
Primary outcomes:
change in per cent
predicted FVC
Secondary outcomes:
categorical FVC
(5-point scale), PFS,
worsening IPF, dyspnoea,
6MWT distance, worst
peripheral oxygen
saturation (SpO2) during
the 6MWT, per cent
predicted DLCO, fibrosis,
mortality
Length of follow-up:
72 weeks from the date
the last patient was
enrolled
Noble et al. 201162
Capacity study 004
Country: Australia,
Belgium, Canada,
France, Germany,
Ireland, Italy, Mexico,
Poland, Spain,
Switzerland, UK, USA
Design: RCT
Number of centres:
110 centres
Funding: InterMune
1. Pirfenidone 2403mg/day,
n= 174
2. Pirfenidone 1197mg/day,
n= 87
3. Placebo, n= 174
Dose details: the dose was
increased to the full dose over
2 weeks
Duration of treatment:
72 weeks
Inclusion criteria: aged 40–80 years,
diagnosis of IPF in the previous
48 months, no evidence of
improvement in measures of disease
severity over the preceding year.
Predicted FVC of ≥ 50%, predicted
DLCO of ≥ 35%, either predicted
FVC or DLCO ≤ 90%, 6MWT
distance of ≥150m
Excluded: obstructive airway
disease, connective tissue disease,
alternative explanation for ILD,
those on a waiting list for a lung
transplant
Primary outcomes:
change in per cent
predicted FVC
Secondary outcomes:
categorical FVC
(5-point scale), PFS,
worsening IPF, dyspnoea,
6MWT distance, worst
peripheral oxygen
saturation (SpO2) during
the 6MWT, per cent
predicted DLCO, mortality
Length of follow-up:
72 weeks from the date
the last patient was
enrolled
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TABLE 4 Summary of included studies (continued )
Study Intervention details Key eligibility criteriaa Outcomes
Taniguchi et al. 201065
Country: Japan
Design: RCT
Number of centres: 73
Funding: public sector
grants. Drug and
placebo from Shionogi
& Co., Ltd
1. Pirfenidone 1800mg/day,
n= 108
2. Pirfenidone 1200mg/day,
n= 55
3. Placebo, n= 104
Dose details: doses increased
in a stepwise manner over
4 weeks
Duration of treatment:
52 weeks
Inclusion criteria: aged 20–75 years,
IPF diagnosed using ATS/ERS and
clinical diagnostic criteria guidelines
for IIP in Japan. Independently
evaluated HRCT scans. Probably UIP
by surgical lung biopsy. Arterial
oxygen saturation criteria of
(1) oxygen desaturation of ≥5%
difference between resting SpO2
and the lowest SpO2 during a
6MET; and (2) the lowest SpO2
during the 6MET of ≥ 85% while
breathing air
Excluded: decrease in symptoms
(preceding 6 months); use of
immune-suppressants and/or
oral corticosteroids at a dose
of >10mg/day–1 (preceding
3 months); clinical features of IIP
other than IPF; coexisting lung
conditions (stated) or severe
respiratory infection
Primary outcomes:
change in VC to week 52
Secondary outcomes: PFS
time, change in lowest
SpO2 during the 6MET.
PaO2, PA – aO2, TLC and
DLCO, acute exacerbation,
markers of interstitial
pneumonias, symptoms
Length of follow-up:
52 weeks
Azuma et al. 200566
Country: Japan
Design: RCT
Number of centres: 25
Funding: Shionogi &
Co., Ltd
1. Pirfenidone 1800mg/day,
n= 73
2. Placebo, n= 36
Dose details: doses increased
in a stepwise manner over
1 week
Duration of treatment:
9 months
Inclusion criteria: histological
evidence of UIP not mandatory,
HRCT evidence of definite or
probable UIP required. Presence
of bibasilar inspiratory crackles,
abnormal PFTs, and increased
serum levels of damaged-
pneumocyte markers. Aged
20–75 years with PaO2 ≥ 70mmHg
at rest and demonstrated SpO2 of
≤ 90% during exertion while
breathing air, 1 month before
enrolment
Excluded: a decrease in symptoms
(preceding 6 months), use of
immunosuppressive and/or oral
prednisolone >10mg/day (preceding
3 months), clinical suspicion of IIP
other than IPF, coexisting lung
conditions (defined); uncontrolled
diabetes, comorbid conditions
Primary outcomes:
change in the lowest
SpO2 during the 6MET
Secondary outcomes:
resting PFTs while
breathing air (VC, TLC,
DLCO PaO2), disease
progression by HRCT
patterns, acute
exacerbation, serum
markers of pneumocyte
damage, QoL
Length of follow-up:
minimum of 9 months
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TABLE 4 Summary of included studies (continued )
Study Intervention details Key eligibility criteriaa Outcomes
Thalidomide
Horton et al. 201255,75
Country: USA
Design: randomised
crossover trial
Number of centres:
one
Funding: Celgene
Corporation
1. Thalidomide, n= 23
2. Placebo, n= 23
Dose details: 50mg oral daily,
increased to 100mg if no
improvement in cough occurred
after 2 weeks (21 of 22 receiving
thalidomide and 23 of 23
receiving placebo)
Duration of treatment: 12 weeks
each treatment with a 2-week
washout period between
treatments
Inclusion criteria: aged > 50 years,
clinical history consistent with IPF
(symptom duration ≥ 3 months and
≤ 5 years) and chronic cough
(defined as > 8 weeks’ duration,
that adversely affected QoL and
not due to other identifiable
causes). HRCT scans consistent
with IPF or surgical lung biopsy
demonstrating UIP, FVC between
40% and 90% predicted, TLC
between 40% and 80% predicted,
and DLCO between 30% and 90%
predicted
Exclusion criteria: pregnancy,
female with childbearing potential,
toxic or environmental exposure
to respiratory irritants, collagen
vascular disease, airflow
obstruction, active narcotic
antitussive use, peripheral vascular
disease or neuropathy, inability to
give informed consent, allergy or
intolerance to thalidomide, life
expectancy < 6 months (opinion of
investigators)
Primary outcomes:
cough-specific quality of
life
Secondary outcomes:
cough, respiratory QoL
Method of assessing
outcome: cough-specific
QoL measured by CQLQ.
Cough measured by a
10-cm VAS. Respiratory
QoL measured by SGRQ
Length of follow-up:
12 weeks
Sildenafil (severe IPF)
Zisman and colleagues
IPFCRN 201072
Country: USA
Design: RCT
Number of centres: 14
Funding: NHLBI; the
Cowlin Fund (Chicago
Community trust);
Pfizer; Masimo
1. Sildenafil, n= 89
2. Placebo, n= 91
Dose details : sildenafil, oral,
20mg, three times daily
Duration of treatment:
12 weeks
Inclusion criteria: diagnosis of IPF
as defined by the 2000 ATS/ERS
consensus criteria, in an advanced
stage (a DLCO of < 35% predicted)
Excluded: 6MWT distance
< 50m; a difference > 15% in
the 6MWT distance between
two pre-randomisation walks;
emphysema extent greater fibrotic
change; treatment with
medications containing nitrates;
aortic- or idiopathic hypertrophic
subaortic stenosis; within 30 days
of screening: pulmonary
rehabilitation; initiation or change
in dose of treatment for IPF;
treatments for pulmonary
hypertension with prostaglandins,
endothelin-1 antagonists, or other
phosphodiesterase inhibitors;
a resting oxygen saturation of
< 92% while breathing 6 litres
of supplemental oxygen; waiting
list for lung transplantation
Primary outcomes:
presence or absence of
an improvement of at
least 20% in the 6MWT
distance at 12 weeks
Secondary outcomes:
changes in the 6MWT
distance, degree of
dyspnoea, QoL, FVC,
DLCO, arterial partial
pressure of oxygen and
arterial oxygen
saturation, and the
alveolar–arterial oxygen
gradient while breathing
ambient air, adverse
events, hospitalisations,
death
Length of follow-up:
12 weeks
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TABLE 4 Summary of included studies (continued )
Study Intervention details Key eligibility criteriaa Outcomes
Non-pharmacological interventions
Disease management programme/pulmonary rehabilitation
Lindell et al. 201074
Country: USA
Design: RCT
Number of centres:
one
Funding:
Fairbanks-Horix
Foundation
1. Program to Reduce IPF
Symptoms and Improve
Management (PRISIM), n= 10
pairs
2. Usual care, n= 11 pairs
Description of interventions:
6-weekly group sessions
attended by patients and care
partners. Each session 2 hours.
Also group exercises
Usual care participants were seen
by members of the clinical care
team at every 3–6 months
Duration of treatment: 6 weeks
Inclusion criteria: aged >21 years, be
able to read and understand English,
to be diagnosed with IPF, to have a
FVC reflecting moderate IPF (FVC
55–70% predicted) or severe IPF
(<55% predicted). Care partners
were required to be aged >21 years,
be able to read and understand
English, to live with or care for the
patient with IPF
Diagnostic criteria for IPF not stated
Excluded: not stated
Primary outcomes: not
specified as primary or
secondary outcomes.
Dyspnoea (UCSDSBQ);
anxiety (BAI); depression
(Beck Depression
Inventory-II); stress (PSS);
QoL (SF-36)
Length of follow-up:
unclear
Jastrzebski et al.
200861
Country: Poland
Design: CCT
Number of centres:
one
Funding: not translated
1. Inspiratory muscle training,
n= 16
2. Control, n= 14
Description of intervention: not
translated in full. Appears that
both groups received pulmonary
rehabilitation, described as general
body conditioning exercises
Duration of treatment:
12 weeks (two 6-week cycles)
Inclusion criteria: diagnosis by
ATS/ERS criteria in patients aged
> 50 years, and by lung biopsy
in patients < 50 years. At least
2 years’ duration of disease and in
remission
Excluded: >20mg prednisolone
per day, duration of treatment
>2 years, use of home oxygen
therapy
Primary outcomes: not
specified as primary or
secondary. Dyspnoea
(oxygen cost diagram,
BDI). QoL (SF-36), 6MWT
(distance, dyspnoea in
Borg’s scale), maximal
inspiratory pressure,
lung function tests (IC,
TLC, VC, FEV1, DLCOSB,
DLCO/VA)
Length of follow-up:
12 weeks
Nishiyama et al. 200873
Country: Japan
Design: RCT
Number of centres:
one
Funding: Japanese
Ministry of Health,
Labour and Welfare
1. Pulmonary rehabilitation
programme (PRP), n= 15
(13 analysed)
2. Control, n= 15
Description of intervention:
general programme of pulmonary
rehabilitation, not specific to IPF.
Twice-weekly programme of
exercise and peripheral muscle
training. Some educational
lectures were also held
No details of control group provided
Duration of treatment:
10-week programme
Inclusion criteria: < 75 years,
diagnosis using ATS/ERS consensus
criteria, stable IPF, shortness of
breath on effort, no infection or
exacerbations in the previous
3 months
Excluded: severe comorbid
illnesses, collagen vascular diseases,
the need for long-term oxygen
therapy and previous treatment
with corticosteroids or
immunosuppressives
Primary outcomes: not
specified as primary or
secondary. Pulmonary
function tests (FVC, FEV1,
TLC, PaO2, PaCO2,) DLCO,
6MWT; BDI; SGRQ
Length of follow-up:
10 weeks after the start
of the programme
6MET, 6-minute exercise test; BAI, Beck Anxiety Inventory; BDI, Baseline Dyspnoea Index; CPI, Composite Physiologic Index;
CQLQ, Cough Quality of Life Questionnaire; CRP, clinical, radiological, physiological; DLCOSB, diffusing capacity of the lung
for carbon monoxide, single breath; EQ-5D, European Quality of Life-5 Dimensions; FEV1, forced expiratory volume in
1 second; IPFCRN, Idiopathic Pulmonary Fibrosis Clinical Research Network; NHLBI, National Heart, Lung and Blood Institute;
PA – aO2, alveolar – arterial oxygen partial pressure; PANTHER, Prednisone, Azathioprine, and N-acetylcysteine: a study THat
Evaluates Response in idiopathic pulmonary fibrosis; PaO2, partial pressure of oxygen in arterial blood; PFT pulmonary
function test; PSS, Perceived Stress Scale; SF-36, Short-Form questionnaire-36 items; SpO2, peripheral oxygen saturation;
UCSDSBQ, University of California, San Diego, Shortness-of-Breath Questionnaire; VAS, visual analogue scale.
a Further details of inclusion and exclusion criteria for each included study can be seen in Appendix 5.
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Pharmacological interventions for mild to moderate idiopathic
pulmonary fibrosis
Azathioprine
One RCT compared azathioprine and prednisolone with placebo and prednisolone in 27 participants.70
Azathioprine and prednisolone use in the UK is limited; however, these interventions were included as they
are still occasionally used. Azathioprine was prescribed at a rate of 3mg/kg/day (to not exceed 200mg/day)
for the 12 months of the study. Prednisolone was commenced at 1.5mg/kg/day (to not exceed 100mg/day)
for 2 weeks, and was then decreased at a rate of 20mg/day until 40mg/day was reached, which was then
prescribed for 2 weeks. After this time, and depending on tolerance, this was subject to further decreases
of 5 or 10mg/day every 2 weeks. The maintenance dose was no more than 20mg/day for the remaining
months of the study. The primary outcome was not stated in this study, which measured FVC and survival at
follow-up (at least 12 months). The study did not provide details of any power calculation and, with the
small sample size, may be underpowered to detect an effect in the outcome measures reported.
Participants were included in this study if they had a diagnosis of IPF supported by lung biopsy and were
previously untreated and newly diagnosed. Criteria for progressive clinical disease were set as seen in
Table 4, with participants being required to meet one or more of these to be eligible for the trial. Exclusion
criteria can be seen in Table 4. However, prior to 2000, NSIP and IPF were classified together, and it is
possible that this study included patients who would be diagnosed with NSIP according to current criteria.
The mean age of participants was 58 years in the treatment group and 54 years in the comparison group.
There were a greater proportion of males in the comparator group (53% vs. 36% in the intervention
group). Participants had been diagnosed with IPF for approximately 23–26 months and their baseline
per cent predicted FVC was in the region of 65–70%. Baseline per cent predicted DLCO ranged from 40%
in the control group to 48% in the treatment group. No details were provided of the participants’
smoking histories.
Participants were able to cross over to the other treatment arm for a number of stated reasons
(see Appendix 5), including adverse events unresponsive to treatment, disease progression and participants
request. During the study, three participants crossed over because of clinical deterioration: two from the
placebo and prednisolone group, and one from the azathioprine and prednisolone group. Four participants
from each group died before completion. Results from this trial are reported in Assessment of effectiveness
of pharmacological interventions for mild to moderate idiopathic pulmonary fibrosis, Azathioprine.
BIBF 1120 (nintedanib)
One RCT71 investigated the use of a new agent for IPF, BIBF 1120 (referred to in the RCT as BIBF 1120,
also known as nintedanib). This trial was a dose-finding study assessing four doses of BIBF 1120 against a
placebo comparator. Currently, the treatment is unlicensed in IPF. It has been included in the current
review as it may become a relevant treatment in the future. Caution is, therefore, recommended in the
interpretation of these data as no confirmatory phase III trials are currently published.
Four randomised groups received doses of BIBF 1120 of 50mg/day, 100mg/day, 200mg/day and
300mg/day, respectively. A fifth group received matched placebo. Doses of BIBF 1120 were escalated
using a stepwise approach, beginning with the lowest dose of BIBF (or placebo) and each stepwise
increase being reviewed by a data monitoring committee before proceeding. For the purpose of the
current review, the 300mg/day group versus placebo group is described as this is the treatment group
that the trial authors concentrated on. Details of the lower-dose groups have been data extracted,
however, and can be seen in Appendix 5. Treatment was for 52 weeks. Four hundred and thirty-two
participants were randomised (four did not participate) to the five groups, with each group having 85 or
86 participants (see Table 4), meeting the requirement of the power calculation for this study. The primary
outcome in this study was the annual rate of decline in FVC. Secondary outcomes included lung function
tests [FVC, DLCO, peripheral oxygen saturation (SpO2) and TLC]; the 6MWT; QoL assessed by the SGRQ;
acute exacerbations; survival; and adverse events. End-point assessment was at 54 weeks.
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Individuals with a diagnosis of IPF that was consistent with the ATS/ERS 2000 criteria, and were diagnosed
within the previous 5 years, were eligible for inclusion. Participants were also required to be at least
40 years old and have a FVC that was at least 50% and a DLCO that was between 30% and 79%
predicted. Those with continuous oxygen supplementation, the likelihood of lung transplant or a life
expectancy of < 2.5 years were excluded (see Table 4 for further exclusion criteria that were specified in
this study). Baseline characteristics of the participants were observed to be similar between the treatment
groups. The mean age at baseline was approximately 65 years in all groups, and the proportion of males
ranged from 72% to 77%. Approximately 22–34% of participants had their diagnosis made on the basis
of results from a surgical lung biopsy and the time since diagnosis was in the region of 1.0–1.4 years.
Baseline lung function parameters ranged from 79.1% to 85.5% for per cent predicted FVC, and 3.7 to
3.9 mmol/minute/kPa for DLCO. Smoking history of participants was not reported and the 6MWT was
similarly not measured. The proportion of participants discontinuing study medication ranged from 16.3%
(200mg/day) to 37.6% (300mg/day) in the BIBF 1120-treated participants, and was 28.2% in the
placebo-treated participants. In addition, four individuals who were randomised in the study did not
participate, although the reasons were not provided. The study reports that 85.7% of discontinuations
were due to adverse events. The study also reports the numbers of participants who had their doses
reduced (see Appendix 5 for details). Results from this trial are reported in Assessment of effectiveness of
pharmacological interventions for mild to moderate idiopathic pulmonary fibrosis, BIBF 1120 (nintedanib).
N-acetylcysteine (alone or in combination)
Three RCTs investigated the use of NAC for IPF. In two RCTs, NAC was used in combination with
prednisolone and azathioprine,67,68 and in the other RCT NAC was given as a monotherapy in an inhaled
(nebulised) form.69 The combination of NAC, prednisolone and azathioprine is hereafter referred to as
‘triple therapy’. The use of triple therapy or inhaled NAC is limited in the UK; however, these were
included as they are occasionally used in clinical practice.
Demedts and colleagues67 randomised participants to two groups: triple therapy (n= 92), or placebo,
prednisolone and azathioprine (referred to here as ‘dual therapy’) (n= 90). The dose of NAC in this study
was 600mg, three times per day. Azathioprine was given at a rate of 2mg/kg/day and prednisolone
was given in a reducing dose from 0.5mg/kg/day for month 1, 0.4 mg/kg/day for month 2, 0.3 mg/kg/day
for month 3, until 10mg per day during months 4–6. This maintenance dose was then continued until
study completion after month 12. The Raghu and colleagues Idiopathic Pulmonary Fibrosis Clinical Research
Network (IPFCRN) 2012 trial68 randomised participants to three groups: NAC monotherapy, triple therapy
and placebo. The trial publication reports data for the triple-therapy (n= 77) and placebo (n= 78) groups
only, which were analysed at an interim time point (mean follow-up of 32 weeks). The triple-therapy arm
was discontinued at this point by the data safety and monitoring committee, with the comparison of NAC
monotherapy and placebo continuing to study end (anticipated publication was 2014). NAC was prescribed
at a dose of 600mg orally, three times each day, in this study. Azathioprine was prescribed at a maximum
of 150mg/day based on ideal weight, concurrent use of allopurinol, and thiopurine methyltransferase
(TPMT) activity. Prednisone was provided in a decreasing dose from 0.5mg/kg per day of ideal body weight
to 0.15mg/kg during 25 weeks. The duration of treatment was up to 60 weeks. In the Homma and
colleagues trial,69 NAC was given as an inhalation of 352.4mg diluted with saline to a total volume of 4ml,
twice per day via a nebuliser, to 51 participants. The comparison was made with a no-treatment group,
which the authors also described as a placebo group. The duration of treatment was 48 weeks in this trial.
The primary outcomes reported in these studies were similar, although different lengths of follow-up
were used. In the Demedts and colleagues trial,67 the primary outcome was the change in absolute
VC and DLCO. In the Raghu and colleagues IPFCRN 2012 trial,68 the primary outcome was change in FVC.
The Homma and colleagues trial69 has absolute change in FVC as their primary outcome. Secondary
outcomes in the Demedts and colleagues67 trial included per cent predicted VC, per cent predicted DLCO,
alveolar volume, dyspnoea, QoL and adverse events. The length of follow-up was 12 months. Secondary
outcomes in the Raghu and colleagues IPFCRN 2012 trial68 included rate of death, acute exacerbation rate,
time to disease progression, DLCO, 6MWT distance, QoL, dyspnoea and adverse events. The analysis was
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undertaken after 60 weeks. Secondary outcomes in the Homma and colleagues trial69 included 6MWT
distance, per cent predicted VC, TLC, DLCO, disease progression, dyspnoea and adverse events. End-point
assessment was at the end of treatment, 48 weeks. Of the three RCTs, only Demedts and colleagues67
had an adequate sample size based on power calculations (Homma and colleagues69 did not report
a calculation).
In the Demedts and colleagues67 trial comparing triple therapy with dual therapy, participants were eligible
for the study if they were aged between 18 and 75 years and had a histological or radiologic pattern typical
of UIP. In those aged < 50 years they also required evidence of IPF from either a surgical or a thoracoscopic
lung biopsy. The duration of IPF had to be > 3 months and the VC no greater than 80% predicted or a TLC
< 90% predicted, with a single breath DLCO of < 80% predicted. Other specific inclusion criteria can be
found in Table 4 and Appendix 5. Key exclusion criteria were contraindication or intolerance to the study
treatments, use of prednisolone or azathioprine in the month prior to randomisation, coexistent diseases,
or treatments that interfere with IPF. Table 4 and Appendix 5 provide further detail of exclusion criteria for
this trial. The Raghu and colleagues IPFCRN 2012 trial68 included only those aged between 35 and 85 years
with mild to moderate lung function impairment, defined as FVC at least 50% and DLCO at least 30%
of predicted values. Diagnosis of IPF was required using the ATS/ERS 2011 consensus criteria (full details of
inclusion criteria are provided in Table 4). Those with a forced expiratory volume in 1 second (FEV1)–FVC
ratio of < 0.65, a partial pressure of oxygen in arterial blood (PaO2) of < 55mmHg or residual volume
> 120% predicted were excluded. Other exclusion criteria included listed for lung transplantation, history
of other cardiac or liver diseases (see Table 4 for further details). In the Homma and colleagues69 trial,
participants were required to have well-defined IPF by the ATS/ERS 2011 criteria and Japanese criteria, aged
between 50 and 79 years, and classed as having stage I or stage II disease (details provided in Table 4).
Exclusion criteria can be seen in Table 4 and include improvement in symptoms during the preceding
3-month period, and use of a number of treatments for IPF.
Baseline characteristics of the participants in the Demedts and colleagues trial67 and the Raghu and
colleagues IPFCRN 2012 trial68 appear to be similar. Participants in the Homma and colleagues trial69 differ
from the other two trials on some factors. Mean age of participants was similar across all three trials, with a
range of 62–69 years. Similar proportions of male participants were also seen across the three trials, with
a range of 69–77%. The mean time since diagnosis of IPF was approximately 3 years for participants in both
arms of the Homma and colleagues69 trial. In the Raghu and colleagues IPFCRN 2012 trial,68 participants had
been diagnosed for approximately 1 year (0.9 years in the intervention arm vs. 1.1 years in the placebo arm).
The participants had been diagnosed with IPF for approximately 1.5 years in the Demedts and colleagues
trial67 (19.9 months in the intervention group and 18.9 months in the placebo group). Approximately 50% of
participants in the trial by Demedts and colleagues67 and the 2012 trial by Raghu and colleagues (IPFCRN)68
had been diagnosed on the basis of a lung biopsy, with similar rates between groups. The rates of lung
biopsy was not reported in the Homma and colleagues trial.69 The baseline per cent predicted VC was
64.76% in the intervention group and 66.57% in the placebo group of the Demedts and colleagues trial,67
and 69.3% in the intervention group and 72.1% in the placebo group of the Raghu and colleagues IPFCRN
2012 trial.68 The baseline per cent predicted FVC was higher in the Homma and colleagues trial,69 at 89.2%
in the intervention group and 88.7% in the control group. Predicted DLCO per cent at baseline was also
similar between participants in the two triple-therapy trials,67,68 with this ranging from 42.1% to 45.3%.
In the inhaled NAC study,69 the per cent predicted DLCO ranged between 64.4% and 72.3% in the control
and treated groups, respectively. Only the Raghu and colleagues IPFCRN 2012 trial68 reported baseline
6MWT, which was 362.0m in the triple-therapy arm and 368.9m in the placebo arm. Previous and current
smokers made up the largest proportion of participants in the three trials, with those having never smoked
being in the region of 31–39% in the Demedts and colleagues trial,67 26–30% in the Raghu and colleagues
IPFCRN 2012 trial68 and 24–26% in the Homma and colleagues trial.69
In the Demedts and colleagues trial,67 20% of participants randomised to treatment with triple therapy,
and 21% of participants randomised to treatment with dual therapy withdrew from the study (reasons
provided in Appendix 5). Twenty-seven randomised participants were not treated (12 in the triple-therapy
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arm and 15 in the double-therapy arm). In the majority of cases this was because the diagnosis was not
confirmed. Treatment modifications were permitted, with treatments being adapted according to the
preference of each centre. Standard therapy was changed for 13 participants in the triple-therapy arm and
11 in the double-therapy arm. The withdrawal rate in the Raghu and colleagues IPFCRN 2012 trial68 was
reported to be six (8%) participants from the triple-therapy arm and three (4%) from the placebo arm
(reasons provided for both groups in Appendix 5). Treatment discontinuations were also reported
and were seen to be statistically significantly higher in the triple-therapy arm [23 (30%) discontinued
prednisolone, 31 (40%) azathioprine and 24 (31%) NAC, with 20 (26%) discontinuing all three] than in
the placebo arm [three (4%) discontinued placebo prednisolone, four (5%) placebo azathioprine and four
(5%) placebo NAC, with three discontinuing all three placebos]; p< 0.001. In the Homma and colleagues69
trial, six participants in the inhaled NAC arm were excluded from the efficacy data set and eight in the
control group (reasons provided in Appendix 5). For the safety analysis, seven participants in the NAC
treated group and three in the control group were excluded (reasons given). In total, 38 (74.5%)
completed the study in the NAC group and 38 (77.6%) completed the study in the placebo group. No
details of dose discontinuations or modifications were provided. Results from these trials are reported in
Assessment of effectiveness of pharmacological interventions for mild to moderate idiopathic pulmonary
fibrosis, N-acetylcysteine (alone or in combination).
Pirfenidone
Four RCTs compared pirfenidone with placebo. Pirfenidone is currently available in the UK for patients
meeting certain criteria (see Chapter 1, Description of technologies under assessment). Two RCTs in Japan
used pirfenidone at a dose of 1800mg per day,65,66 and two RCTs in Europe used pirfenidone at a dose of
2403mg per day.62 These European trials were reported within one publication, and are referred to as the
Capacity 004 and Capacity 006 trials. The doses are understood to be different because the participants’
average body compositions are different between Japanese and European populations. In two of the RCTs,
participants were randomised to a third comparison arm: this was of pirfenidone 1197mg per day in
Capacity 004,62 and 1200mg per day in the trial by Taniguchi and colleagues.65 On advice from our
advisory group, the present review will concentrate on the outcomes for the higher doses (1800mg and
2403mg per day) from Taniguchi and colleagues65 and Capacity 004,62 respectively, as these are aligned
with the licensed indications for pirfenidone in these respective populations. Full details of the outcomes
for the lower doses can be seen in Appendix 5. Therapy was for 72 weeks in the two Capacity trials,62
52 weeks in the trial by Taniguchi and colleagues65 and 9 months in the trial by Azuma and colleagues.66
The primary outcome in the two Capacity trials was the change in per cent predicted FVC; in the
Taniguchi and colleagues trial, this was change in VC litres, and in the Azuma and colleagues trial
the primary outcome was the change in the lowest SpO2 during the 6MWT. Secondary outcomes
include progression-free survival (PFS), dyspnoea, 6MWT distance, and per cent predicted DLCO in the
Capacity trials,62 and PFS, TLC, DLCO and acute exacerbations in the Taniguchi and colleagues trial.65
Secondary outcomes in the Azuma and colleagues66 trial include VC, TLC, DLCO, disease progression, acute
exacerbations and QoL. All the included trials report data on adverse events and follow-up was undertaken
at the end of the treatment period in all four studies (72 weeks in the Capacity trials,62 52 weeks in the
Taniguchi and colleagues trial65 and 9 months in the Azuma and colleagues trial66). All four studies had
reasonable sample sizes; only the two Japanese RCTs reported details of a sample size calculation with the
sample size being adequately powered.
Eligibility criteria for the two Capacity trials were identical. Participants were eligible if they were aged
between 40 and 80 years, had their diagnosis of IPF within 48 months and had no evidence of improvement
in measures of disease severity over the preceding year. Participants were also required to have a FVC of at
least 50%, a predicted DLCO of at least 35%, either predicted FVC or DLCO of ≤ 90%, and the distance
walked on the 6MWT of at least 150m. Key exclusion criteria included evidence of obstructive airway
disease, connective tissue disease, alternative explanation for ILD, and those on the waiting list for a lung
transplant. In the Taniguchi and colleagues trial,65 participants were eligible for inclusion if they were aged
between 20 and 75 years and had IPF diagnosed using ATS/ERS guidelines and diagnostic criteria from Japan.
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Lung function criteria included oxygen desaturation with at least a 5% difference between resting SpO2 and
the lowest SpO2 during a 6MWT, and the lowest SpO2 during the 6MWT of at least 85% while breathing air.
Participants were excluded if they had a decrease in symptoms during the preceding 6 months, had used
any immunosuppressants or corticosteroids at a dose of > 10mg/day in the preceding 3 months, or had
coexisting lung conditions, a severe respiratory infection or clinical features suggestive of another form of an
interstitial pneumonia. Participants were eligible for inclusion in the Azuma and colleagues66 trial if they had
evidence on HRCT of definite or probable UIP, abnormal pulmonary function tests, bibasilar inspiratory
crackles, and increased serum levels of damaged-pneumocyte markers. Participants were required to be aged
between 20 and 75 years with a partial pressure of oxygen of at least 70mmHg at rest and SpO2 of ≤ 90%
during exertion. Exclusion criteria were similar to those in the Taniguchi and colleagues65 trial, i.e. a decrease
in symptoms during the preceding 6 months, had used in the preceding 3 months any immunosuppressant
agents or corticosteroids at a dose of > 10mg/day, or had coexisting lung conditions, a severe respiratory
infection or clinical features suggestive of another form of an interstitial pneumonia. In addition, participants
with uncontrolled diabetes or other comorbidities were excluded.
Some participants’ characteristics appear to differ between the four included studies (see Table 5).
Some 47–58% of participants in the Capacity trials62 were diagnosed within 1 year. In the Taniguchi and
colleagues65 trial, the proportion of participants diagnosed within the last year ranged between 35%
and 39%, and in the Azuma and colleagues66 trial this ranged between 17% and 28%. Larger proportions
of participants in these two trials were diagnosed 3 years or more before inclusion into the trials (36–40%
in Taniguchi and colleagues65 and 49–54% in the Azuma and colleagues trials,66 respectively). As per the
inclusion criteria for the Capacity trials,62 all participants would have been diagnosed within 4 years but
further details of the breakdown of time since diagnosis were not reported. Surgical lung biopsy rates were
lower in the two Japanese trials, in the region of 21–29% having had a lung biopsy. In the Capacity trials,
the proportion having had a lung biopsy ranged from 37% to 55%. Demographic characteristics of the
participants in the four trials, in terms of age and sex, appear to be reasonably similar. In the Capacity
trials,62 the mean age of participants was in the region of 66–68 years, in the Taniguchi and colleagues65
trial the mean age ranged from 64–65 years, and in the Azuma and colleagues trial66 the mean age was
approximately 64 years in both arms. The proportion of participants who were male was 72% in the
Capacity 006,62 between 68% and 75% in the Capacity 004,62 between 78% and 86% in the Taniguchi
and colleagues trial,65 and between 86% and 94% in the Azuma and colleagues66 trial.
Lung function tests at baseline indicated that participants in the Japanese trials were likely to have
more ‘mild’ IPF, with per cent predicted FVC ranging from 76% to 82% across the two studies65,66 and
per cent predicted DLCO ranging between 52% and 58%. These parameters ranged from 73% to 76%
for per cent predicted FVC, and 46% to 48% for per cent predicted DLCO in the two Capacity trials,62
although the differences between these two trials are not clinically significant and are within the error of
the tests. The distance walked on the 6MWT was in the region of 378–417m in the Capacity trials,62
but was not recorded at baseline in the two Japanese studies. The ratio of former or current smokers to
those who had never smoked was in the range of approximately 65% : 35% in the Capacity trials and
90% : 10% in the two Japanese trials (see Table 5 for full details).
In the two Capacity trials,62 numbers and reasons for withdrawal from the study and numbers and reasons
for discontinuation of treatment were provided. In Capacity 006, there were 13 (7.6%) withdrawals in the
pirfenidone group and nine (5.2%) in the placebo group. In Capacity 004, the numbers were 13 (7.5%) in
the pirfenidone 2403mg/day group, five (5.7%) in the pirfenidone 1197mg/day group and eight (4.6%)
in the placebo group. Reasons for withdrawal can be seen in Appendix 5. Treatments were discontinued
in 34 (19.9%) of the participants treated with pirfenidone in the Capacity 006 study, compared with
31 (17.9%) of the participants treated with placebo (most were for adverse events, but for full details of
reasons provided see Appendix 5). In Capacity 004, these numbers were 38 (21.8%) in the pirfenidone
2403mg/day group, 17 (19.5%) in the pirfenidone 1197mg/day group and 31 (17.8%) in the placebo
group. In both studies, dose modifications could be made but no details were reported of the number of
participants having modifications to the treatment dose. The Azuma and colleagues66 study report only
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that one participant from each group was excluded for violation of inclusion criteria (1.4% pirfenidone
and 2.8% placebo); no details of the number of participants with a dose modification were reported.
Treatments were discontinued in 16 (22.2%) of the participants treated with pirfenidone group and eight
(22.8%) in the placebo group (for reasons, see Appendix 5). In the high-dose pirfenidone arm of the study
by Taniguchi and colleagues,65 40 (37%) withdrew. The rates of withdrawal in the low-dose group and the
placebo group were 15 (27%) and 31 (30%), respectively. Reasons for withdrawal were provided and can
be seen in Appendix 5. In addition, eight participants were excluded from the study after randomisation.
Results from these trials are reported in Assessment of effectiveness of pharmacological interventions for
mild to moderate idiopathic pulmonary fibrosis, Pirfenidone.
Thalidomide
One randomised crossover trial compared thalidomide and placebo in 24 participants.55 Participants were
randomised to receive either thalidomide or placebo for 12 weeks, followed by a 2-week washout period and
then the alternative treatment for a further 12 weeks. Thalidomide was prescribed at a dose of 50mg by
mouth at bedtime, with the dose increased to 100mg if no improvement in cough occurred after 2 weeks.
This occurred in 21 of 22 participants receiving thalidomide and 23 of 23 participants receiving placebo.
The trial aimed to determine the efficacy of thalidomide in supressing cough. The primary outcome
measure was cough-specific QoL, measured by the Cough Quality of Life Questionnaire (CQLQ),
and secondary outcomes were cough measured by a visual analogue scale (VAS) and the SGRQ. No lung
function tests were reported. Sample size calculations were based on the CQLQ. No data on the minimum
clinically important difference in CQLQ or data on the variance in IPF patients were available; therefore,
calculations were based on the ability to recruit 20 participants, which would provide 80% power to
detect a difference of 4.67 units with a two-sided alpha error level of 5% in a two-treatment crossover
study, based on the assumption that the within-patient SD of the response variance would be 5.0 units.
Participants were included in this study if they had a clinical history consistent with IPF (symptom duration
≥ 3 months and ≤ 5 years) and chronic cough (defined as > 8 weeks’ duration, that adversely affected QoL
and was not due to other identifiable causes) and were aged > 50 years. Participants were also required to
have HRCT scans consistent with IPF or surgical lung biopsy demonstrating UIP, FVC between 40% and
90% predicted, TLC between 40% and 80% predicted, and DLCO between 30% and 90% predicted.
Exclusion criteria can be seen in Table 4. The mean age of participants was 68 years, and 78% were male.
The mean time from diagnosis was 1.7 years (range 0.25–4.9 years). Mean baseline per cent predicted
FVC was 70% and per cent predicted DLCO was 57%. No details of smoking history were provided.
Of the 24 participants randomised, 23 were treated and 20 completed both treatment periods. Incomplete
data on three participants who received placebo first but withdrew before completion of the thalidomide
period were also included in the analysis. Results from this trial are reported in Assessment of effectiveness
of pharmacological interventions for mild to moderate idiopathic pulmonary fibrosis, Thalidomide.
Pharmacological interventions for severe idiopathic
pulmonary fibrosis
Sildenafil
One RCT72 compared the use of sildenafil with a matched placebo in 180 participants (89 and 91 in
the two groups, respectively). Sildenafil was given orally at a dose of 20mg, three times per day, for a
12-week period. The primary outcome of this study was the presence or absence of an improvement of at
least 20% in the 6MWT distance at 12 weeks. Secondary outcomes included the degree of dyspnoea,
QoL, FVC, DLCO, and adverse events. The study was adequately powered to detect a difference in the
primary outcome.
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Individuals with a diagnosis of IPF that was consistent with the ATS/ERS 2000 consensus criteria, and with
an advanced stage of IPF (as defined by a DLCO of < 35% predicted), were eligible for inclusion. The study
excluded those with a 6MWT distance of < 50m at baseline, those receiving treatments for pulmonary
hypertension, those on the waiting list for a lung transplant or with a resting oxygen saturation of < 92%
while on supplemental oxygen therapy (see Table 4 for further exclusion criteria that were specified in this
study). Baseline characteristics of the participants were similar between the treatment groups (although
arterial oxygen saturation was reported to be statistically significant, the values reported appear to be
similar). The mean age or participants ranged between 68 and 70 years and the proportion of males was
75% in both groups. The time since diagnosis was in the region of 2 years. No details were provided
about the proportion who had received their diagnosis on the basis of results from a surgical lung biopsy.
Per cent predicted FVC was 55% in the sildenafil group and 59% in the placebo group and DLCO was
between 26% and 27% predicted. The distance walked on the 6MWT on the second test at baseline
was 246m in the sildenafil-treated group and 270m in the placebo group. Some 68–69% of participants
had a history of smoking (no further details provided).
There were eight (8.9%) participant dropouts from the sildenafil group (reasons provided in Appendix 5) and
six (6.6%) from the placebo group (see Appendix 5 for details). No details of treatment discontinuations or
dose modifications were reported. Results from this trial are reported in Assessment of effectiveness of
pharmacological interventions for severe idiopathic pulmonary fibrosis, Sildenafil.
Non-pharmacological interventions
Disease management programmes
One RCT74 investigated a disease management programme with a usual-care comparator group. This study
randomised 10 participant pairs (patients and carers) to the intervention and 11 to the comparison group.
The intervention consisted of a group programme which was held for 2 hours once a week for 6 weeks.
Participants and their caregivers attended the programme, which also included group exercises. The content
for the sessions was developed collaboratively by a pulmonary clinical nurse specialist, a psychiatric clinical
specialist and an advanced care planning instructor. The sessions included background information about
IPF, causes and treatments; controlling moods and feelings; planning for uncertainty; communication;
and symptom management. No details of the background of the group facilitator were provided. Usual-care
participants were seen by their clinical team at an interval of every 3–6 months with an optional monthly
support group and a nurse specialist available by telephone if required. Psychological counselling was
provided if indicated but not offered on a routine basis. Both groups received a book entitled ‘Feeling
Good: The New Mood Therapy’, which the treatment group referred to in their group exercises and the
usual-care control participants could read at their leisure. It is unclear when the follow-up occurred.
Outcomes measured in the RCT were measures of dyspnoea, anxiety, depression, stress and QoL. The study
is described as a pilot study and, therefore, no sample size calculation was undertaken.
To be eligible for the study, participants were required to be aged > 21 years and have a diagnosis of IPF
reflecting moderate IPF (stated as a per cent predicted FVC of 55–70%) or severe (stated as a per cent
predicted FVC of < 55%). The diagnostic criteria for IPF were not stated; however, all participants had
received either a surgical lung biopsy or HRCT. Participants’ ages ranged from 65 years in the intervention
arm to 67 years in the comparator arm. The duration of diagnosis of IPF was not reported. Seventy per cent
of participants in the intervention arm were male, compared with 82% of participants in the comparator
arm. There was a difference in the proportion of participants who had received a surgical lung biopsy
between groups, with 30% in the intervention group and 81% in the comparator group. Baseline per cent
predicted FVC was categorised into three groups: > 55%, 50–55% and < 50%. The proportions of
participants in these three categories were 80%, 10% and 10%, respectively, in the disease management
group, compared with 60%, 20% and 20%, respectively, in the usual-care controls. Baseline DLCO, 6MWT
distance and smoking history were not reported. Two (18%) participants in the control group discontinued
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the programme having either died or received a lung transplant. Results from this trial are reported in
Assessment of effectiveness of non-pharmacological interventions for severe idiopathic pulmonary fibrosis,
Disease management programmes.
Pulmonary rehabilitation
One RCT evaluated pulmonary rehabilitation, assessing this against a control group,73 and one CCT
compared inspiratory muscle training in addition to pulmonary rehabilitation (which was described as being
general body conditioning exercises) with the pulmonary rehabilitation alone (control).61 In the RCT by
Nishiyama and colleagues,73 30 participants were randomised to the two groups: 15 in the intervention
group and 15 in the control. The intervention lasted for 10 weeks and consisted of two sessions each
week focusing on exercise and peripheral muscle training, together with some educational lectures in one
RCT.73 The exercises included use of a treadmill, with supplemental oxygen given to maintain oxygen
saturation > 90%, strength training using elastic bands, arm raising and knee extensions. No details were
provided about the trainer. Details of the control intervention were not reported. In the Jastrzebski and
colleagues CCT,61 30 participants were randomised, with 16 in the intervention group and 14 in the
control group, and the intervention lasted for 12 weeks and was over two 6-week cycles; no other details
were translated.
The primary outcome was not described in these studies, which between them measured lung function
(including FVC, TLC and DLCO), 6MWT distance, dyspnoea and QoL.61
,73 End-point assessment was
at the end of the 10- and 12-week programmes, respectively. No sample size calculation was reported
in the study publication for the Nishiyama and colleagues RCT.73 Owing to limitations of the translation of
the Jastrzebski and colleagues61 study, it is unclear whether or not this was reported.
Individuals < 75 years of age with a diagnosis of IPF using the major criteria of the ATS/ERS 2002
consensus criteria – stable IPF (no infection of exacerbations in the previous 3 months) and shortness of
breath on effort – were eligible for inclusion in the Nishiyama and colleagues RCT.73 Having severe
comorbid illnesses, being on long-term oxygen supplementation and having been previously treated with
corticosteroids or immunosuppressents were reasons for exclusion (see Table 4 for further exclusion criteria
specified in this study). Jastrzebski and colleagues61 included those with IPF diagnosed by ATS/ERS criteria if
aged over 50 years, and by lung biopsy in those below 50 years. Participants had to have had IPF for at
least 2 years to be included in the trial, but those who had a duration of treatment of more than 2 years,
were receiving more than 20mg of prednisolone per day, or were using home oxygen therapy were
excluded. The mean age at baseline across the two studies61,73 ranged from 56 to 68 years, and the
proportion of males ranged from 60% to 92%. Surgical lung biopsy rates and the time since diagnosis
were not reported. Per cent predicted FVC ranged from 66.1% to 69.2% for the two trials.61,73 Per cent
predicted DLCO ranged from 38.1% to 59.4%, and the 6MWT distance from 385m to 487.4 m. In the
Jastrzebski and colleagues CCT,61 there were no differences between the groups at baseline. In the
Nishiyama and colleagues RCT,73 the groups were reported to be statistically significantly different at
baseline on the PaCO2 mmHg and the Baseline Dyspnoea Index (BDI) score. Two (13.4%) participants from
the pulmonary rehabilitation group withdrew prior to the start of the programme in the Nishiyama and
colleagues study73 and four participants did not complete the study in the Jastrzebski and colleagues
study.61 Results from these trials are reported in Assessment of effectiveness of non-pharmacological
interventions for severe idiopathic pulmonary fibrosis, Pulmonary rehabilitation.
Quality of included studies
The methodological quality of reporting varied across studies (Table 6). Six RCTs55,62,67,68,71 described an
adequate randomisation procedure which ensured both true random assignment to treatment groups
and adequate concealment of allocation. Five RCTs provided details of the methods of generating the
randomisation sequence, but details demonstrating adequate concealment of allocation were not
presented.65,66,70,72,74 The remaining two RCTs69,73 provided no details of the methods of generating the
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randomisation sequence or the allocation procedure used, and, consequently, are rated as unclear on
these quality factors. Without adequate published information, it is not possible to assess whether or not
there is a risk of selection bias in these studies, with the allocation sequence being open to possible
manipulation. As a non-RCT, the CCT was assessed as ‘no’ on these two factors.61
In 10 studies, the participants appeared to be similar across groups at baseline on key demographic and
prognostic characteristics.61,62,65–68,70–72 This question was not applicable to the crossover trial as all participants
received both interventions.55 In one RCT,69 baseline characteristics were presented for a subset of
participants only (those who provided end-point data) and therefore it was not possible to judge this factor.
In two RCTs,73,74 the groups were seen to have some differences in characteristics at baseline. Three of the
RCTs reported details suggesting adequate blinding of both care providers, participants and outcome
assessors;55,62 however, the authors of the crossover trial noted that thalidomide has characteristic effects that
might have alerted participants to the identity of the drug. Many of the studies were described as double
blind, but methods undertaken to ensure that this occurred were not presented. For the majority of studies,
therefore, these factors were marked as unclear. In two non-pharmacological RCTs,73,74 there was no double
blinding, which given the disparity in the treatment and comparator interventions is not surprising; however,
these trials do not discuss this. In the CCT, no details were provided in the translated methods; however, as
the translation of the paper was not in full this has been marked as unclear on these criteria.61 Details of
blinding for outcome assessors were not reported in 9 of the 14 studies,61,65–68,70–73 which may lead to
detection bias.
There was no imbalance in the rate of dropouts between treatment arms in eight of the RCTs. In four RCTs,
an imbalance was observed; however, the studies adequately explained the cause of the imbalance.55,68,73,74
One further RCT71 also had an imbalanced dropout rate but in this trial the information provided did not
allow an assessment of the reason for this. The CCT was considered unclear on this factor owing to
limitations in the translation. Information to judge the likelihood of selective reporting of outcomes was
not clear in nine studies. In one study71 the protocol was available and there was no evidence of selective
reporting of outcomes. Selective reporting of outcomes was evident in three RCTs67,69,74 and one CCT.61
Six RCTs62,68,70–72 reported using an intention-to-treat (ITT) analysis, with only one not providing the definition
used.68 In addition, one RCT did not use the term ITT but appeared to follow ITT principles.55 Six RCTs did
not report an ITT analysis and the CCT was considered unclear on this factor owing to limitations in the
translation. Reasons for missing data were adequately explained by nine RCTs,55,62,65–68,71,72,75 unclear in one
RCT70 and classed as inadequate in three RCTs as there was no discussion of numbers and reasons for any
attrition.69,73,74 The CCT was considered unclear on this factor owing to limitations in the translation.
One RCT55 used a crossover design and an assessment was made of the appropriateness of the design,
which can be seen in Appendix 5. A crossover design in this case was deemed to be appropriate despite
IPF being a disease that deteriorates over time because the RCT was of a short duration only.
Assessment of effectiveness of pharmacological interventions
for mild to moderate idiopathic pulmonary fibrosis
This section reports the results from the included studies of pharmacological interventions. Results are
described narratively and tabulated, and where appropriate have been displayed in forest plots. In most
cases these forest plots present the results from the different comparisons only. Where meta-analysis of
data was undertaken, this is indicated. Where BIBF 1120 is included the comparison is between the
300mg/day dose with placebo only. Likewise, pirfenidone includes the comparison between the high dose
and placebo only. Figures present treatments for mild IPF and severe IPF in some cases.
Meta-analyses that were undertaken are also presented within these figures where it was appropriate to
statistically pool data.
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Azathioprine
Survival
At 12 months, four participants in each treatment group of the Raghu and colleagues70 trial had died.
Survival estimates based on an additional observational period (presumed duration of 9 years) were
compared between those treated with azathioprine and prednisolone, and those treated with placebo and
prednisolone, and were reported in an unadjusted and age-adjusted data set (Table 7). The HR of survival
in the unadjusted set was 0.48 (95% CI 0.17 to 1.38), a non-statistically significant effect (p= 0.16). In the
age-adjusted analysis, the azathioprine group were seen to show a survival advantage over those treated
with placebo (HR 0.26, 95% CI 0.08 to 0.88), suggesting a 64% reduction in the risk of death with
azathioprine; however, it is unclear if this is statistically significant (two p-values are reported: p= 0.02
using a large sample approximation and p= 0.05 using the randomisation test). Moreover, the likely
inclusion of participants with NSIP may explain this treatment effect, and the small sample size and
potential risk of bias in this study should be considered when interpreting these data.
Forced vital capacity
There was no significant difference in FVC per cent predicted at 12 months (difference of 4.8%; p= 0.87)
or in the proportion of participants categorised as ‘improved’ (Table 8 and Figure 2).
TABLE 7 Overall survival: azathioprine
Study
details
Estimated overall survival Mortality
Outcome Arm Mean At 12 months
Raghu
et al.70
Survival, all patients Prednisone and placebo (n= 13) NR 4
Prednisolone and azathioprine (n= 14) NR 4
HR (95% CI); p-value 0.48 (0.17 to 1.38);
p= 0.16
Survival, all patients
adjusted for age
Prednisone and placebo (n= 13)
Prednisolone and azathioprine (n= 14)
HR (95% CI); p-value 0.26 (0.08 to 0.88);
p= 0.02
NR, not reported.
TABLE 8 Forced vital capacity outcomes: azathioprine
Study Outcome
Interventions
Difference between
groups
Prednisone/azathioprine
(n= 10)
Prednisone/placebo
(n= 9)
Raghu
et al.70
Change in per cent predicted
FVC (SE) at 12 months
6.5 (5.3) 1.7 (7.4) 4.8%;a p= 0.87
Per cent predicted FVC (%)b
Improved 5 (35.7) 3 (23.1) % improved; p= 0.68
Unchanged 3 (21.4) 3 (23.1)
Deteriorated 6 (42.9) 7 (53.8)
SE, standard error.
a Calculated by reviewer.
b Improvement was defined as at least a 10% improvement in FVC, deteriorated was defined as at least a 10%
decrement, and any lesser degree of change were categorised as unchanged.
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Diffusing capacity of the lung for carbon monoxide
There was no significant difference in DLCO per cent predicted at 12 months (difference 6.4%; p= 0.70),
or in the proportion of participants categorised as ‘improved’ (Table 9 and Figure 3).
Other secondary outcomes
Raghu and colleagues70 also report the partial pressure of oxygen as an outcome measure, the results of
which can be found in Appendix 5.
Adverse events
Adverse events reported in the Raghu and colleagues70 trial can be seen in Table 10. Overall, there
were 28 adverse events in the azathioprine-treated group and 25 in the placebo-treated group. More
participants treated with placebo reported a subjective adverse event (gastrointestinal or neuropsychiatric)
than those treated with azathioprine, and more azathioprine-treated participants had vertebral fractures.
All other adverse events were reasonably well matched between the two groups, although this is based on
observation of the data only.
Summary
One small study with an unclear risk of bias provided data on the effectiveness of azathioprine and
prednisolone compared with placebo and prednisolone. This trial may include participants who would be
diagnosed with NSIP according to current criteria. Treatment with azathioprine and prednisolone led to an
improvement in survival compared with placebo and prednisolone when this was age-adjusted, but did not
lead to improvements in measures of lung function. Azathioprine did not appear to lead to significant
adverse events when compared with placebo over the 12-month duration of this study. Caution is required
in the interpretation of these data in the light of the small sample size, potential risk of bias and possible
inclusion of NSIP.
TABLE 9 Diffusing capacity of the lung for carbon monoxide outcomes: azathioprine
Study Outcome
Interventions
Difference between
groups
Prednisone/azathioprine
(n= 10)
Prednisone/placebo
(n= 9)
Raghu
et al.70
Change in per cent predicted
DLCO (SE)
7.3 (5.3) 0.9 (5.7) 6.4%;a p= 0.70
Per cent predicted DLCO (%)
Improvedb 3 (21.4) 2 (15.4) % improved; p= 1.00
Unchangedb 6 (42.9) 5 (38.5)
Deterioratedb 5 (35.7) 6 (46.2)
SE, standard error.
a Calculated by reviewer.
b Improvement defined as at least a 10% improvement in DLCO, deteriorated as at least a 10% decrement in DLCO, and
any lesser degree of change as unchanged.
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BIBF 1120 (nintedanib)
As discussed above, the narrative synthesis in the present report concentrates on the BIBF 1120 300 mg/day
treatment group, compared with placebo, reported in the Richeldi and colleagues71 publication. Full details
of outcomes from the lower-dose groups and their comparisons with placebo can be found in Appendix 5.
Forced vital capacity
The annual rate of decline in FVC was the primary outcome in this study. After 54 weeks this was
lower (0.06 l) in the BIBF 1120 300mg/day-treated group than in the placebo-treated group (0.19 l).
The difference-between-groups (0.13 l) comparison was not statistically significant (p= 0.06) using the
prespecified closed testing procedure for multiplicity. With hierarchical testing this was statistically
significant (p= 0.01). A statistically significant difference was seen between the absolute change in FVC at
54 weeks between BIBF 1120 300mg/day and placebo (p= 0.001), and the absolute change in per cent
predicted FVC at 54 weeks between the two groups (p< 0.001), as seen in Table 11. Figures 2 and 4
show, graphically, the mean change in per cent predicted FVC and in FVC litres, respectively. The
proportion of participants with a reduction in mean FVC of > 10% or 200ml was lower in the BIBF 1120
300mg/day group than that seen in the placebo group (23.8% vs. 44%, respectively). This was shown to
be statistically significantly different between groups (p= 0.004) and is displayed in Figure 5. It is unclear
whether this was calculated as an absolute or relative change in FVC.
TABLE 10 Adverse events: azathioprine
Adverse events Prednisone and azathioprine (n= 14) Prednisone and placebo (n= 13)
Any 28 25
Subjective
Gastrointestinal 3 6
Neuropsychiatric 1 4
Objective
Elevated liver enzymes 1 0
Vertebral fractures 3 0
Acne 0 1
Cushingoid features 5 4
Hypertension 2 1
Diabetes treatment (oral) 2 3
Diabetes treatment (insulin) 2 0
Congestive heart failure 0 2
Myocardial infarction 1 1
Urosepsis 1 1
Bacterial pneumonia 2 0
Herpes zoster 1 0
Cataracts 1 1
Myopathy 2 1
Peptic ulcer disease 1 1
Pancytopenia 0 0
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Diffusing capacity of the lung for carbon monoxide
The Richeldi and colleagues71 publication stated that it measured DLCO as an outcome measure; however,
no data were reported at follow-up for this outcome.
Six-minute walk test
The Richeldi and colleagues71 publication stated that it measured the 6MWT as an outcome measure;
however, no data were reported at follow-up for this outcome.
Other secondary outcomes
Richeldi and colleagues71 also reported the oxygen saturation and the TLC as outcome measures, the
results of which can be found in Appendix 5.
Acute exacerbations
The incidence of acute exacerbations was statistically significantly lower in the BIBF 1120 300mg/day-
treated participants than in the placebo-treated participants in the Richeldi and colleagues trial (Table 12).71
The rates were 15.7 per 1000 patient-years in the placebo group and 2.4 per 1000 patient-years in the
BIBF 1120 300mg/day-treated group (p= 0.02). This equated to a RR of 0.16 (95% CI 0.03 to 0.70)
in favour of treatment.
St George’s Hospital Respiratory Questionnaire
The total score, symptoms score, activity score, and impacts score on the SGRQ were reported as change
from baseline scores at follow-up (54 weeks) in the Richeldi and colleagues71 trial. As can be seen in
Table 13, the change scores were statistically significantly different between the BIBF 1120 300mg/day
group and placebo group for the change in total score, symptom score and activity score. No statistically
significant effect of BIBF 1120 was seen on the impacts score of the SGRQ.
The authors stated in the publication that the minimally clinical important difference (MCID) in total score
on the SGRQ is 4 points, and they analysed the proportion of participants improving by at least 4 points.
The proportions improving by at least four points on the SGRQ total score was 29.1% in the BIBF
1120 300mg/day-treated group compared with 16.1% in the placebo-treated group (p= 0.03). It should
be noted that elsewhere in the publication it states that the MCID is 5–8 points. For a fuller description
of the SGRQ, see Chapter 4, Systematic review of health-related quality of life studies.
TABLE 12 Acute exacerbation rate: BIBF 1120
Study Outcome
Interventions
Difference between
groups
BIBF 1120 300mg/day
(n= 85)
Placebo
(n= 85)
Richeldi et al.
201171
Incidence of acute exacerbations,
n per 100 patient-years
2.4 15.7 13.3;a p= 0.02
Incidence of acute exacerbations,
RR (95% CI) compared with placebo
0.16 (0.03 to 0.70) NA
NA, not applicable.
a Calculated by reviewer.
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Deaths
The number of deaths from respiratory causes was reported in the Richeldi and colleagues71 trial. These
were two (2.4%) in the BIBF 1120 300mg/day arm and eight (9.2%) in the placebo arm (Table 14). The
paper reports that the difference between groups was not statistically significant (p= 0.06).
Deaths from any cause were more similar between the two groups, with seven (8.2%) participants dying
from any cause in the BIBF 1120 300mg/day treatment arm and nine (10.3%) in the placebo-treated arm
(p-value not reported, paper stated not significant).
TABLE 14 Adverse events: BIBF 1120
Adverse events BIBF 1120 300mg/day (n= 85) Placebo (n= 85)
Deaths from respiratory causes, n 2a 8
Deaths from any cause, n 7 9
Adverse events, any, n (%) 80 (94.1) 77 (90.6)
Adverse events occurring in > 10%
in any study arm, n (%)
Diarrhoea 47 (55.3) 13 (15.3)
Cough 8 (9.4) 17 (20.0)
Nausea 20 (23.5) 8 (9.4)
Bronchitis 9 (10.6) 11 (12.9)
Dyspnoea 6 (7.1) 11 (12.9)
Progression of IPF 4 (4.7) 11 (12.9)
Vomiting 11 (12.9) 4 (4.7)
Upper abdominal pain 10 (11.8) 3 (3.5)
Nasopharyngitis 6 (7.1) 11 (12.9)
URTI 7 (8.2) 13 (15.3)
Headache 11 (12.9) 5 (5.9)
Fatigue 9 (10.6) 7 (8.2)
Decreased appetite 13 (15.3) 0
Severe adverse events 19 (22.4) 20 (23.5)
Serious adverse events 23 (27.1) 26 (30.6)
Fatal adverse events 1 (1.2) 12 (14.1)
Adverse events requiring hospitalisation 23 (27.1) 22 (25.9)
Drug-related adverse event 55 (64.7) 25 (29.4)
Adverse events leading to discontinuation 26 (30.6) 22 (25.9)
Respiratory, thoracic and mediastinal disorders 4 (4.7) 10 (11.8)
GI disorders (see also below) 14 (16.5) 2 (2.4)
Infections and infestations 0 6 (7.1)
Cardiac disorders 0 6 (7.1)
continued
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Adverse events
The study reports on a range of adverse events (see Table 14). The proportion with any adverse event was
similar across both groups, with 94.1% of those treated with BIBF 1120 300mg/day and 90.6% of the
placebo-treated group having an adverse event recorded. On observation of the data, more participants
treated with BIBF 1120 300mg/day had diarrhoea, nausea, vomiting, abdominal pain, headache or
decreased appetite (see also specific gastrointestinal events in Table 14), and more participants treated
with placebo had upper respiratory tract infection (URTI) and nasopharyngitis. The rate of severe adverse
events and serious adverse events appears to be similar between the two groups, as is the rate of
hospitalisation due to adverse events (see Table 14). More fatal adverse events occurred in the placebo
group than the BIBF 1120 300mg/day-treated group. Adverse events categorised as drug-related
occurred in 64.7% of BIBF 1120 300mg/day-treated participants, compared with 29.4% of
placebo-treated participants.
Summary
BIBF 1120 at 300mg/day led to more favourable outcomes than placebo on some measures of the FVC,
rate of acute exacerbations and the number of deaths. The primary outcome in this study was the annual
rate of decline in FVC, and the observed benefit did not reach statistical significance. QoL as reported on
the SGRQ was generally favourable in those treated with BIBF 1120 300mg/day. Serious adverse event
rates and hospitalisation rates appear to be similar between the two groups. BIBF 1120 300mg/day led to
more gastrointestinal events than placebo. Treatment with placebo led to more respiratory events. Risk
of bias was low in this study. This study also randomised participants to three other treatment groups
according to the dose of BIBF 1120 and results for these can be seen in Appendix 5.
TABLE 14 Adverse events: BIBF 1120 (continued )
Adverse events BIBF 1120 300mg/day (n= 85) Placebo (n= 85)
GI adverse events, n (%)
Any 63 (74.1) 27 (31.8)
Severe diarrhoea 4 (4.7) 0
Serious diarrhoea 3 (3.5) 0
Serious GI, % 4.7% 0
Severe GI, % 5.9% 0
Related to treatment (any GI) 48 (56.5) 11 (12.9)
Related to treatment (diarrhoea) 36 (42.4) 5 (5.9)
Reduced dose due to GI adverse event 9 (10.6) 0
Discontinuation due to any GI adverse event 14 (16.5) 2 (2.4)
Discontinuation due to diarrhoea 10 (11.8) 0
Mean number days with diarrhoea, n 85.4 6.5
Discontinuation due to nausea, % 4.7% 0%
Discontinuation due to vomiting, % 2.4% 1.2%
GI, gastrointestinal; URTI, upper respiratory tract infection.
a p= 0.06.
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N-acetylcysteine alone or in combination
Progression-free survival
In the Raghu and colleagues IPFCRN 2012 trial,68 the outcome of time to death or disease progression,
defined as a relative drop in FVC of > 10%, was reported. Although not labelled as such, this has been
considered as PFS as this definition has been applied in other included studies (see Assessment of
effectiveness of pharmacological interventions for mild to moderate idiopathic pulmonary fibrosis,
Pirfenidone) to mean PFS. The HR for the estimate of PFS between the triple-therapy group and the
placebo group was not reported in the trial. The publication states that there was no statistically significant
difference in the risk of death or disease progression between groups; however, no p-value was reported
to support this. The Kaplan–Meier plot was published in the study article.
Progression-free survival was not reported as an outcome in the Demedts and colleagues67 trial comparing
triple therapy with double therapy, or the trial by Homma and colleagues69 comparing inhaled NAC
with control.
Time to death/time to death or hospitalisation
The HR for time to death or the HR for time to death or disease progression was not reported in the
Raghu and colleagues IPFCRN 2012 trial.68 The Kaplan–Meier plots were published in the study article.
In the same study,68 the HR for time to death or hospitalisation was reported to be 12.11 (95% CI 2.83 to
51.85, p< 0.0001), indicating a shorter time to death or hospitalisation in the triple-therapy-treated population.
Outcomes relating to time to death or hospitalisation were not reported in the Demedts and colleagues67
trial comparing triple therapy with double therapy, or the trial by Homma and colleagues69 comparing
inhaled NAC with control.
Discussion of all-cause mortality, respiratory mortality and any-cause mortality or hospitalisation is
provided below.
Forced vital capacity
Demedts and colleagues67 compared triple therapy with double therapy and assessed the VC in litres
and the VC per cent predicted. At 12 months it can be observed that the change in VC was lower in the
triple-therapy group than the double-therapy group; however, no statistical analysis of the difference
between groups was undertaken (Table 15). Figure 4 presents results graphically where it can be
seen that treatment with triple therapy is approaching statistical significance on this outcome (95% CI
touches the line of no effect). A statistically significant difference in the mean VC litres between groups
in favour of triple therapy at 12 months was observed (difference 0.18; p= 0.02) when using the least
squares (LS) mean method. The final value per cent predicted VC was also shown to be statistically
significantly different between groups at 12 months when using the LS mean method (with the LS mean
the difference was 4.79%; p= 0.02), but not when calculating the mean difference using the unadjusted
data (see Table 15 and Figure 2, calculated by reviewer). The mean change from baseline in VC per cent
predicted was not reported. All of the analyses were undertaken using the last observation carried forward
(LOCF) approach.
After a mean follow-up of 32 weeks of treatment, no difference in mean change in FVC litres between
triple therapy and placebo in the Raghu and colleagues IPFCRN 201268 trial was observed (p= 0.85)
(see Table 15 and Figure 4).
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Inhaled NAC therapy did not confer a statistically significant benefit over no-treatment control on FVC
litres in the Homma and colleagues69 trial (difference 60ml; p= 0.27) (see Table 15 and Figure 4). In this
study, data were dichotomised into two categories: those with a decline of < 10% FVC litres, and those
with a decline of > 10% FVC litres. It is uncertain if these were a priori groups or post hoc. Data were not
presented for the proportions within the treated and placebo groups; however, the differences between
groups in these two categories were presented (see Table 15), but these did not reach the threshold for
statistical significance. The results of this study need to be interpreted cautiously given the uncertain risk of
bias identified when assessing the study quality.
TABLE 15 Forced vital capacity outcomes: NAC therapies
Study Outcome
Interventions
Difference between
groups (95% CI)
NAC, azathioprine,
prednisolone (n= 80)
Placebo, azathioprine,
prednisolone (n= 75)
Demedts et al.
200567
VC, mean (SD), l, at
12 months, LOCF
n= 71
2.22 (0.77)
n= 68
2.17 (0.71)
VC, l, mean change at
12 months, LOCF
(95% CI)
–0.06 (–0.14 to 0.02) –0.19 (–0.29 to –0.09) 0.13a
VC, l, LS mean (SD),
LOCF at 12 months
n= 71
2.27 (0.05)
n= 68
2.10 (0.05)
0.18 (0.03 to 0.32);
p= 0.02
VC, % predicted, mean
(SD) at 12 months, LOCF
63.14 (19.98) 61.59 (15.17) Not reported
VC, % predicted, LS
mean (SD) at 12 months,
LOCF
65.13 (1.85) 60.34 (1.85) 4.79 (0.80 to 8.77);
p= 0.02
NAC/prednisolone/
azathioprine (n= 77) Placebo (n= 78)
Raghu et al.
IPFCRN 201268
FVC change (95% CI), l,
at interim analysis
–0.24 (–0.33 to –0.15) –0.23 (–0.32 to –0.14) –0.01 (–0.14 to 0.11);
p= 0.85
NAC (n= 38) Control (n= 38)
Homma et al.
201269
Mean FVC (SD), l,
at 48 weeks
2.67 (0.84) 2.51 (0.68) Not stated
Mean change (SD) in
FVC, ml, at 48 weeks
–90ml (300) –150ml (200) 60ml; p= 0.2661
% with a decline of
> 10% FVC at 48 weeks
Data not shown Data not shown 36.4% lower in the
NAC group than
control
% with a decline of
< 10% in FVC at
48 weeks
Data not shown Data not shown 14.8% greater in the
NAC group than
control; p= 0.42
a Calculated by reviewer.
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Diffusing capacity of the lung for carbon monoxide
All three included trials using NAC therapy alone or in combination recorded DLCO (Table 16, see Figures 3
and 6). This was reported as the mean change in mmol/minute/mmHg and per cent predicted DLCO in the
Demedts and colleagues67 trial of triple therapy versus double therapy and the Homma and colleagues69
trial of inhaled NAC versus control, and DLCO mmol/minute/mmHg only in the Raghu and colleagues
IPFCRN 201268 trial of triple therapy versus placebo. Triple therapy led to a smaller decline in DLCO mmol/
minute/mmHg after 12 months than double therapy in the Demedts and colleagues67 study; however,
statistical analysis was not undertaken on the difference between groups on these change scores. The
mean value of DLCO (see Table 16) was statistically compared between groups and showed a statistically
significant difference in favour of triple therapy (difference 0.75, 95% CI 0.27 to 1.23; p= 0.003) when
using the LS mean method. On the per cent predicted DLCO, a similar pattern was observed in the mean
values, where there was a difference between groups of 5.08% (95% CI 1.17% to 8.99%, p= 0.01).
In the Raghu and colleagues IPFCRN 201268 study, the difference in DLCO change from baseline (corrected
for haemoglobin) was not statistically significant (difference 0.06; p= 0.93) between triple therapy and
placebo. Homma and colleagues69 did not report data on these outcomes; they reported only that there
were no statistically significant differences between groups at 48 weeks.
Six-minute walk test
The 6MWT was reported in two of the RCTs evaluating NAC68,69 (Table 17). The difference between
groups in the change in the distance walked on the 6MWT favoured placebo in the Raghu and colleagues
IPFCRN 201268 trial, although the difference was not statistically significant between the two groups.
TABLE 16 Diffusing capacity of the lung for carbon monoxide: NAC therapy studies
Study Outcome
Interventions
Difference between
groups
NAC, azathioprine,
prednisolone (n= 80)
Placebo, azathioprine,
prednisolone (n= 75)
Demedts et al.
200567
DLCO mean (SD)
mmol/minute/kPa at
12 months, LOCF
n= 68
3.74 (1.99)
n= 63
3.20 (1.26)
DLCO mmol/minute/kPa
mean change at
12 months, LOCF
(95% CI)
–0.11 (–0.47 to 0.25) –0.70 (–0.95 to –0.45)
DLCO mmol/minute/kPa,
LS mean (SD), LOCF
n= 68
3.85 (0.17)
n= 63
3.10 (0.18)
0.75 (0.27 to 1.23);
p= 0.003
DLCO per cent predicted,
mean at 12 months,
LOCF
40.85 (14.85) 38.75 (14.75) Not reported
DLCO per cent predicted,
LS mean at 12 months,
LOCF
41.6 (1.35) 36.52 (1.45) 5.08 (1.17 to 8.99);
p= 0.01
NAC/prednisolone/
azathioprine (n= 77) Placebo (n= 78)
Raghu et al.
IPFCRN 201268
DLCO corrected, change
from baseline
–1.72 (–2.73 to –0.71) –1.66 (–2.65 to –0.67) –0.06 (–1.48 to 1.35);
p= 0.93
NAC (n= 38) Control (n= 38)
Homma et al.
201269
DLCO Data not shown Data not shown States NS
DLCO per cent predicted Data not shown Data not shown States NS
NS, not significant.
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The Homma and colleagues69 study comparing inhaled NAC with placebo reported that the distance
walked was not statistically significantly different between groups, although the data were not provided in
the study publication.
Lowest SpO2 during the 6MWT was also stated to be an outcome in the Homma and colleagues69 trial;
however, data were not reported. The publication states there were no statistically significant differences
between those treated with inhaled NAC and those treated as controls (p-value not reported).
Other secondary outcomes
Other outcomes reported in these studies include TLC; clinical, radiological, physiological (CRP) scoring
system; exercise performance; and HRCT outcome. The results can be found in Appendix 5.
Dyspnoea
Dyspnoea was reported as an outcome in the three included RCTs investigating NAC therapy alone or in
combination (Table 18). Different measures of dyspnoea were used. In the Demedts and colleagues trial67
of triple therapy compared with dual therapy, a dyspnoea score which measured breathlessness on a scale
TABLE 17 Six-minute walk test: NAC interventions
Study Outcome
Interventions
Difference between
groups
NAC/prednisolone/
azathioprine (n= 77) Placebo (n= 78)
Raghu et al.
IPFCRN 201268
6MWT at baseline 362.0 (113.0) 368.9 (117.3)
6MWT distance change
from baseline, m
–93.0 (–142.0 to –44.1) –73.6 (–118.4 to –28.7) –19.5 (–85.9 to 46.9);
p= 0.56
NAC (n= 38) Control (n= 38)
Homma et al.
201269
6MWT distance Data not presented Data not presented States NS
NS, not significant.
TABLE 18 Dyspnoea outcomes: NAC
Study Outcome
Interventions
Difference between
groups
NAC, azathioprine,
prednisolone (n= 80)
Placebo, azathioprine,
prednisolone (n= 75)
Demedts et al.
200567
Dyspnoea scorea at
12 months, LS mean (SD),
LOCF
8.88 (0.49) 9.20 (0.51) –0.32 (–1.72 to 1.09);
p= 0.65
NAC/prednisolone/
azathioprine (n= 77) Placebo (n= 78)
Raghu et al.
IPFCRN 201268
USCDSBQb 10.6 (3.60 to 17.6) 8.01 (1.67 to 14.3) 2.57 (–6.87 to 12.0);
p= 0.59
NAC (n= 38) Control (n= 38)
Homma et al.
201269
% improved or stable
dyspnoea
86.8% (33/38)
Two improved,
31 stable
84.2% (32/38)
One improved,
31 stable
p= 1.00
UCSDSBQ, University of California, San Diego, Shortness-of-Breath Questionnaire.
a Dyspnoea scores range from 0 to 20.
b UCSDSBQ total score ranges from 0 to 120, with higher scores indicating greater shortness of breath.
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from 0 to 20 was used. On this measure, higher scores indicate worse dyspnoea. In the Raghu and
colleagues IPFCRN 2012 trial68 of triple therapy compared with placebo, the USCDSBQ scale was used.
This scale rates shortness of breath on a scale from 0 to 120, with higher scores indicating greater
breathlessness. The Homma and colleagues69 study reported the proportion of participants with improved
or stable dyspnoea (definition not provided). Dyspnoea scores were not statistically significantly different
between triple therapy and double therapy in the Demedts and colleagues trial (p= 0.65)67 or between
triple therapy and placebo in the Raghu and colleagues IPFCRN 2012 trial68 (see Table 18). The proportion
of participants with improved or stable dyspnoea were similar in the inhaled NAC therapy arm and the
control arm in the Homma and colleagues trial69 (p= 1.00).
Acute exacerbations
The rate of acute exacerbations were reported in the Raghu and colleagues IPFCRN 201268 trial
comparing triple therapy with placebo (Table 19). There were five (6%) acute exacerbation incidents in
the triple-therapy group and no incidents in the placebo group. Analysis of the difference between groups
was not reported. Acute exacerbations were not reported as an outcome in the Homma and colleagues69
study; however, the number of participants excluded from the analysis because of acute exacerbations was
recorded. These were four in the placebo group and one in the inhaled NAC group.
Quality of life
Demedts and colleagues67 and the Raghu and colleagues IPFCRN 201268 trial assessed QoL using the
SGRQ. However, results were not reported by Demedts and colleagues;67 therefore, no conclusions can be
made regarding QoL comparing triple therapy with double therapy. As noted previously, the SGRQ has a
total score and three subscales; each scale ranges from 0 to 100, with lower scores indicating better QoL.
The Raghu and colleagues IPFCRN 201268 group reported all scales of the SGRQ and also assessed QoL by
the Short Form questionnaire-36 items (SF-36) and the European Quality of Life-5 Dimensions (EQ-5D).
The SF-36 measures functional health and well-being scores on eight scales that correlate with two
aggregate scores (physical and mental health). Each score ranges from 0 to 100, with a higher score
indicating better function. Scores are normalised to a mean (SD) of 50 (10). The EQ-5D measures general
QoL on a self-report questionnaire on a scale of 0 to 1.00 (higher score indicates better QoL) and on a VAS
(described in the Raghu and colleagues IPFCRN 2012 trial as a thermometer score) with a range of 0 to
100 (higher indicates better QoL). For a fuller description of the SF-36 and EQ-5D, see Chapter 4,
Systematic review of health-related quality of life studies. Homma and colleagues did not report QoL as
an outcome.
Full results can be seen in Table 20. In the Raghu and colleagues IPFCRN 201268 trial, the change in SGRQ
scores in those treated with triple therapy was lower (better) than in those treated with placebo; however,
the differences were not statistically significant on total score or two of the subscales (only the symptoms
score was statistically significantly different; p= 0.014). On the SF-36 in this study, the difference between
groups on the physical score was not statistically significant (p= 0.58). On the SF-36 mental score, the
change from baseline score was smaller (better) in the triple-therapy group than the placebo group, and
the difference was statistically significant (p= 0.027). On the two EQ-5D indices, the difference in changes
in scores between the two groups was not statistically significant (see Table 20).
TABLE 19 Acute exacerbations: NAC therapy
Study Outcome
Interventions
Difference between
groups
NAC/prednisolone/
azathioprine (n= 77) Placebo (n= 78)
Raghu et al.
IPFCRN 201268
Acute exacerbation rate 5 (6%) 0 Not reported
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TABLE 20 Quality of life outcomes: NAC therapy
Study
Outcome (outcomes all
assessed at interim
analysis, up to 60 weeks)
Interventions
Difference between
groups
NAC/prednisolone/
azathioprine (n= 77) Placebo (n= 78)
Raghu et al.
IPFCRN 201268
SGRQa total score (SD) at
baseline
38.7 (17.4) 39.4 (17.4)
SGRQ total score (95% CI)
change
4.29 (–1.14 to 9.73) 7.50 (2.57 to 12.4) –3.20 (–10.5 to 4.13);
p= 0.39
SGRQ symptoms score (SD)
at baseline
49.4 (21.1) 45.6 (21.8)
SGRQ symptoms score
(95% CI) change
–4.42 (–11.9 to 3.1) 8.31 (1.47 to 15.2) –12.7 (–22.9 to –2.61);
p= 0.014
SGRQ activity score (SD) at
baseline
51.1 (19.0) 52.7 (21.0)
SGRQ activity score
(95% CI) change
7.33 (1.05 to 13.6) 10.3 (4.66 to 16.0) –2.99 (–11.4 to 5.46);
p= 0.49
SGRQ impacts score (SD) at
baseline
27.8 (19.2) 28.8 (17.3)
SGRQ impacts score
(95% CI) change
5.23 (–0.80 to 11.3) 5.80 (0.34 to 11.27) –0.57 (–8.71 to 7.57);
p= 0.89
SF-36b aggregate physical
score (SD) at baseline
40.3 (9.8) 40.6 (9.3)
SF-36 aggregate physical
score (95% CI) change
–4.18 (–7.40 to –0.97) –2.96 (–5.90 to –0.02) –1.23 (–5.58 to 3.13);
p= 0.58
SF-36 aggregate mental
score (95% CI) at baseline
53.9 (9.6) 55.7 (7.4)
SF-36 aggregate mental
score (95% CI) change
0.96 (–2.51 to 4.44) –4.35 (–7.50 to –1.20) 5.31 (0.62 to 10.00);
p= 0.027
EQ-5Dc score (SD) at
baseline
0.8 (0.2) 0.8 (0.2)
EQ-5D score (95% CI)
change
–0.07 (–0.14 to –0.00) –0.02 (–0.09 to 0.04) –0.05 (–0.14 to 0.05);
p= 0.31
EQ-5D thermometer
response (SD) at baseline
76.8 (15.5) 78.1 (15.4)
EQ-5D thermometer
response (95% CI) change
–6.81 (–13.0 to –0.67) –6.66 (–12.4 to –0.94) –0.15 (–8.54 to 8.24);
p= 0.93
a Scores range from 0 to 100, with lower scores indicating better QoL.
b Score ranges from 0 to 100, with a higher score indicating better function.
c Scale of –0.59 to 1.00 (higher score indicates better QoL).
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Adverse events and mortality
A range of adverse events were reported by Demedts and colleagues67 and these are summarised in
Table 21. The study report that none of the differences between the study groups were significant, except
for those relating to bone marrow toxicity, which occurred in 4% of participants receiving triple therapy
and in 13% receiving double therapy; p= 0.03. Detailed descriptions of the types of events included in
these categories were reported but have not been data extracted. There were seven deaths in the
triple-therapy arm and eight in the dual-therapy arm (9% vs. 11%, respectively) of the Demedts and
colleagues67 study and this was not statistically significant between the two groups (p= 0.69).
The Raghu and colleagues IPFCRN 2012 group report data on the rate of serious adverse events in the
triple-therapy and placebo arms of their trial.68 These can be seen in Table 22, where it can be seen that
the event rate of any serious adverse event was 31% in the triple-therapy arm, compared with 10% in the
placebo arm (p= 0.001). Respiratory system serious adverse events contributed the most to the difference
observed, and were also seen to be statistically significantly higher in the participants in the triple-therapy
arm, compared with the placebo arm (p= 0.03). All other serious events recorded in the study were not
statistically significantly different between the two groups.
TABLE 21 Adverse events: Demedts et al.67
Adverse events occurring in at
least 5% of participants
Number of patients (%),
number of events
Number of patients (%),
number of events
NAC, azathioprine,
prednisolone (N= 80)
Placebo, azathioprine,
prednisolone (N= 75)
All adverse events 72 (90), 322 67 (89), 303
Respiratory tract infection 20 (25), 22 24 (32), 27
Dyspnoea 16 (20), 16 19 (25), 21
Fever 15 (19), 17 10 (13), 10
Liver-function test abnormal 14 (18), 15 11 (15), 13
Cough 13 (16), 15 16 (21), 17
Abdominal pain 12 (15), 12 7 (9), 7
URTI 11 (14), 11 13 (17), 15
Blood glucose ↑ 9 (11), 9 11 (15), 12
C-reactive protein ↑ 6 (8), 7 3 (4), 3
Blood alkaline phosphatase ↑ 6 (8), 6 1 (1), 1
Blood lactate dehydrogenase ↑ 6 (8), 6 2 (3), 2
Back pain 6 (8), 6 5 (7), 6
Respiratory failure 5 (6), 5 1 (1), 1
Bone marrow toxic effects 3 (4), 3a 10 (13), 10a
Oedema 3 (4), 3 5 (7), 5
Headache 3 (4), 4 6 (8), 6
Asthenia 3 (4), 3 5 (7), 5
Influenza-like illness 3 (4), 3 5 (7), 5
Muscle cramp 1 (1), 1 4 (5), 4
Deaths 7 (9%) 8 (11%)b
a p= 0.03.
b p= 0.69.
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Specific adverse events with a significant between-group difference from the Raghu and colleagues IPFCRN
201268 trial can be seen in Table 23. Overall, there was a higher proportion of individuals with an adverse
event in the triple-therapy arm than in the placebo arm (p= 0.09), with rates of general disorder, skin
disorder and renal and urinary system disorders also being recorded more frequently in the triple-therapy
arm than in the placebo arm. All other adverse events, which were labelled as non-serious and had
non-significant between-group differences, were reported by the study publication and can be seen in
Appendix 5. The hospitalisation rates (all-cause) were also seen to be statistically significantly different
between the two groups, with 23 (30%) of the triple-therapy participants and seven (9%) of the placebo
participants being hospitalised during the 60 weeks of the study; p< 0.001.
The Raghu and colleagues IPFCRN 2012 trial68 reported mortality outcomes under a number of different
categories (Table 24). All-cause mortality was statistically significantly greater in the triple-therapy-treated
participants (10%) than the placebo-treated participants (1%); p= 0.01. A similar pattern was observed in
the rates of respiratory mortality (9% triple therapy, 1% placebo; p= 0.02). HRs for estimated any-cause
mortality and any-cause mortality or hospitalisation were also seen to favour placebo (see Table 24).
Estimated any-cause mortality or at least a 10% decline in FVC was similar across the two groups.
TABLE 22 Serious adverse events: IPFCRN 201268
Serious adverse event rate
NAC, azathioprine,
prednisolone, n (%) (N= 77) Placebo, n (%) (N= 78) p-value
Any 24 (31) 8 (10) 0.001
Respiratory system 12 (16) 4 (5) 0.03
Infectious 5 (6) 1 (1) 0.12
Gastrointestinal 1 (1) 3 (4) 0.62
Cardiac 3 (4) 0 0.12
General disordera 3 (4) 0 0.12
Neoplasm 2 (3) 0 0.25
Metabolism 1 (1) 0 0.50
Musculoskeletal system 0 1 (1) 1.00
Nervous system 1 (1) 0 0.50
Reproductive system 1 (1) 0 0.50
a Includes all serious adverse events that did not fall into another body-system category, including drug reactions and
drug fever.
TABLE 23 Adverse events: IPFCRN 201268
Adverse eventsa
NAC, azathioprine,
prednisolone, n (%) (N= 77) Placebo, n (%) (N= 78) p-value
Any 68 (88) 61 (78) 0.09
General disorder 34 (44) 21 (27) 0.03
Skin 13 (17) 4 (5) 0.02
Renal and urinary system 10 (13) 1 (1) 0.005
a Specific adverse events with a significant between-group difference. For other adverse events, see Appendix 5.
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Frequently recorded adverse events in the study by Homma and colleagues69 can be seen in Table 25.
The paper states that there were no significant differences in the number of adverse events reported
for the two groups. The severity of the events was less than grade 2. No adverse events were recorded in
participants in the control group. There were some grade 1 and grade 2 adverse events (bacterial
pneumonia, cough, sore throat and hypercholesterolaemia) in the inhaled NAC group.
Summary
Triple therapy did not confer any improvement on the FVC compared with placebo in one study but did
confer an improvement on the VC when compared with double therapy in one other study. Inhaled
single-therapy NAC did not confer a statistically significant benefit over a control intervention in a third
included study. Secondary outcomes including DLCO and 6MWT were reported with mixed results. There were
no differences in rates of dyspnoea in the three studies. QoL did not appear to differ between participants
treated with triple therapy when compared with placebo, and acute exacerbations were greater with triple
therapy but not significantly. Triple therapy led to more deaths, serious adverse events and adverse events
than placebo in one trial. In the other two studies, adverse events did not differ significantly between
randomised groups. Of the three studies, two had a low risk of bias; however, the third study by Homma
and colleagues69 had an unclear risk of bias and therefore results should be interpreted with caution.
TABLE 24 Mortality and hospitalisation outcomes: IPFCRN 201268
Mortality and hospitalisation
outcomes
NAC, azathioprine,
prednisolone (n= 77) Placebo (n= 78) p-value
All-cause mortality, n (%) 8 (10) 1 (1) 0.01
Respiratory mortality, n (%) 7 (9) 1 (1) 0.02
Estimated any-cause mortality
at 60 weeks, % (95% CI)
19.8 (9.9 to 37.2) 2.0 (0.3 to 13.6) HR 9.26 (1.16 to 74.1);
0.01
Estimated any-cause mortality
or hospitalisation, % (95% CI)
43.6 (30.7 to 59.0) 16.9 (8.7 to 31.5) HR 3.74 (1.68 to 8.34);
< 0.001
Estimated any-cause mortality
or ≥ 10% decline in FVC, % (95% CI)
36.3 (23.7 to 53.0) 32.4 (19.7 to 50.3) HR 1.46, (0.70 to 3.05);
0.30
All-cause hospitalisations, n (%) 23 (30) 7 (9) < 0.001
TABLE 25 Adverse events: Homma et al.69
Adverse events NAC (n= 44) Control (n= 46)
Bacterial pneumonia
Grade 1 2 0
Grade 2 2 0
Cough
Grade 1 1 0
Grade 2 1 0
Sore throat
Grade 1 2 0
Grade 2 0 0
Hypercholesterolaemia
Grade 1 2 0
Grade 2 0 0
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Pirfenidone
Time to progression
Time to progression (TTP) was calculated in the two Capacity trials62 (Table 26). TTP was defined as
the time to ‘worsening’ of IPF, with no further details provided. The HR for the estimated TTP was not
statistically significant in the Capacity study 006 (HR 0.73, 95% CI 0.43 to 1.24; p= 0.248) or in the
Capacity study 004 (HR 0.84, 95% CI 0.50 to 1.42; p= 0.515), with no benefit of pirfenidone seen.62
Progression-free survival
Progression-free survival was defined in the two Capacity trials62 as time to confirmed ≥ 10% decline in
per cent predicted FVC, ≥ 15% decline in per cent predicted DLCO, or death. The HR for estimated PFS was
not statistically significant in the Capacity study 006 (HR 0.84, 95% CI 0.58 to 1.22; p= 0.355) but was
statistically significant in the Capacity study 004 [HR 0.64 (95% CI 0.44 to 0.95); p= 0.023], indicating a
36% reduction in the risk of death or disease progression with pirfenidone treatment (Table 27).62
TABLE 26 Time to progression: pirfenidone
Study details HR (95% CI)
Noble et al. 201162
Capacity study 006
0.73 (0.43 to 1.24); p= 0.248
Noble et al. 201162
Capacity study 004
0.84 (0.50 to 1.42); p= 0.515
Time to progression defined as time to ‘worsening’ of
IPF – no further details provided.
TABLE 27 Progression-free survival: pirfenidone
Study details
Estimated PFS
Arm n/N
Noble et al. 201162
Capacity study 006a
Pirfenidone 126/171
Placebo 123/171
HR, p-value HR 0.84 (0.58 to 1.22); p= 0.355
Noble et al. 201162
Capacity study 004a
Pirfenidone 138/174
Placebo 116/174
HR, p-value HR 0.64 (0.44 to 0.95); p= 0.023
bTaniguchi et al. 201065 Pirfenidone high dose 45/106
Placebo 40/104
HR, p-value HR not reported, HD p= 0.0280
a PFS defined as time to confirmed ≥ 10% decline in per cent predicted FVC, ≥15% decline in per cent predicted DLCO or
death. Kaplan–Meier plots available.
b PFS defined as death and/or ≥ 10% decline in VC from baseline, or when VC data not obtainable (due to worsening
respiratory symptoms). Kaplan–Meier plot available.
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In the Taniguchi and colleagues65 trial, PFS was defined as death or a ≥ 10% decline in VC from baseline.
In this study the HRs were not reported. The publication states that the HR for the high-dose pirfenidone
group versus placebo was statistically significantly (p= 0.03) in favour of treatment (the HR for the
low-dose pirfenidone group vs. placebo was not). There is an uncertain risk of bias in this study, which
should be taken into account when interpreting these data.
Forced vital capacity
The two Capacity trials62 report the mean change in per cent predicted FVC at 72 weeks (see Table 27). In
the Capacity 006 trial, the difference between groups (0.6%) was not statistically significant (p= 0.501).62
In the Capacity 004 trial, the difference of 4.4% between groups was shown to be statistically significantly
different (p= 0.001).62 Combining these two trials in a random-effects meta-analysis (see Figure 2)
demonstrated no statistical difference overall (mean difference 2.61, 95% CI –1.11 to 6.33; p= 0.17) and
moderate statistical heterogeneity between the trials (I2= 45%). Taniguchi and colleagues65 reported the
mean change in VC litres at 52 weeks. In this study the difference in change in VC between the high-dose
pirfenidone group (1800mg/day) and placebo was seen to be statistically significant (difference 0.07 litres;
p= 0.04). In the RCT by Azuma and colleagues66 at 6 months the mean change in VC litres was not
statistically significantly different between those treated with pirfenidone 1800mg/day and those treated
with placebo (difference 0.07; p= 0.10) (see Table 27 for full details). At 9 months a statistically significant
difference between groups was seen, with the mean change in VC between groups being 0.10 litres
(p= 0.04). Combining these two trials in a fixed-effects meta-analysis (see Figure 4) showed a statistically
significant benefit of treatment with pirfenidone compared with placebo (mean difference 0.08, 95% CI
0.03 to 0.12; p= 0.0006) and no statistical heterogeneity between the trials (I2= 0%).
The FVC/VC outcomes (both per cent predicted FVC/VC and mean change in FVC/VC) from the four included
pirfenidone studies were combined in a random-effects meta-analysis using the standardised mean difference
(Figure 6). A statistically significant benefit of treatment with pirfenidone (standardised mean difference 0.24,
95% CI 0.06 to 0.41; p= 0.008) was found. Moderate statistical heterogeneity was present, as indicated by
the I2 test (45%). The uncertain risk of bias in the Azuma and colleagues66 and Taniguchi and colleagues65
studies should be noted when interpreting the effects shown.
The Capacity trials62 also reported the proportion of participants with a decline in FVC of at least 10%
(Table 28 and Figure 5). It is unclear if this was calculated as an absolute or relative change. In the
Capacity 006 study, 23% of participants treated with pirfenidone and 27% of participants treated
with placebo showed a decline of at least 10% in the per cent predicted FVC. Statistical analysis was
undertaken on five categories of change in FVC per cent predicted in this study (severe decline ≥ 20%;
moderate decline < 20% but ≥ 10%; mild decline < 10% but ≥ 0; mild improvement > 0 but < 10%;
moderate improvement ≥ 10%) and this showed no statistically significant differences between groups in
the proportion of participants within these categories. In Capacity 004, 20% of participants in the
pirfenidone group and 35% of participants in the placebo group showed a decline on the per cent
predicted FVC of at least 10%. In the analysis of all five categories in this study, a statistically significant
effect of pirfenidone was seen (p= 0.01). It is unclear whether or not these subgroup analyses were
adequately powered to detect a difference and, therefore, caution is required in their interpretation.
Azuma and colleagues66 also report VC litres in a categorical analysis, using three categories: ‘improved’,
‘stable‘ and ‘deteriorated’ (see Figure 5). Improvement was defined as at least a 10% improvement in VC,
deteriorated was defined as at least a 10% decrease in VC, and any other value was categorised as stable.
It is unclear whether this was calculated as an absolute or relative change. At 9 months a statistically
significant difference between groups was observed on this categorical analysis (p= 0.003). The proportion
of participants with an improvement in their VC was 9% in the pirfenidone group and 0% in the placebo
group. The proportion with a decline in their VC was 13% in the pirfenidone group and 36% in the
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placebo group, and those classified as stable were 78% in the pirfenidone group and 64% in the placebo
group. It is unclear whether or not the analysis of these data was adequately powered, and in addition,
the analysis was not undertaken on the ITT population (n= 67 out of 72 pirfenidone and n= 33 out of
35 placebo) and caution is, therefore, required in the interpretation of these data.
Combining the three trials in a random-effects meta-analysis demonstrated a significant effect in favour of
pirfenidone on the proportion of people with a decline in FVC of ≥ 10% (RR 0.62, 95% CI 0.41 to 0.93;
p= 0.02 see Figure 5). Moderate statistical heterogeneity was present between the trials (I2= 57%).
TABLE 28 Forced vital capacity outcomes: pirfenidone
Study Outcome
Interventions
Difference between
groups (95% CI)
Pirfenidone
2403mg/day (n= 171) Placebo (n= 173)
Noble et al.
201162
Capacity
study 006
Mean change per cent
predicted FVC at 72 weeks
–9.0% (SD 19.6) –9.6% (SD 19.1) 0.6% (–3.5 to 4.7);
p= 0.501
Proportion with a decline
in FVC ≥ 10%
39 (23%) 46 (27%) 3.8 (–2.7 to 10.2);
p= 0.440a
Pirfenidone
2403mg/day (n= 174) Placebo (n= 174)
Noble et al.
201162
Capacity
study 004
Mean change per cent
predicted FVC at 72 weeks
–8.0% (SD 16.5) –12.4% (SD 18.5) 4.4% (0.7 to 9.1);
p= 0.001
Proportion with a decline
in FVC ≥ 10%
35 (20%) 60 (35%) 14.4 (7.4 to 21.3);
p= 0.01a
High-dose 1800mg
pirfenidone (n= 108) Placebo (n= 104)
Taniguchi et al.
201065
Adjusted (LOCF) mean
change in VC, l (SE)
at 52 weeks
n= 104
–0.09 (0.02)
n= 103
–0.16 (0.02)
0.07 (0.03); p= 0.0416
Unadjusted mean
change in VC, l (SE)
n= 67
2.36 (0.73)
n= 72
2.42 (0.75)
Not tested
Pirfenidone 1800mg
(n= 72) Placebo (n= 35)
Azuma et al.
200566
Mean (SD) change VC, l,
at 6 months
–0.01 (0.21) –0.08 (0.19) 0.07;b p= 0.0995
Mean (SD) change VC, l,
at 9 months
–0.03 (0.22) –0.13 (0.19) 0.10;b p= 0.0366
Categorical analysis,c
9 months
n= 67 n= 33
Improved 6 (9%) 0 p= 0.0028
Stable 52 (78%) 21 (64%)
Deteriorated 9 (13%) 12 (36%)
SE, standard error.
a p-value from an analysis of five categories: severe decline (≥ 20%), moderate decline (< 20% but ≥ 10%), mild decline
(< 10% but ≥ 0%), mild improvement (> 0% but < 10%) and moderate improvement (≥ 10%).
b Calculated by reviewer.
c Changes of 10%.
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Diffusing capacity of the lung for carbon monoxide
All four included pirfenidone trials report data on the DLCO at end point (Table 29). In the Capacity 006
study62 the mean change from baseline in the per cent predicted DLCO at 72 weeks was not statistically
significant between the two groups (–9.8% vs. –9.2%, pirfenidone vs. placebo, respectively; p= 0.996).
This was also the case in the Capacity 004 study62 (mean change from baseline –7.9% vs. –9.9%,
pirfenidone vs. placebo, respectively; p= 0.145), and when combining these two trials in a meta-analysis
(mean difference 0.68, 95% CI –0.87 to 3.22; p= 0.6; see Figure 3). The mean change in DLCO ml/minute/
mmHg in the Taniguchi and colleagues65 trial was also not statistically significantly different between
the high-dose pirfenidone and placebo arms (p= 0.23) after 52 weeks. Finally, mean change in DLCO
ml/minute/mmHg was not statistically significant between the pirfenidone-treated participants and the
placebo-treated participants at either 6 months (p= 0.49) or 9 months (p= 0.21) in the Azuma and
colleagues trial.66 However, combining these last two trials in a meta-analysis produces a beneficial effect
in favour of pirfenidone that approaches statistical significance (mean difference 0.53, 95% CI –0.00 to
1.05; p= 0.05; Figure 7).
A categorical analysis of DLCO was also reported by Azuma and colleagues.66 Three categories, ‘improved’,
‘stable‘, and ‘deteriorated’, were used, where a change of 15% was used to categorise either improvement
(+15%) or deterioration (–15%), and all other values were categorised as stable. At 9 months no statistically
significant difference between groups was observed on the categorical analysis (p= 0.158). The proportion of
participants with an improvement in their DLCO was 16% in the pirfenidone group and 6% in the placebo
group. The proportion with a decline in their DLCO was 36% in the pirfenidone group and 47% in the
placebo group, and those classified as stable were 50% in the pirfenidone group and 47% in the placebo
group. Caution is required in the interpretation of these data.
TABLE 29 Diffusing capacity of the lung for carbon monoxide outcomes: pirfenidone
Study Outcome
Interventions
Difference between
groups
Pirfenidone 2403mg/day
(n= 171) Placebo (n= 173)
Noble et al.
201162
Capacity
study 006
Mean change in DLCO
(% predicted)
–9.8 –9.2 –0.5 (–3.2 to 2.2);
p= 0.99
Pirfenidone 2403mg/day
(n= 174) Placebo (n= 174)
Noble et al.
201162
Capacity
study 004
Mean change in DLCO
(% predicted)
–7.9 –9.9 2.0 (–0.4 to 4.4);
p= 0.15
High-dose 1800mg
pirfenidone (n= 108) Placebo (n= 104)
Taniguchi et al.
201065
Change in DLCO n= 96
–0.88
n= 98
–1.36
p= 0.24
Pirfenidone 1800mg (n= 72) Placebo (n= 35)
Azuma et al.
200566
Mean (SD) change
DLCO ml/minute/mmHg
at 6 months
–0.50 (2.07) –0.83 (2.16) p= 0.49
Mean (SD) change
DLCO ml/minute/mmHg
at 9 months
–0.57 (2.15) –1.19 (2.30) p= 0.21
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Six-minute walk test
The mean change on the distance walked on the 6MWT was reported in the two Capacity RCTs
(Table 30). In the Capacity study 006, a statistically significant treatment effect for pirfenidone was seen
at 72 weeks, with a 31.8m difference in the distance walked between the two groups seen (p= 0.0009).
In the Capacity study 004, there was no statistically significant effect of treatment with pirfenidone
(difference in the distance walked 16.4m; p= 0.171).
All four pirfenidone studies report data on the lowest SpO2 during the 6MWT (Table 31 and Figure 8).
In neither of the Capacity studies was a statistically significant difference between groups observed
at 72 weeks (Capacity 006: difference –0.5, p= 0.893; Capacity 004: difference 0.8, p= 0.087).
TABLE 30 Six-minute walk test outcomes: pirfenidone
Study Outcome
Interventions
Difference between
groups
Pirfenidone 2403mg/day
(n= 171)
Placebo
(n= 173)
Noble et al. 201162
Capacity study 006
6MWT at baseline 378.0 (82.2) 399.1 (89.7)
Mean change in 6MWT
distance, m
–45.1 –76.9 31.8 (3.2 to 60.4);
p= 0.0009
Pirfenidone 2403mg/day
(n= 174)
Placebo
(n= 174)
Noble et al. 201162
Capacity study 004
6MWT at baseline 411.1 (91.8) 410.0 (90.9) 16.4 (–10.9 to 43.7);
p= 0.17
TABLE 31 Lowest SpO2 during the 6MWT, % pirfenidone
Study Outcome
Interventions
Difference between
groups
Pirfenidone 2403mg/day
(n= 171)
Placebo
(n= 173)
Noble et al. 201162
Capacity study 006
Mean change in worst
SpO2 during 6MWT, %
–1.9 –1.3 –0.5 (–1.7 to 0.7);
p= 0.89
Pirfenidone 2403mg/day
(n= 174)
Placebo
(n= 174)
Noble et al. 201162
Capacity study 004
Mean change in worst
SpO2 during 6MWT, %
–1.5 –2.3 0.8 (–0.2 to 1.8);
p= 0.09
High dose 1800mg
pirfenidone (n= 108)
Placebo
(n= 104)
Taniguchi et al.
201065
Change in lowest SpO2
during the 6MET (SE)
n= 99
–1.70 (0.35)
n= 100
–1.53 (0.35)
–0.17 (0.50);
p= 0.74
Pirfenidone 1800mg
(n= 72)
Placebo
(n= 35)
Azuma et al.
200566
Mean (SD) change lowest
SpO2 during 6MET, % at
6 months
0.6364 (3.5502) –0.5484
(3.7933)
p= 0.15
Mean (SD) change lowest
SpO2 during 6MET, % at
9 months
0.4697 (3.8838) –0.9355
(3.3559)
p= 0.07
6MET, 6-minute exercise test; SE, standard error.
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In the Taniguchi and colleagues65 study, after 52 weeks no statistically significant differences between the
high-dose pirfenidone group and placebo (p= 0.74) was observed. The change in the lowest SpO2 on
the 6MWT was the primary outcome in the Azuma and colleagues66 trial. No statistically significant
differences were observed when analysed at 6 months’ (p= 0.148) or at 9 months’ (p= 0.722) follow-up.
Combining the four trials in a random-effects meta-analysis found no significant difference in SpO2 during
the 6MWT (mean difference 0.49, 95% CI –0.32 to 1.30; p= 0.24). Moderate statistical heterogeneity was
evident (I2= 45%) between the trials (see Figure 8).
Azuma and colleagues66 also report a categorical analysis (improved, stable, deteriorated) of the SpO2
during the 6MWT at 9 months. A > 4% increase was classified as ‘improved’, a ≤ 4% decrease was
classified as ‘deteriorated’ and any values in between these two was classified as ‘stable’. Analysis of these
data showed a statistically significant treatment effect in favour of pirfenidone (p= 0.02), although caution
is required as this was unlikely to be a powered analysis, and the population was not the ITT population.
Treatment with pirfenidone led to an improvement in 24% of cases, compared with 6% of cases in the
placebo group. More participants deteriorated in the placebo group (18% pirfenidone, 33% placebo);
however, the rates of participants classified as having a stable SpO2 during the 6MWT were similar
(58% vs. 61%, pirfenidone vs. placebo group, respectively).
Other secondary outcomes
Other outcomes reported in these studies include TLC, partial pressure of oxygen and HRCT outcome, the
results of which can be found in Appendix 5.
Dyspnoea
Dyspnoea was measured by the University of California, San Diego, Shortness-of-Breath Questionnaire
(UCSDSBQ) in the two Capacity trials, the results of which can be seen in Table 32.62 The UCSDSBQ
indicates severity of dyspnoea on a scale from 0 to 5 on 21 activities of daily living, along with three
ratings on limitations caused by dyspnoea or fear of dyspnoea, for a total score ranging from 0 to 120,
with a higher score indicating more dyspnoea. There were no statistically significant differences between
the intervention and placebo groups on this outcome in either study (p= 0.604 Capacity 006; p= 0.509
Capacity 004). Dyspnoea was also reported by Azuma and colleagues;66 however, the measure used was
not described and no data were reported except the p-value which indicated no statistical significant
difference between groups (p= 0.64).
TABLE 32 Dyspnoea outcomes: pirfenidone
Study Outcome
Interventions
Difference between
groups
Pirfenidone
2403mg/day (n= 171)
Placebo
(n= 173)
Noble et al. 201162
Capacity study 006
Mean change in
UCSDSBQ scorea
11.9 13.9 –2.0 (–7.6 to 3.6);
p= 0.60
Pirfenidone
2403mg/day (n= 174)
Placebo
(n= 174)
Noble et al. 201162
Capacity study 004
Mean change in
UCSDSBQ scorea
12.1 15.2 –3.1 (–8.5, 2.3);
p= 0.51
Pirfenidone (n= 72)
Placebo
(n= 35)
Azuma et al. 200566 Dyspnoea (not defined) Data not reported Data not
reported
p= 0.64
a UCSDSBQ total score ranges from 0 to 120, with higher scores indicating greater shortness of breath.
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Acute exacerbations
The rate of acute exacerbations was reported by two of the pirfenidone studies (Table 33). At 52 weeks
Azuma and colleagues66 demonstrated a statistically significant difference in the rate of acute exacerbations
in those treated with pirfenidone and those treated with placebo, in favour of pirfenidone (0% vs. 14%,
respectively; p= 0.003). Taniguchi and colleagues65 also reported the incidence of acute exacerbation but
found no difference between the high-dose pirfenidone and placebo groups at 52 weeks (see Table 33).
Quality of life
Only the study by Azuma and colleagues66 reported having measured QoL; however, no data for this
outcome were reported in the trial publication. The paper stated that there was no statistically significant
difference between groups (p= 0.8720).
Adverse events
Serious adverse events were recorded in the Capacity RCTs62 and can be seen in Table 34, which shows
IPF-related serious adverse events occurring in at least two participants in any treatment group. The rate of
any serious adverse event was observably similar between those treated with pirfenidone and those treated
with placebo in the Capacity study 00662 (pirfenidone 7.6% vs. 9.8% placebo), although no statistical
testing of these rates were reported. All other serious adverse events reported in the study appear to be
comparable between the treated and untreated study populations (see Table 34). A similar pattern was
seen in the treatment arms of the Capacity 004 study (see Table 34).
TABLE 33 Acute exacerbations: pirfenidone
Study Outcome
Interventions
Difference between
groups
Pirfenidone 1800mg
(n= 72)
Placebo
(n= 35)
Azuma et al. 200566 Acute exacerbation 0 5/35 (14%) 14%; p= 0.0031
High-dose 1800mg
pirfenidone (n= 108)
Placebo
(n= 104)
Taniguchi et al. 201065 Acute exacerbation rate 6 (5.6%) 5 (4.8%) NS
NS, not significant.
TABLE 34 Serious adverse events for pirfenidone occurring in ≥ two people
SAEs Pirfenidone, n (%) (N= 171) Placebo, n (%) (N= 173)
Capacity 00662
IPF 13 (7.6) 17 (9.8)
Pneumonia 7 (4.1) 7 (4.0)
Respiratory failure 4 (2.3) 6 (3.5)
Coronary artery disease 6 (3.5) 0
Acute respiratory failure 2 (1.2) 3 (1.7)
Bronchitis 0 5 (2.9)
Atrial fibrillation 2 (1.2) 1 (0.6)
Renal failure 2 (1.2) 2 (1.2)
Fall 2 (1.2) 1 (0.6)
continued
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TABLE 34 Serious adverse events for pirfenidone occurring in ≥ two people (continued )
SAEs Pirfenidone, n (%) (N= 171) Placebo, n (%) (N= 173)
Hypotension 2 (1.2) 1 (0.6)
Prostate cancera 2 (1.6) 0
Colitis 2 (1.2) 0
Hip fracture 2 (1.2) 0
Hypertension 0 2 (1.2)
Hypoxia 0 2 (1.2)
Intervertebral disc protrusion 2 (1.6) 0
Liver function test abnormal 2 (1.2) 0
Nephrolithiasis 2 (1.2) 0
Sick sinus syndrome 2 (1.2) 0
Transitional cell carcinoma 0 2 (1.2)
Pirfenidone 2403mg/day,
n (%) (N= 174) Placebo, n (%) (N= 174)
Capacity 00462
IPF 13 (7.5) 14 (8.0)
Pneumonia 4 (2.3) 6 (3.4)
Respiratory failure 2 (1.1) 2 (1.1)
Bronchitis 2 (1.1) 2 (1.1)
Lobar pneumonia 2 (1.1) 2 (1.1)
Myocardial infarction 0 4 (2.3)
Acute respiratory failure 2 (1.1) 3 (1.7)
Angina pectoris 2 (1.1) 1 (0.6)
Atrial fibrillation 1 (0.6) 1 (0.6)
Coronary artery disease 0 2 (1.1)
Pneumothorax 3 (1.7) 0
Pulmonary embolism 1 (0.6) 1 (0.6)
Syncope 3 (1.7) 1 (0.6)
Dyspnoea 0 3 (1.7)
Non-cardiac chest pain 2 (1.1) 2 (1.1)
Prostate cancera 0 2 (1.6)
Aortic aneurysm 2 (1.1) 0
Chest pain 3 (1.7) 0
Hypoxia 1 (0.6) 2 (1.1)
Acute renal failure 1 (0.6) 0
Bladder cancer 2 (1.1) 0
Gastro-oesophageal reflux disease 2 (1.1) 0
SAE, serious adverse event.
a Percentage based on number of males in each treatment group.
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All four included studies report details of any adverse events in their respective trials. In both Capacity
trials,62 adverse events occurring in 10% or more of participants receiving pirfenidone and an incidence of
1.5 times or greater in placebo were reported (Table 35). The authors state that events were generally mild
or moderate, without clinical consequences. Rates of any adverse events were seen to be similar between
treatment group and placebo in both studies. Nausea, fatigue, diarrhoea and rash were the most
frequently reported adverse events in the pirfenidone-treated participants (incidence in the region of
25–38% in both Capacity studies). Rates of these adverse events were in the region of 13% to 21% in the
placebo-treated participants (for full details see Table 35). No statistical analyses of the rates between the
groups were reported. All other adverse events appeared to be similar across groups with the exception of
dyspepsia, which was seen to be more widely recorded in the pirfenidone groups.
Adverse events recorded in ≥ 5% participants in either the high-dose pirfenidone or the placebo group in the
Taniguchi and colleagues trial65 can be seen in Table 36. The rate of any adverse events was similar across
the pirfenidone treatment arm and the placebo arm (high dose vs. placebo p= 0.50). However, there were
some specific adverse events that were seen to be statistically significantly different between treatment and
placebo groups. Photosensitivity was seen in 51.4% of high-dose pirfenidone participants, compared with
22.4% of placebo participants (p< 0.01). Anorexia, dizziness and raised glutamyl-transpeptidase were all
higher in those treated with high-dose pirfenidone than in those treated with placebo (see Table 36 for
details). Two adverse events were more common in the placebo group than the high-dose pirfenidone group:
nasopharyngitis and URTIs (Table 36). The report also provides details of statistical analyses of the rates
between the two pirfenidone groups, which can be seen in Appendix 5. Specific adverse events leading
to discontinuations for each treatment group were also reported but not data extracted. The numbers of
dropouts for any adverse events were discussed earlier in this chapter (see Pharmacological interventions for
mild to moderate idiopathic pulmonary fibrosis, Pirfenidone). No one particular adverse event appears to have
been a more common reason for discontinuation.
Azuma and colleagues66 reported adverse events occurring in ≥ 10% of participants at 6 months. Rates
of any adverse events were statistically significantly higher in the pirfenidone group than in the placebo
group (p= 0.04) (Table 37). Photosensitivity, stomach discomfort, anorexia, nausea, fatigue and raised
glutamyl-transpeptidase were all statistically significantly more common with pirfenidone than they
were with placebo. All other adverse events were similar between the comparison groups. Reasons for
treatment discontinuations were also reported by Azuma and colleagues66 and can be seen in Appendix 5.
Although adverse events were more frequently reported to be a reason for discontinuation, none of the
specific adverse events or adverse events in general was statistically significantly more likely to lead
to discontinuation.
Summary
On measures of FVC, pirfenidone appears to demonstrate an effect when compared with placebo
treatment. One trial (Capacity 00662) appears to be an outlier with results being non-significant and the
reason for this is unclear. Results on other outcomes such as DLCO, 6MWT distance and the oxygen
saturation during the 6MWT generally showed no effect of treatment with pirfenidone, with the exception
of the 6MWT in the Capacity 006 trial.62 Acute exacerbations were assessed in two studies, with results
favouring pirfenidone in one but not the other study. QoL outcomes were not reported and, therefore,
the effect of pirfenidone on QoL cannot be estimated. Adverse event rates were generally similar
between those treated with pirfenidone and those treated with placebo, although some specific adverse
events (gastrointestinal events and photosensitive skin rashes) appear more likely with pirfenidone.
Two studies had low risk of bias, but two had an unclear risk of bias which should be considered when
interpreting results.
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TABLE 35 Adverse events: pirfenidone (Capacity trials)
AEs Pirfenidone, n (%) (N= 171) Placebo, n (%) (N= 173)
Capacity 00662
Any AE 169 (99) 170 (98)
Nausea 65 (38) 28 (16)
Fatigue 56 (33) 35 (20)
Diarrhoea 56 (33) 37 (21)
Rash 58 (34) 22 (13)
Dizziness 30 (18) 18 (10)
Dyspepsia 36 (21) 10 (6)
Gastro-oesophageal reflux 10 (6) 12 (7)
Vomiting 23 (14) 8 (5)
Insomnia 12 (7) 11 (6)
Arthralgia 16 (9) 11 (6)
Anorexia 18 (11) 6 (4)
Abdominal distension 18 (11) 8 (5)
Photosensitivity reaction 17 (10) 4 (2)
Urinary tract infection 16 (9) 20 (12)
Pirfenidone 2403mg/day,
n (%) (N= 174) Placebo, n (%) (N= 174)
Capacity 00462
Any AE 171 (98) 169 (97)
Nausea 60 (35) 32 (18)
Fatigue 48 (28) 36 (21)
Diarrhoea 43 (25) 30 (17)
Rash 53 (31) 18 (10)
Dizziness 33 (19) 17 (10)
Dyspepsia 30 (17) 16 (9)
Gastro-oesophageal reflux 26 (15) 14 (8)
Vomiting 24 (14) 7 (4)
Insomnia 22 (13) 12 (7)
Arthralgia 20 (12) 13 (8)
Anorexia 19 (11) 7 (4)
Abdominal distension 15 (9) 12 (7)
Photosensitivity reaction 25 (14) 2 (1)
Urinary tract infection 19 (11) 9 (5)
Stevens–Johnson syndrome 0 0
Toxic epidermal necrosis 0 0
AE, adverse event.
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TABLE 36 Adverse events: pirfenidone (Taniguchi et al.65)
AEs ≥ 5%
Arm, n (%)
Difference,
p-value
High-dose pirfenidone
(N= 109a) Placebo (N= 107a)
Any 109 (100) 106 (99.1) p= 0.50
Photosensitivity 56 (51.4) 24 (22.4) p< 0.01
Anorexia 18 (16.5) 3 (2.8) p< 0.01
Abdominal discomfort 3 (2.8) 0 p= 0.25
Dizziness 8 (7.3) 1 (0.9) p= 0.04
Nasopharyngitis 54 (49.5) 70 (65.4) p= 0.02
URTI 1 (0.9) 9 (8.4) p< 0.01
γ-GTP elevation 25 (22.9) 10 (9.3) p< 0.01
WBC decrease 4 (3.7) 0 p= 0.12
AE, adverse event; γ-GTP, glutamyl-transpeptidase; WBC, white blood cell.
a Analysis on the full patient cohort including those reported to be ineligible and excluded post randomisation because no
post-baseline data were available.
TABLE 37 Adverse events: pirfenidone (Azuma et al.66)
AEs occurring in ≥ 10% at
6 months
Arm, n (%)
p-valuePirfenidone (N= 72) Placebo (N= 35)
Any 72 (98.6) 32 (88.9) p= 0.040
Photosensitivity 32 (43.8) 0 p= 0.000
Stomach discomfort 22 (30.1) 3 (8.3) p= 0.0143
Anorexia 23 (31.5) 2 (5.6) p= 0.0030
Nausea 16 (21.9) 2 (5.6) p= 0.0314
Heartburn 12 (16.4) 1 (2.8) p= 0.0566
Drowsiness 17 (23.3) 6 (16.7) p= 0.4672
Fatigue 16 (21.9) 1 (2.8) p= 0.0102
URTI 12 (16.4) 3 (8.3) p= 0.3767
Fever 6 (8.2) 4 (11.1) p= 0.7271
Elevation of GOT 4 (5.5) 6 (16.7) p= 0.0785
Elevation of γ-GTP 20 (27.4) 3 (8.3) p= 0.0249
Urinary occult blood positive 6 (8.2) 4 (11.1) p= 0.7271
Elevation of CRP 15 (20.5) 10 (27.8) p= 0.4694
AE, adverse event; CRP, C-reactive protein; GOT, glutamic oxaloacetic transaminase; γ-GTP, glutamyl-transpeptidase.
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Thalidomide
The randomised crossover trial of thalidomide aimed to determine the efficacy of thalidomide in supressing
cough, and as such the outcome measures focused on measurement of cough and QoL.55 No lung
function tests were reported.
Cough and quality of life
Cough measured by VAS and cough-related QoL measured by the CQLQ were statistically significantly
improved after 12 weeks of thalidomide compared with placebo (Table 38). The authors state that the
MCID of the CQLQ in IPF is unknown, but the MCID for the Leicester Cough Questionnaire, which has
been shown to be similar to the CQLQ, is 1.3. A mean difference in score of 11.4 on the CQLQ is,
therefore, likely to be a clinically important effect. Sensitivity analyses undertaken to explore the effect of
missing data found that thalidomide use resulted in a statistically significant improvement in CQLQ scores
in each of the analyses. A statistically significant improvement in the total score, symptom domain and
impact domain, but not the activity domain, of the SGRQ was also found with thalidomide (see Table 38).
Adverse events
Significantly more people experienced at least one adverse event with thalidomide than with placebo
(77% vs. 22%; p= 0.001) (Table 39). The most common adverse events with thalidomide were
constipation (36%), dizziness (27%), viral upper respiratory tract infection (URTI) (23%) and malaise (14%).
Adverse events requiring dose reduction occurred in three people [constipation in two (9%) and
bradycardia in one (5%)].
TABLE 38 Cough and QoL outcomes: thalidomide
Study Outcome
Interventions
Mean difference between groups
(95% CI); p-value
Thalidomide
(n= 23)
Placebo
(n= 23)
Horton et al.
201255,75
CQLQ, mean (SD) at baseline 60.5 (12.0)
CQLQ, mean (SD) at 12 weeks 47.2 (13.4) 58.7 (14.0) –11.4 (–15.7 to –7.0); p< 0.001
Cough VAS, mean (SD) at
baseline
64.8 (21.4)
Cough VAS, mean (SD) at
12 weeks
32.2 (26.1) 61.9 (26.5) –31.2 (–45.2 to –17.2); p< 0.001
SGRQ total, mean (SD) at
baseline
57.4 (18.8)
SGRQ total, mean (SD) at
12 weeks
43.9 (16.0) 56.9 (17.1) –11.7 (–18.6 to –4.8); p= 0.001
SGRQ symptom domain, mean
(SD) at baseline
67.7 (19.7)
SGRQ symptom domain, mean
(SD) at 12 weeks
50.3 (20.9) 62.0 (18.3) –12.1 (–22.2 to –2.0); p= 0.018
SGRQ impact domain, mean
(SD) at baseline
48.1 (20.7)
SGRQ impact domain, mean
(SD) at 12 weeks
34.3 (16.1) 49.0 (19.4) –13.1 (–19.7 to –6.6); p< 0.001
SGRQ activity domain, mean
(SD) at baseline
64.3 (22.7)
SGRQ activity domain, mean
(SD) at 12 weeks
60.9 (14.2) 65.8 (18.7) –3.3 (–9.8 to 3.2); p= 0.31
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Summary
One small randomised crossover trial with a low risk of bias provided data on the effectiveness of
thalidomide for supressing cough in IPF. Cough, cough-related QoL and respiratory-related QoL were
significantly improved with thalidomide compared with placebo. Adverse events were experienced with
thalidomide. Caution is required in the interpretation of these data given the small sample size.
Assessment of effectiveness of pharmacological interventions
for severe idiopathic pulmonary fibrosis
Sildenafil
Forced vital capacity
The results for per cent predicted FVC from the trial by the IPFCRN 2010 group (Zisman and colleagues)72
can be seen in Table 40. After 12 weeks of treatment there was no statistically significant effect for
sildenafil, compared with placebo (mean difference 0.32, 95% CI –1.12 to 1.76; p= 0.66). Figure 2
presents the results of FVC graphically, where it can be seen that the CIs cross the line of no effect.
TABLE 39 Adverse events: thalidomide
Adverse events, n (%) Thalidomide (N= 22) Placebo (N= 23)
Participants with ≥ 1 adverse event 17 (77)a 5 (22)a
Participants with a serious adverse event (influenza) 0 1 (4)
Adverse events requiring dose reduction
Constipation 2 (9) 0
Bradycardia 1 (5) 0
Adverse events requiring drug discontinuation
(progressive illness or inability to travel for visits)
2 (9) 1 (4)
Gastrointestinal adverse events
Constipation 8 (36) 1 (4)
Change in taste 2 (9) 0
Dry mouth 2 (9) 0
Anorexia 1 (5) NR
General adverse events
Dizziness 6 (27) 0
Malaise 3 (14) 0
Oedema 2 (9) 0
Rash 2 (9) 0
Sleepiness NR 1 (4)
Respiratory adverse event: worsening dyspnoea 2 (9) 2 (9)
Infectious adverse event: viral URTI 5 (23) 1 (4)
Cardiac adverse event: bradycardia 1 (5) 0
NR, not reported.
a p= 0.001.
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Diffusing capacity of the lung for carbon monoxide
Treatment with sildenafil led to a statistically significantly lower rate of decline of per cent predicted DLCO
from baseline than treatment with placebo: –0.33 versus –1.87%, respectively; p= 0.04 (Table 41 and
see Figure 3).
Six-minute walk test
The presence of an improvement of at least 20% in the 6MWT distance at 12 weeks was the primary
outcome measure in the Zisman and colleagues IPFCRN 201072 trial of sildenafil. As seen in Table 42,
the proportions with an improvement of at least 20% were not statistically significantly different between
groups (10% vs. 7% in the sildenafil and placebo groups, respectively; p= 0.39).
Other secondary outcomes
Other outcomes reported in the Zisman and colleagues IPFCRN 2010 trial72 include the partial pressure of
oxygen, carbon dioxide and the oxygen saturation, the results of which can be found in Appendix 5.
Acute exacerbations
The incidence of acute exacerbation was not statistically significantly different between groups in the
Zisman and colleagues IPFCRN 201072 trial, with 2% of the sildenafil-treated participants and 4% of
the placebo-treated participants being recorded as having had an acute exacerbation (Table 43).
Dyspnoea
Two scales were used to measure dyspnoea in the Zisman and colleagues IPFCRN 201072 trial (Table 44):
the UCSDSBQ and the Borg Dyspnoea Index. The UCSDSBQ was described above. The minimally important
difference for this is reported by the study authors to be five points. The Borg Dyspnoea Index measures
perceived breathlessness on a scale of 0 (none) to 10 (maximum) and the authors report that this has a
TABLE 40 Forced vital capacity: outcomes sildenafil
Study Outcome
Interventions
Difference between
groupsSildenafil (n= 89) Placebo (n= 91)
Zisman et al.
IPFCRN 201072
FVC (% predicted),
mean change
(95% CI) at 12 weeks
–0.97 (–2.00 to 0.06) –1.29 (–2.30 to –0.28) 0.32 (–1.12 to 1.76);
p= 0.66
TABLE 42 Six-minute walk test outcomes: sildenafil
Study Outcome
Interventions
Difference between
groupsSildenafil (n= 89) Placebo (n= 91)
Zisman et al.
IPFCRN 201072
6MWT at baseline 246.39 (103.40) 269.55 (129.83)
6MWT improvement in
distance of ≥ 20%
9 (10%) 6 (7%) 3%;a p= 0.39
a Calculated by reviewer.
TABLE 41 Diffusing capacity of the lung for carbon monoxide outcomes: sildenafil
Study Outcome
Interventions
Difference between
groupsSildenafil (n= 89) Placebo (n= 91)
Zisman et al.
IPFCRN 201072
DLCO (% predicted),
mean change
–0.33 (–1.36 to 0.71) –1.87 (–2.91 to –0.83) 1.55 (0.08 to 3.01);
p= 0.04
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minimally important difference of 1. In this study the Borg Dyspnoea Index was applied after the participants
had undertaken the 6MWT. The difference between groups was statistically significant when dyspnoea was
measured using the UCSDSBQ (difference –6.58; p= 0.006) but was not statistically significantly different
between groups on the Borg Dyspnoea Index after the walk test (difference –0.34; p= 0.16).
Quality of life
Quality of life of participants in the trial by Zisman and colleagues (IPFCRN)72 was measured using the SGRQ,
the SF-36 and the EQ-5D. The scoring for the SGRQ was previously described [see Assessment of effectiveness
of pharmacological interventions for mild to moderate idiopathic pulmonary fibrosis, BIBF 1120 (nintedanib)
and Pirfenidone] and fuller details can be found in Chapter 4 (see Systematic review of health-related quality
of life studies). The trial authors report that the MCID for the SGRQ is 5–8 points. The SF-36 measures
aggregate scores on separate subscales for physical and mental health (see Chapter 4, Systematic review of
health-related quality of life studies for more detail), with higher scores indicating better function. The study
authors state that the SF-36 has a MCID of 2–4 points in IPF. The EQ-5D measures general QoL on a
self-report questionnaire, with higher scores indicating better QoL (see Chapter 4, Systematic review of
health-related quality of life studies) and on a VAS with a range of 0 to 100 (higher indicates better QoL).
The study reports that the MCID is approximately 0.08 for the self-report questionnaire and 7 points
for the VAS.
The changes from baseline scores of the SGRQ total score, symptoms score, activity score and impacts
score were statistically significantly improved in those treated with sildenafil, compared with those treated
with placebo (Table 45). On the SF-36 physical and mental health scores, and the EQ-5D self-report index
and the VAS, there were no statistically significant differences between the two groups after 12 weeks of
therapy. The study reported the baseline and end-point values on each of the SF-36 components, and full
details of these can be seen in Appendix 5. Only the change from baseline score on the general health
component was statistically significant between groups [sildenafil –1.04 (95% CI –2.52 to 0.44), placebo
–3.89 (95% CI –5.37 to –2.42), difference 2.86 (95% CI 0.76 to 4.95); p= 0.008].
TABLE 43 Acute exacerbations: sildenafil
Study Outcome
Interventions
Difference between
groupsSildenafil (n= 89) Placebo (n= 91)
Zisman et al.
IPFCRN 201072
Acute exacerbation, n (%) 2 (2) 4 (4) 2%; p= 0.68
TABLE 44 Dyspnoea outcomes: sildenafil
Study Outcome
Interventions
Difference between
groupsSildenafil (n= 89) Placebo (n= 91)
Zisman et al.
IPFCRN 201072
UCSDSBQ (SD) at baselinea 50.71 (22.00) 43.28 (20.18)
UCSDSBQ mean change
(95% CI)
0.22 (–3.10 to 3.54) 6.81 (3.53 to 10.08) –6.58 (–11.25 to –1.92);
p= 0.006
Borg Dyspnoea Index after
walk test (SD) at baselineb
3.82 (1.95) 3.33 (1.73)
Borg Dyspnoea Index after
walk test, mean change
(95% CI)
0.04 (–0.30 to 0.37) 0.37 (0.04 to 0.70) –0.34 (–0.81 to 0.14);
p= 0.16
a UCSDSBQ total score ranges from 0 to 120, with higher scores indicating greater shortness of breath.
b Measures perceived breathlessness on a scale of 0 (none) to 10 (maximum).
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TABLE 45 Quality of life outcomes: sildenafil
Study Outcome
Interventions
Difference between
groupsSildenafil (n= 89) Placebo (n= 91)
Zisman et al.
IPFCRN 201072
SGRQa mean total score
(range) at baseline
54.55 (16.46) 51.72 (15.86)
SGRQ mean (95% CI)
change in total score at
12 weeks
–1.64 (–3.91 to 0.64) 2.45 (0.17 to 4.72) –4.08 (–7.30 to –0.86);
p= 0.01
SGRQ mean (SD)
symptoms score at
baseline
58.20 (17.75) 53.99 (18.90)
SGRQ mean (95% CI)
change in symptoms
score at 12 weeks
–3.58 (–7.02 to –0.13) 2.15 (–1.30 to 5.61) –5.73 (–10.61 to –0.85);
p= 0.02
SGRQ mean (SD) activity
score at baseline
71.20 (17.50) 68.02 (17.63)
SGRQ mean (95% CI)
change in activity score at
12 weeks
–1.15 (–3.68 to 1.38) 2.49 (0.00 to 4.99) –3.64 (–7.20 to –0.09);
p= 0.04
SGRQ mean (SD) impacts
score at baseline
43.20 (19.26) 39.77 (18.81)
SGRQ mean (95% CI)
change in impacts score
at 12 weeks
–0.88 (–3.72 to 2.02) 2.82 (–0.03 to 5.67) –3.70 (–7.76 to 0.37);
p= 0.07
SF-36b aggregate physical
scorec (SD) at baseline
33.17 (9.19) 34.84 (8.69)
SF-36 mean change
(95% CI) aggregate
physical score at 12 weeks
–0.51 (–1.86 to 0.83) –0.35 (–1.68 to 0.99) –0.17 (–2.06 to 1.73);
p= 0.86
SF-36 aggregate mental
score (SD) at baseline
49.53 (9.76) 50.58 (9.52)
SF-36 mean change
(95% CI) aggregate
mental score at 12 weeks
1.30 (–0.59 to 3.18) 3.02 (1.15 to 4.89) –1.72 (–4.38 to 0.93);
p= 0.20
EQ-5Dd self-report score
(SD) at baseline
0.71 (0.24) 0.74 (0.19)
EQ-5D mean change
(95% CI) self-report
questionnaire at
12 weeks
–0.01 (–0.06 to 0.03) –0.03 (–0.08 to 0.01) 0.02 (–0.04 to 0.08);
p= 0.54
EQ-5D VAS (SD) at
baseline
66.49 (17.45) 67.66 (16.98)
EQ-5D mean change
(95% CI) VAS at
12 weeks
0.48 (–3.10 to 4.06) –1.81 (–5.34 to 1.73) 2.28 (–2.75 to 7.32);
p= 0.37
a Scores range from 0 to 100, with lower scores indicating better QoL.
b Score ranges from 0 to 100, with a higher score indicating better function.
c SF-36 individual components can be seen in Appendix 5.
d Scale of –0.59 to 1.00 (higher score indicates better QoL).
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Adverse events
Serious adverse events were reported where at least one event was recorded during follow-up in the
Zisman and colleagues IPFCRN 201072 trial. These are shown in Table 46 within each of the major organ
classes presented in the publication. Appendix 5 has the complete details of each condition within each
major class. The number of participants with at least one serious adverse event was similar between
groups, with 15% and 16% for the sildenafil and placebo groups, respectively (see Table 46). In terms of
number of events, the study publication reports that among all participants, 14 serious adverse events
occurred in the sildenafil group and 23 in the placebo group. The rates of serious adverse events by each
major organ class were also similar between the two groups.
A range of adverse events were reported for those randomised to treatment with sildenafil and those
randomised to treatment with placebo and can be seen in Table 47, which reports these for each of the
major organ classes presented in the report. As can be seen, there are no statistically significant differences
in the proportion of adverse events recorded between the two groups. The rate of occurrence of any
adverse events was 90% in the sildenafil-treated participants, compared with 87% in the placebo-treated
participants. The majority of adverse events in both groups were either respiratory or infections.
Deaths from any cause were reported in the Zisman and colleagues IPFCRN 2010 trial,72 with two (4%)
participant deaths in the sildenafil-treated arm and four in the placebo-treated arm. There was no
statistically significant difference between the proportions of deaths (p= 0.43).
Summary
The primary outcome of a 20% improvement on the 6MWT was not significant in the study comparing
sildenafil with placebo. Lung function as measured by the FVC was also not statistically significant, but the
DLCO results favoured treatment with sildenafil and this may, therefore, represent a pulmonary vascular
effect. Dyspnoea may be improved (depending on the measure used and test conditions) and acute
exacerbations showed similar rates between groups. QoL was better in those treated with sildenafil when
measured using the SGRQ, but not when using the SF-36 or the EQ-5D. Serious adverse events and
adverse events showed similar rates between groups in this 12-week study. This study had an unclear risk
of bias, which should be considered when interpreting the results.
TABLE 46 Serious adverse events for sildenafil and placebo, by major organ system
SAEs
Number (%) with at least one SAE;
number observed (assumed by reviewer) Difference
between
groupsSildenafil (n= 89) Placebo (n= 91)
Any 13 (15); 14 15 (16); 23 p= 0.73
Respiratory, thoracic or mediastinal disorder 7 (8); 7 9 (10); 11 p= 0.63
Infection or infestation 3 (3); 4 2 (2); 2 p= 0.68
Cardiac disorder 1 (1); 1 3 (3); 3 p= 0.62
Gastrointestinal disorder 2 (2); 2 1 (1); 1 p= 0.62
Hepatobiliary disorders 0 1 (1); 1 p= 0.99
Injury, poisoning and procedural complications 0 1 (1); 3 p= 0.99
Neoplasms benign, malignant and unspecified 0 1 (1); 1 p= 0.99
Nervous system disorders 0 1 (1); 1 p= 0.99
Death from any cause, n (%) 2 (2) 4 (4) p= 0.43
SAE, serious adverse event.
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Assessment of effectiveness of non-pharmacological
interventions for idiopathic pulmonary fibrosis
Disease management programmes
The trial by Lindell and colleagues74 did not report lung function tests as outcomes. Two outcomes of
relevance to the present systematic review were measures of dyspnoea and QoL. Other outcomes that
were reported can be found in Appendix 5 [these were anxiety as measured by the Beck Anxiety Inventory
(BAI), depression as measured by the Beck Depression Inventory-II and stress as measured by the Perceived
Stress Scale (PSS)]. This study had an uncertain risk of bias.
Dyspnoea
Participants’ dyspnoea was measured in the Lindell and colleagues74 trial using the UCSDSBQ. This
measures shortness of breath on a scale of 0–120, with higher scores indicating more breathlessness. After
the 6-week disease management programme or the usual care control, the scores on the UCSDSBQ were
not statistically significantly different between the two groups (p= 0.972) (Table 48). No change scores of
the UCSDSBQ were provided.
TABLE 47 Adverse events for sildenafil and placebo, by major organ system
AEs
Number (%) with at least one AE;
number of adverse events observed Difference
between
groupsSildenafil (n= 89) Placebo (n= 91)
Any body system and event 80 (89.9); 442 79 (86.8); 453 p= 0.52
Respiratory, thoracic and mediastinal disorders 46 (51.7); 85 52 (57.1); 86 p= 0.46
Infections or infestations 42 (47.2); 58 39 (42.9); 52 p= 0.56
Nervous system disorders 35 (39.3); 56 35 (38.5); 58 p= 0.91
Gastrointestinal disorders 32 (36.0); 45 27 (29.7); 43 p= 0.37
General disorders and administration site
conditions
27 (30.3); 45 26 (28.6); 44 p= 0.80
Musculoskeletal and connective tissue disorders 25 (28.1); 34 20 (22.0); 33 p= 0.34
Vascular disorders 15 (16.9); 19 13 (14.3); 16 p= 0.64
Skin and subcutaneous tissue disorders 12 (13.5); 21 14 (15.4); 15 p= 0.72
Cardiac disorders 11 (12.4); 15 13 (14.3); 15 p= 0.70
Investigations 10 (11.2); 11 13 (14.3); 18 p= 0.54
Psychiatric disorders 6 (6.7); 7 16 (17.6); 21 p= 0.03
Eye disorders 12 (13.5); 17 9 (9.9); 10 p= 0.45
Metabolism and nutritional disorders 5 (5.6); 5 11 (12.1); 16 p= 0.13
Blood and lymphatic system disorders 7 (7.9); 7 2 (2.2); 2 p= 0.10
Ear and labyrinth disorders 5 (5.6); 5 3 (3.3); 5 p= 0.49
Injury, poisoning and procedural complications 3 (3.4); 5 4 (4.4); 6 p= 0.99
Renal and urinary disorders 3 (3.4); 3 4 (4.4); 5 p= 0.99
Neoplasms benign, malignant and unspecified 2 (2.2); 2 3 (3.3); 3 p= 0.99
Hepatobiliary disorders 0 2 (2.2); 3 p= 0.50
Reproductive system and breast disorders 1 (1.1); 1 1 (1.1); 1 p= 0.99
AE, adverse event.
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Quality of life
Quality of life of participants in the Lindell and colleagues74 trial was measured using the SF-36 and results
can be seen in Table 49. As discussed previously, the SF-36 measures QoL within two domains: physical
and mental health. Each scale is scored from 0 to 100, with a higher score indicating better function
(see also Chapter 4, Systematic review of health-related quality of life studies). After 6 weeks the SF-36
physical health score was lower (worse) in the participants assigned to the disease management
programme than in those assigned to the usual care control. The difference between the groups was
statistically significant (p= 0.038). No change scores on the SF-36 were provided. The scores on the SF-36
mental health scale were not statistically significantly different between the two interventions (p= 0.772).
Summary
One small pilot study with an unclear risk of bias reported limited evidence on the effects of a disease
management programme in IPF. The disease management programme did not lead to any significant
differences in dyspnoea. QoL appears to be adversely affected on measures of physical health but not on
measures of mental health. The study was designed to obtain pilot data for a future study and is unlikely
to be sufficiently powered.
Pulmonary rehabilitation
Forced vital capacity
After the 10-week pulmonary rehabilitation programme or usual care, the FVC was very similar between
the two groups in the Nishiyama and colleagues73 trial (p-value not stated; Table 50). The FVC, litres, at
end point was not changed from baseline measurements in either group. This study had an uncertain risk
of bias.
In the Jastrzebski and colleagues CCT61 it is reported that there were no statistically significant changes in
the results of lung function tests (assumed to include VC as this was an outcome) after 12 weeks, but
no data were reported.
TABLE 49 Quality of life outcomes: disease management programme
Study Outcome
Interventions
Difference
between
groups
Disease management
(n= 10)
Usual care control
(n= 9)
Lindell et al. 201074 SF-36 physical adjusted mean
(SD) at 6 weeksa
31.06 (4.61) 36.04 (4.63) p= 0.038
SF-36 mental adjusted mean
(SD) at 6 weeks
55.98 (2.71) 55.61 (2.71) p= 0.772
a Score ranges from 0 to 100, with a higher score indicating better function.
TABLE 48 Dyspnoea outcomes: disease management programme
Study Outcome
Interventions
Difference
between
groups
Disease management
(n= 10)
Usual care control
(n= 9)
Lindell et al. 201074 UCSDSBQ adjusted mean (SD)
scorea at 6 weeks
49.51 (22.64) 49.88 (22.64) p= 0.972
a UCSDSBQ total score ranges from 0 to 120, with higher scores indicating greater shortness of breath.
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Six-minute walk test
The distance walked on the 6MWT was statistically significantly lower in the pulmonary rehabilitation
group than in the usual care group at 10 weeks (p< 0.01) in the Nishiyama and colleagues73 trial
(Table 51). This does not take into account the differences at baseline between the groups on this measure
where the distance was also lower in the pulmonary rehabilitation group. When the mean change is
estimated (by reviewers) it can be observed that there is a positive change in the distance walked in the
pulmonary rehabilitation group and a negative change in the distance walked in the control group,
but these data cannot be compared statistically to establish if there are any differences between the
two groups.
The distance walked on the 6MWT at 12 weeks was 600.8m in the intervention group and 544.5m in the
control group of the Jastrzebski and colleagues study61 (see Table 51). The study reports only within-group
comparisons, however, so it is unclear whether or not this is a statistically significant difference. The 6MWT
distance at 6 weeks is also reported in this study and data can be found in Appendix 5.
Dyspnoea
Dyspnoea was measured using the BDI in the Nishiyama and colleagues73 RCT of pulmonary rehabilitation
versus control. The BDI comprises three categories: functional impairment, magnitude of task and
magnitude of effort. The total BDI score ranges from 0 to 12, with higher scores denoting milder dyspnoea.
Results can be found in Table 52. The difference between groups after the 10-week programme was small
and not statistically significant (p-value not reported). The change in BDI was not presented but has been
calculated here, where it can be seen that the BDI did not change in the pulmonary rehabilitation group
and improved only slightly in the control group.
TABLE 50 Forced vital capacity outcomes: pulmonary rehabilitation
Study Outcome
Interventions
Difference between
groups
Pulmonary rehabilitation
(n= 13) Control (n= 15)
Nishiyama et al. 200873 FVC, l, at 10 weeks 2.1 (0.4) 2.0 (0.8) 0.03 (–0.13 to 0.19);
NS
NS, not significant.
TABLE 51 Six-minute walk test outcomes: pulmonary rehabilitation
Study Outcome
Interventions
Difference between
groups
Inspiratory muscle
training (n= 16) Control (n= 14)
Jastrzebski et al. 200861 6MWT at baseline 487.4 (100.2) 485.6 (111.9)
6MWT distance (m)
at 12 weeks
600.8 (93.7) 544.5 (121.5) Not reported
Pulmonary
rehabilitation
(n= 13) Control (n= 15)
Nishiyama et al. 200873 6MWT at baseline 385 (116) 476 (128)
6MWT distance (m) 427 (84) 472 (130) 46.3 (8.3 to 84.4);
p< 0.01
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In the Jastrzebski and colleagues study,61 outcomes using both the Borg Dyspnoea Index and the BDI
were reported. These included the Borg Dyspnoea Index before and after the 6MWT, the BDI functional
impairment, magnitude of task, magnitude of effort, and the summary score. Results for the Borg
Dyspnoea Index and summary score of the BDI at 12 weeks can be seen in Table 52, where it appears that
these did not differ significantly between groups; however, no between-group analysis was presented in
the study to confirm this. Results of the BDI functional impairment, magnitude of task and magnitude of
effort and dyspnoea outcomes at 6 weeks can be found in Appendix 5.
Quality of life
Quality of life of participants in the RCT of pulmonary rehabilitation was assessed using the SGRQ.73
As discussed previously, the SGRQ has a total score and three subscales, and each scale ranges from a score
of 0 to 100 (lower scores indicating better QoL). Table 53 summarises the results from the Nishiyama and
colleagues73 trial where the SGRQ outcomes were statistically compared using the end-point scores. This
showed that the difference between the groups was statistically significant only on the total score (p< 0.05),
suggesting that those in the control group had better QoL than those participating in the pulmonary
rehabilitation programme. This does not take into account differences on these scales that were observed
between the two groups at baseline where the pulmonary rehabilitation group had worse QoL. When the
change from baseline scores are estimated, it would appear that QoL improved in the pulmonary rehabilitation
group whereas it declined in the control group, although this is based on observation of the data only.
In the Jastrzebski and colleagues study,61 QoL was assessed using the SF-36. This measure is described in
more detail in Chapter 4 (see Systematic review of health-related quality of life studies). Data from the
12-week assessment of the individual SF-36 components and the two summary scores can be seen in
Table 53. No statistical analysis was presented of the comparison between treatment groups; however,
it can be observed that scores were similar between groups.
TABLE 52 Dyspnoea outcomes: pulmonary rehabilitation
Study Outcome
Interventions
Difference between
groups in change
from baseline
Inspiratory muscle
training (n= 16) Control (n= 14)
Jastrzebski et al.
200861
Borg Dyspnoea Indexa before
6MWT at baseline
1.7 (1.1) 1.9 (1.0)
Borg Dyspnoea Index before
6MWT at 12 weeks
1.2 (0.5) 1.6 (1.6) Not reported
Borg Dyspnoea Index after 6MWT
at baseline
5.3 (2.2) 5.2 (2.3)
Borg Dyspnoea Index after 6MWT
at 12 weeks
3.8 (2.3) 4.2 (2.1) Not reported
BDIb summary score at baseline 6.1 (2.3) 6.07 (2.3)
BDI summary score at 12 weeks 7.9 (2.7) 6.4 (2.5) Not reported
Pulmonary
rehabilitation
(n= 13) Control (n= 15)
Nishiyama et al.
200873
BDIb at baseline 6.7 (1.4) 8.4 (1.5)
BDI score 6.7 (1.3) 8.0 (2.2) 0.4 (–0.6 to 1.4); NS
NS, not significant.
a Borg dyspnoea ranges from a scale of 0 (none) to 10 (maximum) breathlessness.
b BDI score ranges from 0 to 12, with higher score denoting milder dyspnoea in daily living.
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TABLE 53 Quality of life outcomes: pulmonary rehabilitation
Study Outcome
Interventions
Difference between
groups
Inspiratory muscle
training (n= 16)
Control
(n= 14)
Jastrzebski
et al. 200861
SF-36 PF at baseline 54.4 (23.6) 54.3 (17.4)
SF-36 PF at 12 weeks 68.1 (22.3) 62.5 (14.5) Not reported
SF-36 RP at baseline 42.8 (32.0) 44.6 (24.4)
SF-36 RP at 12 weeks 65.6 (31.5) 64.3 (30.6) Not reported
SF-36 BP at baseline 68.9 (27.2) 66.8 (22.2)
SF-36 BP at 12 weeks 75.7 (20.7) 69.6 (17.8) Not reported
SF-36 GH at baseline 37.8 (17.7) 37.4 (11.1)
SF-36 GH at 12 weeks 44.2 (22.4) 42.4 (13.6) Not reported
SF-36 VT at baseline 54.4 (18.2) 52.5 (13.3)
SF-36 VT at 12 weeks 60.0 (16.4) 57.1 (16.9) Not reported
SF-36 SF at baseline 58.9 (23.5) 58.0 (14.4)
SF-36 SF at 12 weeks 75.8 (30.8) 68.7 (18.2) Not reported
SF-36 RE at baseline 68.8 (39.4) 69.0 (44.3)
SF-36 RE at 12 weeks 70.8 (29.5) 78.6 (28.1) Not reported
SF-36 MH at baseline 64.2 (17.7) 65.1 (17.9)
SF-36 MH at 12 weeks 68.7 (16.8) 66.3 (20.2) Not reported
SF-36 PCS at baseline 38.4 (8.2) 36.1 (9.1)
SF-36 PCS at 12 weeks 44.8 (6.0) 42.3 (5.8) Not reported
SF-36 MCS at baseline 46.6 (9.9) 46.5 (10.9)
SF-36 MCS at 12 weeks 47.8 (11.22) 47.8 (11.6) Not reported
Pulmonary
rehabilitation (n= 13)
Control
(n= 15)
Nishiyama
et al. 200873
SGRQ symptoms score (SD) at baseline 56.4 (22.3) 38.0 (25.8)
SGRQ symptoms score (SD) at 10 weeks 53.4 (25.8) 40.6 (21.2) –5.7 (–18.7 to 7.2); NS
SGRQ symptoms score change 3 –2.6
SGRQ activity score (SD) at baseline 64.7 (17.1) 50.4 (26.2)
SGRQ activity score (SD) at 10 weeks 62.5 (16.9) 54.0 (22.6) –5.8 (–14.7 to 3.1); NS
SGRQ activity score change 2.2 –3.6
SGRQ impacts score (SD) at baseline 39.7 (17.6) 29.9 (23.7)
SGRQ impacts score (SD) at 10 weeks 36.5 (17.5) 32.9 (23.5) –6.2 (–12.8 to 0.3); NS
SGRQ impacts score change 3.2 –3
SGRQ total score (SD) at baseline 50.2 (16.3) 37.8 (22.7)
SGRQ total score (SD) at 10 weeks 47.3 (17.4) 40.9 (20.7) –6.1 (–11.7 to 0.5);
p< 0.05
SGRQ total score change 2.9 –3.1
BP, bodily pain; GH, general health; MCS, mental cumulative score; MH, mental health; NS, not significant; PCS, physical
cumulative score; PF, physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
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Other secondary outcomes
Other outcomes reported in the Nishiyama and colleagues73 trial include FEV1, TLC, and the partial pressure
of oxygen and carbon dioxide, the results of which can be found in Appendix 5. Other outcomes reported
in the Jastrzebski and colleagues study61 include inspiratory capacity and oxygen cost diagram, the results
of which can be found in Appendix 5.
Summary
One study with an unclear risk of bias and one with a high risk of bias provided limited data on the
effectiveness of a pulmonary rehabilitation programme or the addition of inspiratory muscle training, on
IPF. Results are uncertain as to the effects of these types of intervention, and there were baseline
differences between groups on many key outcomes (QoL, 6MWT), which should be considered when
interpreting the results of one of the studies. On measures of lung function (FVC) and dyspnoea, there
does not appear to be a beneficial effect of the programme.
Network meta-analysis
Network meta-analysis is an extension of conventional, pairwise, meta-analysis combing direct and indirect
RCT evidence. This approach allows simultaneous comparison of multiple treatments from trials comparing
different sets of treatments (provided there is a connected network). It is based on the assumption that,
on a suitable scale, we can add and subtract the within-trial estimates of relative treatment effects. In this
case, the difference in effect between treatments A and B is equal to the difference in effects between
treatments A and C, and B and C: a difference in differences model A – B= (A –C) – (B –C).76,77 When
direct randomised evidence is limited or unavailable, NMA is increasingly being used to inform clinical
decision-making and its use has been embraced by reimbursement agencies including NICE in the UK and
endorsed by health technology assessment bodies such as the International Society for Pharmacoeconomics
and Outcomes Research.78,79 NMA is typically performed in a Bayesian framework using vague priors to
ensure posterior estimates are based on the observed data.
The IPF NMA focused on the FVC end point as clinical evidence has established a correlation with disease
progression80 and, thus, FVC drives the economic model (discussed in Chapter 4, Independent economic
evaluation). Ten studies met the inclusion criteria and were included in the analysis (Table 54). The
two non-pharmacological interventions were excluded from the NMA on clinical advice as they are not
interchangeable treatments with the pharmacological interventions, but are rather given alongside them.
In addition, thalidomide was excluded from the RCT as the focus of treatment is not to improve lung
function. Inhaled NAC was considered separately from triple therapy as it has a different method
of administration. Between-study heterogeneity has been examined in the systematic review section
of this report.
The FVC end point was measured on two continuous scales: FVC per cent predicted; and absolute change
from baseline (litres). Where both scales were presented in the same trial (Richeldi and colleagues71), per
cent predicted was preferred as this measure was adjusted for age, height and sex. Trials were relatively
homogeneous apart from Zisman and colleagues IPFCRN 2010,72 which studied a more severe IPF
population. This trial has nevertheless been included in the analysis as it only compares with placebo and,
thus, does not impact on the other relative treatment effects; it may impact on the between-study SD
which will be considered in a sensitivity analysis. It is also worth observing that the 1991 study by Raghu
and colleagues70 is in a very small population (n= 19). Furthermore, clinical opinion has identified that
studies published prior to 2000 may have included NSIP patients along with IPF, with NSIP patients
performing better.1,8 This might have biased outcomes for Raghu and colleagues70 if there were more NSIP
subjects in the treatment arm; however, this is not reported. In any case, this study’s effect on the analysis
is dominated by the larger study that contributes azathioprine data.
The resulting evidence network is illustrated in Figure 9.
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TABLE 54 Forced vital capacity data used in the analysis
Study Treatment FVC measure Mean (SD) n
Taniguchi et al. 201065 Pirfenidone Litres –0.09 (0.20) 104
Placebo Litres –0.16 (0.20) 103
Richeldi et al. 201171 BIBF 1120 Per cent predicted –1.04 (9.1) 85
Placebo Per cent predicted –6.0 (9.4) 85
Raghu et al. 199170 Azathioprine Per cent predicted 6.5 (16.8) 10
Placebo Per cent predicted 1.7 (22.2) 9
Raghu et al. 201268 NAC triple Litres –0.24 (0.40) 77
Placebo Litres –0.23 (0.40) 78
Zisman et al. 201072 Sildenafil Per cent predicted –0.97 (4.9) 89
Placebo Per cent predicted –1.29 (4.8) 91
Homma et al. 201269 Inhaled NAC Litres –0.09 (0.3) 38
Placebo Litres –0.15 (0.2) 38
Demedts et al. 200567 NAC triple Litres –0.06 (0.34) 71
Azathioprine Litres –0.19 (0.41) 68
Capacity 00662 Pirfenidone Per cent predicted –9 (19.6) 171
Placebo Per cent predicted –9.6 (19.1) 173
Capacity 00462 Pirfenidone Per cent predicted –8 (16.5) 174
Placebo Per cent predicted –12.4 (18.5) 174
Azuma et al. 200566 Pirfenidone Litres –0.03 (0.22) 72
Placebo Litres –0.13 (0.19) 35
Pirfenidone
NAC triple Sildenafil
Placebo
BIBF 1120
Inhaled NACAzathioprine
FIGURE 9 Evidence network for the FVC end point.
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Were the network star-shaped,81 with each treatment compared only with placebo, the NMA results would
approximate the traditional pairwise meta-analysis in Figures 2–8. However, in this case there is one closed
loop in the evidence network (placebo ↔ NAC triple therapy ↔ azathioprine) (see Figure 9). The presence
of both direct and indirect evidence allows us to compare azathioprine with placebo directly and indirectly
via NAC triple therapy and vice versa. Because of this closed loop, there is also potential for inconsistency
between the direct and indirect evidence within the network.
The standardised mean difference approach was developed to combine treatment effects reported in
distinct continuous measures which essentially measure the same thing and convert them to a common
scale.82 The assumption underlying this analysis is that mean change in FVC per cent predicted is measuring
the same thing as absolute change in FVC, albeit we know that FVC per cent predicted is adjusted for age,
height, sex and race. The mean difference between treatment arms is divided by the SD; thus, the effect
measures are adjusted to be defined in terms of units of SD. A disadvantage is that the standardised mean
difference measure is difficult to interpret and thereby populate a cost-effectiveness model.
Treatment effects are converted to standardised mean difference using Hedges’ adjusted g method
(Table 55). This was preferred over Cohen’s method to overcome potential small sample bias;82 one study
consists of only 19 subjects split between two arms (Raghu and colleagues70). A sensitivity analysis was
conducted using Cohen’s method. The standardised mean difference calculation is performed with the
treatment effect being subtracted from placebo; this is in order to produce output suitable for use in an
economic model (where the treatment benefit is expressed as reduction in the rate of decline compared
with placebo). The negative values in the table below, therefore, represent a treatment benefit.
The standardised mean difference scale measures were then meta-analysed as contrast data (mean
differences) using the Decision Support Unit NMA code.83 Fixed- and random-effects models were
conducted in OpenBUGS (OpenBUGS Foundation, www.openbugs.net/w/Overview, with best model fit
determined by deviance information criterion (DIC).84 Models were run for a burn in of 20 k simulations,
which were discarded, and a further 100 k simulations for estimation. Two chains were run, each
with different starting values. Trace, Brooks Gelman Rubin and density plots were examined to ensure
that models had converged.85 Results [means, standard errors and 95% credible intervals (CrIs)] are
reported in Table 56. The OpenBUGS model code is provided in Appendix 6. A validation of the code
was conducted in SAS (SAS Institute Inc., Cary, NC, USA) and is reported in Appendix 7.
TABLE 55 Forced vital capacity outcome data converted to standardised mean difference scale (Hedges’ g method)
Study Treatment Control SMD SE (SMD)
Taniguchi et al. 201065 Pirfenidone Placebo –0.35 0.14
Richeldi et al. 201171 BIBF 1120a Placebo –0.53 0.16
Raghu et al. 199170 Azathioprine Placebo –0.23 0.46
Raghu et al. 201268 NAC triple Placebo 0.02 0.16
Zisman et al. 201072 Sildenafil Placebo –0.07 0.15
Homma et al. 201269 Inhaled NAC Placebo –0.23 0.23
Demedts et al. 200567 NAC triple Azathioprine –0.34 0.17
Capacity 00662 Pirfenidone Placebo –0.03 0.11
Capacity 00462 Pirfenidone Placebo –0.25 0.11
Azuma et al. 200566 Pirfenidone Placebo –0.47 0.21
SE, standard error; SMD, standardised mean difference.
a BIBF 1120 compares the 300mg/day dose with placebo.
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Parameters stabilised between 5000 and 10,000 simulations. There was no evidence to suggest that
the random-effect model was a better fit than the fixed effect; a difference in DIC of 2–3 is needed
to be indicative of improved fit.84 There was also considerable uncertainty around the random-effects
between-study SD. The random-effects model incorporates a measure of between-study variation
(heterogeneity) into the calculations, thereby increasing the standard error, and can therefore be viewed
as a more conservative estimate.86 There were insufficient data to allow random-effects variances to
vary between treatments. Neither BIBF 1120 nor pirfenidone reached statistical significance using the
random-effects model; therefore, a scenario using the random-effects estimates is included as a
sensitivity analysis.
Only the fixed-effect results for BIBF 1120 and pirfenidone were statistically significant, reducing the rate of
decline in FVC compared with placebo. The results for BIBF 1120, inhaled NAC and sildenafil were very
similar to the trial results. The pirfenidone estimate was a meta-analysis of the four individual trials, with
more weight given to the larger Capacity trials.62 The azathioprine estimate was driven by the indirect
estimated via NAC triple therapy over the small placebo study. Similarly, the NAC triple therapy estimate
assumed more weight via the direct route to placebo rather than the indirect evidence via the small
azathioprine study.
However, we still have interpretation difficulties with the summary standardised mean difference scores.
To make these interpretable, and thereby usable in our cost-effectiveness model, we converted the
standardised mean difference scores to log-odds ratios using the following formulae:87
logOR=
πﬃﬃﬃ
3
p SMD (1)
and
se (logOR)=
πﬃﬃﬃ
3
p se (SMD) (2)
This transformation assumes that the data have a logistic distribution and that within-study arms have
equal variances. The within-study variances appear equal in Table 54, apart from the small azathioprine
study (Raghu and colleagues70) and the Demedts and colleagues study.67 Nevertheless, F-tests (F= 0.57,
p= 0.42; F= 0.69, p= 0.12, respectively) show it is likely that the two groups come from populations with
equal variances. Without access to individual patient-level data, the distributional assumption is hard to
TABLE 56 Forced vital capacity NMA results (vs. placebo), standardised mean differences
Comparator
Fixed effects Random effects
Mean SE 95% CrI Mean SE 95% CrI
Azathioprine 0.25 0.21 –0.16 to 0.66 0.15 0.38 –0.63 to 0.81
BIBF 1120 –0.53 0.16 –0.84 to –0.23 –0.53 0.37 –1.24 to 0.17
NAC triple therapy –0.03 0.15 –0.33 to 0.27 –0.08 0.32 –0.73 to 0.49
Inhaled NAC –0.23 0.23 –0.68 to 0.22 –0.23 0.41 –1.00 to 0.53
Pirfenidone –0.21 0.06 –0.34 to –0.09 –0.25 0.18 –0.62 to 0.08
Sildenafil –0.07 0.15 –0.36 to 0.23 –0.07 0.37 –0.76 to 0.63
reSD NA NA 0.24 0.24
DIC 2.02 1.99
NA, not applicable; reSD, random-effects standard deviation; SE, standard error.
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verify, hence a sensitivity analysis assumed a normal distribution. Table 57 reports the standardised mean
differences converted to log-odds ratios and odds ratios for use in the economic model. Odds ratios for
slowing the decline in FVC are plotted in Figure 10.
Odds ratios of < 1 are indicative of reducing FVC decline relative to placebo. Only BIBF 1120 and
pirfenidone produced a statistically significant decline in rate of FVC decline relative to placebo (odds ratios
and 95% CrI < 1). A head-to-head comparison of BIBF 1120 versus pirfenidone showed a trend favouring
BIBF, although this was not statistically significant (see Table 57).
TABLE 57 Network meta-analysis fixed-effects results, converted to log-odds ratios for slowing the decline in FVC
Comparator (vs. placebo)
Log-odds ratios Odds ratios
Mean 95% CrI Mean 95% CrI
Azathioprine 0.44 –0.30 to 1.19 1.56 0.74 to 3.29
BIBF 1120 –0.97 –1.52 to –0.41 0.38 0.22 to 0.66
NAC triple therapy –0.06 –0.60 to 0.48 0.94 0.55 to 1.62
Inhaled NAC –0.42 –1.24 to 0.40 0.66 0.29 to 1.49
Pirfenidone –0.39 –0.62 to –0.16 0.68 0.54 to 0.85
Sildenafil –0.12 –0.65 to 0.41 0.89 0.52 to 1.51
Head-to-head comparison
BIBF 1120 vs. pirfenidone –0.58 –1.18 to 0.03 0.56 0.31 to 1.03
Azathioprine
BIBF 1120
NAC triple therapy
Inhaled NAC
Pirfenidone
Sidenafil
1.56 (0.74 to 3.29)
0.38 (0.22 to 0.66)
0.94 (0.55 to 1.62)
0.66 (0.29 to 1.49)
0.68 (0.54 to 0.85)
0.89 (0.58 to 1.51)
0.05 0.25 1.00
Odds ratio (log scale)
5.00 25.00
FIGURE 10 Forest plot of odds ratios slowing the decline in FVC (treatments vs. placebo).
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Following best practice, we examined the level of agreement or consistency between the direct and
indirect evidence.88 We used the Bucher and colleagues89 method to calculate the indirect estimates using
the consistency equations and compared with the direct estimate, i.e.
ω^BC =d
D
BC−d
l
BC =d
D
BC − (d
D
AC −d
D
AB), (3)
where ω^ is the inconsistency parameter, and dD and dl are the direct and indirect evidence, respectively,
comparing, for example, treatments B and C. The variance is then given by:
var ω^BC = vard
D
BC þ vardlBC = vardDBC þ vardDAB þ vardDAC (4)
These are then used to calculate a z-score which is then compared with the standard normal distribution:
zBC =
ω^BCﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
varω^BC
p (5)
While more elaborate methods, such as Dias and colleagues’90 node-splitting, plots of posterior mean
deviance91 or net heat plots92 have been proposed for more complex networks with many loops, the
Bucher and colleagues89 approach is more efficient here as we have a simple network with only one loop
and no multiarm trials. It is only necessary to calculate one measure of inconsistency within each loop;
the others are intuitively the same.88 The results of the calculations are presented in Table 58.
We can conclude that there is no evidence of inconsistency present in this treatment loop (p= 0.25). While
the mean estimates from the azathioprine studies disagree, there is huge variability around the small
Raghu and colleagues70 study, which rules out any clear inconsistency.
In our sensitivity analysis, an alternative parameterisation was applied for the log-odds ratio, assuming that
the data are normally distributed,93 whereby a multiplier of 1.65 was applied to the mean and standard
error standardised mean difference estimates. This resulted in slightly lower treatment effects and narrower
CrIs but did not affect statistical significance (Table 59).
Fixed-effect results using Cohen’s parameterisation were unchanged apart from azathioprine versus
placebo, which gave an odds ratio of 1.57 (95% CrI 0.76 to 3.26).
In another sensitivity analysis using the random-effects results, arguably a more conservative scenario, none
of the treatments reached statistical significance compared with placebo (Table 60).
Excluding the sildenafil study did not affect the log-odds ratios and had negligible impact on the
between-study deviation, 0.23 (SD 0.23) compared with 0.24 (SD 0.24), when the study was included.
TABLE 58 Inconsistency estimates based on Bucher’s equations
Loop Pair
Direct, dD Indirect, dl Inconsistency, ω^
z-score p-valueMean (SD) Mean (SD) Mean (SD)
Azathioprine, NAC
triple, placebo
Azathioprine,
placebo
–0.23 (0.46) 0.36 (0.23) –0.59 (0.52) –1.14 0.25
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Existing systematic reviews
Five existing systematic reviews have been identified with relevance to the research question in the present
review, and these have been briefly summarised here.94–98
Spagnolo and colleagues,94 in a Cochrane systematic review of non-steroid agents in the treatment of IPF
(either as sole agents or in addition to corticosteroid treatment), identified 15 RCTs of relevance. Most of
these were placebo-controlled trials and the interventions included were interferon gamma-1 beta,
pirfenidone, cyclophosphamide, etanercept, imatinib, bosentan, colchicine, azathioprine, NAC and
anticoagulant. Five of the interventions (eight RCTs) were not eligible for inclusion in the current review
and two other RCTs of potentially eligible interventions did not meet the inclusion criteria of the present
review. Included RCTs that were also included in the present review were three RCTs of pirfenidone62,65
and one of azathioprine.70 The date of the last searches of the Cochrane review was April 2010.
A separate Cochrane systematic review, by Richeldi and colleagues,95 searched for evidence of the effects
of corticosteroids in IPF. The date of the last searches was June 2008, at which time no trials were
identified that met the inclusion criteria.
TABLE 59 Network meta-analysis fixed-effects results, converted to log-odds ratios for slowing the decline in FVC
(assuming normal distribution)
Comparator (vs. placebo)
Log-odds ratios Odds ratios
Mean 95% CrI Mean 95% CrI
Azathioprine 0.40 –0.27 to 1.08 1.50 0.76 to 2.95
BIBF 1120 –0.88 –1.39 to –0.37 0.41 0.25 to 0.69
NAC triple therapy –0.05 –0.55 to 0.44 0.95 0.58 to 1.55
Inhaled NAC –0.38 –1.13 to 0.36 0.68 0.32 to 1.44
Pirfenidone –0.35 –0.56 to –0.15 0.70 0.57 to 0.86
Sildenafil –0.11 –0.59 to 0.37 0.90 0.55 to 1.45
Head-to-head comparison
BIBF 1120 vs. pirfenidone –0.53 –1.07 to 0.02 0.59 0.34 to 1.03
TABLE 60 Network meta-analysis random-effects results, converted to log-odds ratios for slowing the decline in FVC
Comparator (vs. placebo)
Log-odds ratios Odds ratios
Mean 95% CrI Mean 95% CrI
Azathioprine 0.27 –1.15 to 1.47 1.32 0.32 to 4.34
BIBF 1120 –0.97 –2.24 to 0.31 0.38 0.11 to 1.36
NAC triple therapy –0.15 –1.33 to 0.90 0.86 0.27 to 2.45
Inhaled NAC –0.43 –1.81 to 0.96 0.65 0.16 to 2.61
Pirfenidone –0.45 –1.12 to 0.15 0.64 0.33 to 1.16
Sildenafil –0.12 –1.38 to 1.14 0.89 0.25 to 3.13
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A systematic review of interferon gamma-1 beta for IPF was undertaken by Bajwa and colleagues in
2005.96 This intervention was not eligible for the present systematic review. Four studies were included.
King and colleagues97 presented the results of a systematic review and meta-analysis of pirfenidone in a
conference abstract in 2011. Four RCTs were included, all of which were included in the present review.
The abstract was sponsored by InterMune, the sponsor of pirfenidone in the UK, and was discussed in
more detail in Network meta-analysis.
Ryerson and colleagues98 focused their systematic review on the treatment and correlates of dyspnoea in
IPF. Searches were undertaken until November 2010 and studies of any design were eligible if they
included at least 10 adults with IPF. Twenty-nine studies met the inclusion criteria; eight of these were
RCTs, all of which were identified in searches of the present systematic review.
Ongoing randomised controlled trials
Twenty-five ongoing studies of possible relevance have been identified. Eight of these were phase III RCTs
and are summarised here. Seventeen were phase II studies and are summarised in Table 61.
TABLE 61 Ongoing/recently completed phase II studies of potential relevance
Treatment details Estimated completion Link
BIBF 1120 Completed http://clinicaltrials.gov/show/NCT01136174
Pirfenidone March 2013a http://clinicaltrials.gov/show/NCT01504334
Carbon monoxide July 2014 http://clinicaltrials.gov/show/NCT01214187
SAR156597 October 2013 http://clinicaltrials.gov/show/NCT01529853
Sirolimus November 2015 http://clinicaltrials.gov/show/NCT01462006
Pulmonary rehabilitation December 2013 http://clinicaltrials.gov/show/NCT01499745
Sildenafil, losartan, sildenafil
and losartan
May 2013a http://clinicaltrials.gov/show/NCT00981747
STX-100 December 2013 http://clinicaltrials.gov/show/NCT01371305
Lysophosphatidic acid receptor
antagonist
January 2015 http://clinicaltrials.gov/show/NCT01766817
Tralokinumab May 2015 http://clinicaltrials.gov/show/NCT01629667
Simtuzumab July 2014 http://clinicaltrials.gov/show/NCT01769196
Cognitive–behavioural therapy February 2014 http://clinicaltrials.gov/show/NCT01738711
GS-6624 Unknown www.clinicaltrialsregister.eu/ctr-search/search?
query=eudract_number:2012–001571–36
VRP700 Unknown http://apps.who.int/trialsearch/Trial.aspx?
TrialID=EUCTR2012–005794–31-GB
Lecithinized superoxide
dismutase nebuliser
Unknown http://apps.who.int/trialsearch/Trial.aspx?TrialID=
JPRN-UMIN000009572
Oxygen Unknown http://apps.who.int/trialsearch/Trial.aspx?
TrialID=ACTRN12611001154998
Oxygen Unknown http://apps.who.int/trialsearch/Trial.aspx?TrialID=
JPRN-UMIN000005098
a Date as per trial register.
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A study protocol for a multicentre RCT comparing exercise training with a usual care control was
published in February 2013.63 This RCT aims to recruit 116 participants with ILD and will analyse data
for those with IPF in planned subgroup analyses. The primary outcome for this RCT will be the 6MWT
distance and follow-up is planned for 6 months. The study will be powered to detect a difference in
the change in 6-minute walk distance (6MWD) in the IPF subgroup. The research is funded by the ATS
Foundation, the Pulmonary Fibrosis Foundation, the Institute of Breathing and Sleep, the Eirlene Lucas
Foundation and the National Health and Medical Research Council (MRC) of Australia. It is not clear from
the publication when the study aims to be completed.
A placebo-controlled RCT of BIBF 1120 300mg/day is currently ongoing. Patient recruitment is complete
and the follow-up planned for 52 weeks. The study has an estimated enrolment of 515 participants and the
effects of treatment will be tested on the primary outcome measure of annual rate of decline in FVC.
The study is funded by Boehringer Ingelheim Pharmaceuticals (http://clinicaltrials.gov/show/NCT01335464,
http://clinicaltrials.gov/show/NCT01619085).
A placebo-controlled RCT of pirfenidone is currently ongoing, although patient recruitment is complete.
The study, known as the ASCEND trial, has a planned follow-up of 52 weeks and an estimated
enrolment of 500 participants. The primary outcome measure is the change in the per cent predicted FVC.
The study is funded by InterMune and the estimated final outcome assessment is February 2014
(http://clinicaltrials.gov/show/NCT01366209).
A RCT of sildenafil compared with placebo is currently recruiting participants with either COPD or IPF. It is
unclear whether or not the IPF participant data will be reported separately. The study is sponsored by the
Rabin Medical Centre, Israel, and plans to recruit 60 participants (http://clinicaltrials.gov/show/NCT01382368).
A placebo-controlled RCT of cotrimoxazole is under way in Spain. Participants will be followed for
24 weeks and efficacy will be evaluated by the decline in FVC per cent predicted. The study is sponsored
by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla and is expected to complete
in September 2014 (http://clinicaltrials.gov/show/NCT01777737).
An ongoing RCT tested the effectiveness of pulmonary rehabilitation as measured by the 6MWT is
expected to be completed in September 2013. The study has a usual care comparator group and
is anticipating recruiting 50 participants. The study is funded by the Department of Veterans Affairs
(http://clinicaltrials.gov/show/NCT01118221).
Another ongoing RCT is also assessing the effects of a pulmonary rehabilitation programme compared
with usual care. The study is sponsored by Klinikum Berchtesgadener Land der Schön-Kliniken and aims to
recruit 78 IPF participants. The primary outcome of the 6MWT will be assessed at 3 months’ follow-up.
The study aims to complete in July 2015 (http://clinicaltrials.gov/show/NCT01772667).
The effectiveness of treatment with fibrangi is being assessed in an ongoing RCT in the Islamic Republic of
Iran. The study, funded by Pars Roos Biotechnology Co., is aiming to recruit 20 participants. The primary
outcome measure is the DLCO which will be assessed 3 months after cessation of treatment. The
recruitment status is complete but there are no details as to when study completion is anticipated
(http://apps.who.int/trialsearch/Trial.aspx?TrialID=IRCT138806152425N1).
In addition, the NAC versus placebo arms of the Raghu and colleagues68 trial are expected to report
in 2014.
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Chapter 4 Economic analysis
Introduction
The aim of this section is to assess the cost-effectiveness of the different interventions for managing
patients with IPF, including pharmacological and non-pharmacological interventions, compared with BSC in
the UK. The economic evaluation incorporates:
l a systematic review of the literature on the cost-effectiveness of the different pharmacological and
non-pharmacological interventions for managing patients with IPF
l a systematic review of studies assessing HRQoL in people with IPF, and
l an independent economic model developed specifically for this evaluation focusing on those
interventions shown to be clinically effective in the systematic review (see Chapter 3), presenting the
structure, parameterisation and results of the analysis.
Systematic review of existing cost-effectiveness evidence
A systematic review of the literature was undertaken to identify economic evaluations of interventions to
manage IPF. The purpose was to assess the current evidence base for the cost-effectiveness of different
interventions and to identify whether or not there was a need to conduct further economic modelling.
If further modelling is required, the methods and parameters used in previous cost-effectiveness studies
will be assessed to help inform the development of a new or updated evaluation.
The sources and search terms used the systematic literature search are described in Appendix 1 and
details of the study selection, data extraction and quality assessment processes are outlined in Chapter 2
(see Study selection and data extraction).
Results of the systematic review
Searches identified a total of 225 references after deduplication; only two full references were retrieved
(Figure 11). The majority of the 223 references excluded at the first screening for the review were due to
an incorrect participant group or study type. Of the two studies retrieved as full papers, only one was
judged to have met the inclusion criteria for the systematic review.99 The other study was a review of an
unpublished evaluation, providing insufficient information about the study itself.100 The characteristics,
methodological quality and results of the included economic evaluation are outlined in Tables 62 and 63
and are discussed below. Data extractions and quality assessment can be seen in Appendix 9.
Critical appraisal of the studies
The economic evaluation by Hagaman and colleagues99 included in the systematic review of cost-effectiveness
focused on the evaluation of a test (i.e. TPMT testing) to identify patients with IPF who may incur severe
adverse effects (i.e. leukopenia) that are associated with a component of a standard therapy for managing
IPF (i.e. azathioprine which is administered with NAC and prednisolone).99 It compared strategies that used
or did not use the test prior to standard treatment and with an additional conservative therapy option.
Although the use of the TPMT tests was not the focus of the inclusion criteria for this systematic review, the
study also incorporated a comparison of standard treatments for IPF. This allowed an initial assessment of
those treatments and, more importantly, an opportunity to examine the structure and data sources for the
model with a view to its use in the model being developed for the current evaluation. The study by Hagaman
and colleagues99 evaluation was a cost–utility analysis within the US health-care system.99 The study provided
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References for retrieval
and screening
Titles and abstracts
inspected
(n = 225)
Total identified from
searching
(after deduplication)
Excluded
(n = 223)
Excluded
(n = 1; study type)
Studies described in our review
(n = 1)
FIGURE 11 Flow chart of identification of studies for inclusion in the review of cost-effectiveness.
TABLE 62 Critical appraisal checklist of economic evaluation60
Item Hagaman et al.99 Comments
1. Is there a clear statement of the decision
problem?
Ya
2. Is the comparator routinely used in UK NHS? ? The intervention (screening) appears to be in
more routine use than no screening
3. Is the patient group in the study similar to
those of interest in UK NHS?
? Limited information is provided about the
patient group, with parameter values from
different clinical and ethnic groups
4. Is the health-care system comparable with the
UK?
? US health-care system, though limited details
provided
5. Is the setting comparable with the UK? Y Secondary care
6. Is the perspective of the model clearly stated? N No, although costs are clearly stated
7. Is the study type appropriate? Y
8. Is the modelling methodology appropriate? ? Limited details provided. Only considers
1-year time horizon, with all events occurring at
0.5 years on average
9. Is the model structure described and does it
reflect the disease process?
Y
10. Are assumptions about model structure listed
and justified?
N
11. Are the data inputs for the model described
and justified?
? Not all inputs are described and justified
(e.g. utility estimates, resource use)
12. Is the effectiveness of the intervention
established based on a systematic review?
N
13. Are health benefits measured in QALYs? Y
14. Are health benefits measured using a
standardised and validated generic
instrument?
? Not stated
15. Are the resource costs described and
justified?
? Costs are stated, justification for resources not
provided
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clear statements of the decision problem being assessed, used an appropriate model structure to reflect the
disease process, included measures of benefit, resource use and cost and undertook an assessment of
uncertainty through sensitivity analyses. It is less clear whether or not the study was relevant to the UK setting
in terms of the comparators used, the patient group included or the nature of the service provided. It is also
uncertain whether or not the modelling methodology was appropriate, the parameter values used were
justified, the health benefits used were valid generic measures, and whether or not the modelling had been
validated. No information was provided about the perspective, assumptions or discount rates used and it
appears than none of the parameters were obtained through a systematic approach. While many of the
apparent limitations in the evaluation may reflect the lack of detail in the reporting of the study, it causes
uncertainty about the adequacy of the approach taken and the validity of the results.
TABLE 62 Critical appraisal checklist of economic evaluation60 (continued )
Item Hagaman et al.99 Comments
16. Have the costs and outcomes been
discounted?
N
17. Has uncertainty been assessed? Y Limited details provided
18. Has the model been validated? ? Not stated
?, unclear; N, no; QALY, quality-adjusted life-year; Y, yes.
a States that the comparison will be between azathioprine, NAC and prednisolone with and without TPMT testing before
initiating therapy and a conservative therapy strategy (i.e. no specific pharmacological treatment for IPF and using only
supportive measures).
TABLE 63 Characteristics of economic evaluations
Characteristics Study details
Author Hagaman et al.99
Publication year 2010
Country USA
Funding source Not stated
Study type Cost–utility analysis
Perspective Not stated
Study population IPF patients eligible for azathioprine treatment (no details stated)
Intervention(s) TPMT screening prior to treatment with azathioprine, NAC and steroids
Intervention effect Reduced incidence of leukopenia
Currency base US$ 2007
Model type Decision tree
Time horizon 1 year
Baseline cohort Not stated
Base-case results ICER of US$29,663 for comparison of azathioprine, NAC and prednisolone with and without prior
TMPT testing
ICER, incremental cost-effectiveness ratio.
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Modelling approach
Hagaman and colleagues used a decision tree model to examine the cost-effectiveness of the addition of
TPMT testing for people with IPF prior to initiating standard treatment.99 The model evaluated three
treatment arms for managing IPF, specifically azathioprine, NAC and steroids (prednisolone) ‘triple therapy,’
with and without prior TPMT testing, and a conservative therapy option (no specific pharmacological
treatment for IPF, only supportive measures).
Patients undergoing TPMT testing prior to treatment were categorised into three different treatment
groups depending on TPMT activity. Patients with normal TPMT activity received standard doses of
azathioprine, NAC and prednisolone at the outset of treatment. Intermediate TPMT activity resulted in
patients receiving a reduced dose of azathioprine and standard doses of NAC and prednisolone. Where
TPMT activity was absent, patients received conservative therapy. Although thresholds for defining TPMT
activity and dosages for the different regimens are not specified, references are provided for guidance on
recommended levels. Patients who did not undergo TPMT testing received either standard doses of
azathioprine, NAC and prednisolone or conservative therapy at the start of treatment.
Subsequent changes in treatment were incorporated within the model. Although Hagaman and colleagues
state that this was based on clinical practice, no information was provided to justify the treatments
subsequently given.99 When patients suffered from severe complications following treatment with
azathioprine, NAC and prednisolone, specifically leukopenia requiring hospitalisation, and survived, they
were crossed over to receive conservative therapy. Where leukopenia following treatment with
azathioprine, NAC and prednisolone was less severe and could be managed on an outpatient basis, the
dose of azathioprine was reduced. Hagaman and colleagues state that other non-TPMT complications
related to gastrointestinal symptoms may require discontinuation of treatment; however, they do not
indicate the subsequent management strategies used.99 Patients who survive leukopenia or who do
not experience leukopenia may remain stable without progression, incur progression of IPF or die.
No systematic review was undertaken to identify evidence on the prevalence of TPMT activity, efficacy of
treatment with azathioprine, NAC and prednisolone or conservative therapy, the occurrence of complications
or for estimates on HRQoL. Instead, Hagaman and colleagues identified specific studies providing an estimate
of the different parameters, which do not always focus solely on the relevant patient group.99 Prevalence of
TPMT activity originated from a population-based cohort study of the distribution of phenotypic TPMT
activity in 14,545 Spanish patients with diseases amenable to treatment with azathioprine.101 Gisbert and
colleagues101 found that TPMT activity was low in 0.5% of the cohort, intermediate in 11.9% and high
in 87.6%. Treatment efficacy was assessed through disease progression, defined by a decline in FVC of at
least 10%. A RCT (included in the clinical systematic review) comparing azathioprine, NAC and prednisolone
with NAC and prednisolone in patients with IPF found that 37% of the former had progressed at 12 months
compared with 51% in the latter (statistically significant difference – p-value not stated).67 The occurrence of
leukopenia by TPMT activity was taken from two studies of patients with inflammatory bowel disease who
were treated with azathioprine.102,103 A weighted average was calculated, showing that 5% of patients with
normal TPMT activity, 21.4% with intermediate activity and 100% with no activity developed leukopenia
following full-dose azathioprine. It was assumed from studies in alveolar haemorrhage and atopic dermatitis
that a reduced dose would half the risk to 10%.104,105 Estimates of HRQoL are presented for progression of
IPF (base case 0.63, range for sensitivity analysis 0.5 to 0.9), leukopenia (0.95, range 0.92 to 0.98) and
complicated leukopenia (0.76, range 0.66 to 0.86). Although there is no discussion about the HRQoL data,
the studies from which they originate include patients with cancer and IPF.
The model adopted a 1-year time horizon, with all events (i.e. treatment-related adverse events, disease
progression and death) assumed to occur on average at 0.5 years. It is unclear whether or not the time
horizon was sufficient to capture all events, given that median survival ranged from 2 to 4 years from
diagnosis. Limited information was provided concerning the basis for the structure of the model,
the assumptions used or the parameterisation of the model.
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Estimation of quality-adjusted life-years
Hagaman and colleagues estimated that patients receiving azathioprine, NAC and prednisolone with prior
TPMT testing would gain 2.62 quality-adjusted life years (QALYs) during the 12-month time horizon, while
those not undergoing TPMT testing would gain 2.61 QALYs. In contrast, patients receiving conservative
therapy would gain 2.50 QALYs.99
Estimation of costs
Hagaman and colleagues included direct costs only in the evaluation, which were in 2007 US$.99 Estimates
were obtained from routinely published sources, including medication costs from www.drugstore.com and
costs for procedures, office visits and hospitalisations from average Medicare reimbursement costs using
current procedural terminology or diagnosis-related group codes. Costs of adverse events include both
institutional and professional services. Detailed microcostings for baseline costs are provided; however,
the basis for decisions concerning resource use and values for sensitivity analyses are not discussed.
No source is provided for the cost of the TPMT assay. A summary of the cost estimates is provided in
Appendix 9. Hagaman and colleagues estimated that the total cost per patient using azathioprine, NAC
and prednisolone with prior TPMT testing was US$15,818 and without TPMT testing was US$15,802. The
cost of treatment with conservative therapy was US$9691 per patient.99
Cost-effectiveness results
The base-case results presented by Hagaman and colleagues showed that azathioprine, NAC and
prednisolone with prior TPMT testing was the most effective option and also the most costly.99 The
strategy without TPMT testing before treatment with azathioprine, NAC and prednisolone was excluded
by extended dominance, having a higher incremental cost-effectiveness ratio (ICER) than other more
expensive options. The base-case ICER for azathioprine, NAC and prednisolone with prior TPMT testing
compared with conservative therapy was US$49,156 per QALY. Comparison of azathioprine, NAC and
prednisolone with and without prior TPMT testing was undertaken, excluding extended dominance, which
resulted in an ICER of US$29,663 per QALY.
Sensitivity analyses were undertaken on all parameters in the model, with the frequency of abnormal TPMT
alleles, the probability of developing leukopenia and treatment efficacy reported as having considerable
impact on the ICERs. An increase in the prevalence of abnormal TPMT alleles to ≥ 12% produced ICERs
below US$50,000 per QALY when compared with both the no-TPMT testing strategy and conservative
therapy. When frequencies of abnormal TPMT alleles are above 13.5%, the TPMT testing strategy dominates
the no TPMT testing strategy. Increasing the probability of leukopenia following treatment with reduced-dose
azathioprine in those with intermediate TPMT activity resulted in an increase in the cost relative to the
non-TPMT testing strategy. As a result, the TPMT testing strategy was no longer cost-effective when
the probability increased to be above 12%. Comparison of treatment efficacy between azathioprine, NAC
and prednisolone following TPMT testing and conservative therapy showed that patients receiving the former
had a consistently lower probability of progression than the latter (approximately 13% lower) at the
US$50,000 willingness-to-pay (WTP) threshold (i.e. as rates of progression on conservative therapy increase,
the strategy with TPMT testing remains cost-effective at increasingly high rates of progression following its use).
It is stated that other parameters used in the model had less effect on the results. Unfortunately, details
concerning any of the sensitivity analyses are limited and therefore it is difficult to interpret the robustness of
the model in terms of structural or parameter uncertainty.
Summary
A systematic review of cost-effectiveness studies identified one economic evaluation of interventions to
manage patients with IPF.99 Its primary focus was on the benefits of a testing strategy prior to treatment
with a standard intervention, with the intention of limiting the occurrence of serious adverse effects.
Although the outcomes of the evaluation may not have been strictly relevant to the current report, the
evaluation provides a basis for developing a de novo model (see Independent economic evaluation) and for
providing parameters for the evaluation.
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Systematic review of health-related quality of life studies
A systematic review was undertaken to assess the HRQoL of people with IPF. The aim of the review was to
provide data to populate the economic model with health-state utility values appropriate to conduct a
cost–utility analysis and to calculate the benefits of interventions in terms of QALYs. The sources and search
terms used are described in Appendix 1. Studies reporting HRQoL in people with IPF were eligible for
inclusion if they used either generic preference-based measures or the SGRQ, which is a disease-specific
instrument used in IPF. Other recently developed disease-specific instruments such as the St George’s
Respiratory Questionnaire IPF (SGRQ-I),106 the ‘A Tool to Assess QOL in IPF’ (ATAQ-IPF)107 and the King’s Brief
Interstitial Lung Disease (K-BILD)108 measures were not eligible for inclusion as there are currently no
methods to map results of these to utility measures required for economic evaluation. Data from any study
designs were eligible for inclusion in the systematic review. The inclusion and exclusion criteria for the review
are shown in Table 64.
The search strategy identified 423 articles that were potentially relevant and one additional publication was
identified in the searches for the systematic review of clinical effectiveness (reported in Chapter 3). The
titles and abstracts were screened, with the full text of 52 studies retrieved for further inspection. After
checking the retrieved papers, 23 studies met the inclusion criteria. A summary of the selection process is
presented in Figure 12. A list of the excluded studies is shown in Appendix 10.
Nine studies61,109–116 assessed HRQoL using the SF-36, seven used the SGRQ,55,73,117–122 five studies used both
the SF-36 and SGRQ123–127 and two studies used the SF-36, the SGRQ and the EQ-5D68,72 (Table 65).
TABLE 64 Inclusion/exclusion criteria for HRQoL of people with IPF
Category Criteria
Patients People with IPF. If data are lacking, participants with other ILDs will also be considered eligible
for inclusion
Outcomes Generic, preference-based (VAS/TTO/SG) measures such as EQ-5D, SF-36/6D and HUI were eligible.
The disease-specific SGRQ was also included
Study design Studies eligible for inclusion were either primary studies (prospective or retrospective observational
studies) collecting QoL data, or trials where QoL data were reported as outcomes
HUI, Health Utilities Index; SF-36/6D, Short-Form 36 or 6 dimensions; SG, standard gamble; TTO, time trade-off.
References for retrieval and screening
(n = 52; three were included in the
clinical effectiveness systematic review)
Titles and abstracts
inspected
Total identified from searching
(after deduplication)
(n = 423)
Excluded
(n = 372)
Excluded
(n = 28)
Studies included in
systematic review
(n = 23; in 24 publications)
Identified in clinical
effectiveness searches
(n = 1)
FIGURE 12 Flow chart of identified studies for HRQoL review in IPF.
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TABLE 65 Characteristics of studies included in HRQoL systematic review
Study details Study population Details of HRQoL instrument(s)
Studies reporting EQ-5D (also SF-36 and SGRQ)
Raghu et al. IPFCRN 201268
Country: USA
Setting: outpatient clinic
RCT
Triple therapy compared with placebo
(also included in Chapter 3)
Number: 155 (another 81 but data not
shown)
Age: ≈ 68 years
M/F (%): 116/39 (75/25)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: ranged between
69% and 72%
EQ-5D index
EQ-5D VAS
SF-36 (aggregate scores only)
SGRQ
Zisman et al. IPFCRN 201072
Country: USA
Setting: outpatient clinic
RCT
Sildenafil compared with placebo
(also included in Chapter 3)
Number: 180
Age: ≈ 69 years
M/F (%): 150/30 (83/17)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: ranged between
55% and 59%
EQ-5D index
EQ-5D VAS
SF-36
SGRQ
Studies reporting SF-36 alone
Mermigkis et al. 2013116
Country: Greece
Setting: outpatient clinic
Single-arm cohort study (before and
after)
Continuous positive airways pressure
therapy
Number: 12
Age: 67.1 years
M/F (%): 10/2 (83/17)
Diagnosis: ATS/ERS criteria
FVC per cent predicted: 77.1%
SF-36
Overall score only presented
Kozu et al. 2011113
Country: Japan
Setting: outpatient clinic
Single-arm cohort study (before and
after)
Pulmonary rehabilitation programme
(8 weeks)
Number: 65
Age: 67.5 years
M/F (%): 46/19 (70/30)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: ranged between
51% and 83%
SF-36
Data presented by MRC dyspnoea
grade
Kozu et al. 2011114
Country: Japan
Setting: outpatient clinic
Cohort study (before and after) and
additional control group
Pulmonary rehabilitation programme
(8 weeks)
Number: 45
Age: 67.5 years
M/F (%): 37/8 (82/18)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 68.6%
SF-36
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TABLE 65 Characteristics of studies included in HRQoL systematic review (continued )
Study details Study population Details of HRQoL instrument(s)
Ozalevli et al. 2010110
Country: Turkey
Setting: participants’ home
Single-arm cohort study (before and
after)
Home-based pulmonary rehabilitation
programme
Number: 15
Age: 62.8 years
M/F (%): 10/5 (67/33)
Diagnosis: based on ATS/ERS criteria
FVC% predicted: 71.6%
SF-36
Jastrzebski et al. 200861
Country: Poland
Setting: Outpatient clinic
CCT
Inspiratory muscle training
Number: 30
Age: 56.35
M/F (%): 19/11 (63/37)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 69.2%
SF-36
Tomioka et al. 2007115
Country: Japan
Setting: outpatient clinic
Cohort study (cross-sectional and
longitudinal)
No intervention
Number: 46
Age: 69.9 years
M/F (%): 32/14 (70/30)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 71.0%
SF-36 presented only as deviation
values against national reference
values
Jastrzebski et al. 2005112
Country: Poland
Setting: outpatient clinic
Cohort study (cross-sectional and
longitudinal) with additional control
group
No intervention
Number: 16
Age: 48.3 years
M/F (%): 11/5 (69/31)
Diagnosis: based on ATS/ERS criteria
and meeting criteria for lung transplant
FVC per cent predicted: 44.0%
SF-36
Baddini Martinez et al. 2002111
Country: Brazil
Setting: outpatient clinic
Cohort study
No intervention
Number: 30
Age: 58.6 years
M/F (%): 18/12 (60/40)
Diagnosis: by lung biopsy or HRCT,
criteria used not reported
FVC per cent predicted: 61.9%
SF-36
Martinez et al. 2000109
Country: Brazil
Setting: outpatient clinic
Matched controlled study. Control
group matched for sex and age
No intervention
Number: 34
Age: 58.29 years
M/F (%): 20/14 (59/41)
Diagnosis: by lung biopsy or HRCT,
criteria used not reported
FVC per cent predicted: 62.41%
SF-36
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TABLE 65 Characteristics of studies included in HRQoL systematic review (continued )
Study details Study population Details of HRQoL instrument(s)
Studies reporting SF-36 and SGRQ
Verma et al. 2011123
Country: Canada
Setting: outpatient clinic
Cohort study
No intervention
Number: 137
Age: 59.4 years
M/F (%): 90/47 (66/34)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 61.7%
SF-36
SGRQ
Raghu et al. 2010125
Country: Europe (including UK),
USA, Canada, Israel
Setting: outpatient clinic
RCT (post-hoc analysis)
Bosentan compared with placebo
Number: 158
Age: 65.2 years
M/F (%): 112/42 (71/29)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 67.7%a
SF-36
SGRQ
Swigiris et al. 2010126
Country: Europe (including UK),
USA, Canada, Israel
Setting: outpatient clinic
Retrospective analysis of RCT data
Bosentan compared with placebo
Number: 158
Age: 65.12 years
M/F (%): 73/27 (73/27)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 66.97%
SF-36
SGRQ
Lutogniewska et al. 2010127
Country: Poland
Setting: unknown
Single-cohort study with subgroup data
for IPF
No intervention
Number: 30
Age: not reported
M/F (%): not reported
Diagnosis: not reported
FVC per cent predicted: not reported
SF-36
SGRQ
Zimmerman et al. 2007124
Country: Brazil
Setting: outpatient clinic
Cohort study
No intervention
Number: 20
Age: 61.4 years
M/F (%): 12/8 (60/40)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 70.4%
SF-36
SGRQ
Horton et al. 201255,75
Country: USA
Setting: university
RCT
Thalidomide
Number: 23
Age: 67.6 years
M/F (%): 18/5 (78/22)
Diagnosis by lung biopsy or HRCT,
criteria used not reported
FVC per cent predicted: 70.4%
SGRQ
continued
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TABLE 65 Characteristics of studies included in HRQoL systematic review (continued )
Study details Study population Details of HRQoL instrument(s)
Nishiyama et al. 2012122
Country: Japan
Setting: outpatient clinic
Retrospective cohort study
No intervention
Number: 87
Age: 66.3 years
M/F (%): 77/10 (89/11)
Diagnosis by ATS/ERS criteria
FVC per cent predicted: 75.0%
SGRQ
Nishiyama et al. 200873
Country: Japan
Setting: outpatient clinic
RCT
Pulmonary rehabilitation compared with
control (also included in Chapter 3)
Number: 28
Age: 66.3 years
M/F (%): 21/7 (75/25)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 67.4%
SGRQ
De Vries et al. 2000117
Country: the Netherlands
Setting: university hospital setting
Focus groups/cross-sectional survey
No intervention
Number: 10
Age: 61.1 years
M/F (%): 4/6 (40/60)
Diagnosis: not stated
FVC per cent predicted: not reported
SGRQ
WHOQOL-100 (data not extracted)
Peng et al. 2008118
Country: China
Setting: outpatient clinic
Cohort study (cross-sectional and
longitudinal)
No intervention
Number: 68
Age: 64 years
M/F (%): 54/14 (79/21)
Diagnosis: by lung biopsy or HRCT
FVC per cent predicted: 66%
SGRQ
Nishiyama et al. 2005119
Country: Japan
Setting: outpatient clinic
Cohort study
No intervention
Number: 41
Age: 64 years
M/F (%): 35/6 (85/15)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 76.6%
SGRQ
Tzanakis et al. 2005120
Country: Greece
Setting: outpatient clinic
Matched controlled study
No intervention
Number: 25
Age: 66 years
M/F (%): 21/4 (84/16)
Diagnosis: based on ATS/ERS criteria
FVC per cent predicted: 68.8%
SGRQ
F, female; M, male; WHOQOL, World Health Organization Quality of Life.
a Reported in linked publication;128 see Chapter 3.
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Two studies used the EQ-5D.68,72 Both of these studies were also included in the systematic review of
clinical effectiveness (see Chapter 3). The EQ-5D is a widely used instrument developed to measure health
utility. It comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) which can be rated with either three or five levels of severity (ranging from no
problems to extreme problems) depending on the precise measure chosen.129,130 Scores from the health
states are converted through value sets (or preference weights) obtained from general population studies
to generate a single utility value.129,130 This utility ranges from 0.59 to 1 and represents health on a
continuum from worst to best (negative values are valued as worse than dead). The value sets applied can
be derived using either a VAS or time trade-off (TTO) technique. The former requires members of the
general population to indicate where they believe an individual health state should be positioned on a
scale ranging from worst imaginable health to best imaginable health. The TTO technique requires
members of the general population to imagine that they live in a particular health state for 10 years and to
then specify the amount of time they are willing to give up to live in full health. Applying these population
value sets to the data allows generation of a utility value which has a societal perspective. This is,
therefore, appropriate for use in health economic evaluations. The EQ-5D also has a VAS where individuals
are required to rate their health on a vertical (thermometer) score ranging from worst imaginable
health state (0) to best imaginable health state (100). This is a patient-based score which, therefore,
is not representative of the general population, and as a result is not appropriate for use in health
economic evaluation.130
Sixteen studies reported the SF-36;61,68,72,109–116,123–127 one of these studies61 was also included in the
systematic review of clinical effectiveness (see Chapter 3). The SF-36 is a generic measure of health status.
It is a 36-item survey and has eight scales covering functional health and well-being concepts.131 These are
physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional
and mental health. The eight scales are aligned to their demonstrated validity to measure either physical
health or mental health to aid the interpretation of the SF-36.132 The first scale (physical functioning) has
been shown to be the most valid measure of physical health, and the last scale (mental health) the most
valid measure of mental health. The scales in between these are ordered according to their respective
validity in measuring concepts of physical or mental health, with vitality and general health being
moderately valid for both aspects of health.132 Scores can also be combined to generate physical and
mental health summary scores. Normative values for the UK have been published by a number of groups,
including the Health Survey for England133 and the ONS Omnibus Survey of Britain.134 While there are
limitations associated with any source of normative data, for example the demographic composition of the
populations used will vary, these are essential to interpret results of the measure for the population of
interest. For pragmatic reasons for the purposes of this systematic review, the normative data from the
ONS has been used to aid the interpretation of the effects IPF has on HRQoL, as this has a reasonably wide
UK base. Many of the included studies were not from UK populations (see below) and therefore
observations on the impact of IPF on HRQoL, as measured by the SF-36, made in the current review should
be treated as illustrative only.
Fourteen studies report data on the SGRQ.55,68,72,73,117–127 The SGRQ is a disease-specific measure which
aims to assess the impact of obstructive airways disease on overall health, daily life and perceived
well-being.135 It comprises 50 items within two parts, which cover three components of symptoms, activity
and impact. A total score can also be calculated which summarises the impact of the disease on overall
health status. Scores range from 0 to 100, where higher scores indicate greater negative impact on HRQoL.
Few studies have investigated normative values for general populations. Population norms provided in the
SGRQ manual136 have been used to aid the interpretation of the data from the studies included in this
systematic review (see Results, St George’s Hospital Respiratory Questionnaire for more details).
Only one multicentre study (two publications from the same study125,126) included participants from
centres within the UK. Two other multicentre studies were US-based only.68,72 The remaining studies were
single-centre studies from countries such as Japan (six studies73,112–115,122), Brazil (three studies109,111,124),
Poland (three studies61,112,127), Turkey (one study110), Canada (one study123), the Netherlands (one study117),
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China (one study118), Greece (two studies116,120) and the USA (one study55). Generalisability of these
populations to those seen in current UK practice may, therefore, be limited. Most of the included studies
were undertaken in hospital outpatient clinics. Sample sizes were generally small, ranging from 12 to
180 participants, with 15 studies including fewer than 50 participants. The average age of the participants
ranged from 48 years to 69 years. Males were the dominant sex in all but one study,117 with proportions of
males ranging from approximately 58% to 85% in the remaining studies.
All studies were published after 2000. The diagnosis of IPF was according to the ATS/ERS criteria in
17 studies;61,68,72,73,110,112–116,119,120,122–126 four studies stated that surgical lung biopsy or HRCT were used but
did not state what criteria were used to assess the findings of these tests.55,109,111,118 Two studies117,127 did
not report how the diagnosis was made. Per cent predicted FVC was reported in 21 of the included
studies.55,61,68,72,73,75,109–116,118–120,122–126 This ranged between approximately 62% and 77% in the majority
of studies (n= 18) (see Table 65); one study had a much milder population (83%)113 and two studies had
more severe populations (≈ 57%)72 and (44%).112 Therefore, there were a mixture of mild, moderate and
severe cases of IPF if per cent predicted FVC is used as a proxy for disease severity.
Study designs varied. Six studies55,68,72,73,125,126 were based on five RCTs of interventions where HRQoL was
an outcome measure, one was a CCT,61 and four studies were cohort ‘before-and-after’ studies that
tested HRQoL at baseline and then again after an intervention;110,113,114,116 one of these also had a control
group of patients with COPD.114 Five studies111,119,122–124 were single-cohort studies with no intervention,
three112,115,118 were single-cohort studies that collected HRQoL data at two different time points (one also
had an additional control group112), two studies109,120 were cohort studies with matched controls, one
was a cohort study with subgroup data127 and one117 was a combination of a focus group and survey.
Seven of the 16 studies using the SF-36 did not report the overall physical or mental health summary
scores,109–111,113,114,124,125 one study reported only the overall summary scores (at baseline),68 one study
reported only an overall score encompassing both physical health and mental health component scores,116
and one study did not present any useful data, reporting data as deviation values from national
reference values.115
The limitations of the methodological designs of these studies and potential for bias should be considered
in the interpretation of these data.
Results
European Quality of Life-5 Dimensions
Two RCTs report the EQ-5D at baseline and after an active intervention.68,72 As comparisons between
groups were not required for the purpose of this systematic review of HRQoL, the placebo group
baseline data have been summarised (Table 66; for further study details see Chapter 3). The baseline FVC
per cent predicted in one RCT was 72% in the placebo group,68 indicating a mild to moderate population,
and 58% in the second RCT, indicating a moderate to severe IPF population.72 The EQ-5D index in the
placebo group of the mild to moderate population was 0.8 (SD 0.2) and 0.74 (SD 0.19) in the moderate
TABLE 66 European Quality of Life-5 Dimensions scores from placebo group of included RCTs
Outcome Raghu et al. IPFCRN 201268 Zisman et al. IPFCRN 201072
FVC per cent predicted at baseline 72.1 (14.1) 58.73 (14.12)
EQ-5D Index at baseline 0.8 (0.2) 0.74 (0.19)
EQ-5D VAS (SD) at baseline 78.1 (15.4) 67.66 (16.98)
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to severe population, as seen in Table 66. Neither study reports what population tariff was applied to the
patient-generated scores on the EQ-5D; however, given that the RCTs were both undertaken by the same
research group in the USA, we have assumed that US preference weights were applied to generate the
EQ-5D index score in both trials.
Both of these RCTs also presented data on the EQ-5D VAS; these were 78.1 (SD 15.4)68 and 67.66
(SD 16.68)72 in the placebo groups at baseline in the two studies, respectively.
Short Form questionnaire-36 items
Thirteen studies61,72,109–114,123–127 provided data for the individual scales of the SF-36 and two68,116 presented
data only for the aggregate scales (Table 67). Four studies68,72,112,125 were RCTs that provided baseline data
for both treatment arms, but as comparisons between arms were not required for the purpose of this
systematic review, the placebo group population data have been summarised (the treated group
population data can be seen in Appendices 5 and 11). Twelve studies included participants with a range of
FVC per cent predicted at baseline of approximately 58–72% (see Table 67), including subgroups within
this range in one study.61,68,72,109–111,113,114,123–126 In another study, the baseline characteristics of the
participants with FVC per cent predicted indicated more severe IPF participants (44%)112 and one other
study113 provided outcomes for four severity groups based on the MRC dyspnoea scale, and their
corresponding mean FVC per cent predicted ranged from 83% to 51% as can be seen in Table 67.
One study, in participants who were listed for lung transplantation, did not report the baseline FVC per
cent predicted.127
Average (mean or median) scores on the different SF-36 scales varied across the studies, and this is likely in
part to be a reflection of the different country of origin of the studies, the sample sizes which for many
studies were small, and differences in participants including their ages, sex distribution and the severity of
IPF. To aid interpretation we have crudely grouped the studies into those with an average baseline FVC per
cent predicted 71–83% (to reflect a ‘mild’ IPF patient group); those with an average baseline FVC per cent
predicted of 55–70% (to reflect a ‘moderate’ IPF patient group); and those with an average baseline FVC
per cent predicted of < 55% (to reflect a ‘severe’ IPF patient group), in line with Nathan and colleagues.22
However, interpretation of the ranges of results should be treated with caution. The one study that did not
report FVC per cent predicted at baseline was categorised in the moderate group as participants were
listed for lung transplantation.127
Four studies included populations or subgroups that had a mean FVC per cent predicted within the range of
71–83% (‘mild’ IPF),68,110,113,116 two of which included data for the individual components of the scale.110,113
The scores on the physical functioning scale of the SF-36 ranged between 55 and 56 and the scores on the
mental health scale ranged between 50 and 62. Of the eight scales on the SF-36, these two have been
shown to be the most valid measures of their respective constructs. Of the remaining scales relating to
physical health, scores in these two populations ranged from 25 to 56 (role physical) and about 67 (bodily
pain). Of the remaining scales relating to mental health, scores in these two populations ranged from
63 to 76 (social functioning) and from 29 to 67 (role emotional). The two scales that encompass elements
of both physical health and mental health (general health and vitality) had ranges of scores of 51–57 and
52–55, respectively. The two studies show wide variance in some of the scales but overall it appears that IPF,
in people who may crudely be characterised as having IPF of ‘mild’ severity, has a detrimental effect on
HRQoL as measured by the SF-36 when compared observationally with age-standardised population norms
for the UK131 (Table 68).
Eleven studies included populations that may reflect a moderately severe IPF patient group (baseline per
cent predicted FVC 55–70%).61,72,109,111,113,114,123–127 In one study, there were two patient subgroups falling
within this range, one with a baseline FVC per cent predicted of 60% and one with 67%, and these have
been treated as two separate cohorts for the present review.113 Table 67 shows the scores on the eight
domains of the SF-36 as measured in these studies; as can be seen, there are large variations in scores.
The scores on the physical functioning and mental health scales ranged from 19 to 54 and from 42 to 76,
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respectively, suggesting that physical health is more affected than mental health when compared
(by observation only) with the UK norms for people of these age ranges (see Table 68). Other physical
health scores had similarly wide ranges, from 20 to 58 on the role physical and from 47 to 79 on the
bodily pain scales. Other mental health scores of social functioning and role emotional ranged from
33 to 81 and from 31 to 100, respectively. The general health and vitality scales of the SF-36 ranged
from 24 to 53 and 27 to 53, respectively. Scores vary widely between the studies; however, IPF of
‘moderate’ severity does appear to negatively affect HRQoL, as measured by the SF-36, when compared
observationally with age-standardised population norms for similarly aged people in the UK.
Two studies included populations or subgroups that had a mean FVC per cent predicted of < 55%,
reflecting severe IPF.112,113 Data were from a subgroup of participants with baseline FVC per cent predicted
of 51% from one study.113 In the second study the mean FVC per cent predicted was 44%. In this latter
study no measures of variance were provided for the mean scores reported. As can be seen in Table 67,
scores on the physical functioning scale of the SF-36 ranged from 16 to 45 across the two cohorts,
and scores on the mental health scale ranged between 35 and 50. On the other physical health scores,
the ranges were 20–43 for role physical but higher (62–66) for bodily pain. On the other mental health
domains of social functioning and role emotional, the ranges seen in these three cohorts were 30–58 and
19–65, respectively. The scores for general health and vitality ranged from 20 to 28 and from 19 to 38,
respectively. From these patterns it can be seen that ‘severe’ IPF has a detrimental effect on most aspects
of QoL as measured by the SF-36 (see Table 68).
Across all of the included studies there is wide variation in scores, which makes overall interpretation
difficult. This is likely to be a reflection of the differences in study design, participants and sample sizes of
the studies, as discussed above.
TABLE 68 Short Form questionnaire-36 items dimension norms from British ONS survey, for those aged
55–84 years131
Dimensions by age
and sex
PF,
mean
(SD)
RP,
mean
(SD)
BP,
mean
(SD)
GH,
mean
(SD)
VT,
mean
(SD)
SF,
mean
(SD)
RE,
mean
(SD)
MH,
mean
(SD)Sex
Age group
(years)
Male 55–64 79.0
(25.6)
70.0
(41.9)
75.6
(28.3)
63.1
(26.9)
63.4
(25.0)
84.4
(26.1)
86.3
(31.5)
78.3
(19.5)
65–74 76.2
(26.4)
74.4
(38.6)
78.8
(26.0)
64.8
(24.2)
65.0
(25.0)
86.0
(25.1)
89.5
(28.0)
81.4
(18.0)
75–84 65.4
(27.5)
68.7
(41.1)
75.7
(26.8)
61.3
(26.7)
57.7
(26.5)
77.0
(28.0)
82.9
(35.3)
77.1
(19.4)
Female 55–64 77.2
(27.1)
75.2
(39.3)
73.2
(28.9)
67.4
(26.1)
60.5
(24.3)
85.0
(25.2)
77.7
(38.7)
74.0
(20.5)
65–74 70.0
(26.8)
71.2
(40.2)
72.9
(27.8)
65.1
(24.1)
61.5
(23.1)
85.7
(26.1)
87.0
(31.1)
78.8
(18.5)
75–84 52.9
(28.4)
57.9
(42.4)
66.7
(30.7)
58.7
(23.0)
51.9
(23.7)
75.2
(29.9)
82.7
(34.4)
74.6
(19.6)
BP, bodily pain; GH, general health; MH, mental health; PF, physical functioning; RE, role emotional; RP, role physical;
SF, social functioning; VT, vitality.
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St George’s Hospital Respiratory Questionnaire
Fourteen studies assessed HRQoL using the SGRQ.55,68,72,73,117–120,122–127 IPF severities at baseline were similar,
ranging from 59% to 77%. While the five RCTs55,68,72,73,125 reported baseline data for two treatment arms,
comparisons between groups were not required for the purpose of this systematic review and, as such,
the placebo group data have been summarised here (the treated group population data can be seen in
Appendices 5 and 11).
Scores on the different subscales of the SGRQ varied across the studies, and may reflect, in part, the
differences between the studies in terms of the country, sample size and participant characteristics. In
common with the review of the SF-36, we have crudely grouped the studies into those with mean baseline
FVC per cent predicted 71–83% (to reflect a ‘mild’ IPF patient group) and those with a mean baseline FVC
per cent predicted of 55–70% (to reflect a ‘moderate’ IPF patient group). There were no studies with a
mean baseline FVC per cent predicted of < 55% (therefore reflecting a ‘severe’ IPF patient group).
Interpretation of the ranges of results should be treated with caution.
Three studies68,119,122 included a population that had a baseline FVC (per cent predicted) of > 71% (‘mild’ IPF)
and results can be seen in Table 69. In these studies the mean score on the symptoms scale was between
40 and 46 and the score on the activity scale between 45 and 53. There appeared to be less effect of IPF on
HRQoL as measured by the impacts scale, where the mean score ranged from 29 to 32. Overall, the total
score on the SGRQ for this population was 36–39. This appears to be higher than the suggested population
norms for the SGRQ as seen in Table 70, and suggests that IPF at a ‘mild’ severity has an impact on HRQoL
as measured by the SGRQ.
Nine studies included populations that had baseline FVC per cent predicted between 55% and 70%, and
may represent IPF of ‘moderate’ severity.55,72,73,118,120,123–126 Two additional studies117,127 did not report the
baseline FVC per cent predicted but are also described here as the descriptions of the populations in
the journal paper suggest that the individuals are unlikely to be mild IPF. Scores on the SGRQ ranged from
38 to 68 for symptoms, 36 to 82 for activity, 30 to 65 for impact and 38 to 64 for the total score. This
suggests that the effect on HRQoL may be greater in populations with more ‘moderate’ IPF than in those
with ‘mild’ IPF, and worse again than the suggested population norms for this measure (see Table 70).
Summary of health-related quality of life review
l The systematic review found 23 relevant studies.
l Two studies were identified that used the preferred measure of HRQoL, the EQ-5D, 16 used the SF-36
and 14 the SGRQ.
l Types of studies were mixed; some RCTs were included of which the present review focused on the
placebo groups at baseline, other designs were before-and-after studies, single-cohort studies, cohort
studies with matched controls, and cohort studies with a longitudinal analysis of data. Although not
formally critically appraised, these studies have potential for bias and results should, therefore, be
treated with caution.
l Results were mixed but appear to show that IPF has an adverse effect on HRQoL compared with
population norms, and this is likely be diminish as IPF become more severe.
l Results of EQ-5D from the placebo arms of two included studies from an international research group
for IPF suggest that in a ‘mild’ population the utility is 0.8 and in a more ‘severe’ population the utility
diminishes to 0.74.
l Few studies were undertaken with UK participants and therefore generalisability of these data to a UK
population is likely to be low.
DOI: 10.3310/hta19200 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 20
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115
TABLE 69 St George’s Hospital Respiratory Questionnaire scores at baseline, mean (SD) unless stated
Study N
FVC per cent
predicted Symptoms Activity Impacts Total
‘Mild’ IPF
Nishiyama et al. 2012122 87 75.0 45.0 (23.3) 48.0 (24.7) 31.6 (20.7) 39.0 (20.2)
Raghu et al. IPFCRN 201268 78 72.1 45.6 (21.8) 52.7 (21.0) 28.8 (17.3) 39.4 (17.4)
Nishiyama et al. 2005119
Placebo group
41 76.6 40.1 (24.6) 44.5 (26.7) 28.9 (19.8) 35.7 (20.6)
‘Moderate’ IPF
Verma et al. 2011123 137 61.7 59.8 (95% CI
56.2 to 63.4)
81.6 (95% CI
78.7 to 84.4)
54.1 (95% CI
50.6 to 57.6)
63.4 (95% CI
60.4 to 66.3)
Zisman et al. IPFCRN 201072 91 58.73 53.99 (18.9) 68.02 (17.63) 39.77 (18.81) 51.72 (15.86)
Raghu et al. 2010125
Placebo group
158 67.7 54.8a (95% CI
47.9 to 59.1)
59.5a (95% CI
56.0 to 65.6)
30.5a (95% CI
25.7 to 38.4)
44.3a (95% CI
40.2 to 50.0)
Swigiris et al. 2010126 158 66.97 50.1 (21.9) 60.6 (22.8) 33.7 (20.6) 44.8 (19.5)
Horton et al. 201255 23 70.4 67.7 (19.7) 64.3 (22.7) 48.1 (20.7) 57.4 (18.8)
Lutogniewska et al. 2010127 30 NR 58.7 (20.3) 70.4 (20.1) 65.4 (24.8) 64.0 (19.0)
Zimmermann et al. 2007124 20 70.4 46.4 (20.3) 62.4 (19) 43.6 (20.9) 48.4 (17.9)
Nishiyama et al. 200873 28 67.4 38.0 (25.8) 50.4 (26.2) 29.9 (23.7) 37.8 (22.7)
Peng et al. 2008118 68 66 65 (16) 56 (15) 49 (19) 54 (15)
Tzanakis et al. 2005120 25 68.8 55.9 (25.3) 36.2 (21.4) 29.6 (21) 37.7 (18.9)
De Vries et al. 2000117 10 NR 56.0 (20.2) 38.7 (22.7) 46.1 (20.8) 44.5 (17.8)
NR, not reported.
a Median.
TABLE 70 Means for SGRQ scores in normal subjects with no history of respiratory disease (modified from the
SGRQ manual136)
Characteristics Symptoms Activity Impacts Total
N= 74
Age: 46 (range 17–80) years
FEV1 per cent predicted: 95 (91–99)
12 (95% CI 9 to 15) 9 (95% CI 7 to 12) 2 (95% CI 1 to 3) 6 (95% CI 5 to 7)
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Independent economic evaluation
Overview of economic evaluation
A comparison was made of the costs and benefits of pharmacological interventions for the treatment of
IPF within the framework of a decision-analytic economic model. The cost-effectiveness of six interventions
against BSC was assessed: azathioprine and prednisolone, BIBF 1120, NAC triple therapy, inhaled NAC,
pirfenidone, and sildenafil. Non-pharmacological interventions were not included, for reasons discussed in
Chapter 3 (see Network meta-analysis). Thalidomide was not included as it is not currently used as a
disease-modifying intervention. In the context of the model the terms placebo and BSC are considered to
be equivalent, although BSC is preferred because it is more descriptive of treatment actually received.
The patient population included in the economic model reflects to some extent the patient populations of
the key trials included in the systematic review of clinical effectiveness (see Chapter 3) as treatment effects
are taken from these trials.62,65–72 Transition probabilities for IPF progression are taken from the Capacity
trial62 where average age at baseline in the pooled population was 66 years, and 73% were men. This is
broadly comparable with the UK IPF population, which between 1990 and 2004 had a mean age at
presentation of 71 years, and was 62% male.11 All-cause mortality in the model is defined using these UK
data. Mean overall FVC per cent predicted at baseline in the Capacity trial was 74.7% (see Table 5).
The analysis takes the perspective of the NHS and Personal Social Services in the UK. The lifelong costs and
benefits associated with each treatment are estimated by the economic model. The base price year for
costs is 2012. Future costs and benefits are discounted at 3.5% per annum as recommended by the UK
Treasury.138 The interventions act to slow the rate of decline in FVC per cent predicted. The estimates of
intervention effectiveness used by the model for reduced rate of decline in FVC per cent predicted are
obtained from the NMA reported in Chapter 3.
Methods for economic analysis
Model structure
A Markov state-transition model was developed to simulate the progression of IPF in a cohort of patients
and to estimate the cost-effectiveness of the pharmacological treatments under consideration. The model
was constructed using the TreeAge Pro 2013 software (TreeAge Software Inc., Williamstown, MA, USA).
The model structure was informed by a review of the available literature and expert opinion on the clinical
progression of the disease. The decision to use a Markov cohort structure in preference to a patient-level
model was pragmatic and based on available data. While a patient-level model is more flexible in
reproducing patient experience, it requires more data and/or modelling assumptions. These data were not
available and it was felt that such a model would, therefore, be less robust than a Markov model.
The model uses four distinct health states: unprogressed IPF, progressed IPF, lung-transplant and dead
(Figure 13). Non-dead health states are associated with a HRQoL utility and a cost estimate. Progression is
defined by an absolute decline in FVC per cent predicted of ≥ 10% from a baseline (recently diagnosed)
value. Acute exacerbations are not modelled as separate health states but are associated with a cost and
utility decrement.
All patients start the model in the unprogressed state and may then either stay in the unprogressed state;
suffer an acute exacerbation and move to the progressed state; move to the progressed state without
acute exacerbation; or die. From the progressed state a patient may either stay in the progressed state;
suffer an acute exacerbation and return to the progressed state; undergo a lung transplant; or die. From
the lung transplant state patients may either remain in the lung transplant state or move to the dead state
(see Figure 13).
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Model cycle length is 1 month and a lifetime horizon of 30 years is adopted in the base case, which is
sufficiently long to capture all clinically and economically important events. A half-cycle correction
was applied.
The baseline disease progression parameters used in the model were obtained from the IPF clinical
literature (Section 3). These inform the monthly probability of an absolute decline of 10% or more in FVC
per cent predicted; the monthly probabilities of death from IPF (unprogressed and progressed states); and
the monthly probabilities of an acute exacerbation (unprogressed and progressed states). Other sources
were used to inform the probability of a lung transplant; survival after lung transplant; and all-cause
mortality by age.
Parametric curves were fitted to Kaplan–Meier PFS data for treatment with BSC in order to provide the
probability of disease progression in this treatment arm. The outputs of the NMA of FVC described in
Chapter 3 were used to modify this probability for each treatment and so provide a treatment-specific
probability of progression. Overall survival curves were fitted to the progressed state and lung transplant
Kaplan–Meier survival data in order to provide the probability of death in each cycle for these
health states.
The costs included in the model are those for drug treatment; long-term oxygen use; oxygen monitoring;
acute exacerbation of IPF; lung transplant; and adverse events associated with treatment. Full details of the
costs used in the model are given in Data sources.
The model includes the following assumptions:
l All patients enter the model in the unprogressed state.
l Patients who experience a ≥ 10% absolute decline in FVC per cent predicted are considered to be in
the progressed health state.
l Acute exacerbations are associated with a drop in FVC per cent predicted of ≥ 10% in an
unprogressed patient.
Possible acute
exacerbation
Possible acute
exacerbation
Possible acute
exacerbation
IPF
(no progression)
IP
F 
d
ia
g
n
o
si
s
Possible acute
exacerbation
Lung transplant
Dead
IPF progression
FIGURE 13 Influence diagram for the Southampton Health Technology Assessments Centre (SHTAC) IPF
cost-effectiveness model.
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l The utility decrement associated with acute exacerbation lasts for 1 month.
l No lung transplants occur in patients who are in the unprogressed disease state. It is only possible to
transit to the lung transplant state from the progressed disease state.
l Pharmacological treatment has a constant effect on relative rate of FVC per cent predicted decline
compared with BSC in the unprogressed state, irrespective of the time for which the treatment is taken
or the FVC achieved.
l Treatments are assumed to act solely on the rate of FVC decline and do not have an additive effect on
the incidence of acute exacerbation.
l Home oxygen is not used in the unprogressed state but all progressed IPF patients use home oxygen
on a long-term basis.
l Treatment-emergent adverse events are not modelled with separate health states. They are instead
reflected in additional costs associated with the relevant treatment.
It is further assumed that a per cent predicted FVC of ≥ 70% in an IPF patient population at baseline
indicates unprogressed IPF. The FVC per cent predicted at baseline of recently diagnosed IPF in the key
trials is generally > 70% (see Chapter 3) and this is, consequently, an appropriate, if somewhat arbitrary,
threshold for distinguishing between progressed and unprogressed IPF when information on prior rate of
predicted FVC per cent decline is not available. In common with the key trials, we do not impose an upper
limit on FVC per cent predicted when defining unprogressed IPF.
An absolute decline of ≥ 10% in FVC per cent predicted is an established marker of disease progression
and mortality in patients with IPF.67,139,140 FVC or VC decline has been used as a marker of disease
progression in many RCTs among IPF populations62,141,142 and guidelines recommend that an absolute
decrease in FVC of ≥ 10% can be used as a surrogate marker for mortality.140 Recent work has indicated
that a relative decline in FVC may be similarly prognostic of mortality.139 However, given the available
evidence, this economic evaluation uses absolute decline in FVC per cent predicted of ≥ 10% as its marker
of disease progression.
In each cycle, the total costs and QALYs are calculated by multiplying the individual costs and HRQoL of
each model state by the proportion of the model cohort in that state for each of the treatments. The total
discounted lifetime costs and QALYs are calculated by aggregating the costs and QALYs for all cycles.
The ICER of each of the treatments versus BSC is calculated as
ICER=
Cost of treatment− cost of BSC
QALYs of treatment−QALYs of BSC
(6)
The associated net monetary benefit (NMB) of a specific treatment compared with BSC may be
calculated as
NMB= incremental QALYsWTP− incremental costs, (7)
where the incremental QALYs and incremental costs are simply the denominator and numerator,
respectively, of Equation 6 and WTP is the maximum amount a decision-maker is prepared to pay per
QALY gained.143 As long as the NMB is more than zero, a treatment is cost-effective, and larger NMBs
represent greater cost-effectiveness than smaller NMBs. The NMB framework facilitates comparison of
multiple treatment options simultaneously and it is used in later analysis to identify the most cost-effective
treatment at various assumed costs for BIBF 1120.
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Model validation
The model was validated by checking the model structure, calculations and data inputs for correctness.
The structure was reviewed by clinical experts to establish that it was appropriate for the disease and its
treatment. Internal consistency was examined by varying input values and subsequent verification that any
change to the input values produced changes in the model outputs of the expected direction and
magnitude. To establish its external consistency, the model results were compared with outcomes reported
in trial and other publications.
Evaluation of uncertainty
The evaluation of the cost-effectiveness of pharmacological treatments for IPF is based on uncertain
information which includes uncertainty about the clinical effects of treatment, HRQoL while in the various
health states, and resource use. Such uncertainty is examined using deterministic and probabilistic
sensitivity analyses (PSAs).
One-way deterministic sensitivity analyses were conducted to test the robustness of the cost-effectiveness
results to variations in parameter input values when altered one at a time (see Results of independent
economic analysis).
Joint variation and potential correlation in multiple parameters was addressed using PSA (see Results of
independent economic analysis). In the PSA, probability distributions were assigned to the parameter point
estimates used in the base-case analysis. The model was then run for 1000 iterations with parameter
values sampled at random from these distributions. The uncertainty surrounding the cost-effectiveness
of the treatments is represented on a cost-effectiveness acceptability curve (CEAC), which plots the
probability that an intervention will be cost-effective at a particular WTP threshold.
Scenario analysis was used to investigate the effect of uncertainty in model assumptions and structure.
Value of information
Decision-makers are interested in the value of further research to gain more precise information on
uncertain parameters in an economic model, and need to identify the research priorities where additional
information would provide the most benefit. Value of information (VOI) analysis attempts to answer these
questions by analysing the hypothetical case for which perfect information could be obtained through
further research.144 The expected value of perfect information (EVPI) shows the value of reducing the
uncertainty around the decision of whether or not to adopt the intervention. If the EVPI is greater than
the cost of obtaining new information, then further research will be valuable. The EVPI is estimated for
different cost-effectiveness thresholds and this gives an indication of an upper cost bound for further
research at these thresholds.
Expected value of perfect information analysis alone does not indicate what further information to
obtain. In order to determine what further research would have the most effect in reducing uncertainty,
a partial EVPI is conducted. In this analysis, the uncertainty around particular input parameters in the
model is investigated.
Value of information analysis was conducted to investigate the expected pay-off of further research into
selected treatments for IPF and is described in Results of independent economic analysis.
Data sources
Unprogressed state: probability of progression
The baseline risk of disease progression in the economic model is taken from the Capacity trials
(see Chapter 3).62 These were large RCTs with 347 patients in the pooled placebo population who were
followed up for 72 weeks (16.5 months). Mean per cent predicted FVC at baseline in the pooled placebo
population was approximately 75%, and so the population meets the model definition of unprogressed
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IPF. PFS was defined as a composite of time to either confirmed ≥ 10% decline in per cent predicted FVC;
≥ 15% decline in per cent predicted DLCO; or death. Kaplan–Meier curves for this outcome are given in the
trial publication.62 Numbers experiencing a confirmed ≥ 10% decline in per cent predicted FVC were also
reported as a secondary endpoint. The high numbers enrolled in the trial and the detailed reporting of
outcomes which broadly coincide with the model definition of IPF progression make this an appropriate
and robust source of data to inform disease progression in the economic model.
The placebo population in the Capacity trial is considered to correspond to the BSC treatment arm in the
economic model. PFS probabilities in the pooled placebo population were extracted from a Kaplan–Meier
plot in the trial publication using the digitising software Engauge (Engauge Digitizer, San Francisco, CA, USA:
http://digitizer.sourceforge.net) and the method of survival curve reconstruction described in Guyot and
colleagues.145 Parametric survival curves were then fitted to the observed data using Stata software
(StataCorp LP, College Station, TX, USA) in order to extrapolate PFS beyond the 72 weeks in the trial.
In line with the recommendation of Latimer,146 all of the ‘standard’ parametric models were considered
(exponential, Weibull, Gompertz, log-logistic and log-normal).
Akaike information criterion (AIC) values obtained for each distribution are given in Table 71 which
shows that the log-normal and Weibull distributions provide the best fit to the data based on this
criterion. The Gompertz and exponential distributions fit the data less well. The log-normal and Weibull
fits are compared graphically in Figure 14. The figure demonstrates that while the initial behaviour
of the log-normal and Weibull fits is similar, the log-normal predicts better PFS than the Weibull after
approximately 2 years. PFS predicted by the log-normal fit at 10 years is approximately 6% and declines
only slowly after this. The Weibull fit is, therefore, considered to be more clinically plausible and is
preferred in the model base case. The log-normal fit is examined in scenario analysis discussed in
Results of independent economic analysis.
Progression-free survival, as reported in the Capacity trials, is for model purposes confounded with decline
in DLCO. The numbers experiencing only a categorical change in FVC ≥ 10% in the pooled population from
both Capacity trials is reported in Noble and colleagues62 but no Kaplan–Meier curve is supplied for this
outcome. The TTP outcome also does not incorporate deaths, which are included in PFS and are required
by the model. PFS data are consequently adopted for use in the model.
TABLE 71 Values of AIC obtained for parametric survival models fitted to reconstructed PFS data from
Capacity trial62
Model AIC
Log-normal 640.4
Weibull 641.6
Log-logistic 641.7
Gompertz 648.9
Exponential 669.5
Lower values of AIC indicate a better fit to the data.
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Unprogressed state: probability of death from idiopathic pulmonary fibrosis
Given that the model uses a PFS curve to inform disease progression in the base case, all deaths in the
unprogressed state are incorporated in the monthly probability of progression discussed above (there are
no deaths in those remaining in the unprogressed state). The conditional probability that a patient has
died, given that they are moving out of the PFS state, is, consequently, required. The Capacity trial reports
34 deaths from any cause in the pooled placebo population.62 The total number of patients moving out of
the PFS state is not reported in the trial publication but from the survival curve reconstruction described
above we estimate that there were 138 such events. Assuming that all reported deaths in this trial
occurred to patients in the unprogressed state gives a probability of death, given progression of 34/138, of
0.25 (see Table 74). Variations to this proportion are examined in sensitivity analysis.
Progressed state: overall survival
The monthly probability of death in the progressed state is obtained from the overall survival Kaplan–Meier
curve given in Richeldi and colleagues139 for IPF patients exhibiting a ≥ 10% absolute decline in FVC per
cent predicted at 12 months after diagnosis. This decline is consistent with the definition used by the
economic model of progression. The study is more recent and follows a bigger sample (n= 26) than other
published studies which differentiate survival by FVC decline147,148 and, consequently, it was adopted to
inform the economic model.
Overall survival probabilities were extracted from the Kaplan–Meier curve using the digitising software
Engauge and the method of survival curve reconstruction described in Guyot and colleagues.145
Parametric survival curves were then fitted to the observed data using Stata software to allow for more
straightforward examination of uncertainty in transition probabilities in the economic model, and in
order to extrapolate overall survival beyond the 5 years of observed data. All of the ‘standard’ parametric
models were considered (exponential, Weibull, Gompertz, log-logistic and log-normal).146
The exponential distribution provided the best fit to the data based on the AIC (Table 72). This fit
represents the data reasonably well and is the distribution adopted in the economic model base case
(Figure 15). The alternative functional forms of Weibull and Gompertz provide similar fits to the observed
Kaplan–Meier curve as the exponential and so were not examined in sensitivity analysis (see Figure 15).
The exponential fit to the overall survival data gives the monthly probability of death from IPF in the
progressed disease state as 0.0304 (see Table 74).
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FIGURE 14 Kaplan–Meier plot of PFS in the pooled placebo population of the Capacity trials62 compared with
fitted log-normal and Weibull PFS curves.
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The data in Figure 15 represent patients who have experienced a ≥ 10% absolute decline in FVC per cent
predicted and in this respect conform to the economic model definition of IPF progression. However, they
also pertain to a particular rate of decline as they were obtained for patients with ≥ 10% decline at 1 year
after diagnosis. The data may consequently overstate the probability of death for those in the progressed
state who have experienced a ≥ 10% decline in FVC per cent but did so over a longer time period than
1 year. Alternative, less steep overall survival curves for those in the progressed state are examined in
deterministic sensitivity analysis described in Results of independent economic analysis.
Acute exacerbation
The baseline probability of an acute exacerbation while in the unprogressed state is taken from a study
by Song and colleagues.17 This was a retrospective review of 461 patients in South Korea who were
diagnosed with IPF according to the ATS/ERS criteria between 1990 and 2009. Two hundred and sixty-nine
of the cases were biopsy-proven. Acute exacerbation was defined by the criteria of Collard and colleagues.6
FVC per cent predicted was > 70% at baseline and so the patient group meets the model definition
of unprogressed IPF. Three-year incidence of first acute exacerbation was found to be 20.7% and
corresponding 1-year incidence was 14.2%. This compares with the incidence of 10–14% reported in
Chapter 1 (see Description of underlying health problem). The 3-year incidence of 20.7% is converted to a
monthly probability of 0.006 for use in the economic model (see Table 74).149 The 1-month probability of
death from acute exacerbation is also taken from Song and colleagues and is 0.5 (see Table 74).
TABLE 72 Values of AIC obtained for parametric survival models fitted to reconstructed overall survival data from
Richeldi et al.139
Model AIC
Exponential 83.1
Gompertz 84.8
Weibull 85.0
Log-normal 86.8
Log-logistic 87.2
Lower values of AIC indicate a better fit to the data.
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FIGURE 15 Overall survival curves fitted to data from Richeldi et al.139 for IPF patients with ≥ 10% absolute decline
in FVC per cent predicted at 12 months.
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Given the model assumption that acute exacerbations entail a drop in FVC per cent predicted of ≥ 10% in
an unprogressed patient, all patients undergoing acute exacerbation move out of the unprogressed state
and are included in the monthly probability of progression discussed above. In order to reflect the costs
and utility decrement associated with acute exacerbation, the model calculates the probabilities that a
progressing patient has either survived or died from an acute exacerbation using Bayes’ theorem:
p(AjB) ¼ p(BjA)p(A)
p(B)
, (7)
where, for the probability that a progressing patient has a survived an acute exacerbation, p(B) is the
1-month probability of moving to the progressed state; p(A) is the 1-month probability of an acute
exacerbation in the unprogressed state; p(B|A) is the 1-month probability of surviving an acute exacerbation;
and p(A|B) is the probability that a progressing patient has survived an acute exacerbation (see Table 74
for all input probabilities). The probability that a progressing patient dies from an acute exacerbation is
calculated using the same method.
A transition cost and utility decrement are applied to those undergoing an acute exacerbation before they
transit to their destination state, i.e. progressed or dead (see Figure 13). The utility decrement is assumed
to last for 1 month only.
The probability of acute exacerbation while in the progressed state is drawn from the placebo arm of the
sildenafil trial.72 FVC per cent predicted was < 60% at baseline in this trial, thus meeting the model
definition of progressed disease. Four of 91 patients experienced acute exacerbation on the placebo arm in
the 12-week follow-up period,72 giving a monthly probability of acute exacerbation of 0.016, more than
twice the monthly probability of acute exacerbation for the unprogressed health state (see Table 74).
The overall survival curve used to inform transitions from the progressed state already incorporates deaths
due to acute exacerbation. The proportion of these deaths due to acute exacerbation is calculated using
Bayes’ theorem with the method described above. The proportion of acute exacerbations in those
remaining in the progressed state is calculated in the same way. A transition cost and 1-month utility
decrement are then applied to those undergoing an acute exacerbation before they transit to their
destination state, i.e. progressed or dead (see Figure 13).
Lung transplant frequency in progressed idiopathic pulmonary
fibrosis patients
Specific criteria have been proposed to guide referral of IPF patients for lung transplant (see Chapter 1,
Current service provision). These include a reduction of 10% in FVC over a 6-month follow-up period.
The NHS Choices website currently states that a lung transplant is used to treat people with advanced
lung disease who are failing to respond to other treatment.150 Notwithstanding the fact that clinicians may
make a quick referral for a deteriorating IPF patient even if they do not meet the established criteria
(see Chapter 1, Current service provision), it is assumed in the economic model that only patients with
progressed IPF are eligible for a lung transplant.
The UK Cardiothoracic Transplant Audit notes 166 lung transplants in the UK in 2010–11.151 Using the IPF
incidence and prevalence in the UK given by Navaratnam and colleagues,13 and outputs from the
economic model, leads to an estimate for the size of the progressed IPF population in the UK of
approximately 4505. Given that 17% of lung transplants are for IPF patients (see Chapter 1, Current
service provision), the overall annual probability of lung transplant for a progressed IPF patient in the UK is
0.0062, or 0.6%, equivalent to 28 transplants per year (see Table 74). This probability does not reflect
comorbidities or other factors which may make progressed patients ineligible for transplant and reduce the
effective population size to < 4505, and so will understate the probability of transplant achieved in practice
for a patient on the waiting list. It is, however, a necessary assumption in the economic model where
patients in the progressed state are not differentiated by comorbidity or other status.
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The figure of 28 lung transplants per year is in line with the range of 23–33 given in Chapter 1
(see Current service provision). Variations to the annual probability of lung transplant are examined in a
sensitivity analysis.
Survival after lung transplant
Figure 17 in the 28th Annual Report of the Registry of the ISHLT gives a Kaplan–Meier survival curve for
IPF patients after lung transplant between 1990 and 2008.151 The standard parametric survival curves were
fitted to a digitised copy of this curve in order to inform survival after lung transplant in the economic
model.146 The digitising software Engauge was used, followed by the method of survival curve
reconstruction described in Guyot and colleagues.145
The Weibull and log-normal distributions were found to provide the best fit to the data by the AIC
(Table 73) and are compared with the observed Kaplan–Meier curve in Figure 16. Figure 16 shows that
5-year survival after lung transplant is 40–50% in all cases, in line with the survival estimate given in
Chapter 1 (see Current service provision).
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FIGURE 16 Observed Kaplan–Meier survival by IPF diagnosis for adult lung transplants performed between
January 1990 and June 2008,152 compared with fitted Weibull and log-normal survival curves.
TABLE 73 Values of AIC obtained for parametric survival models fitted to reconstructed lung transplant overall
survival data152
Model AIC
Weibull 22,257
Log-normal 22,262
Gompertz 22,391
Exponential 22,506
Log-logistic 22,527
Lower values of AIC indicate a better fit to the data.
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Lung transplant is associated with high hazard of death soon after transplant, which reduces as time
progresses.151 Both the Weibull and log-normal curves overestimate lung transplant survival until around
30 months after transplant (see Figure 16). Because of this poor initial fit to the data, it was decided to use
the observed Kaplan–Meier probability of mortality in the first 30 months after transplant. After this time
the model uses the fitted Weibull survival curve to estimate post-lung transplant mortality as it provides a
slightly better fit to the observed data than the log-normal, and also provides a more clinically plausible
extrapolation of survival, i.e. with a progressive decline in survival after around 170 months, rather than a
levelling-off as seen in the log-normal curve (see Figure 16).
The lung transplant state is modelled as a tunnel state because the hazard of death after lung transplant
varies over time and it is not the starting state – new patients enter the state throughout the model
time horizon.
A summary of baseline transition probabilities used in the economic model is given in Table 74.
TABLE 74 Summary of baseline probabilities
Variable
Source point estimate
(time period)
Point estimate per
1-month model cycle Source
Unprogressed state – probability
of progression or death
NA – KM data Not constant – Weibull
curve
Noble et al.62
Unprogressed state – probability
of death from IPF given
progression
0.25 0.25 Noble et al.62 and survival
curve reconstruction
Unprogressed state – probability
of acute exacerbation
0.207 (3 years) 0.006 Song et al.17
Progressed state – probability
of acute exacerbation
0.044 (12 weeks) 0.016 IPFCRN Zisman et al.72
1 month probability of death from
acute exacerbation
0.5 0.5 Song et al.17
Progressed state – probability
of death from IPF
NA – KM data 0.0304 Richeldi et al.139
Progressed state – probability
of lung transplant
0.0062 (1 year) 0.0005 RCS151 Navaratnam et al.13
17% (NHS Blood and
Transplant, 25 February 2013,
personal communication)
Lung transplant state – probability
of death
NA – KM data Not constant – Weibull
curve
Christie et al.152
KM, Kaplan–Meier; NA, not applicable; RCS, Royal College of Surgeons.
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All-cause mortality associated with age
The general underlying risk of mortality was modelled using a cohort life table generated from the
2009–11 male and female interim life tables for England and Wales.153 The age-related mortality for each
year in the model was determined from these data using the demographic characteristics of IPF patients in
the UK reported in Gribbin and colleagues.11 Specifically, in the base case, patients enter the model at an
age of 71 years, and a 62%/38% male/female split is assumed.
Treatment effects
Absolute rate of decline in forced vital capacity
The effects of the various pharmacological treatments on slowing down (or speeding up) the rate of
decline in FVC per cent predicted are derived from the NMA described in Chapter 3 (see Network
meta-analysis). It is assumed in the model that the odds ratio obtained from the standardised mean
difference in FVC seen in the key trials can be applied to an absolute decline in FVC per cent predicted of
10%, even when a 10% absolute decline in FVC per cent predicted was not seen in a trial itself. This is
equivalent to assuming that a pharmacological treatment has a constant effect on relative rate of FVC
per cent decline compared with BSC in the unprogressed state, irrespective of the time for which the
treatment is taken or the FVC achieved.
The odds ratios for the treatment effects given in Table 59 are used in the economic model. The odds
ratios shown in this table assume that the standardised mean difference data are normally distributed,93
and this results in slightly smaller treatment effects and narrower CrIs than the alternative parameterisation
(see Table 57). The treatment effects are applied to the baseline probability of disease progression given by
the curve fitted to PFS data for BSC (see Figure 14). The baseline probability is converted to odds before it
is multiplied by the odds ratio, as follows:
oddsi =
p
1−p
∗ORi, (8)
where oddsi is the odds of progression for treatment i, p is the baseline monthly probability of progression
in the BSC arm, and ORi is the treatment effect of the ith treatment.
The odds of progression for treatment i are converted back to a monthly probability using the
following formula:
pi =
oddsi
1þ oddsi , (9)
where pi is the monthly probability of progression for treatment i.
In the base case, for all treatments except sildenafil, treatment effects are applied only in the unprogressed
disease state. For sildenafil, the effect of treatment is applied to the progressed disease state only. This
conforms to the study populations of the relevant trials. The application of treatment effects in both
unprogressed and progressed disease states is examined in scenario analysis described in Results of
independent economic analysis.
Treatments are assumed to act solely on the rate of FVC decline and do not have a separate additive effect
on the incidence of acute exacerbation. Any benefits in reduced acute exacerbation incidence associated
with a pharmacological treatment are considered to be reflected in the change in rate of FVC decline
associated with the treatment.
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Health-related quality of life
The economic model applies different utility values to each of the non-dead health states. These are not
differentiated by treatment received. Any impact of treatment on HRQoL is assumed to occur because
of delay to disease progression, and this delay is already accounted for in the model. The utility values used
for the health states are discussed below.
Unprogressed and progressed idiopathic pulmonary fibrosis
The systematic review of clinical effectiveness and HRQoL (see Systematic review of health-related quality
of life studies) identified two studies which used the EQ-5D to establish health state values in IPF
patients.68,72 The sildenafil trial72 included a population of severe IPF patients with a baseline mean FVC
per cent predicted of 59% for the placebo arm. This group meets the model definition for progressed IPF.
The placebo population of the triple-therapy NAC trial68 had a baseline mean FVC per cent predicted of
72% on the placebo arm, and so meets the model definition of unprogressed IPF.
Both studies were conducted under the auspices of the IPFCRN, with all study centres in North America.
Neither study protocol mentions the tariff used in calculation of EQ-5D health state values but it may be
assumed to be the US tariff. Huang and colleagues129 note that for assessing treatment benefit in a
single population, the use of either the UK or the US EQ-5D weights as a measure of HRQoL will not
change inferences.
Given that both the sildenafil and the NAC studies were conducted by the same clinical network, it is
likely that their estimates of EQ-5D are consistent and, consequently, it is reasonable to contrast them
in the economic model. The model adopts the self-report questionnaire EQ-5D value of 0.8 (± 0.2)
for the placebo population at baseline, given in Raghu and colleagues,68 as the estimate of utility in the
unprogressed IPF health state. The self-report questionnaire EQ-5D value of 0.74 (± 0.19) for the placebo
population at baseline, given in Zisman and colleagues,72 is used as the estimate of utility in the progressed
IPF health state (Table 75).
Other studies in the systematic review of HRQoL (see Systematic review of health-related quality of life
studies) use the SF-36 to measure HRQoL. Mapping the SF-36 scores reported in these studies to EQ-5D
using the algorithm of Ara and Brazier156 (their Equation 1) was investigated. However, for the single study
which reported both SF-36 and EQ-5D,72 the mapped EQ-5D value of 0.46 was very low compared with
the directly elicited EQ-5D value of 0.74. Longworth and Rowen157 recommend that mapping of utilities
should usually be viewed as a second best solution to direct collection of data. For this reason, a decision
was made to use directly collected EQ-5D in the economic model.
TABLE 75 European Quality of Life-5 Dimensions utility values by model health state
Model health state EQ-5D (SD) Source
Unprogressed IPF 0.80 (0.20) IPFCRN Raghu et al.68
Progressed IPF 0.74 (0.19) IPFCRN Zisman et al.72
Lung transplant
0–6 months after transplant 0.71 (0.38) Anyanwu et al.154 (weighted average assuming two-thirds
single and one-third double lung)
7–18 months after transplant 0.72 (0.31) Anyanwu et al.154 (weighted average assuming two-thirds
single and one-third double lung)
19–36 months after transplant 0.70 (0.33) Anyanwu et al.154 (weighted average assuming two-thirds
single and one-third double lung)
> 36 months after transplant 0.68 (0.38) Anyanwu et al.154 (weighted average assuming two-thirds
single and one-third double lung)
Acute exacerbation decrement 0.20 (not available) Lloyd et al.155
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Lung transplant
The utility associated with the lung transplant state is taken from a UK-based study by Anyanwu and
colleagues,154 which assessed the HRQoL in lung transplantation using the EQ-5D. This study finds that utility
after transplant tends to increase through time in cases of a bilateral transplant (within the follow-up
period), but decreases through time for a single lung transplant. Although, since April 2006 the number of
bilateral sequential lung grafts has increased to 72.3% of total lung transplant activity,151 IPF is a disease
of older adults and, traditionally, single lung transplant has been preferred over double lung transplant
because it is not such a major operation (see Chapter 1, Current service provision). A double lung transplant
may be performed in younger IPF patients. Given this mix of transplant types, we use a weighted average of
the single and double transplant utilities reported in Anyanwu and colleagues154 in the economic model. We
assume that two-thirds of IPF patients receive a single lung transplant, and that one-third receive a double
lung transplant. The weighted average utilities are given in Table 75 by time after transplant.
The weighted utilities after lung transplant initially increase from 0.71 to 0.72, then decrease to 0.68 after
36 months. These utilities are, in all cases, lower than the utility value assumed for progressed IPF of 0.74
(see Table 75). These differences may arise because of the relative age of the lung transplant utility data
which were collected in 1998,154 in contrast to the more recent progressed state utility value for which data
were collected between 2007 and 2009.72 It is worth noting that the EQ-5D value for the intervention
population at baseline, reported in Zisman and colleagues,72 is 0.71, lower than the value of 0.74 obtained
for the placebo population which is used in the economic model. We examine variations to these base-case
utilities in deterministic and PSAs described in Results of independent economic analysis.
Acute exacerbations
No studies were found which directly examined EQ-5D in acute exacerbations of IPF. HRQoL for patients
experiencing acute exacerbation is obtained from a study by Lloyd and colleagues,155 which concerned
hospitalised asthma patients experiencing an acute exacerbation. The sample size with hospitalisations in
this study was only five. However, the mean EQ-5D decrement for these five, of 0.2, is in agreement
with the mean decrement of 0.19 found by Menn and colleagues158 for acute exacerbations in COPD
using a German EQ-5D tariff. In the absence of better data, this decrement has been used in the economic
model (see Table 75). Variations to the decrement are examined in sensitivity analysis (see Results of
independent economic analysis).
Summary
A summary of the health state utility values used in the economic model is given in Table 75. To avoid
double counting, the pharmacological treatments for IPF are assumed to not have any effect on HRQoL
beyond that achieved by delaying the progress of the disease.
Costs
Five types of cost are considered in the economic model:
1. Costs associated with a particular pharmacological treatment. These include both the costs of the drug
and the monitoring costs associated with the treatment.
2. Hospital admission costs arising from acute exacerbations of IPF.
3. Ongoing non-pharmacological treatment costs for management of the condition. These include
oxygen costs and the costs of long-term oxygen monitoring.
4. Costs associated with lung transplant.
5. Cost of adverse events attributed to the pharmacological intervention.
Treatment costs
Drug unit costs were taken, where available, from the NHS electronic drugs tariff for May 2013.159
Otherwise, costs were taken from British National Formulary (BNF) 65160 or other appropriate online
sources (Table 76). Dose information was obtained from either BNF 65 or the NICE clinical guideline for
IPF,31 except for BIBF 1120 for which doses were drawn from the trial publication.71
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TABLE 76 Drug unit costs, doses and monitoring costs used in the economic model
Drug Standard dose Unit cost of intervention
Drug cost
per month Monitoring costs
Monitoring
cost total
per month
Azathioprine 2mg/kg
125mg/day assumed31
Cost per 25mg 28-tab
pack= £4.71
Cost per 50mg 56-tab
pack= £4.20
Cost per day= £0.32159
£9.69 13 liver function
tests, seven full
blood counts and
one TPMT assay
assumed per year
at total annual
cost of £279.9631
£23.33
BIBF 1120 150mg two times
daily71
Currently unlicensed.
Use assumed cost of
pirfenidone (month 2
onwards)+ 50%
£3273.71 Not known –
none applied
–
NAC 600mg three times
daily31
Only available as an
unlicensed generic.
Cheapest cost found
for 600mg 250-tab
pack= £18.47 (supplied by
Now® Foods, price on
www.amazon.co.uk,
17 May 2013)
Cost per day= £0.22
£6.75 No additional
monitoring
required
–
Inhaled NAC 352.4mg two times
daily, diluted with
saline to a total volume
of 4ml69
Acetylcysteine cost
per 200mg/ml 10ml
ampoule= £2.25
(as Parvolex®, Phoenix)
Sodium chloride nebuliser
solution cost per
20 × 2.5ml= £11.50
Cost per day= £1.94
assuming no wastage160
Nebuliser cost= £79.78
(one-off)a
Face mask cost= £0.59
(one per month assumed)a
£59.14 No additional
monitoring
required
Pirfenidone 267mg three times
daily for first week;
534mg three times
daily for second week;
801mg three times
daily ongoing
Cost per 267mg 63-tab
pack= £501.92
Cost per 267mg 252-tab
pack= £2,007.70
Cost per 267mg 270-tab
pack= £2,151.10
Cost per week
For week 1= £167.31
For week 2= £334.62
For weeks 3+= £501.92160
Month 1=
£1680.55
Month 2+=
£2182.47
Eight liver
function tests per
48 weeks23
Assumed number
of tests per
year= 9
Cost of liver
function test
including nurse
time= £13.1231
Cost of tests per
year= £118.08
£9.84
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The costs of monitoring associated with treatment were also included in the economic model and are
given in Table 76, together with full details of assumed doses, unit costs and data sources.
BIBF 1120 was, at the time of writing (June 2013), unlicensed and a price is not available from standard
sources. The manufacturer (Boehringer Ingelheim) was contacted with a request for price information. Their
response indicated that the price is currently commercially sensitive and therefore unavailable. Consequently,
the model uses an assumed cost for BIBF 1120. This is fixed at the monthly cost of pirfenidone plus 50%
in the base case but is subject to full sensitivity analysis (see Results of independent economic analysis).
Acute exacerbations
The cost of an acute exacerbation was estimated as the activity-weighted average cost of the DZ25A
and DZ25B currency codes given in NHS Reference Costs 2011–12.161 These codes relate to fibrosis or
pneumoconiosis either with or without complications and comorbidities. Elective inpatient data were excluded
from calculations of the weighted average of DZ25A and DZ25B as they do not represent sudden unplanned
deterioration in IPF. The calculated unit cost and lower and upper quartiles used in sensitivity analysis are given
in Table 77. These general costs were used for all treatments, as no treatment-specific acute exacerbation
costs were available.
TABLE 76 Drug unit costs, doses and monitoring costs used in the economic model (continued )
Drug Standard dose Unit cost of intervention
Drug cost
per month Monitoring costs
Monitoring
cost total
per month
Prednisolone 40mg daily for first
4 weeks
30mg daily for
weeks 5–8
20mg daily for
weeks 9–12
10mg daily thereafter31
Cost per 5mg 28-tab
pack= £3.43
Cost per week
For weeks 1–4= £6.86
For weeks 4–8= £5.15
For weeks 8–12= £3.43
For weeks 12+= £1.86
For month
1= £29.23
For month
2= £21.18
For month
3= £13.28
For month
4+= £8.11
Assessment for
corticosteroid
complications.
Annual cost of
£220.1131
£18.34
Sildenafil By mouth, 20mg three
times daily
Cost per 20mg 90-tab
pack= £373.50160
Cost per day= £12.45
£378.95 No additional
monitoring
required
a University Hospital Southampton NHS Foundation Trust Procurement Team, 17 July 2013, personal communication.
TABLE 77 Unit costs assumed by economic model
HRG/code Description
Unit cost
(£)
Lower
quartile (£)
Upper
quartile (£) SD (£)
DZ25A
DZ25B
Fibrosis or pneumoconiosis, with and without CC
(excluding elective inpatient data)
1361.04 1002.20 1578.20 –
DZ38Z Oxygen assessment and monitoring 173.94 121.40 209.37 –
– Home oxygen – 12 months’ supply 824.30 – – 142.80
DZ01Z Lung transplant (excluding outpatient procedures) 35,468.61 28,334.00 36,356.36 –
CC, complications and comorbidities; HRG, Healthcare Resource Group.
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Oxygen and oxygen monitoring costs
The economic model assumes that home oxygen is not used in the unprogressed state, but that all
progressed IPF patients use home oxygen on a long-term basis. This is associated with a monitoring cost
and the cost of the oxygen itself.
The cost of oxygen assessment and monitoring is taken from currency code DZ38Z given in NHS Reference
Costs 2011–12.161 A weighted average of items under currency code DZ38Z was calculated and is given
in Table 77, together with the lower and upper quartiles used in sensitivity analysis. A frequency of
two oxygen-monitoring assessments per year is assumed.
The cost of oxygen was taken from the home oxygen service costing tool made available by the UK
Department of Health.162 This tool estimates the likely cost to a primary care trust (PCT) of providing home
oxygen to patients by year over the period 2012–16, and the additional cost of running a Home Oxygen
Assessment and Review Service to ensure that home oxygen is appropriately prescribed to those people
who clinically need it.163 Using this tool, the baseline cost of oxygen in 2012 was extracted for each of the
151 PCTs it covers. An expected oxygen cost for one patient was obtained using the average proportional
incidence of oxygen subcharge categories within the PCT given by the costing tool. In this way, the
average annual cost to a PCT of home oxygen was calculated as £824.30 per patient, with a SD of
£142.80 (see Table 77).
Lung transplant
The cost of a lung transplant was calculated as a weighted average of items under currency code DZ01Z
in NHS Reference Costs 2011–12, excluding outpatient procedures.161 Outpatient procedures have an
average cost of £140 and do not relate to transplant per se, although they may be a consequence of
transplant. A weighted average unit cost for lung transplant of £35,468.61 was obtained (see Table 77).
Adverse events
The incidence of adverse events for each pharmacological treatment was taken from the studies included
in the systematic review of clinical-effectiveness (see Chapter 3). Although adverse event data are
consistently reported across studies as a percentage of patients, the types of adverse event reported differ
between the studies. Only serious adverse events of Common Terminology Criteria (CTC) grades 3 and 4
which occur in > 5% of patients in any treatment arm are included in the model, as these are considered
to incur additional NHS costs. Adverse events are, moreover, included only if the adverse event incidence
differs significantly between treatment arms, in line with the modelling guidelines of Philips and
colleagues.60 Adverse event costs are generally small in comparison with other costs in the model as
serious events are relatively rare.
The adverse events which required cost estimates were gastrointestinal and respiratory system related.
A mean cost for treatment of each adverse event was obtained from NHS Reference Costs161 using
the currency codes shown in Table 78. When incorporating costs for adverse events into the model,
we used the expected cost per patient shown in Table 78 and assumed that patients would have only one
episode of any adverse event during their treatment. This cost is applied in the first cycle of the model.
Model validation
The Weibull and log-normal PFS predictions from the model are compared with the observed
Kaplan–Meier data for the BSC arm62 in Figure 17. The predictions look very reasonable when compared
with the observed data and the original fitted curves shown in Figure 14. The model thus appears to be
adequate in its simulation of PFS in the BSC arm.
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It was verified that the treatment effects were being correctly applied in the unprogressed state by
producing PFS curves for both pirfenidone and BIBF 1120 and comparing these with predicted PFS in the
BSC arm (Figure 18). Pirfenidone is associated with longer median PFS than BSC, and BIBF 1120 is
associated with longer median PFS than either pirfenidone or BSC. This is consistent with the treatment
effects estimated by the NMA (see Chapter 3, Network meta-analysis).
Overall survival curves for each treatment arm were examined and used to obtain median overall survival
predictions which are shown in Table 79 along with median PFS by treatment arm. The model predicts
median overall survival of 43 months (3.6 years) in the BSC arm which is consistent with the median
survival of 2–5 years given in Noble and colleagues62 and the median survival of 3.03 years estimated by
Navaratnam and colleagues.13
TABLE 78 Mean cost estimates for AEs included in the economic model
Treatment AE Currency code Cost (£) per event
AE incidence
(% patients)
Expected cost per
patient (£) per event
BIBF 112071 Serious GI PA25Aa 3387 4.7 159
Severe GI PA26Ab 1559 5.9 92
Triple NAC68 Respiratory system DZ25Ac 1150 16 184
AE, adverse event; GI, gastrointestinal.
a Major gastrointestinal disorders with complications and comorbidities.
b Other gastrointestinal disorders with complications and comorbidities.
c Fibrosis or pneumoconiosis, without complications and comorbidities.
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FIGURE 17 Progression-free survival predicted by model compared with PFS observed in the Capacity trial
(pooled placebo arm).
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Table 79 also indicates that the difference between median PFS and median overall survival in the BSC arm
is 19.5 months, or 1.6 years. Median survival after a > 10% decline in absolute FVC per cent predicted is
given in the source Richeldi and colleagues data139 as approximately 24.5 months (see Figure 15). These
conditional data may not be recreated exactly from the economic model as the model does not distinguish
overall survival for the progressed state from overall survival overall. After accounting for this dissimilarity,
a reduction of 5 months in the difference of medians appears of satisfactory magnitude and varies in the
expected direction given the mortality associated with a ≥ 10% decline in FVC per cent predicted. In
summary, the model appears to be performing adequately when compared with external data sources.
Results of independent economic analysis
This section reports the cost-effectiveness of the pharmacological treatments compared with BSC in a
cohort of IPF patients.
Base-case results for all treatments are given in Table 80 and are shown on the cost-effectiveness plane in
Figure 19. The cost-effectiveness frontier, which indicates the maximum health gain which may be attained
for any given level of spending on the available treatment options, is also shown in Figure 19. The only
three treatments on the cost-effectiveness frontier are BSC, inhaled NAC and BIBF 1120. Table 80 gives
the total discounted costs for all treatments together with the discounted QALYs expected for patients in
the cohort, by treatment arm. The associated ICERs comparing each treatment with both BSC and the next
best option (the next cheapest option on the cost-effectiveness frontier) are also shown.
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FIGURE 18 Progression-free survival predicted by model, by treatment arm.
TABLE 79 Median PFS and overall survival predicted by model, by treatment arm
Treatment arm Median PFS (months) Median OS (months) Difference (OS-PFS)
BSC 23.5 43 19.5
Pirfenidone 29 50 21
BIBF 1120 40 61.5 21.5
OS, overall survival.
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Table 80 and Figure 19 indicate that azathioprine and prednisolone is dominated by BSC as it is more
costly but gives rise to fewer total QALYs than BSC. NAC triple therapy is associated with an ICER of
£41,811 per QALY when compared with BSC but does not lie on the cost-effectiveness frontier because
of extended dominance by a blend of BSC and inhaled NAC. Inhaled NAC is associated with an ICER
of £5037 per QALY when compared with the next best option (BSC). Sildenafil and pirfenidone are
dominated by inhaled NAC and are not cost-effective at a WTP of £30,000 per QALY when compared
with BSC. BIBF 1120 is the most costly treatment (assumed) but is also associated with the greatest
number of QALYs. It has an ICER of £132,659 per QALY when compared with BSC and an ICER of
£209,251 when compared with the next best option (inhaled NAC).
TABLE 80 Summary of base-case cost-effectiveness results for all treatments
Treatment Total costs (£) Total QALYs
ICER vs. BSC
(£/QALY)
ICER vs. next best option
(£/QALY)
BSC 3084 2.98 – –
Azathioprine and
prednisolone
4313 2.66 Dominated Dominated
NAC triple therapy 5021 3.03 41,811 Extended dominance
Inhaled NAC 5029 3.37 5037 5037
Sildenafil 12,008 3.11 68,116 Dominated
Pirfenidone 70,118 3.34 190,146 Dominated
BIBF 139,613 4.01 132,658 209,246
BIBF uses an assumed cost.
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FIGURE 19 Cost-effectiveness plane and frontier for all treatments.
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Although Table 80 and Figure 19 indicate that inhaled NAC is the only cost-effective treatment compared
with BSC at a WTP threshold of £30,000 per QALY, the treatment effect of inhaled NAC does not achieve
statistical significance at the 95% level in the NMA (see Table 59), and so it is unlikely that this treatment
would be adopted in clinical practice. The clinical effectiveness review also notes that this study had an
unclear risk of bias (see Table 6). The treatments which achieve statistical significance in the NMA are
pirfenidone and BIBF 1120. Results for only these treatments are shown on the cost-effectiveness plane
in Figure 20.
It is clear from Table 80 that neither BIBF nor pirfenidone is a cost-effective treatment option for IPF at a
WTP of £30,000 per QALY. Compared with BSC, pirfenidone has an ICER of £190,146 per QALY gained,
and BIBF 1120 has an ICER of £132,658 per QALY gained. Pirfenidone is subject to extended dominance
by a blend of BSC and BIBF 1120 and does not lie on the cost-effectiveness frontier (see Figure 20).
In summary, although these base-case findings indicate that inhaled NAC is a cost-effective treatment
option for IPF based on a point estimate of its efficacy, this estimate does not achieve statistical
significance. On this basis, inhaled NAC is unlikely to be adopted as a treatment option in clinical practice.
No other pharmacological intervention is cost-effective at a WTP threshold of £30,000 per QALY in the
model base case.
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FIGURE 20 Cost-effectiveness plane and frontier for BSC, pirfenidone and BIBF 1120.
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Sensitivity analysis
Deterministic and PSAs were conducted in order to investigate the effect of uncertainty in model
parameter values on the cost-effectiveness results. Deterministic sensitivity analysis was used to highlight
the most influential parameters while the effect of uncertainty and interaction in multiple parameters
was examined using PSA. Scenario analysis was used to investigate the effect of uncertainty in model
assumptions and structure. An additional one-way sensitivity analysis was performed on the price of BIBF
1120 in order to identify a price at which it becomes a cost-effective treatment option compared with BSC
at a WTP of £20,000 and £30,000.
Each parameter was assumed to follow a probability distribution and these are given, with the distribution
parameters, in Table 81. For beta distributions, the distribution parameters were fitted using either the
method of moments or information on the sample size and number of events when available. Distribution
parameters were fitted to the gamma distributions using the method of moments. In cases where a
standard error or SD was not supplied in the source literature, the standard error was calculated using an
arbitrary ± 20% from the base-case value. Correlation between the parameters of the Weibull distribution
used to inform disease progression was incorporated by sampling from a bivariate normal distribution with
covariance matrix as specified in Table 81. Possible correlation between treatment effects obtained from
the NMA was addressed by using values sampled from the converged Markov chain (see Table 81).
The model parameters were varied in deterministic sensitivity analysis between the 2.5th and 97.5th
percentiles of the assumed parameter distribution of the mean value, and these are given in Table 81.
Table 82 gives upper and lower bounds for parameters examined in deterministic sensitivity analysis only.
TABLE 81 Parameters, distributions and associated upper and lower values used in probabilistic and deterministic
sensitivity analysis
Name Distribution Distribution parameters
Mean/base
case
2.5th
percentile
97.5th
percentile
Costs
Acute exacerbation Gamma α= 10.16
β= 133.95
£1361 £657 £2317
Lung transplant Gamma α= 35.57
β= 997.09
£35,469 £24,784 £48,038
O2 monitoring Gamma α= 7.11
β= 24.45
£174 £71 £323
O2 Gamma α= 5031.30
β= 0.16
£824 £802 £847
Probabilities
Acute exacerbation
unprogressed state
Beta α= 75
β= 287
0.207 0.167 0.250
Acute exacerbation
progressed state
Beta α= 4
β= 87
0.044 0.012 0.094
Death from acute
exacerbation within
1 month
Beta α= 38
β= 37
0.5 0.394 0.619
continued
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TABLE 81 Parameters, distributions and associated upper and lower values used in probabilistic and deterministic
sensitivity analysis (continued )
Name Distribution Distribution parameters
Mean/base
case
2.5th
percentile
97.5th
percentile
Death in unprogressed
state
Beta α= 34
β= 104
0.246 0.178 0.321
Lung transplant Beta α= 28
β= 4477
0.006 0.004 0.009
OS and PFS curve parameters
OS progressed state Normala SE= 0.213 –3.549 –3.966 –3.131
PFS Bivariate normala
Lambda Covariance matrix

0:1404
−0:0287 0:0062

–5.412 –5.668 –5.194
Shape 0.469 0.459 0.480
Utilities
Unprogressed state Beta α= 248.8
β= 62.2
0.80 0.754 0.842
Progressed state Beta α= 358.2
β= 125.8
0.74 0.700 0.778
After lung transplant
0–6 months Beta α= 20.0
β= 8.2
0.71 0.533 0.859
7–18 months Beta α= 29.4
β= 11.6
0.72 0.571 0.842
19–36 months Beta α= 33.8
β= 14.2
0.70 0.568 0.822
> 36 months Beta α= 41.1
β= 19.3
0.68 0.558 0.791
Decrement
associated with acute
exacerbationb
Beta α= 19.8
β= 79.2
0.20 0.128 0.284
Treatment effects (FVC decline)
Azathioprine and
prednisolone
WinBUGSc output from NMA used to preserve
any correlation in treatment effects (sample of
1000 iterations used, taken after burn-in of
50,000 iterations with thinning interval of 50)a
0.40 –0.27 1.08
BIBF 1120 –0.88 –1.39 –0.37
Inhaled NAC –0.38 –1.13 0.36
NAC –0.05 –0.55 0.44
Pirfenidone –0.35 –0.56 –0.15
Sildenafil –0.11 –0.59 0.37
OS, overall survival; SE, standard error.
a Parameters on log scale.
b Distribution calculated after arbitrary ± 20% variation applied to mean to obtain standard error.
c WinBUGS, MRC Biostatistics Unit, Cambridge, UK.
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Deterministic sensitivity analysis
Tables 83 and 84 show the results of the deterministic sensitivity analyses for pirfenidone and BIBF 1120
compared with BSC for the most influential parameters. Tornado diagrams depicting the range in ICER
given in these tables are shown in Figures 21 and 22.
TABLE 82 Parameters examined in deterministic sensitivity analysis only with upper and lower values
Parameters Base case Lower value Upper value
Age of cohort entering model 71 65 75
Discount rate for costs 3.5 0 6
Discount rate for health 3.5 0 6
TABLE 83 Deterministic sensitivity analyses for pirfenidone vs. BSC
Variable
Low
value
High
value
Minimum ICER
(£/QALY)
Maximum ICER
(£/QALY) Difference
Treatment effect on FVC decline –
pirfenidone (log-odds ratio)
–0.56 –0.15 126,431 417,752 291,321
Discount rate utilities 0 0.06 158,838 214,124 55,286
Utility of unprogressed state 0.754 0.842 180,062 202,572 22,510
Discount rate costs 0 0.06 181,928 203,155 21,227
Progressed state OS parameter –3.966 –3.131 186,925 196,960 10,035
Shape parameter PFS Weibull curve 0.459 0.480 188,814 191,767 2953
Lambda parameter PFS Weibull curve –5.668 –5.194 189,200 191,566 2366
Probability of death given progression 0.178 0.321 188,951 191,245 2294
Utility in the progressed state 0.700 0.778 189,499 190,765 1266
Utility decrement associated with acute
exacerbation
0.128 0.284 190,059 190,248 189
Probability of LT 0.00413 0.0087 190,065 190,243 178
Probability of acute exacerbation
(unprogressed state)
0.167 0.25 190,073 190,231 159
Probability of acute exacerbation
(progressed state)
0.012 0.094 190,058 190,201 143
Generic cost of acute exacerbation 657 2317 190,093 190,219 127
LT utility months 36+ 0.558 0.791 190,092 190,196 104
Age of cohort entering model 65 75 190,112 190,185 73
Cost of oxygen monitoring 71 323 190,118 190,166 48
Probability of death from acute
exacerbation
0.394 0.619 190,132 190,160 29
LT utility months 19 to 36 0.568 0.822 190,135 190,157 22
LT utility months 7 to 18 0.571 0.842 190,136 190,155 19
LT utility months 0 to 6 0.533 0.859 190,140 190,152 12
Cost of LT 24,784 48,038 190,140 190,152 12
Cost of oxygen 802 847 190,144 190,148 4
LT, lung transplant; OS, overall survival.
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TABLE 84 Deterministic sensitivity analyses for BIBF 1120 vs. BSC
Variable
Low
value
High
value
Minimum ICER
(£/QALY)
Maximum ICER
(£/QALY) Difference
Treatment effect on FVC decline – BIBF
(log-odds ratio)
–1.39 –0.37 96,399 272,859 176,460
Discount rate utilities 0 0.06 108,168 151,739 43,571
Discount rate costs 0 0.06 125,025 145,149 20,124
Utility of unprogressed state 0.754 0.842 125,622 141,327 15,705
Progressed state OS parameter –3.966 –3.131 130,419 137,413 6994
Shape parameter PFS Weibull curve 0.459 0.480 131,884 133,606 1722
Probability of death given progression 0.178 0.321 131,832 133,412 1580
Lambda parameter PFS Weibull curve –5.668 –5.194 132,087 133,554 1467
Utility in the progressed state 0.700 0.778 132,206 133,090 883
Utility decrement associated with acute
exacerbation
0.128 0.284 132,599 132,726 127
Probability of LT 0.0041 0.0087 132,601 132,725 124
Generic cost of acute exacerbation 657 2,317 132,606 132,728 122
Probability of acute exacerbation
(unprogressed state)
0.167 0.250 132,601 132,715 114
Probability of acute exacerbation
(progressed state)
0.012 0.094 132,588 132,701 113
LT utility months 36+ 0.558 0.791 132,619 132,693 74
Age of cohort entering model 65 75 132,633 132,684 52
Cost of oxygen monitoring 71 323 132,630 132,677 47
Probability of death from acute
exacerbation
0.394 0.619 132,635 132,672 37
LT utility months 19 to 36 0.568 0.822 132,650 132,665 15
LT utility months 7 to 18 0.571 0.842 132,651 132,664 14
Cost of LT 24,784 48,038 132,651 132,664 12
LT utility months 0 to 6 0.533 0.859 132,653 132,662 9
Cost of oxygen 802 847 132,656 132,660 4
LT, lung transplant; OS, overall survival.
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–Treatment effect on FVC decline – pirfenidone
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FIGURE 21 Tornado diagram showing results of deterministic sensitivity analysis for pirfenidone vs. BSC.
Bars indicate spread in ICER between parameter bounds (£000). OS, overall survival.
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FIGURE 22 Tornado diagram showing results of deterministic sensitivity analysis for BIBF vs. BSC. Bars indicate
spread in ICER between parameter bounds (£000). OS, overall survival.
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The results indicate that the ICER is, above all, very sensitive to the assumed treatment effects of
pirfenidone and BIBF 1120, as there is a very wide difference in the ICERs produced by the low and high
values of these parameters. However, even in the best case, the ICERs for both treatments are above
£90,000 per QALY when compared with BSC, at £126,431 per QALY for pirfenidone and £96,399
per QALY for BIBF 1120 (see Tables 83 and 84, respectively). In the worst case, the ICERs for both
treatments are above £250,000 per QALY gained.
A degree of sensitivity is also shown to the discount rates for utilities and costs; to assumed utility
in the unprogressed state; and to the parameter used for the overall survival curve in the progressed state.
However, the differences in ICER here are all less than one-quarter of the differences associated
with the treatment effect variation.
Figure 23 shows the NMB associated with BSC, pirfenidone and BIBF 1120 at a WTP of £30,000 per QALY
gained. In this analysis, the cost of BIBF 1120 was varied between £0 and £5000 per month, while the
cost of the other two treatment options was held constant.
The monthly cost of BIBF 1120 assumed in the model base case is £3274. Figure 23 demonstrates that,
given a WTP of £30,000 per QALY, BIBF 1120 must cost less than £736 per month to be considered as
the cost-effective treatment option compared with BSC and pirfenidone. At BIBF 1120 costs higher than
this, BSC treatment is preferred as it has a higher NMB. Using a lower WTP, of £20,000, the corresponding
monthly cost threshold for BIBF 1120 is £489.
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FIGURE 23 One-way sensitivity analysis of monthly cost of BIBF 1120, showing effect on BIBF 1120 NMB compared
with BSC and pirfenidone.
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Probabilistic sensitivity analysis
Parameters entered in PSA and their assumed distributions are given in Table 81. One thousand
simulations were run.
The mean PSA results are presented in Table 85 and are similar to the results for the base case given in
Table 80. Scatterplots for cost and health outcomes are shown in Figures 24 and 25 for pirfenidone and
BIBF 1120, respectively. The CEAC for all treatments is given in Figure 26 and indicates that at the £20,000
WTP threshold, inhaled NAC has the highest probability (65%) of being cost-effective. Inhaled NAC also
has the highest probability of being cost-effective (64%) at a WTP of £30,000 per QALY. At £90,000
and £100,000 WTP thresholds, BIBF 1120, the other undominated treatment in the base-case analysis,
has the probability of being cost-effective of 0.2% and 2%, respectively (see Figure 26). BIBF 1120 has a
higher probability of being cost-effective than BSC at WTP thresholds in excess of £110,000 per QALY.
TABLE 85 Baseline PSA cost-effectiveness results vs. BSC
Treatment Mean total costs (£) Mean total QALYs ICER vs. BSC (£/QALY)
BSC 3126 3.00 –
Azathioprine and prednisolone 4391 2.72 Dominated
NAC triple therapy 5086 3.07 25,147
Inhaled NAC 5074 3.40 4866
Sildenafil 12,405 3.15 58,555
Pirfenidone 70,266 3.36 184,099
BIBF 140,749 4.06 129,878
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FIGURE 24 Scatterplot of the costs and health benefits from PSA: pirfenidone vs. BSC.
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FIGURE 25 Scatterplot of the costs and health benefits from PSA: BIBF vs. BSC.
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Scenario analysis
In addition to the sensitivity analyses, three alternative scenarios were examined to investigate the
uncertainty surrounding the structural assumptions made by the model.
Exponential fit to progression-free survival data from Noble and colleagues62
The model base case uses a Weibull fit to PFS data. The use of a log-normal fit to these data was
examined and produced the results given in Table 86.
Median PFS is greater with a log-normal fit than with a Weibull (see Figure 14) and, consequently, Table 86
shows more QALYs accruing to each treatment arm than in the base case (see Table 80). Total costs are
also greater than the base case, but overall ICERs compared with BSC are reduced to £121,519 per QALY
gained for pirfenidone and £95,786 per QALY gained for BIBF 1120. Pirfenidone is still subject to extended
dominance by a blend of BSC and BIBF 1120. Neither pharmacological treatment is cost-effective at a WTP
threshold of £30,000 per QALY.
Treatment continuation after progression
The model base case assumes that pharmacological treatment is discontinued on progression of IPF,
for all treatments except sildenafil, and that sildenafil is only used after progression. This assumption is in
line with the trials which inform the evidence for these treatment effects. However, it is possible that
treatments would be effective for both unprogressed and progressed cases to some degree. Table 87
shows the results obtained when the treatment effect is also applied after disease progression (for all
treatments except sildenafil) and before disease progression (sildenafil only). The estimates of the effects of
the treatments are assumed to be the same and they act in a similar fashion, i.e. by delaying progression
or death from IPF.
Total QALYs and total costs for the pharmacological treatments are higher than the base case (see Table 80)
but ICERs compared with BSC are lower. The pirfenidone ICER of £159,825 per QALY gained compares
with £190,146 achieved in the base case, while the BIBF 1120 ICER of £115,892 per QALY gained
compares with £132,658 achieved in the base case. Pirfenidone continues to be subject to extended
dominance by a blend of BSC and BIBF 1120.
TABLE 86 Cost-effectiveness results using log-normal fit to PFS data
Treatment Total costs (£) Total QALYs ICER vs. BSC (£/QALY) ICER vs. next best option (£/QALY)
BSC 3069 3.69 – –
Pirfenidone 115,671 4.62 121,519 Extended dominance
BIBF 273,966 6.52 95,786 95,786
TABLE 87 Cost-effectiveness results assuming treatment continuation after progression
Treatment Total costs (£) Total QALYs ICER vs. BSC (£/QALY) ICER vs. next best option (£/QALY)
BSC 3084 2.98 – –
Pirfenidone 131,378 3.79 159,825 Extended dominated
BIBF 275,674 5.33 115,892 115,892
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Log-normal fit to progression-free survival data and treatment continuation
after progression
This scenario combines the previous two scenarios and assumes both a log-normal fit to PFS data and
treatment continuation after IPF progression. Results are given in Table 88. Total costs and total QALYs in
the treatment arms are higher than in either of the separate scenarios, but total costs in the BSC arm
do not increase at the same rate. Consequently, the ICERs achieved are worse than the ICERs shown in
Table 86 for the log-normal-only scenario.
Expected value of perfect information for inhaled N-acetylcysteine and
BIBF 1120
The base-case results for the IPF model indicate that inhaled NAC is the only non-dominated treatment
within the £30,000 per QALY WTP threshold. However, the treatment effect of inhaled NAC does not
achieve statistical significance in the NMA and, as such, is unlikely to be adopted in clinical practice. The
potential benefit of reducing the uncertainty around the inhaled NAC treatment effect was examined in
EVPI and EVPPI analyses. The EVPI of BIBF 1120 compared with BSC was also investigated, as base-case
results show that it is similarly undominated by other treatments.
Expected value of perfect information and EVPPI were calculated for current and future IPF populations,
assuming an annual IPF incidence in the UK of 5000,13 a discount rate of 3.5% and a conservative
estimate of 5 years for the lifetime of the decision problem. The PSA was run for 1000 iterations; in EVPPI
analysis this was repeated for 50 different values of the inhaled NAC treatment effect.
Figure 27 displays the population EVPI at increasing thresholds of WTP for inhaled NAC compared with
BSC and for BIBF 1120 compared with BSC. At a threshold for cost-effectiveness of £20,000 per QALY,
the population EVPI in the case of inhaled NAC versus BSC is £19.4M, and in the case of BIBF 1120 versus
BSC is £0 (see Figure 27). This indicates that there is some value in further research into inhaled NAC, but
that there is no value in further research into BIBF 1120 at the £20,000 WTP threshold. The EVPI of £0 for
BIBF 1120 arises because given the assumed probability distributions and base-case values, BIBF 1120 is
never cost-effective at the £20,000 WTP threshold. However, the base-case price of BIBF 1120 is assumed,
and fixed in PSA, and variations to its price would affect this finding.
The EVPPI for the treatment effect of inhaled NAC at a WTP of £20,000 per QALY is £15.8M. This makes
up a large proportion of the total EVPI for inhaled NAC versus BSC at £20,000 per QALY (£19.4M, see
Figure 27) and demonstrates that the treatment effect of inhaled NAC has a large bearing on the
uncertainty in this comparison. This is consistent with the results of the deterministic sensitivity analyses,
which indicate that the model is most sensitive to assumed treatment effects. These findings suggest that
any future research into the treatments considered should, as a priority, focus on reducing the uncertainty
in estimates of the treatment effect of inhaled NAC versus BSC.
TABLE 88 Cost-effectiveness results assuming treatment continuation after progression and log-normal fit to
PFS data
Treatment Total costs (£) Total QALYs ICER vs. BSC (£/QALY) ICER vs. next best option (£/QALY)
BSC 3069 3.69 – –
Pirfenidone 172,179 5.03 126,215 Extended dominated
BIBF 383,892 7.58 98,049 98,049
ECONOMIC ANALYSIS
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FIGURE 27 Expected value of perfect information curves for inhaled NAC and BIBF 1120 compared with BSC
(base-case model). (a) Inhaled NAC vs. BSC and (b) BIBF 1120 vs. BSC.
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Summary of independent model of cost-effectiveness
l An independent economic model was developed. The model incorporates three survival curves which
are used to inform the probabilities of transition from three health states: unprogressed IPF, progressed
IPF and lung transplant. Treatment effects are applied in the model base case to the survival curve
which informs transition from the unprogressed disease state. Utility values are applied to the health
states to estimate total QALYs. Costs are included for treatments, treatment monitoring, acute
exacerbations, lung transplant and adverse events.
l The model base-case results show increased survival for five of the treatments compared with BSC, at
increased cost. Only one treatment, inhaled NAC, is cost-effective at a WTP threshold of £30,000, but
its treatment effect does not achieve statistical significance in NMA or the primary study. The clinical
effectiveness review found the primary study to have an unclear risk of bias. Of the remaining
treatments, only pirfenidone and BIBF 1120 achieve a statistically significant treatment effect. However,
pirfenidone is subject to extended dominance by a blend of BSC and BIBF 1120.
l The effect of variation to the parameter values used in the economic model was evaluated in sensitivity
analyses. Results were found to be generally robust to such variation but were particularly sensitive to
changes in value of the treatment effect parameters.
l PSA was used to estimate the probabilities that the treatments are cost-effective at the £20,000 and
£30,000 WTP thresholds. Inhaled NAC was the most cost-effective option at both thresholds, with
a probability of around 65% in both cases.
l The monthly cost of BIBF 1120 is not yet available from conventional sources (e.g. BNF) and was not
provided by the manufacturer. The monthly cost assumed in the model base case is £3274. One-way
sensitivity analysis indicates that BIBF 1120 must cost less than £736 per month to be considered
the cost-effective treatment option at a WTP threshold of £30,000 per QALY, compared with BSC.
l The treatment effect of inhaled NAC compared with BSC is associated with an EVPPI of £15.8M at a
WTP threshold of £20,000. If estimates of this treatment effect can achieve the level of statistical
significance demanded by clinical practice, and are consistent with earlier estimates,69 then inhaled
NAC would represent a clinically acceptable and cost-effective treatment option for IPF at a WTP
threshold of £20,000. Further research to more precisely estimate its effect on rate of FVC per cent
decline is desirable.
ECONOMIC ANALYSIS
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Chapter 5 Discussion
Statement of principal findings
Clinical effectiveness
For patients with mild to moderate IPF, 10 studies evaluating five pharmacological interventions were
included. In a small RCT with an unclear risk of bias, treatment with azathioprine and prednisolone led to
an improvement in survival, compared with placebo and prednisolone (when this was age adjusted), but
not in lung function. It is possible that this trial included participants who would be diagnosed with NSIP
according to current criteria, which may explain the treatment effect. Follow-up was 12 months. BIBF 1120
300mg/day was more favourable on some measures of lung function, rates of acute exacerbations and
the number of deaths, compared with placebo; however, the primary outcome of annual rate of decline in
FVC was not statistically significantly different in this 54-month study. Treatment with NAC was evaluated
in three studies: in combination with azathioprine and prednisolone in two and as a single agent in an
inhaled format in one. Follow-up was approximately 12 months in these studies. Study results were mixed;
there was no benefit from triple therapy for FVC compared with placebo in one study, but there was a
benefit for VC when compared with double therapy in another study. Inhaled single-therapy NAC was not
statistically significantly different from a control intervention. Secondary outcomes were reported, similarly
with mixed results across the three studies. The two studies with triple-therapy interventions had a low risk
of bias; however, the study using nebulised NAC had an unclear risk of bias. Pirfenidone was studied in
four RCTs, and meta-analysis of these shows that pirfenidone appears to demonstrate a favourable effect
on FVC when compared with placebo treatment. However, caution is required in interpreting these data
as outcomes pooled were different and, as a consequence, a standardised mean difference analysis was
undertaken; in addition, the timing of assessment of these outcomes varied (from 48 weeks to 72 weeks).
Results of secondary outcomes were less certain. In a small crossover study, thalidomide appeared to
improve cough, cough-related quality life and respiratory-related QoL, compared with treatment
with placebo.
One study assessed sildenafil for those with moderate to severe IPF; some of the participants in this study
might also have had pulmonary hypertension. Results on the primary outcome, a 20% improvement
on the 6MWT, were not statistically significant between the sildenafil and placebo groups. Results on
secondary outcomes were mixed, with some favourable to sildenafil and others favouring placebo.
This study followed participants for 12 weeks.
Adverse events were generally mild to moderate and were reasonably well balanced between the
treatments and the placebo arms across the studies. The exception was thalidomide, where adverse events
were more common. Severe adverse events appeared to be more common in one study in those treated
with triple therapy.
Three studies evaluated non-pharmacological treatments for people with IPF. Two compared pulmonary
rehabilitation with a control and the other compared a disease management approach with a control.
Results are uncertain as to the effects of pulmonary rehabilitation interventions; differences favouring
pulmonary rehabilitation were seen on some outcomes but not others. There was an uncertain risk of bias
in one study and a high risk of bias in another. There were also baseline differences between groups on
many key outcomes in one study. In both studies, outcomes were assessed immediately after the cessation
of the pulmonary rehabilitation programme (range 10–12 weeks). The third study reported limited
evidence on the effects of a disease management programme in IPF; there were no statistically significant
differences in dyspnoea and QoL results were mixed. This study has an uncertain risk of bias and follow-up
was at 6 weeks, immediately after the programme had completed.
DOI: 10.3310/hta19200 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 20
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
149
A NMA focusing on pharmacological treatments for IPF and assessing FVC end points was undertaken on
six interventions. The FVC end point was measured on two continuous scales [FVC per cent predicted and
absolute change from baseline (litres)] and, as such, the NMA used the standardised mean difference
approach. This converts the outcome measures to a common scale. Only the fixed effect results for BIBF
1120 and pirfenidone were statistically significant, reducing the rate of decline in FVC compared with
placebo. A head-to-head comparison of BIBF 1120 versus pirfenidone showed a trend favouring BIBF,
although this was not statistically significant. Caution is required in the interpretation of the results of the
NMA, as differences in study design and patient populations may cause the results to be biased, and there
was little capacity to formally explore heterogeneity because of the small number of comparators.
Cost-effectiveness
A systematic search of the literature found one full economic evaluation of treatment for patients with IPF,
which examined the benefits of a testing strategy prior to treatment with triple therapy. It did not examine
the cost-effectiveness of any IPF treatment. A systematic review of studies of QoL for patients with IPF
identified 23 relevant studies. Results were mixed but appear to show that IPF has an adverse effect on
HRQoL compared with population norms, and that this is likely to diminish as IPF become more severe.
A new decision-analytic model was developed to estimate the cost-effectiveness of six pharmacological
treatments for IPF. Results from this model were presented for a base-case analysis and a number of
sensitivity and scenario analyses.
The model base-case results show increased survival for five of the treatments compared with BSC, at
increased cost. Only one treatment, inhaled NAC, is cost-effective at a WTP threshold of £30,000, but its
treatment effect does not achieve statistical significance in the single primary study identified,69 or in NMA.
The clinical effectiveness review found the primary study to have an unclear risk of bias. PSA results for the
six treatments and BSC show that inhaled NAC has a probability of 65% of being cost-effective at a WTP
of £20,000. Only pirfenidone and BIBF 1120 achieve a statistically significant treatment effect in NMA but
each has a probability of 0% of being cost-effective at a WTP of £30,000 per QALY.
The monthly cost of BIBF 1120 is not yet available from conventional sources (e.g. BNF), and was not
provided by the manufacturer. The monthly cost assumed in the model base case is £3274. One-way
sensitivity analysis indicated that BIBF 1120 must cost less than £736 per month to be considered the
cost-effective treatment option compared with BSC at a WTP threshold of £30,000 per QALY.
If estimates of the inhaled NAC treatment effect can achieve the level of statistical significance demanded
by clinical practice, and are consistent with earlier estimates,69 then inhaled NAC would represent a
clinically acceptable and cost-effective treatment option for IPF at a WTP threshold of £20,000. VOI
analysis was undertaken to determine the expected value of this uncertainty. Considering only BSC and
inhaled NAC, the EVPI is £19.4M at a WTP threshold of £20,000 per QALY. The EVPPI, for the treatment
effect of inhaled NAC alone, is £15.8M at a WTP threshold of £20,000. This indicates that a large part
of the overall inhaled NAC versus BSC EVPI stems from uncertainty in the inhaled NAC treatment effect,
and that, consequently, further research into this effect should be a research priority.
General discussion
The findings of this evidence synthesis provide evidence on the effectiveness and cost-effectiveness of a
range of interventions which are currently used, or proposed to be used, in the management of IPF in
the UK. No previous systematic reviews have included all potentially relevant treatments for IPF, and
there have been only limited economic evaluations in this area. The results of this evidence synthesis
will, therefore, be of value to clinicians and patients, and complement recent national guidance
by NICE in the UK.31 The past few years have seen an increasing interest in the management of IPF, with
pharmacological companies evaluating a range of potential interventions, and a number of influential
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bodies producing guidelines. The current state of the evidence suggests that there are few treatments that
have any effect on surrogate outcomes which can be linked through evidence to patient-related outcomes
such as mortality (some specific issues related to some of the interventions reviewed are discussed below).
In terms of a cure, it is considered that lung transplantation is the only intervention available which has
curative intention; however, no evidence on lung transplant was eligible for inclusion in this evidence
synthesis and so this could not be evaluated formally.
Overall, there was a scarcity of studies on symptom control. Good practice guidelines suggest that, as IPF is
an incurable disease, patients diagnosed with it should be provided with specialist palliative care from the
point of diagnosis, and yet in terms of evidence that would meet the inclusion criteria of this review, there is
little documented about the most beneficial approaches to palliation in IPF. A palliative care approach may
be helpful, and often the reason that there is limited evidence is because it has not been tested in a specific
group, in which case it may be appropriate to use evidence from similar conditions where the evidence
base is more complete. In this synthesis, evidence, albeit limited, for symptomatic control of cough suggests
that thalidomide may have the potential to improve QoL. Non-pharmacological interventions to improve
control, anxiety and QoL would appear to have some potential benefit but, again, the quality of the
evidence base is generally poor. Despite the limited evidence on pulmonary rehabilitation, it is likely that,
overall, there may be potential benefits that are less easy to quantify in an intervention study. While it is
important for clinicians to discuss the limitations in the evidence base for treatments such as pulmonary
rehabilitation with patients, the evidence base in other areas of respiratory medicine is more certain and this
information may allow patients the opportunity to access these treatments at a time when there are very
few treatments available, and until the evidence base is more complete.
One included intervention, azathioprine, is no longer indicated in IPF but was included by the advisory
group because there are some patients who still receive azathioprine treatment in restricted circumstances.
The included study used azathioprine in combination with prednisolone; as noted in the results section
(see Assessment of effectiveness of pharmacological interventions for mild to moderate idiopathic
pulmonary fibrosis), this was a small study, and there was the possibility that a proportion of patients
might actually have had NSIP, which has generally been shown to be more responsive to treatment.
The treatment effect shown in this trial may well have been due to this factor and, therefore, results
should be interpreted cautiously.
At present, BIBF 1120 does not have marketing authorisation for this indication. BIBF 1120 is a potential
treatment for IPF which, at the time of writing, has only been studied in a dose-ranging RCT where the
primary outcome measure was not statistically significant. Ongoing RCTs of BIBF 1120 will report in
the coming years and the effects of this treatment can be evaluated more fully at this time.
The evidence for NAC therapy is complicated to interpret given the differences in the three studies included
in the systematic review. To work out the standalone effect of NAC overall is difficult, given that two studies
compare NAC in combination with azathioprine and prednisolone (triple therapy) and in the other NAC
in an inhaled format was used. The comparators also differed, with one comparing triple therapy with
placebo, one comparing triple therapy with azathioprine and prednisolone, and the other comparing
inhaled NAC with a control. In addition, the doses of prednisolone used varied between the studies; for
example, in the Raghu and colleagues IPFCRN 201268 trial, higher doses were used than in the Demedts and
colleagues study67 and than are likely to be used in current practice. The NAC versus placebo results from
the Raghu and colleagues ongoing trial will, in the future, provide evidence of the clinical effectiveness of
single-therapy NAC. Recent guidelines31 suggest that triple therapy is not indicated because of the safety
issues; however, many patients who take NAC believe that they have benefited and may find it difficult to
stop taking it. The recent NICE guideline states that the benefits of NAC therapy are unknown but that
if it is used as a treatment this should be discussed with patients. This would seem to be an appropriate
decision based on the interpretation of the evidence made in this review.
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The NMA and economic evaluation consider inhaled NAC separately from triple therapy as it has a
different method of administration, and NMA results give a treatment effect estimate for inhaled NAC that
is better than the estimate for triple therapy (although not significantly so).
Pirfenidone was subject to a NICE technology appraisal in 2012.23 Pirfenidone was recommended as a
treatment option in IPF where an individual has an FVC between 50% and 80% predicted. In addition, this
is only when the treatment is provided at a previously agreed (undisclosed) discount price. The results on
FVC outcomes were statistically significant when the studies were combined in a meta-analysis. Across
the individual trials, however, one trial showed a different pattern with non-significant results on FVC
measures. It is unclear why this would be the case, especially when considered in the light of the very
similarly conducted trial by the same group. The results of the ongoing trial will be key in the consideration
of the clinical effectiveness of pirfenidone.
Thalidomide is a treatment which has a different proposed indication as it is suggested to be used for the
treatment of cough, which is a common symptom in IPF. Therefore, no attempt to improve lung function
was made in the included trial and as such it was not included in the NMA or economic evaluation.
The proposed indication for the use of sildenafil is for treatment at the more severe end of the spectrum,
and many patients in the severe stages are considered likely to have pulmonary hypertension. Current NICE
guidance does not recommend sildenafil.
Discussion of network meta-analysis
We have used standardised mean differences to synthesise two different measurements of a common FVC
end point. Hedges’ g formulation was preferred over Cohen’s because of the small sample size in one of
the included trials. Alternatively, a bivariate meta-analytic framework could have been used to borrow
strength across these end points.164 While increasingly used in the pairwise NMA, this methodology is
relatively novel in NMA and may require access to individual patient-level data.165
Converting the standardised mean differences to log-odds ratios using an established methodology
facilitated including the widest range of comparators and enabled use of these data in our de novo
cost-effectiveness model (see Chapter 4, Independent economic evaluation). In our NMA, only
two treatments (BIBF 1120 and pirfenidone) showed important differences in slowing the decline in
FVC compared with placebo under a fixed-effect model.
However, there remain concerns with the data. With only 10 studies and seven comparators, there is little
capability to explore heterogeneity within these data using meta-regression techniques. Differences in
study design and patient populations that could modify relative treatment effects may invalidate the
assumption of exchangeability and cause the results of indirect comparisons to be biased. There was
potential heterogeneity in terms of baseline FVC per cent predicted but insufficient data to allow us to
control for this in the analysis. While the Zisman and colleagues IPFCRN 2010 study72 was notably in a
more severe population (defined as DLCO < 35%), its inclusion in the analysis did not affect the estimates
for the other treatment effects as it connected only to placebo. There is also the disagreement between
the estimates for azathioprine (Raghu and colleagues70 and Demedts and colleagues67). While the Raghu
and colleagues trial is very small (19 subjects) and thus subject to high variability, the differences could be
attributable to trial design, unreported heterogeneity between the studies (e.g. proportion of NSIP
subjects), or a placebo effect.166
No published NMA in IPF have been identified. One pairwise meta-analysis of pirfenidone versus placebo
has been presented in abstract form97 and was cited in the manufacturer submission to NICE167 (see also
Chapter 3, Existing systematic reviews). The authors also used standardised mean differences and their
results were similar to those observed here, at around 0.2 SDs. However, owing to longitudinal data
availability in the sponsor’s trials, FVC was modelled at distinct time intervals with the observed treatment
effect maintained up to 72 weeks in the Capacity 004 study but dropping off in the Capacity 006 study.62
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No explanation was offered for this. It would have been interesting if the data had been modelled jointly
in a longitudinal framework (e.g. Ding and Fu168). Furthermore, despite the same data input, the Capacity
004 study appeared to produce slightly different effect estimates from those reported here (at least from
the graph in the abstract), although no data are provided on whether fixed or random effects were
presented or which standardised mean difference formulation was chosen.
Discussion of the modelling approach with respect to diagnosis of idiopathic
pulmonary fibrosis
As discussed in Chapter 1 (see Diagnosis), IPF can be difficult to diagnose and patients can experience
delay in diagnosis from the time of symptomatic presentation. This delay in diagnosis can potentially lead
to variation in the ability to benefit from treatments. Our economic model did not commence at the time
of diagnosis as it was based on the population in the Capacity trial, with patients starting treatment
at a recently diagnosed baseline value. The model, therefore, reflects delays in diagnosis which occurred
in the Capacity trial and an assumption was made that diagnostic delays were the same across all
treatment arms.
There are two separate issues with respect to timing of diagnosis of IPF: time since diagnosis which is
reported, albeit inconsistently, in the clinical trials; and the delay in diagnosis observed in clinical practice.
Time since diagnosis in our model reflects the Capacity trial. With better-reported data we could
potentially have included time since diagnosis as a predictor in the meta-analysis. If it was found to be a
relative treatment effect modifier, this could impact on results. The impact of delay in diagnosis, which is
likely to lead to a variation in health at point of diagnosis, is less clear. We have essentially modelled a
more severe patient subpopulation than those patients who would have been included at time of disease
occurrence. We have no information with which to model this delay in diagnosis or its likely impact on
patients’ ability to benefit or duration of therapy. It may be patients with milder symptoms who are being
missed or not presenting to GPs. It could be argued that more severe patients may respond less well to
treatment or, conversely, they may have more capacity to benefit from treatment. In any case, a consistent
approach has been adopted by excluding this from our model. Our focus on a more severe subpopulation
of IPF equates to less variation (uncertainty) in the model than if we included a factor for delay in
diagnosis. It follows, therefore, that the VOI results are likely to be a more conservative estimate than
would be the case if we were to model delay in diagnosis.
Strengths and limitations of the assessment
The evidence synthesis has the following strengths:
l It is independent of vested interests.
l It has been undertaken following the principles for conducting systematic reviews and economic
evaluations. The methods were set out in a research protocol, which defined the research question,
study selection criteria, quality assessment criteria, data extraction process and the process by which
the methods will be employed at different stages in the systematic review and economic evaluations.
l An advisory group has informed the evidence synthesis from its initiation. The research protocol and a
copy of the draft final report were sent to the advisory group for review and comment. The
interventions to be included were decided by the advisory group to ensure coverage of any treatment
relevant to current management in the NHS.
l The systematic review brings together the evidence for the clinical effectiveness and cost-effectiveness
of treatments for IPF and of HRQoL of people with IPF. This evidence has been critically appraised and
presented in a consistent and transparent manner.
l A new economic model has been developed following recognised guidelines and systematic searches
have been conducted to identify data to populate the different parameters. The main results have been
summarised and presented.
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In contrast, the evidence synthesis has certain limitations:
l Although only one non-English language study was identified and included in the systematic review of
clinical effectiveness, restrictions on translation meant that a full assessment and critique of this study
could not be made. The authors of this primary study were contacted to request additional information
where it was deemed that this might have provided helpful data; however, no responses
were received.
l Many of the included studies compared treatments with placebo; there were few studies directly
comparing different interventions. An indirect comparison through a NMA was performed; however,
there are known limitations in the use of indirect comparisons and, therefore, caution is recommended
in the interpretation of these results.
l A meta-analysis and NMA used the standardised mean difference, which standardises the study
findings so that they are expressed on a common scale. This was our assumption when combining
mean change in FVC per cent predicted with absolute change in FVC, albeit the former was adjusted
for certain baseline characteristics. Interpretation of the results of a meta-analysis using the
standardised mean difference is also not intuitive. A threshold of the magnitude of the effect can be
defined a priori, or, as in this case, the standardised mean differences can be converted to log-odds
ratios using established methodologies. These should be considered when interpreting the results.
l There were insufficient data to explore the heterogeneity between trials in the NMA. Differences in
study design or patient populations, reported or unreported, that could impact on relative treatment
effects could invalidate the assumptions underlying the NMA. In addition, it was not possible to rank
the treatments in the NMA owing to the limited data.
l The economic model uses a relative measure, absolute decline in FVC per cent predicted, as its
measure of disease progression. It is possible that some bias is introduced by use of such a measure as
patients with very different FVC per cent predicted may be considered together in the same disease
state, with an unknown distribution. However, absolute decline in FVC per cent predicted is a standard
measure of disease progression in IPF and insufficient evidence was available to inform rates of disease
progression by treatment at different starting FVCs.
l BIBF 1120 is a new treatment and at the time of writing was not being marketed. An assumed price
was, consequently, used in the economic model. Base-case results will require revision once an actual
price is known.
l The model assumes that a pharmacological treatment has a constant effect on relative rate of FVC per
cent decline compared with BSC, irrespective of the time for which the treatment is taken or the FVC
achieved. This is potentially a generous assumption, as a treatment may become less effective with
time and/or as IPF progresses. Nevertheless, even with this assumption, only one treatment was found
to be cost-effective at a WTP of £30,000 per QALY.
l Model utility values post lung transplant are lower than the utility found for the progressed IPF state.
This suggests no QoL benefit to lung transplant in a progressed IPF population. The post-lung
transplant utility data were obtained more than 10 years ago and may require updating, while further
work on QoL in progressed IPF would help to provide more robust utility estimates for this health state.
Suggested research priorities
Key research recommendations in the recent NICE guideline31 include a recommendation to assess the
effects of pulmonary rehabilitation in IPF. The guideline also recommends research into the effects of
ambulatory oxygen and antireflux therapy. Given the limited evidence base on palliative care measures in
IPF identified in the present evidence synthesis, we are in agreement with these recommendations.
Well-designed studies, preferably RCTs with adequately described interventions, are required, particularly in
the area of pulmonary rehabilitation.
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Inhaled NAC has been studied in only one small RCT in a Japanese population. Although results favoured
treatment with inhaled NAC, the effect was not statistically significant. However, given the limitations of
this study, and the results of the NMA and EVPI, a well-designed RCT of inhaled NAC should be
considered. According to our search of ongoing RCTs, none are currently under way.
One small RCT has been identified that investigates thalidomide for cough in IPF. As a potential
symptomatic treatment, the results of the study show that thalidomide may have some benefits; however,
this needs to be considered in the light of the adverse events. A well-conducted RCT of thalidomide
is recommended.
Lung transplant is seen as a curative treatment for IPF; however, no studies of lung transplant that met the
criteria of the present evidence synthesis have been undertaken in IPF. Although lung transplant in people
with IPF is unlikely to be appropriate for studying in a RCT, a well-conducted prospective cohort study may
provide further evidence of its benefits.
Most of the included pharmacological studies were placebo controlled. A head-to-head trial of BIBF 1120
and pirfenidone may be appropriate, although there are a number of issues that would need to be
considered in any trial design (e.g. sample size, recruitment) and these may mean that a trial is not
feasible. In addition, our economic evaluation suggests that neither treatment is currently cost-effective.
There are a number of ongoing studies that have been identified in the present report; for example, trials
of pirfenidone, BIBF 1120 and single-therapy NAC are ongoing. When these conclude and report their
findings, an update of the present evidence synthesis is recommended.
Conclusions
This evidence synthesis has identified limited evidence of the clinical effectiveness of a number of available
treatments for IPF. Pirfenidone and BIBF 1120 appear to be effective; however, general recommendations
cannot be made in terms of their cost-effectiveness due to limitations in the evidence base. Further
research is required in a number of areas as outlined above.
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Appendix 1 Search strategy
A ll databases searched for the systematic review are presented below. Searches were updated on26 June 2013.
Database searched
Clinical effectiveness
searches
Cost-effectiveness and
QoL searches
Cochrane Central Register of Controlled Trials All available years All available years
Cochrane Database of Systematic Reviews All available years All available years
Database of Abstracts of Reviews of Effects All available years All available years
EMBASE All available years All available years
Health Technology Assessment Database (Centre for Reviews and
Dissemination)
All available years All available years
Medline (Ovid) All available years All available years
Medline in-Process & Other Non-Indexed Citations Searched 26 June 2013
NHS Economic Evaluation Database All available years
Web of Science (Science Citation Index Expanded and
Conference Proceedings Citation Index)
1990–2013 1990–2013
Web of Science (Bioscience Information Centre Previews) All available years All available years
Searched for ongoing trials
National Institute for Health Research Clinical Research Network (NIHR CRN Portfolio, formally UKCRN website)
Current Controlled Trials
Clinical trials.gov
World Health Organization International Clinical Trials Registry Platform
PROSPERO, Centre for Reviews and Dissemination
The MEDLINE search strategy (presented below) for the systematic review of clinical effectiveness was
adjusted as necessary for other electronic databases for both clinical effectiveness and cost-effectiveness
(including quality of life information) searches. Search strategies for the systematic review are available
from the authors on request. Citations identified by the searches were added to a Reference
Manager database.
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Medline search strategy
1. idiopathic pulmonary fibrosis/ (548)
2. IPF.tw. (1925)
3. (idiopath$ and pulmonary and fibro$).tw. (3334)
4. (idiopath$ and (lung and fibro$)).tw. (2502)
5. (((usual or ordinary) adj3 interstiti$) and pneumo$).tw. (698)
6. (((nonspecific or “non specific”) adj3 interstitial) and pneumo$).tw. (583)
7. (idiopath$ and interstiti$ and pneumoni$).tw. (1383)
8. (“usual interstiti$” adj5 (lung or pulmonary or alveoli$)).tw. (191)
9. (“nonspecific interstiti$” adj5 (lung or pulmonary or alveoli$)).tw. (83)
10. (“non specific interstiti$” adj5 (lung or pulmonary or alveoli$)).tw. (38)
11. (cryptog$ and fibro$ and alveoli$).tw. (327)
12. or/1-11 (5331)
13. (“lung disease$” adj5 (interstiti$ or fibrosis or fibrotic)).tw. (5421)
14. pulmonary fibrosis/ (15,120)
15. exp lung diseases interstitial/ (42,412)
16. (pulmonary adj5 (fibrosis or fibrotic)).tw. (10,738)
17. (interstiti$ adj5 (pneumonia or lung or pulmonary or alveoli$)).tw. (12,889)
18. “diffuse parenchymal lung disease”.tw. (82)
19. or/13-18 (65,328)
20. (idiopathic or unexplained or nonspecific or ”non specific”).tw. (178,936)
21. (((unknow$ or uncertain$) adj4 (origin$ or cause$ or aetiol$ or etiol*)) or idiopa$).tw. (102,573)
22. 20 or 21 (207,520)
23. 19 and 22 (6196)
24. 12 or 23 (7352)
25. (cystic adj fibro$).mp. (33,749)
26. 24 not 25 (7191)
27. limit 26 to humans (6808)
28. limit 26 to animals (785)
29. 26 not 27 not 28 (81)
30. 27 or 29 (6889)
31. Randomized Controlled Trials as Topic/ (77,921)
32. randomized controlled trial.pt. (322,018)
33. controlled clinical trial.pt. (83,725)
34. Controlled Clinical Trial/ (83,725)
35. placebos/ (30,626)
36. random allocation/ (73,596)
37. Double-Blind Method/ (113,512)
38. Single-Blind Method/ (15,853)
39. (random* adj2 allocat*).tw. (17,050)
40. placebo*.tw. (133,778)
41. ((singl* or doubl* or trebl* or tripl*) adj (blind* or mask*)).tw. (111,089)
42. crossover studies/ (29,092)
43. (crossover* or (cross adj over*)).tw. (49,865)
44. Research Design/ (65,242)
45. ((random* or control*) adj5 (trial* or stud*)).tw. (424,830)
46. Clinical Trials as Topic/ (158,570)
47. trial.ti. (97,491)
48. randomly.ab. (164,073)
49. (randomized or randomised).ab. (271,090)
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50. or/31-49 (1,044,973)
51. 3 and 50 (257)
52. limit 30 to (controlled clinical trial or randomized controlled trial) (102)
53. 51 or 52 (292)
54. limit 30 to meta analysis (7)
55. 53 or 54 (294)
56. (rat or rats).ti. (676,338)
57. 55 not 56 (292)
58. (official and ”idiopathic pulmonary fibrosis”).ti. (1)
59. 57 OR 58 (293)
Reference lists
The reference lists of retrieved articles were examined for additional studies.
Other searches
The experts advisory group were contacted in order to obtain information about additional references and
any ongoing studies.
British Societies and Conferences
Pulmonary Fibrosis Organisation, ASCEND trial, National Organisation for Rare Diseases, British Lung
Foundation, National Heart Lung and Blood Institute, IPFnet, Coalition for IPF, ATS, British Thoracic Society
and International Meeting on Pulmonary Rare Diseases and Orphan Drugs.
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Appendix 2 Data extraction and quality
assessment template
Reviewer 1: Reviewer 2:
Date: 9/8/12 Version:Study details Participant details
First author et al., year, ref ID
Country:
Design:
Number of centres:
Funding:
Number of participants: total and number per treatment group
Sample attrition/dropout:
Sample crossovers:
Inclusion criteria:
Exclusion criteria:
Intervention details Outcomes
Intervention
1.
2.
Dose details:
Dose modifications:
Concurrent treatment:
Duration of treatment:
Primary outcomes:
Secondary outcomes:
Method of assessing outcome:
Length of follow-up:
Participant characteristics (add column for p-values if reported)
Intervention 1, n= Intervention 2, n=
List here
Comments
Results
Intervention 1, n= Intervention 2, n= Difference, p-value
Outcome 1
Comments
Outcome 2
Comments
Outcome 3
Comments
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Methodology
l Allocation to treatment groups:
l Blinding:
l Comparability of treatment groups:
l Method of data analysis:
l Sample size/power calculation:
l Attrition/drop-out:
General comments
l Generalisability: state severity of disease if reported, or estimate from baseline FVC based on range ≥ 70% ‘mild’,
55–69% ‘moderate’, < 55% severe
l Outcome measures:
l Intercentre variability:
l Conflict of interests:
Quality assessment/risk of biasa Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate?
2. Was the allocation adequately concealed?
3. Were the groups similar at the outset of the study in terms of prognostic factors?
4. Was the care provider blinded?
5. Was the patient blinded?
6. Were outcome assessors blinded to the treatment allocation?
7. (i) Were there any unexpected imbalances in drop-outs between groups? (ii) If so, were
they explained or adjusted for?
8. Is there any evidence to suggest that the authors measured more outcomes than they
reported?
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined?
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate?
a Amend for non RCTs.
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Appendix 3 Clinical trial end points
Most outcomes reported in trials of IPF are surrogate measures. Reliable, objective measures to assessdisease progression and treatment response are poorly defined and not fully validated. Generally,
lung function is the most valid. A number have been found to be associated with mortality. These include
FVC, 6MWT distance, DLCO and dyspnoea. The FVC and 6MWT are suggested to be the best predictors of
mortality at baseline in IPF.80
Other outcomes include HRQoL, PFS, peripheral oxygen saturation (SpO2) during the SMWT, respiratory
hospitalisations, and time to disease progression.
There is heterogeneity in the primary end points used in trials of treatments for IPF.
Clinical significance on these outcomes is often considered using the MCID approach, which is the smallest
difference in an outcome that patients would perceive to be important, either beneficial or harmful, and
lead to a clinician to consider a change in a patients status/therapy.80
Forced vital capacity/vital capacity
Forced vital capacity is measured with a spirometer, and is a measure of the maximum volume of air that
can be expired from the lungs during a forced and complete expiration from a position of full inspiration.
VC is the volume measured at the mouth, between the positions of full inspiration and full expiration.
In obstructive airways disease, the VC may be greater than the FVC as a result of compression and collapse
of narrowed airways during a forced manoeuvre. However, in IPF these two measurements should be the
same and can be assessed as such in trial evidence.
The FVC shows good reliability, and correlates reasonably well with measures of physiologic function,
dyspnoea and HRQoL. It can be measured according to standard protocols.
Forced vital capacity can be reported as either absolute values (litres) or a percentage of a reference value
(predicted) for someone of the same age, sex, height and ethnic group. Reference values are determined
from large population studies. A FVC percentage of 80–120% of the reference value is generally
considered to be within normal limits.
While there is no fixed cut-off for disease severity, Nathan and colleagues22 categorised participants in their
study into terciles of per cent predicted FVC for mild (≥ 70%), moderate (55–69%) and severe (< 55%)
disease. These can be used as a rough idea of severity; however, caution is required because many people
have comorbidities which contribute to their disease severity, and these are not always captured by FVC.
Recently, these terciles were applied by the manufacturer of pirfenidone in their submission to NICE and
these were accepted in the NICE guidance.23
In trials, FVC can be presented as continuous or categorical variables. The former is more sensitive, the
latter more advantageous in terms of interpreting the meaning of any change seen.169 There have been
a number of studies investigating what would be a clinically significant threshold of change on the FVC.
There is an important distinction between these studies: some refer to the threshold in a cohort, and
others to an individual-patient threshold. The traditional threshold for a clinically significant effect of
decline in per cent predicted FVC in an individual accounts for measurement variation in the FVC.
A clinically significant effect in a cohort is likely to be lower as there is no net effect from measurement
variation when the FVC is averaged out.
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Interpreting forced vital capacity within an individual
A decline in per cent predicted FVC of ≥ 10% (absolute change, see below) is recognised as clinically
significant and highly predictive of mortality. A progressive, sustained decrease from baseline in absolute
FVC is recognised in international guidelines as being consistent with progressive disease.10 The Food and
Drug Administration also proposes that a categorical reduction of FVC of ≥ 10% is clinically meaningful.
This degree of decline has been shown to be an independent predictor of mortality, associated with a
1.7- to 4.8-fold increased risk of death over 1 year.146,147,170–172
Interpreting forced vital capacity from within a cohort
More recent studies147,173,174 suggest that even small changes in FVC (e.g. > 5% decline) indicate a poor
prognosis/risk of death within the context of symptomatic deterioration. du Bois and colleagues173 showed
that a 1-year risk of death was more than twofold higher (p< 0.001) in those with a 24-week decline in
FVC between 5% and 10%. The estimated MCID in this study was estimated at 2–6%.
Relative versus absolute change on categorical change in forced vital capacity
per cent predicted
A ≥ 10% decline can be a relative decline (e.g. from 60% to 54%) or an absolute decline (e.g. from 60%
to 50%). How this has been calculated can have an impact on the frequency and prognostic value of
declines in FVC. A recent study139 showed that the frequency of a ≥ 10% decline over 12 months was
almost twice as high using relative change than absolute change. This has important management
implications for the clinician.
The study found that there was no difference in predicting transplant-free survival at 2 years using either
method. The authors suggest, therefore, that using relative decline maximises the changes of identifying
meaningful change without sacrificing prognostic accuracy.
Where trials report a threshold of decline on FVC per cent predicted, for example ≥ 10%, it should be
noted whether this is relative or absolute change to aid interpretation.
Six-minute walk test
This is a measure of exercise tolerance and functional status where the individual is asked to walk on a flat
surface for 6 minutes. It is a reliable measure and shows only small variation within an individual over short
periods of time. It correlates reasonably well with other measures.
The distance walked in the 6MWT is used in a variety of pulmonary diseases and is predictive of mortality
in IPF. At baseline, people with mild to moderate IPF would likely have a distance walked of approximately
400m. A 24-week decrement of > 50m has been associated with a fourfold increase in the risk of death
over the next 12 months (p< 0.001).174
The MCID was estimated as a decline of between 24–45m in one study,174 28m in another126 and
29–34m in a third.142
Studies in IPF have been limited by small sample sizes and narrow patient subsets, and, therefore, can yield
inconsistent results between studies.
Although the test is self-paced, it carries the possibility of interoperator bias.
Diffusing capacity of the lung for carbon monoxide
This measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in
pulmonary capillaries.
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The traditional view is that a reduction from baseline of 15% is significant. A decline in DLCO from
baseline has been associated with decreased survival, although the evidence is less consistent. King and
colleagues171 found that decreases in per cent predicted DLCO of ≥ 15% had no association with mortality.
Flaherty and colleagues170 found that 6- and 12-month decreases in per cent predicted DLCO of ≥ 10%
were not predictors of subsequent mortality. du Bois and colleagues,175 in a large study found that per
cent predicted DLCO and 24-week change in per cent predicted DLCO were independent predictors of
all-cause mortality. However, they also report that DLCO may not be incrementally informative in
differentiating between IPF patients based on their mortality risk.
Changes in DLCO are, therefore, not clear indicators for mortality. In addition, the complex procedure to
measure DLCO means that there is variability in clinical practice and the test is not always available.
Progression-free survival
Progression-free survival has been used in IPF studies using predictive end points such as categorical
changes in FVC and 6MWD.80
Few studies have used PFS and different studies appear to use different composite end points. Caution is,
therefore, required in their interpretation.
Peripheral oxygen saturation during the 6-minute walk test
Desaturation (a decline in oxygen saturation < 88%) during the 6MWT is seen as a marker for increased
risk of mortality.10 There are difficulties with reproducibility for this outcome.
Other lung function outcomes
There has been some suggestion that baseline TLC and alveolar–arterial oxygen difference in partial
pressures (PA – aO2) may be predictive of survival, but no clear threshold exists147 and few trials report
these outcomes.
Dyspnoea
Dyspnoea is a key issue in IPF and baseline dyspnoea correlates with QoL and survival in several studies.10
A variety of different metrics for dyspnoea have been used, including the BDI, the Borg Dyspnoea Index,
the UCSDSBQ and the CRP dyspnoea score. These are validated in other lung diseases.
The Borg Dyspnoea Index measures perceived breathlessness on a scale of 0 (none) to 10 (maximum).
It correlates well with diffusing capacity and blood oxygenation at rest and during exercise.
The UCSDSBQ indicates severity of dyspnoea on a scale from 0 to 5 on 21 activities of daily living, along
with three ratings on limitations caused by dyspnoea or fear of dyspnoea, for a total score ranging from
0 to 120, with higher score indicating more dyspnoea. The minimally important difference for this is
reported by some authors to be 5 points.72
Health-related quality of life
Idiopathic pulmonary fibrosis has an effect on physical health, general health, energy levels, respiratory
symptoms and level of independence.176 The HRQoL among patients has been found to be variable,
however, and this cannot be fully explained by measures of dyspnoea or pulmonary function. There are
no disease-specific measures of HRQoL for IPF. Generic instruments or non-IPF specific instruments have
been used in clinical trials: EQ-5D, SF-36, SGRQ and WHOQOL (World Health Organization Quality of
Life) instrument.
There is uncertainty over whether these are valid in the IPF population or reliable over time, or in response
to specific treatments. As dyspnoea is an issue in IPF, it is uncertain if this is always picked up with the
generic instruments well enough.
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The EQ-5D is a widely used instrument developed to measure health utility. It comprises five dimensions of
health (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which can be rated for
severity. Scores from the health states are converted through value sets (or preference weights) obtained
from general population studies to generate a single utility value.129,130 This ranges from –0.59 to 1 and
represents health on a continuum from worst to best. For more information see Chapter 4, Systematic
review of health-related quality of life studies.
The SF-36 is a generic measure of health status. It is a 36-item survey and has eight scales covering
functional health and well-being concepts.131 Each score ranges from 0 to 100, with a higher score
indicating better function. For more information see Chapter 4, Systematic review of health-related quality
of life studies.
The SGRQ is validated for COPD and other chronic respiratory diseases, and appears to possess reasonable
validity and reliability in IPF.120 It has been found to correlate reasonably with FVC. The SGRQ is a
disease-specific measure which aims to measure the impact of obstructive airways disease on overall
health, daily life and perceived well-being.135 It comprises 50 items within two parts, which cover
three components: symptoms, activity and impact. A total score can also be calculated which summarises
the impact of the disease on overall health status. Scores range from 0 to 100, where higher scores
indicate greater impact on HRQoL. For more information on the SGRQ see Chapter 1, Systematic review of
health-related quality of life studies.
There is an IPF-specific version of the SGRQ, the SGRQ-I,106 which is deemed to have acceptable reliability
and validity; however, this needs further testing. This does not appear to have been used in trials to
date. Other disease-specific instruments such as the ATAQ-IPF107 and the K-BILD108 have also recently
been developed.
Acute exacerbation
Patients with IPF may suffer periods of acute respiratory decline, often due to complications such as
infection but not always from a known cause. These acute exacerbations are characterised by sudden
worsening of respiratory symptoms accompanied by hypoxaemia and the outcome for those who have had
an acute exacerbation is poor. There is uncertainty over what the definition of an acute exacerbation is and
clinical trials do not provide definitions.
Respiratory hospitalisation
Respiratory hospitalisation has been found to be predictor of mortality, but definitions may vary.80,175
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Appendix 4 List of excluded studies with
rationale
Studies excluded at first screen of full papers
Antoniou KM, Alexandrakis MG, Sfiridaki K, Tsiligianni I, Perisinakis K, Tzortzaki EG, et al. Th1 cytokine
pattern (IL-12 and IL-18) in bronchoalveolar lavage fluid (BALF) before and after treatment with interferon
gamma-1b (IFN-gamma-1b) or colchicine in patients with idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis
Vasc Diffuse Lung Dis 2004;21:105–10. (Reason for exclusion: outcomes.)
Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, et al. Exploratory analysis of a phase III
trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting
from treatment. Respir Res 2011;12:143. (Reason for exclusion: study design post hoc subgroup analysis.)
Bando M, Hosono T, Mato N, Nakaya T, Yamasawa H, Ohno S, et al. Long-term efficacy of inhaled
N-acetylcysteine in patients with idiopathic pulmonary fibrosis. Intern Med 2010;49:2289–96. (Reason for
exclusion: study design.)
Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for
treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet
2002;360:895–900. (Reason for exclusion: participants.)
Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, et al. Sildenafil preserves exercise capacity
in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest
2013;143:1699–708. (Reason for exclusion: study design.)
Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short term improvement in exercise capacity and
symptoms following exercise training in interstitial lung disease. Thorax 2008;63:549–54. (Reason for
exclusion: participants.)
Inoue Y, Azuma A, Taniguchi H, Ogura T, Tadayasu Y, Fujimoto T, et al. The pharmacokinetics of BIBF
1120 alone or in combination with pirfenidone in Japanese patients with idiopathic pulmonary fibrosis
(IPF). Respirology 2011;Conference:318. (Reason for exclusion: outcomes.)
Kubo H, Yanai M, Azuma A. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary
fibrosis: a hidden subgroup? Am J Respir Crit Care Med 2013;187:1029–30. (Reason for exclusion:
study design.)
Mackay A. Interferon gamma-1b does not improve survival for patients with idiopathic pulmonary fibrosis.
Thorax 2010;65:186. (Reason for exclusion: study design.)
Polonski L, Krzywiecki A, Polonska A, Tendera M, Cwiertka P, Oklek K, et al. [Effects of long-term oxygen
therapy in patients with idiopathic pulmonary fibrosis. I. Effect on the course of the primary disease and
on pulmonary circulation.] Polskie Archiwum Medycyny Wewnetrznej 1995;94:331–6. (Reason for
exclusion: participants.)
Polonski L, Kusnierz B, Krzywiecki A, Polonska A, Tendera M, Oklek K, et al. [Effects of long-term oxygen
therapy in patients with idiopathic pulmonary fibrosis. II. Effect of oxygen therapy on function of heart
ventricles.] Polskie Archiwum Medycyny Wewnetrznej 1995;94:337–41. (Reason for exclusion:
participants, outcomes.)
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Raghu G, King TE Jr, Behr J, Brown KK, du Bois RM, Leconte I, et al. Quality of life and dyspnoea in
patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010;35:118–23.
(Reason for exclusion: study design post hoc subgroup analysis.)
Shulgina L, Cahn A, Chilvers E, Parfrey H, Clark A, Wilson E, et al. Treating idiopathic pulmonary fibrosis
with the addition of co-trimoxazole. Thorax 2011;Conference:A63–4. (Reason for exclusion: participants.)
Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Wilson EC, et al. Treating idiopathic pulmonary
fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax 2013;68:155–62.
(Reason for exclusion: participants.)
Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, et al. The clinical significance of 5%
change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone
trial. Respir Res 2011;12:93. (Reason for exclusion: study design post hoc subgroup analysis.)
Varney V, Parnell H, Salisbury D, Ratneepan S, Tayar R. A double blind randomised placebo controlled pilot
study of Septrin in the treatment of cryptogenic fibrosing alveolitis. Thorax 2002;57:S49. (Reason for
exclusion: participants.)
Varney VA, Parnell HM, Salisbury DT, Ratnatheepan S, Tayar RB. A double blind randomised placebo
controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease. Pulm Pharmacol Ther
2008;21:178–87. (Reason for exclusion: participants.)
Studies excluded owing to interventions following advisory
group feedback
Alton EW, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on
treatment with cyclosporin A. Respir Med 1989;83:277–9.
Antoniou KM, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, et al. Long-term clinical effects of
interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 2006;28:496–504.
Behr J, Million-Rousseau R, Morganti A, Perchenet L, Raghu G. Efficacy and safety of macitentan in
idiopathic pulmonary fibrosis (IPF) [abstract]. European Respiratory Society Annual Congress, Vienna,
Austria, 1–5 September 2012;40:309s.
Bradford WZ, Starko K, Noble PW. Hospitalization of patients with idiopathic pulmonary fibrosis (IPF) in a
phase 3, randomized, double-blind, placebo-controlled trial of interferon gamma-1B (IFN-gamma 1B).
Chest 2003;124:193S.
Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, et al. Imatinib treatment for
idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med
2010;181:604–10.
Douglas WW, Ryu JH, Swensen SJ, Offord KP, Schroeder DR, Caron GM, et al. Colchicine versus
prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of
the Lung Study Group. Am J Respir Crit Care Med 1998;158:220–5.
Fiorucci F, Lucantoni G, Paone G, Zotti M, Li BE, Serpilli M, et al. Colchicine, cyclophosphamide and
prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently
available therapeutic regimens. Eur Rev Med Pharmacol Sci 2008;12:105–11.
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
182
Gulsvik A, Kjelsberg F, Bergmann A, Froland SS, Rootwelt K, Vale JR. High-dose intravenous
methylprednisolone pulse therapy as initial treatment in cryptogenic fibrosing alveolitis. A pilot study.
Respiration 1986;50:252–7.
Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gomez-Marin O. Sildenafil therapy and
exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010;188:115–23.
Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial
comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in
cryptogenic fibrosing alveolitis. Thorax 1989;44:280–8.
Keogh BA, Bernardo J, Hunninghake GW, Line BR, Price DL, Crystal RG. Effect of intermittent high dose
parenteral corticosteroids on the alveolitis of idiopathic pulmonary fibrosis. Am Rev Respir Dis
1983;127:18–22.
King J, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized
placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med
2008;177:75–81.
King J, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled
trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;184:92–9.
King J, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b
on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised,
placebo-controlled trial. Lancet 2009;374:222–8.
Krowka MJ, Ahmad S, de Andrade JA, Frost A, Glassberg MK, Lancaster LH, et al. A randomized,
double-blind, placebo-controlled study to evaluate the safety and efficacy of iloprost inhalation in adults
with abnormal pulmonary arterial pressure and exercise limitation associated with idiopathic pulmonary
fibrosis. Chest 2007;132:633S.
Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, et al. Anticoagulant therapy for
idiopathic pulmonary fibrosis. Chest 2005;128:1475–82.
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Appendix 5 Data extraction tables in
alphabetical order
Azuma et al.66
Study details Participant details
Azuma et al. 200566
Country: Japan
Design: RCT
Number of centres: 25
Funding: Shionogi & Co., Ltd (licence holder in
Japan for pirfenidone)
Number of participants: 109: pirfenidone n= 73; placebo n= 36
Sample attrition/dropout: one from each group was excluded for
violation of the inclusion criteria
Sample crossovers: acute exacerbation rates in the placebo arm at
6 months meant that the safety board recommended participants be
given pirfenidone. Unclear if this happened; as discussed below all
participants were reported to continue with allocated treatments
until 9 months
Inclusion criteria: histological evidence of UIP not mandatory, HRCT
evidence of definite or probable UIP required. Definite UIP: basal
predominant, subpleural reticular abnormality with traction
bronchiectasis and honeycomb cysts without atypical features of UIP.
Probable UIP: same pattern as definite UIP but without traction
bronchiectasis. Presence of bibasilar inspiratory crackles, abnormal
PFTs, and increased serum levels of damaged-pneumocyte markers
(KL-6 and surfactant proteins A and D). 20–75 years of age with
adequate oxygenation at rest (PaO2 ≥ 70mmHg) and demonstrated
SpO2 of ≤ 90% during exertion while breathing air, within 1 month
before enrolment
Exclusion criteria: a decrease in symptoms during the preceding
6 months; use of immunosuppressive and/or oral prednisolone
>10mg/day during the preceding 3 months; clinical suspicion of IIP
other than IPF; coexisting emphysema (HRCT images of low attenuated
areas in upper lung fields), pulmonary hypertension, asthma,
tuberculosis, sarcoidosis, bronchiectasis other than traction associated,
aspergillosis or respiratory infection; uncontrolled diabetes; comorbid
conditions including malignancy; severe hepatic, renal or cardiac
disease; pregnancy (or its pursuance); breastfeeding; previous use of
pirfenidone; suspicion of poor compliance in adherence to the protocol;
or being unable to understand protocol/written informed consent
Intervention details Outcomes
Intervention
1. Pirfenidone 1800mg (600mg three times daily)
2. Placebo
Dose details:
A dose-titration schedule was used: oral tables
at a dose of 200mg three times daily for 2 days,
400mg three times daily for 2 days, 600mg three
times daily (maximum dose) for 3 days. This was
maintained in patients tolerating it during the study
Dose modifications: patients not tolerating the
maximum dose of 1800mg/day received a reduced,
prespecified regimen utilising the standards for
Classification of Serious Adverse Drug Reactions.
An adverse event of grade 2 or worse, reduced
Primary outcomes: change in the lowest SpO2 during the 6MET
Secondary outcomes: resting PFTs while breathing air (VC, TLC, DLCO
PaO2), disease progression by HRCT patterns, episodes of acute
exacerbation of IPF, change in serum markers of pneumocyte
damage, changes in QoL measurements. Also reports serum KL-6,
surfactant protein-D levels (not data extracted)
Method of assessing outcome:
Lowest SpO2 during 6MET: walk on a treadmill at a constant speed
while breathing air. The SpO2 was continuously measured using a
pulse oximeter. The initial speed was started at 60m/minute and the
investigator, while monitoring the SpO2, adjusted the treadmill speed
to determine an appropriate speed (40–80m/minute) on the basis of
the patient’s comfort to perform the test while the lowest SpO2
reached 90% or below. This speed was then kept constant in the
individual patient at each follow-up visit. The test was stopped if the
SpO2 reached 80%
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Study details Participant details
from nine tablets per day to six tablets/day for
14 days; if persisted or increased reduced to
3 tablets/day for 14 days. If persisted or increased
study medication was discontinued for 14 days.
If resolved, the dose could be increased
up to nine tablets/day again. For adverse event
grade 1, dosage reduction was deferred to the
investigator’s clinical judgement
Concurrent treatment: prednisolone ≤ 10mg/day
was allowed. Cyclophosphamide, azathioprine,
methotrexate, d-penicallimine, colchicine,
erythromycin, interferons, NAC, cyclosporine,
tacrolimus and other experimental agents under
investigation for IPF were not allowed
Duration of treatment: 9 months
HRCT scans were performed in accordance with predetermined
protocol at baseline and 6-month intervals. Three expert radiologists
independently evaluated the pattern of lung fibrosis. Where there
was disagreement (8%), the scans were re-examined by the
radiologists and the Study Co-ordinating Committee to reach a
consensus. Disease worsening was defined as progression in the
extent of UIP pattern compared with baseline
Acute exacerbation was defined as all of worsening; otherwise
unexplained clinical features within 1 month; progression of
dyspnoea over a few days to less than 5 weeks; new radiographic/
HRCT parenchymal abnormalities without pneumothorax or pleural
effusion (e.g. new, superimposed ground-glass opacities); a decrease
in the PaO2 by ≥ 10mmHg; exclusion of apparent infection based on
absence of antibodies in blood, urine and sputum cultures
QoL was measured using the Chronic Respiratory Disease
Questionnaire score and the Hugh-Jones Classification score.
References provided
Length of follow-up: minimum of 9 months. A decision based on
analyses at 6 months recommended early termination of the study;
however, owing to time taken to collect, analyse and report data at
6 months, all participants actually completed 9 months of treatment
Participant characteristics Pirfenidone, n= 72 Placebo, n= 35 p-value
Sex (M/F), % 62/10 (86/14) 33/2 (94/6) 0.3295
Mean (SD) age, years 64.0 (7.1) 64.3 (7.6) 0.8735
Smoking history, %
Current 7 (10) 3 (9) 0.6403
Former 57 (79) 30 (86)
Never 8 (11) 2 (6)
Years since diagnosis, %
< 1 year 20 (28) 6 (17) 0.3830
1–3 years 17 (24) 10 (29)
> 3 years 35 (49) 19 (54)
Surgical lung biopsy, % 15 (21) 8 (23) 0.8066
Prior treatment with oral corticosteroids, %
No 62 (86) 30 (86) 1.0000
Yes 10 (14) 5 (14)
Mean (SD) VC, % predicted 81.6 (20.3) 78.4 (17.2) 0.3978
Mean (SD) TLC, % predicted 78.5 (17.9) 73.9 (16.4) 0.1935
Mean (SD) DLCO, % predicted 57.6 (17.2) 57.7 (13.8) 0.9697
Mean (SD) PaO2 at rest, mmHg 80.3 (7.7) 82.0 (7.6) 0.3063
Mean (SD) lowest SpO2 during 6MET, % 87.1 (3.9) 87.1 (4.2) 0.9891
Mean (SD) log SpO2 area 8.2 (0.3) 8.2 (0.4) 0.8462
Mean (SD) KL-6, U/ml 1427.5 (997.7) 1335.3 (863.3) 0.6243
Mean (SD) SP-D, ng/ml 264.6 (206.0) 233.6 (137.1) 0.3569
Comments: rates of definite/probable UIP on HRCT in the total group were 91/16
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Results Pirfenidone, n= 72 Placebo, n= 35
Difference,
p-value
Mean (SD) change lowest SpO2 during 6MET,
% at 6 months
0.6364 (3.5502) –0.5484 (3.7933) 0.1489
Mean (SD) change lowest SpO2 during 6MET,
% at 9 months
0.4697 (3.8838) –0.9355 (3.3559) 0.0722
Categorical analysis, 9 months n= 66 n= 33
Improved 16 (24%) 2 (6%) 0.0159
Stable 38 (58%) 20 (61%)
Deteriorated 12 (18%) 11 (33%)
Comments: a > 4% increase in the lowest SpO2 during the 6MET was classified as ‘improved’, a ≤ 4% decrease as
‘deteriorated’ and the other values as ‘stable’
Mean (SD) change VC, l, at 6 months –0.01 (0.21) –0.08 (0.19) 0.0995
Mean (SD) change VC, l, at 9 months –0.03 (0.22) –0.13 (0.19) 0.0366
Categorical analysis, 9 months n= 67 n= 33
Improved 6 (9%) 0 0.0028
Stable 52 (78%) 21 (64%)
Deteriorated 9 (13%) 12 (36%)
Comments: classified as ‘improved’, ‘stable’, ‘deteriorated’ (changes of 10%)
Mean (SD) change TLC, l, at 6 months –0.02 (0.34) 0.00 (0.35) 0.7550
Mean (SD) change TLC, l, at 9 months –0.05 (0.39) –0.09 (0.45) 0.6154
Categorical analysis, 9 months n= 64 n= 31
Improved 6 (9%) 2 (6%) 0.0155
Stable 49 (77%) 17 (66%)
Deteriorated 9 (14%) 12 (39%)
Comments: classified as ‘improved’, ‘stable’, ‘deteriorated’ (changes of 10%)
Mean (SD) change DLCO ml/minute/mmHg at 6 months –0.50 (2.07) –0.83 (2.16) 0.4894
Mean (SD) change DLCO ml/minute/mmHg at 9 months –0.57 (2.15) –1.19 (2.30) 0.2120
Categorical analysis, 9 months n= 72 n= 32
Improved 10 (16%) 2 (6%) 0.1580
Stable 33 (50%) 15 (47%)
Deteriorated 29 (36%) 15 (47%)
Comments: classified as ‘improved’, ‘stable’, ‘deteriorated’ (changes of 15%)
Mean (SD) change resting PaO2 mmHg at 6 months –2.09 (9.71) –3.19 (10.97) 0.6171
Mean (SD) change resting PaO2 mmHg at 9 months –2.48 (10.30) –3.66 (10.43) 0.5981
Categorical analysis, 9 months n= 69 n= 34
Improved 18 (26%) 9 (26%) 0.2724
Stable 20 (29%) 4 (12%)
Deteriorated 31 (45%) 21 (62%)
Comments: classified as ‘improved’, ‘stable’, ‘deteriorated’ (changes of 4mmHg)
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Results Pirfenidone, n= 72 Placebo, n= 35
Difference,
p-value
HRCT ‘improved’ 10/65 (15%) 2/29 (7%) 0.0921
Comments: disease worsening on HRCT defined as progression in the extent of UIP pattern compared with baseline.
Reduction of ground-glass and reticular opacities was recognised as improved patterns on HRCT
Acute exacerbation 0 14% (5/35) 0.0031
Dyspnoea Data not reported Data not reported 0.6367
QoL Data not reported Data not reported 0.8720
No significant changes in serum SP-D or KL-6 (data not reported)
Adverse events occurring in ≥ 10% at 6 months
Any 72 (98.6) 32 (88.9) 0.040
Photosensitivity 32 (43.8) 0 0.000
Stomach discomfort 22 (30.1) 3 (8.3) 0.0143
Anorexia 23 (31.5) 2 (5.6) 0.0030
Nausea 16 (21.9) 2 (5.6) 0.0314
Heartburn 12 (16.4) 1 (2.8) 0.0566
Drowsiness 17 (23.3) 6 (16.7) 0.4672
Fatigue 16 (21.9) 1 (2.8) 0.0102
URTI 12 (16.4) 3 (8.3) 0.3767
Fever 6 (8.2) 4 (11.1) 0.7271
Elevation of GOT 4 (5.5) 6 (16.7) 0.0785
Elevation of γ-GTP 20 (27.4) 3 (8.3) 0.0249
Urinary occult blood positive 6 (8.2) 4 (11.1) 0.7271
Elevation of C-reactive protein 15 (20.5) 10 (27.8) 0.4694
Reasons for discontinuation of medication at 9 months
Any adverse event 11 (15.1) 2 (5.6) 0.2132
Photosensitivity 5 (6.8) 0 0.1686
Vomiting 1 (1.4) 0 1.0000
Fever 1 (1.4) 0 1.0000
Abnormality of hepatic function 1 (1.4) 0 1.0000
Dizziness 1 (1.4) 0 1.0000
Facial paralysis 1 (1.4) 0 1.0000
Hepatoma 1 (1.4) 0 1.0000
Headache 0 1 (2.8) 0.3303
Bradycardia 0 1 (2.8) 0.3303
Acute exacerbation 0 5 (13.9) 0.0032
Patient request 3 (4.1) 0 0.5493
Progression of disease 1 (1.4) 1 (2.8) 1.0000
Protocol violation 1 (1.4) 0 1.0000
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Methodology
Allocation to treatment groups: states randomised using a modified permuted-block randomisation method with block sizes
of six
Blinding: states double blind. Outcome assessors for the HRCT scans were blinded to treatment assignment
Comparability of treatment groups: states baseline characteristics were similar, confirmed by p-values shown
Method of data analysis: change from baseline values used the Welch’s t-test. Categorical variables were analysed with the
Wilcoxon test. Analyses of incidences were performed with Fisher’s exact test. For missing values the LOCF principle was used.
A subgroup analysis of those able to complete the 6MET without the SpO2 reaching < 80% was specified after initiation of the
trial (but before breaking the code). This was because 27 participants had been unable to complete the 6MET at baseline
Sample size/power calculation: the prespecified sample size was 90 participants (pirfenidone 60; placebo 30). Based on a simulation
study this minimum number provided statistical power >0.8 to detect assumed efficacy at the significance level of 0.025
Attrition/drop-out: numbers and reasons provided (although numbers for categorical outcomes differ; unclear why)
General comments
Generalisability: severity of disease not stated; based on baseline characteristics participants would be considered to be mild
IPF cases, although approximately half had been diagnosed for more than 3 years. States majority were corticosteroid naive
Outcome measures: appear valid; although QoL scales were not described limited data were reported on this outcome
Intercentre variability: not stated
Conflict of interests: all author conflicts are noted; all had received financial support from either Shionogi or InterMune.
Data were held and analysed by trial sponsor. All authors participated fully in study design and had full access to analysed
data. No restrictions were placed on authors for analyses and reporting
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Unclear
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in drop-outs between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Unclear
9. (i) Did the analysis include an ITT analysis?
(ii) If so, was this defined?
No
10. (i) Did the analysis account for missing data?
(ii) If so, were the methods appropriate?
Yes
Yes
γ-GTP, γ-guanosine triphosphate; 6MET, 6-minute exercise test; GOT, glutamic oxaloacetic transaminase; KL-6, serum levels
of pneumocyte marker KL-6; PFT, pulmonary function test; SP-D, serum level of surfactant protein.
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Demedts et al.67
Study details Participant details
Demedts et al. 200567
Country: Belgium, France, Germany, Italy, Spain,
the Netherlands
Design: RCT
Number of centres: 36
Funding: sponsored by the Zambon group
Number of participants: 182 randomised: NAC n= 92; placebo
n= 90 (27 were excluded, leaving NAC n= 80, placebo n= 75)
Sample attrition/dropout:
Post randomisation, pre treatment:
NAC n= 12 not included (UIP not confirmed, n= 10; withdrawal of
consent, n= 2); placebo n= 15 not included (UIP not confirmed,
n= 12; withdrawal of consent, n= 3)
Post treatment:
NAC n= 16 (20%) withdrew (prohibited therapy, n= 3; withdrawn
by investigator, n= 3; withdrew consent, n= 4; adverse events,
n= 2; non-compliance, n= 1; other, n= 3); deaths n= 7
(disease progression, n= 3; respiratory tract infection, n= 3; heart
failure, n= 1)
Placebo n= 16 (21%) withdrew (prohibited therapy, n= 2;
withdrawn by investigator, n= 2; withdrew consent, n= 4; adverse
events, n= 2; non-compliance, n= 2; ineffective treatment or
worsening of condition, n= 4); deaths n= 8 (disease progression,
n= 4; respiratory tract infection, n= 1; cardiac arrest, n= 1;
myocardial infarction, n= 1; cancer, n= 1)
Sample crossovers: assume none from data presented
Inclusion criteria: 18–75 years, histological or radiologic pattern
typical of UIP after other causes of UIP were ruled out. HRCT
suggestive or consistent with a probable diagnosis of UIP. In those
younger than 50 years, open or thoracoscopic lung biopsy
mandatory and showed a pattern of UIP; lung biopsy optional for
older patients. In the absence of lung biopsy, a transbronchial biopsy
was advocated to exclude alternative diagnoses. Bronchoalveloar
lavage must also have been performed before inclusion and failed to
show features supporting alternative diagnoses (diagnoses confirmed
by independent committees of experts on the basis of published
criteria). Duration of more than 3 months, bibasilar inspiratory
crackles present, dyspnoea score at least 2 on a scale of 0
(minimum) to 20 (maximum), VC of no more than 80% predicted
value or TLC < 90% predicted, and single-breath DLCO < 80%
predicted
Exclusion criteria: standard regimen with prednisolone and
azathioprine contraindicated or not justified for them, or if they
presented with a known intolerance to NAC. Treatment with
prednisolone of at least 0.5mg/kg/day or azathioprine at least
2mg/kg/day during the month before inclusion, or treatment with
NAC of > 600mg/day for more than 3 months in the previous
3 years. Concomitant or pre-existing diseases, abnormalities, or
treatment at study entry or in the past with drugs (e.g. antioxidants
and antifibrotics) that interfere with the diagnosis, severity, therapy
or prognosis of IPF
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Intervention details Outcomes
Intervention
1. NAC 1800mg (600mg three times per day)
2. Placebo
Dose details: NAC at 600mg three times per day
Dose modifications: states if standard therapy had
to be adapted (e.g. for adverse events, poor
compliance or clinical worsening), the participant
was treated according to the preference of each
centre, with a drug-exclusion criteria especially
concerning antioxidants and antifibrotic drugs
taken into consideration. Standard therapy was
changed for 13 participants in the acetylcysteine
arm and 11 in the placebo arm. Three in the
acetylcysteine arm and 11 in the placebo arm
started continuous O2 therapy during the study
period
Concurrent treatment: both treatment and placebo
arms also given prednisolone (starting dose,
0.5mg/kg body weight per day; 0.4mg/kg per day
at month 2; 0.3mg/kg at month 3; progressively
reduced to 10mg per day in months 4–6 and then
maintained until month 12) and azathioprine
(2mg/kg per day) in addition to usual care
Duration of treatment: not stated, assume
12 months
Primary outcomes: absolute changes in VC and DLCO at 12 months
Secondary outcomes: per cent predicted VC, per cent predicted
DLCO, alveolar volume change and per cent predicted CRP score,
dyspnoea score, maximum exercise indexes [load (Wmax) oxygen
uptake (VO2max) and ventilation (VEmax) not extracted], scores of
ground-glass opacities and of fibrosis on HRCT (not extracted),
SGRQ, adverse events, withdrawals and mortality. Also reports a
post hoc categorical analysis of VC (not extracted)
Although drug non-compliance not a stated outcome, paper states
that it (defined by an intake of < 50% of the study medication) was
determined by counting returned tablets
Method of assessing outcomes: VC and DLCO measured according to
the ERS guidelines. CRP score and dyspnoea score: references
provided. SGRQ: no details of validation or administration; for
scoring see below. SGRQ administered every 6 months. Safety was
continuously monitored until 1 month after the participant
completed or withdrew from the study
Length of follow-up: 12 months
Participant characteristics NAC, n= 80 Placebo, n= 75
Sex (M/F), % 69/31 75/25
Mean (SD) age (years) 62 (9) 64 (9)
Smoking status, %
Current 3.8 6.7
Former 57.5 62.7
Never 38.8 30.7
Mean (SD) months since diagnosis [median] 19.9 (28.3) [5.0] 18.9 (33.1) [3.0]
Diagnosed within previous 6 months, n (%) 39 (49) 42 (56)
Underwent surgical biopsy, n (%) 38 (48) 35 (47)
VC, n (%), with:
> 60% 49 (61) 53 (71)
≤ 60% 31 (39) 22 (29)
TLC, volume, l, mean (SD) 3.72 (1.00) 3.72 (0.94)
TLC, % of predicted value, mean (SD) 62.1 (13.9) 61.6 (11.5)
PAO2 – PaO2 at rest, mmHg, mean (SD) 31.6 (13.8) 30.1 (11.8)
PaO2 at rest, mmHg, mean (SD) 70.1 (12.7) 72.0 (11.2)
Total SGRQ score 50 (18) 52 (16)
Receiving continuous O2 8 2
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Participant characteristics NAC, n= 80 Placebo, n= 75
Previous treatments
Prednisone 16 13
Azathioprine 8 5
Both 2 3
VC, mean (SD) litres 2.29 (0.68) 2.36 (0.74)
VC, per cent predicted (SD) 64.76 (15.41) 66.57 (14.42)
DLCO mean (SD) mmol/minute/kPa 3.85 (1.41) 3.90 (1.39)
DLCO per cent predicted (SD) 43.04 (13.10) 44.79 (15.15)
CRP total, mean (SD) 39.73 (15.01) 37.06 (15.88)
CRP without exercise, mean (SD) 32.88 (9.81) 31.69 (9.04)
Dyspnoea score 8.35 (4.44) 7.92 (3.99)
Results (all treated and LOCF data extracted
where numbers are reported, otherwise only
LOCF data)
Acetylcysteine,
n= 80 Placebo, n= 75
Difference
(95% CI); p-value
VC, mean (SD), l, at 12 months n= 55
2.31 (0.79)
n= 51
2.26 (0.72)
NA see below
VC, mean (SD), l, at 12 months, LOCF n= 71
2.22 (0.77)
n= 68
2.17 (0.71)
NA see below
VC, l, mean change at 12 months, LOCF (95% CI) –0.06
(–0.14 to 0.02)
–0.19
(–0.29 to –0.09)
NA see below
VC, l, LS mean (SD), LOCF n= 71
2.27 (0.05)
n= 68
2.10 (0.05)
0.18
(0.03 to 0.32);
p= 0.02a
VC % predicted, mean (SD) at 12 months, LOCF 63.14 (19.98) 61.59 (15.17) Not reported
VC % predicted, LS mean (SD) at 12 months, LOCF 65.13 (1.85) 60.34 (1.85) 4.79
(0.80 to 8.77);
p= 0.02b
DLCO mean (SD) mmol/minute/kPa at 12 months n= 48
4.20 (2.07)
n= 47
3.46 (1.22)
NA see below
DLCO mean (SD) mmol/minute/kPa at 12 months, LOCF n= 68
3.74 (1.99)
n= 63
3.20 (1.26)
NA see below
DLCO mmol/minute/kPa mean change at 12 months,
LOCF (95% CI)
–0.11 (–0.47 to
0.25)
–0.70 (–0.95 to
–0.45)
NA see below
DLCO mmol/minute/kPa, LS mean (SD), LOCF n= 68
3.85 (0.17)
n= 63
3.10 (0.18)
0.75
(0.27 to 1.23);
p= 0.003c
DLCO % predicted, mean at 12 months, LOCF 40.85 (14.85) 38.75 (14.75) Not reported
DLCO % predicted, LS mean at 12 months, LOCF 41.6 (1.35) 36.52 (1.45) 5.08
(1.17 to 8.99);
p= 0.01d
Exercise
Reports maximum exercise load, maximum oxygen update and maximum exercise ventilation, but not extracted as not
directly assessing exercise/function
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Results (all treated and LOCF data extracted
where numbers are reported, otherwise only
LOCF data)
Acetylcysteine,
n= 80 Placebo, n= 75
Difference
(95% CI); p-value
CRP score at 12 months, LS mean (SD), LOCF 37.62 (1.75) 39.33 (1.70) –1.71
(–8.72 to 5.30);
p=0.70e
CRP without exercise, at 12 months, LS mean (SD)
LOCF
30.91 (0.84) 32.50 (0.87) –1.59
(–4.37 to 1.19);
p=0.17f
Dyspnoea score at 12 months, LS mean (SD), LOCF 8.88 (0.49) 9.20 (0.51) –0.32
(–1.72 to 1.09);
p=0.65g
SGRQ, no data reported
Compliance
Adverse events occurring in at least 5% of
participants
Acetylcysteine,
n= 80
Placebo group,
n= 75
p-value
No. of
events
No. of
patients
No. of
events
No. of
patients
All adverse events 322 72 (90) 303 67 (89) See below
Respiratory tract infection 22 20 (25) 27 24 (32)
Dyspnoea 16 16 (20) 21 19 (25)
Fever 17 15 (19) 10 10 (13)
Liver-function test abnormal 15 14 (18) 13 11 (15)
Cough 15 13 (16) 17 16 (21)
Abdominal pain 12 12 (15) 7 7 (9)
URTI 11 11 (14) 15 13 (17)
Blood glucose ↑ 9 9 (11) 12 11 (15)
C-reactive protein ↑ 7 6 (8) 3 3 (4)
Blood alkaline phosphatase ↑ 6 6 (8) 1 1 (1)
Blood lactate dehydrogenase ↑ 6 6 (8) 2 2 (3)
Back pain 6 6 (8) 6 5 (7)
Respiratory failure 5 5 (6) 1 1 (1)
Bone marrow toxic effects 3 3 (4) 10 10 (13)
Oedema 3 3 (4) 5 5 (7)
Headache 4 3 (4) 6 6 (8)
Asthenia 3 3 (4) 5 5 (7)
Influenza-like illness 3 3 (4) 5 5 (7)
Muscle cramp 1 1 (1) 4 4 (5)
States none of the differences between the study groups were significant, except for those related to bone marrow toxicity,
which occurred in 4% of participants receiving acetylcysteine (3/80) and in 13% receiving placebo (10/75); p= 0.03
Detailed descriptions of the types of events included in these categories stated in the paper
Deaths 7 (9%) 8 (11%) p= 0.69
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Methodology
Allocation to treatment groups: states participants randomly assigned to treatment with study medication, with a 1 : 1 ratio of
acetylcysteine to placebo. The randomisation was performed centrally with the use of a computer-generated randomisation list
stratified (in blocks of four) according to country and whether the VC was ≤60% of the predicted value or >60% of the
predicted value. Randomisation appears to have been undertaken prior to HRCT scans assessed for eligibility
Blinding: states is double blind, and placebos were matched. No details of blinding of outcome assessors
Comparability of treatment groups: states no significant differences in baseline characteristics were found between groups
(the final randomised groups)
Method of data analysis: not all randomised were treated (see above). Analyses were based on data from all who were
randomised, met the inclusion criteria, received the trial medication at least once, and underwent at least one baseline
observation. Missing data were replaced by the LOCF method for all who underwent at least one lung-function measurement
post baseline. For the VC analysis the LOCF included 71 and 68 participants receiving acetylcysteine and placebo, respectively,
with data imputed for 20 and 16 participants, respectively. For the DLCO analysis the LOCF included 68 and 63 participants
receiving acetylcysteine and placebo, respectively, with data imputed for 16 and 17 participants, respectively. Used an
ANCOVA with country and treatment group as fixed factors, country-by-treatment as an interaction, and baseline values as
covariates. Modelled all possible combinations of cofactors to obtain the best model and used a likelihood-based method to
test the robustness of the LOCF-ANCOVA analysis, with sensitivity analyses using the LOCF population and the baseline
population, to test the robustness of the analysis. None of the combinations of cofactors included in the fixed-effects
LOCF-ANCOVA analysis were statistically significant and therefore treatment comparisons were unadjusted. As multiple
testing was undertaken the nominal p-value for defining statistical significance was reduced from p< 0.05 to p<0.025
Sample size/power calculation: calculated to provide a power of 80% (α= 0.05 by two-sided test) to detect a treatment
difference between the two groups of 15% for VC and 20% for DLCO after 1 year. On the basis of previous data and with an
expected withdrawal rate of 25% including deaths, a total of 150 participants were to be enrolled. Participants randomised
and included n=155
Attrition/drop-out: numbers and reasons provided
General comments
Generalisability: severity not reported, estimated from baseline VC that participants were predominantly mild to moderate;
however, 20–30% had VC < 60%, indicating more severe disease
Outcome measures: appear appropriate
Intercentre variability: not discussed
Conflict of interests: states that the sponsor held the data but placed no limitations on study design, data analysis or the
content of the manuscript. Authors’ individual declarations of interests are reported
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Methodology
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Yes
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Yes
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in drop-outs between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes than
they reported?
Yes
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? No
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
ANCOVA, analysis of covariance; NA, not applicable.
a Also reports the relative difference of 9%, which is calculated as being [(LS – LOCFacetylcsteine– LS – LOCFplacebo)/LS – LOCFplacebo] × 100.
b Also reports the relative difference of 8% (calculated as stated above).
c Also reports the relative difference of 24%, calculated as stated above.
d Also reports the relative difference of 14%, calculated as stated above.
e Also reports the relative difference of 5%, calculated as stated above.
f Also reports the relative difference of 5%, calculated as stated above.
g Also reports the relative difference of 4%, calculated as stated above.
Also reports baseline characteristics for the 27 participants who were excluded from the study; as these are not presented
per assigned treatment group these are not data extracted here.
Also reports details and results of bronchoalveolar lavage, not extracted here.
CRP scores range from 0 to 100; CRP scores without exercise range from 0 to 70.
Dyspnoea scores range from 0 to 20.
SGRQ: total scores from 0 to 100, with higher scores indicating a worse QoL.
States that more than 85% of participants in both groups took on average >80% of the prescribed daily dose of the drug.
Table 3 in the paper also reports the DLCO : alveolar volume as mmol/minute/kPa and per cent predicted but not
data extracted.
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Homma et al.69
Study details Participant details
Homma et al. 201269
Country: Japan
Design: RCT
Number of centres: 27
Funding: grant from Ministry of
Health, Labour and Welfare
Number of participants: 100. NAC: 51; control: 49
Sample attrition/dropout: states that 90 were included in the full data set for the
assessment of safety. Seventy-six were included in the data set for efficacy.
Numbers and reasons for exclusion were stated in the text as:
NAC group n= 7 (6= non administration of NAC; 1=missing data); control
group n= 3 (1= protocol violation; 2=missing data)
Also presents that numbers and reasons for exclusion from the full analysis set were:
NAC group n= 6 (one acute exacerbation, one pneumonia, four patient request,
protocol violation and other)
Control group n= 8 (four acute exacerbation, one progression of disease, three
patient request, protocol violation and other)
In total: 38 (74.5%) completed the study in the NAC group and 38 (77.6%)
completed the study in the placebo group
Sample crossovers:
Inclusion criteria: patients with well-defined IPF, diagnosed by ATS/ERS guidance and
4th version of Japanese clinical diagnostic criteria for IIP. Histological evidence of UIP
was not mandatory, but HRCT evidence was required (defined as basal predominant,
subpleural reticular abnormality with traction bronchiectasis and honeycomb cysts
without atypical features of UIP). The presence of other typical clinical features,
including bibasilar inspiratory fine crackles, abnormal PFT and increased serum levels of
markers of pneumocyte injury. Aged between 50 and 79 years, firm clinical and
radiological diagnoses of IPF, severity of disease classified as stage I (partial O2
concentration ≥80mmHg at rest), or stage II (partial O2 concentration 70–80mmHg
at rest), a lowest arterial oxygen saturation of >90% during the 6MWT
Exclusion criteria: an improvement in symptoms during the preceding 3 months; use of
NAC, immunosuppressive agents, oral prednisolone or pirfenidone; clinical suspicion
of IIP other than IPF
Intervention details Outcomes
Intervention
1. NAC inhaled, 352.4mg twice daily
2. Control
Dose details:
NAC inhalation of 352.4mg diluted
with saline to a total volume of 4ml,
twice per day, using microair
nebulisers and vibration mesh
technology (NE-U22, Omron
Healthcare, Tokyo), which improves
lung deposition compared with jet
nebuliser systems
Control: states ‘no treatment or
placebo’
Dose modifications: not reported
Concurrent treatment: not reported
Duration of treatment: 48 weeks
Primary outcomes: absolute change in FVC at 48 weeks
Secondary outcomes: changes in lowest arterial O2 saturation, 6MWT distance, PFT
parameters (VC, % predicted VC, TLC, % predicted TLC, DLCO and predicted DLCO),
serum markers of pneumocyte injury (not extracted); disease progression as determined
by HRCT; subjective changes in symptoms such as dyspnoea, adverse events
Method of assessing outcome
HRCT in accordance to a predetermined protocol, with two expert radiologists
evaluating lung fibrosis. Progression of disease was assessed on the basis of HRCT by
consensus between the site investigator and one of the radiologists. Worsening was
defined as progression in the extent of fibrosis and ground-glass opacity compared
with baseline. Stable disease as no change. Improvement as decrease in the extent of
ground-glass opacity compared with baseline
Dyspnoea by serum KL-6 and surfactant protein D levels and Fletcher, Hugh-Jones
classification scores assessed patient dyspnoea during activities of daily living.
Categorised as ‘improved, stable, or deteriorated’ with respect to changes of 20%
for KL-6 and surfactant protein D, or one grade for the Fletcher, Hugh-Jones dyspnoea
classification score
Safety assessed using grading scale of the CTC for adverse events, v3.0
Length of follow-up: 48 weeks
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Participant characteristics NAC, n= 38 Control, n= 38 p-value
Sex, M/F, n (%) 29/9 (76/24) 29/9 (76/24) 1.00
Age, years (mean (SD)) 67.6 (6.4) 68.2 (7.7) 0.78
Smoking, n (%)
Current 3 (7.9) 3 (7.9) 1.00
Former 25 (65.8) 26 (68.4)
Never 10 (26.3) 9 (23.7)
Years since diagnosis, n (%)
< 1 9 (23.7) 5 (13.2) 0.09
1–3 17 (44.7) 14 (36.8)
> 3 12 (31.6) 19 (50)
Mean (SD) years 3.0 (3.4) 3.2 (2.5)
No prior treatment with oral corticosteroids
and NAC, n (%)
38 (100) 38 (100) 1.00
Disease severity stage, n
I 30 31 1.00
II 8 7
FVC % predicted, mean (SD) 89.2 (17.8) 88.7 (15.5) 0.56
VC % predicted, mean (SD) 90.4 (18.3) 89.1 (15.0) 0.95
TLC % predicted, mean (SD) 82.5 (17.4) 81.2 (13.3) 0.84
DLCO % predicted, mean (SD) 72.3 (25.3) 64.4 (20.1) 0.16
Lowest SpO2 during 6MWT, %, mean (SD) 93.1 (2.1) 92.4 (2.0) 0.14
KL-6, U/ml, mean (SD) 995.1 (440.0) 1246.8 (114.9) 0.78
SP-D, ng/ml, mean (SD) 179.6 (102.7) 203.4 (107.4) 0.40
Results NAC, n= 38 Control, n= 38 Difference, p-value
Mean FVC (SD), l, at 48 weeks 2.67 (0.84) 2.51 (0.68) Not stated
Mean change (SD) in FVC, ml –90ml (300) –150ml (200) 60ml; 0.2661
Comments: text states difference was 63ml, but data suggest difference was 60ml
Decline of > 10% FVC Data not shown Data not shown –36.4% in NAC group
Decline of < 10% in FVC Data not shown Data not shown +14.8% in NAC
group; 0.42
Comments: limited data presented and uncertainty whether these were a priori analysed
Lowest SpO2 during 6MWT Data not shown Data not shown States NS
6MWT distance Data not shown Data not shown States NS
VC, l Data not shown Data not shown States NS
VC % predicted Data not shown Data not shown States NS
TLC Data not shown Data not shown States NS
TLC % predicted Data not shown Data not shown States NS
DLCO Data not shown Data not shown States NS
DLCO % predicted Data not shown Data not shown States NS
Serum markers of pneumocyte injury Data not shown Data not shown States NS
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Results NAC, n= 38 Control, n= 38 Difference, p-value
Comments
% improved or stable (by HRCT) 88.6% (31/35)
3 improved, 28 stable
78.1% (25/32)
0 improved, 25 stable
0.33
% with progression (by HRCT) 11.4% (4/35) 21.9% (7/32) NR
Comments: note proportions are calculated on n= 35 (three missing data) for the NAC group and n= 32 (six missing data)
in placebo group
NR, not reported
Also reports data at interim time points but not data extracted
% improved or stable dyspnoea 86.8% (33/38)
2 improved, 31 stable
84.2% (32/38)
1 improved, 31 stable
1.00
% deteriorated 13.2% (5/38) 15.8% (6/38) NR
Comments: no detail of actual scores on the dyspnoea scales used is reported. Also reports data at interim time points but
not data extracted
Frequent adverse events N= 44 N= 46
Bacterial pneumonia
Grade 1 2 0
Grade 2 2 0
Grade 3 0 0
Grade 4 0 0
Cough
Grade 1 1 0
Grade 2 1 0
Grade 3 0 0
Grade 4 0 0
Sore throat
Grade 1 2 0
Grade 2 0 0
Grade 3 0 0
Grade 4 0 0
Hypercholesteraemia
Grade 1 2 0
Grade 2 0 0
Grade 3 0 0
Grade 4 0 0
Comments: states there were no significant differences in the number of adverse events reported for the two groups.
The severity of the events was < grade 2 for the whole NAC group. Not clear what definition of ‘frequent’ was applied
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Methodology
Allocation to treatment groups: randomly assigned to the two groups in a 1 : 1 ratio. No further details reported
Blinding: no blinding of participants, investigators or outcome assessors
Comparability of treatment groups: states that the baseline characteristics were similar across groups. However, baseline
characteristics for those in the final data analysis only were presented
Method of data analysis: changes from baseline values and continuous variables were compared with Wilcoxon test.
Categorical variables and incidence rates by Fisher’s exact test. The principle of LOCF was adopted. Analysis of changes in
FVC and other pulmonary function tests and serum levels of markers of interstitial pneumonia used ANCOVA using the
respective baseline measurements as covariates. States that post hoc subgroup analyses were performed for those with
initial FVC values < 95% of predicted or initial DLCO values < 55% predicted. Data for these subgroups not extracted
Sample size/power calculation: not reported
Attrition/drop-out: numbers and reasons provided. Appears to be similar rate of attrition between the two study groups but
numbers were quite high (24%)
General comments
Generalisability: described as mild to moderate severity. States early stage IPF based on criteria used in Japan, which ranges
from stage I to stage IV, and based on partial arterial O2 concentrations, with stage I being less severe to stage IV more
severe, and no desaturation on the 6MWT distance. States that the severity classification is well correlated with survival in
IPF patients. None had prior treatments
Outcome measures: appear valid
Intercentre variability: not reported
Conflict of interests: paper acknowledges two individuals who worked for Fulcrum Pharma KK and assisted with study
management and data analysis but does not explicitly declare conflicts
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Unclear
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors? Unclear
4. Was the care provider blinded? No
5. Was the patient blinded? No
6. Were outcome assessors blinded to the treatment allocation? No
7. (i) Were there any unexpected imbalances in drop-outs between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Yes
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? No
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? No
NS, not significant; PFT, pulmonary function test.
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Horton et al.55,75
Study details Participant details
Horton et al. 201255,75
Country: USA
Design: randomised crossover trial
Number of centres: one
Funding: Celgene Corporation
Number of participants: 24 randomised: 11 to thalidomide
first, 13 to placebo first according to flowchart (but states
12 and 12 in text)
Sample attrition/dropout: 23 were treated, 20 completed
both treatment periods. During first period, one withdrew
from placebo group due to worsening health, and one
withdrew from thalidomide before receiving treatment due
to lack of interest. During second period, two withdrew
from thalidomide group due to worsening health
Sample crossovers: none unplanned
Inclusion criteria: aged > 50 years, clinical history consistent
with IPF (symptom duration ≥ 3 months and ≤ 5 years) and
chronic cough (defined as > 8 weeks’ duration, that
adversely affected QoL and not due to other identifiable
causes). HRCT scans consistent with IPF or surgical lung
biopsy demonstrating UIP, FVC between 40% and 90%
predicted, TLC between 40% and 80% predicted, and DLCO
between 30% and 90% predicted
Exclusion criteria: pregnancy, female with childbearing
potential, toxic or environmental exposure to respiratory
irritants, collagen vascular disease, airflow obstruction,
active narcotic antitussive use, peripheral vascular disease or
neuropathy, inability to give informed consent, allergy or
intolerance to thalidomide, life expectancy < 6 months
(opinion of investigators)
Intervention details Outcomes
Intervention
1. Thalidomide
2. Placebo
Dose details: 50mg by mouth at bedtime; dose increased to
100mg if no improvement in cough occurred after 2 weeks
(21 of 22 receiving thalidomide and 23 of 23 receiving
placebo)
Dose modifications: not reported
Concurrent treatment: 100mg sodium docusate by mouth
daily to avoid thalidomide-associated constipation, daily
vitamin B complex supplement. Any prescription therapy
for cough was discontinued 2 weeks before study and no
new therapy for cough was started. No patients began
benzonate therapy during trial or reported changes in ACE
inhibitors, angiotensin-receptor blocker, gastro-oesophageal
reflux disease or sinus therapies
Duration of treatment: 12 weeks each treatment with a
2-week washout period between treatments
Primary outcomes: cough-specific QoL
Secondary outcomes: cough, respiratory QoL
Method of assessing outcome:
Cough-specific QoL measured by the CQLQ. Cough
measured by a 10-cm VAS. Respiratory QoL measured by
SGRQ
Length of follow-up: 12 weeks
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Participant characteristics n= 23
Mean age (SD) 67.6 (7.8)
Male/female (%) 18/5 (78/22%)
White (%) 21 (31%)
HRCT diagnosis IPF, n (%) 23 (100)
Surgical lung biopsy, n (%) 5 (21.7)
Mean time from diagnosis (range), months 20.5 (3–59)
Mean FVC (SD), % predicted 70.4 (13.7)
Mean FEV1–FVC ratio (SD) 0.85 (0.54)
Mean TLC (SD), % predicted 63.6 (11.4)
Mean DLCO (SD), % predicted 57.4 (14.4)
Previous IPF treatment, n (%) 15 (65)
NAC 12 (52)
Oxygen 5 (22)
Prednisone 3 (13)
Previous cough treatment, n (%) 8 (35)
Benzonatate 5 (22)
Narcotic 5 (22)
GERD, n (%) 12 (52)
Therapy for GERD reported at study entry
Proton pump inhibitor 10 (43)
High-dose proton pump inhibitor 2 (9)
ACE inhibitor/ARB use, n (%) 7 (30)
Chronic sinusitis, n (%) 8 (34)
Therapy for chronic sinusitis reported at study entry
Antihistamine 5 (22)
Nasal steroids 5 (22)
Decongestant 4 (17)
Leuokotriene 1 (4)
CQLQ, mean (SD) 60.5 (12.0)
Cough VAS, mean (SD) 64.8 (21.4)
SGRQ total, mean (SD) 57.4 (18.8)
SGRQ symptom domain, mean (SD) 67.7 (19.7)
SGRQ impact domain, mean (SD) 48.1 (20.7)
SGRQ activity domain, mean (SD) 64.3 (22.7)
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Results
After 12 weeks of
thalidomide, n= 23
After 12 weeks
of placebo, n= 23
Mean difference
(95% CI); p-value
CQLQ, mean (SD) 47.2 (13.4) 58.7 (14.0) –11.4 (–15.7 to –7.0);
< 0.001
Cough VAS, mean (SD) 32.2 (26.1) 61.9 (26.5) –31.2 (–45.2 to –17.2);
<0.001)
SGRQ total, mean (SD) 43.9 (16.0) 56.9 (17.1) –11.7 (–18.6 to –4.8);
0.001
SGRQ symptom domain, mean (SD) 50.3 (20.9) 62.0 (18.3) –12.1 (–22.2 to –2.0);
0.018
SGRQ impact domain, mean (SD) 34.3 (16.1) 49.0 (19.4) –13.1 (–19.7 to –6.6);
0.001
SGRQ activity domain, mean (SD) 60.9 (14.2) 65.8 (18.7) –3.3 (–9.8 to 3.2);
0.31
Comments: in the mixed-effect linear regression model, the CQLQ score was 11.4 points lower with thalidomide than with
placebo (95% CI –15.7 to –7.0), complete results of mixed-effects models reported but not extracted. Sensitivity analyses to
explore the effect of missing data reported but not extracted; thalidomide use resulted in a statistically significant
improvement in CQLQ scores in each of these sensitivity analyses. NB: different data shown in abstract75
CQLQ consists of 28 questions using Likert-like 4-point scales, with lower scores indicating less effect of cough on HRQoL.
The MCID of the CQLQ in IPF is unknown, but the MCID for the Leicester Cough Questionnaire, which has been shown to
be similar to the CQLQ, is 1.3
SRGQ has 50 items and produces three domain scores and one overall score, measuring, symptoms, activity and impacts
Adverse events, n (%) Thalidomide, n= 22 Placebo, n= 23
Participants with ≥ 1 adverse event 17 (77) 5 (22) p= 0.001
Participants with a serious adverse
event (influenza)
0 1 (4)
Adverse events requiring dose reduction
Constipation 2 (9) 0
Bradycardia 1 (5) 0
Adverse events requiring drug
discontinuation (progressive illness or
inability to travel for visits)
2 (9) 1 (4)
Gastrointestinal adverse events
Constipation 8 (36) 1 (4)
Change in taste 2 (9) 0
Dry mouth 2 (9) 0
Anorexia 1 (5) NR
General adverse events:
Dizziness 6 (27) 0
Malaise 3 (14) 0
Oedema 2 (9) 0
Rash 2 (9) 0
Sleepiness NR 1 (4)
Respiratory adverse event: worsening
dyspnoea
2 (9) 2 (9)
Infectious adverse event: viral URTI 5 (23) 1 (4)
Cardiac adverse event: bradycardia 1 (5) 0
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Methodology
l Allocation to treatment groups: a randomisation schedule was prepared by a third party using a manual algorithm.
A random seed number was generated in Microsoft Excel (Microsoft Corporation, Redmond, WA, USA). The
pharmacist dispensing the study drug was the only person who had access to the treatment assignment
l Blinding: study investigators and participants were blinded. However, it is noted that thalidomide has characteristic effects
that may have alerted participants to the identity of the drug
l Comparability of treatment groups: not applicable (crossover trial)
l Method of data analysis: the VAS of cough was not normally distributed according to the Shaprio–Wilk test. Categorical
variables were compared using the McNemar’s chi-squared test. The association between thalidomide and the primary and
secondary outcomes was analysed using linear mixed-effect models. For each outcome measure, only the value at week 12
of thalidomide or placebo was used. The model contained covariates for treatment, period and treatment sequence as
fixed effects and participants nested within sequence as a random effect. Additional analyses were performed to test the
sensitivity of findings to missing data. The primary analysis was repeated by replacing CQLQ scores with scores from day 0
and with the highest CQCL score. A model was also used that included a covariate for the CQLQ at day 0. Results are
mean (SD) unless stated otherwise
l Sample size/power calculation: sample size calculations were based on the CQLQ. No data on the minimum clinically
important difference in CQLQ or data on the variance in IPF patients were available. Therefore, calculations were based on
the ability to recruit 20 participants, which would provide 80% power to detect a difference of 4.67 units with a two-sided
alpha error level of 5% in a two–treatment crossover study, based on the assumption that the within-patient SD of the
response variance would be 5.0
l Attrition/drop-out: numbers and reasons provided. Data were collected for all planned study visits from 20 participants
and incomplete data on three participants who received placebo first but withdrew before completion of the
thalidomide period. Analysis included all available data
General comments
l Generalisability: participants generally had mild IPF, based on the per cent predicted IPF at baseline, and cough.
Most participants self-referred after learning about the study online, and therefore might not be representative
l Outcome measures: validated measures of QoL and cough. No lung function tests reported
l Intercentre variability: not applicable
l Conflict of interests: Celgene Corporation provided the study drug and funding by had no role in study design,
conduct, analysis or manuscript preparation. Disclosures of authors can be viewed online
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Yes
3. Were the groups similar at the outset of the study in terms of prognostic factors? NA
4. Was the care provider blinded? Yes
5. Was the patient blinded? Yes (but treatment may have
unmasked)
6. Were outcome assessors blinded to the treatment allocation? Yes
7. (i) Were there any unexpected imbalances in drop-outs between groups?
(ii) If so, were they explained or adjusted for?
Yes
Yes
8. Is there any evidence to suggest that the authors measured more outcomes than
they reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Yes (but not described as such)
Yes
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
ACE, angiotensin converting enzyme; ARB, Angiotensin II Receptor Blocker; GERD, gastroesophageal reflux disease.
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Additional quality/methodological questions for crossover trial
1. Is a crossover trial an appropriate design for the condition of interest? Yes (symptomatic treatment
of cough).
2. Was the order of treatments randomised appropriately? Yes.
3. Is there likelihood of serious carry over? No (2-week washout period between treatments).
4. What data are available? (Sometimes if carryover is seen by the triallists, they may provide data for a
‘parallel’ group comparison. However, this brings its own risk of bias.) End of treatment mean and
SD provided.
5. Was the correct analysis applied? Yes: linear mixed-effect models contained covariates for treatment,
period and treatment sequence as fixed effects and participants nested within sequence as a
random effect.
6. Were the dropout rates reported and are these likely to cause a bias? Reported and unlikely to
cause bias.
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Idiopathic Pulmonary Fibrosis Clinical Research Network 201268
Study details Participant details
Raghu et al. IPFCRN 201268
Country: USA
Design: RCT
(PANTHER study)
Number of centres: 25
Funding: grants from the NHLBI and the Cowlin Family
fund. NAC and placebo donated by Zambon (manufacturer)
Number of participants: 236 randomised: NAC alone, n= 81
(data not presented in paper); NAC/prednisolone/
azathioprine, n= 77; placebo n= 78
Sample attrition/dropout: NAC/prednisolone/azathioprine:
six discontinued (two underwent lung transplantation,
two withdrew consent, two had consent withdrawn by
physician); placebo: three discontinued (two withdrew
consent, one had consent withdrawn by physician)
Participants discontinued treatment with one or more of the
active or placebo agents (p< 0.001 between groups for all
comparisons):
NAC/prednisolone/azathioprine: 23 discontinued
prednisolone, 31 azathioprine, 24 NAC (20 discontinued all
three drugs)
Placebo: three discontinued prednisolone placebo, four
azathioprine placebo, four NAC placebo (three discontinued
all three drugs)
Sample crossovers: not reported
Inclusion criteria: IPF aged between 35 and 85 years with
mild to moderate lung function impairment (FVC ≥ 50%
and DLCO ≥ 30% of predicted values), met the modified
criteria of the ATS/ERS/JRS/LATA (2011) for diagnosis of IPF,
had received diagnosis on the basis of HRCT or biopsy
≤ 48 months before enrolment
Exclusion criteria: history of clinically significant environmental
exposure known to cause pulmonary fibrosis (e.g. asbestos);
diagnosis of connective tissue disease; extent of emphysema
greater than the extent of fibrotic change; FEV1–FVC ratio
<0.65 at screening; PaO2 on room air < 55mmHg; residual
volume >120% predicted at screening; evidence of active
infection; significant bronchodilator response on screening
spirometry; screening and enrolment post-bronchodilator
FVC measurements (in litres) differing by >11%; listed for
lung transplantation; history of unstable or deteriorating
cardiac disease; myocardial infarction, coronary artery bypass,
or angioplasty within 6 months of screening; unstable angina
or congestive heart failure requiring hospitalisation within
6 months of screening; uncontrolled arrhythmia; severe
uncontrolled hypertension; known HIV or hepatitis C; known
cirrhosis and chronic active hepatitis; active substance and/or
alcohol abuse; pregnancy or lactation; not using means of
contraception (where appropriate); any clinically relevant lab
abnormalities (specified); homozygous for low thiopurine
S-methyltransferase; overt or persistent clinical depression
(defined); known hypersensitivity to study medication
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Intervention details Outcomes
Intervention
1. NAC/placebo prednisolone/placebo azathioprine
(data not presented in article as ‘ongoing’)
2. NAC/prednisolone/azathioprine
3. Placebo
Dose details: prednisolone commenced at 0.5mg/kg of
ideal body weight and tapered to 0.15mg/kg during
25 weeks. Azathioprine (maximum 150mg/day) was based
on the patient’s ideal weight, concurrent use of allopurinol,
and TPMT activity. NAC prescribed at 600mg orally three
times per day
Dose modifications: detailed algorithms were provided for
dose adjustments in case of potential adverse events
Concurrent treatment: not reported
Duration of treatment: up to 60 weeks
Primary outcomes: change in FVC at 60 weeks
Secondary outcomes: rate of death, time until death,
frequency of acute exacerbation, frequency of maintained
FVC response, time to disease progression, clinical and
physiological measures including: DLCO, 6MWT, CPI,
UCSDSBQ, SGRQ, SF-36, EQ-5D. Adverse events. Also
predefined subgroups (data not presented)
Method of assessing outcome: all deaths, hospitalisations
and suspected acute exacerbations were reviewed by the IPF
net adjudication committee. The definition of an acute
exacerbation was prespecified in accordance with previously
published criteria (ref provided)
Length of follow-up: 60 weeks in the planned analysis. The
study was stopped prior to this, although the timing of this
was not reported it was stated as ‘mid point’. This is likely
to be different for different participants
Participant characteristics
[mean (SD) unless stated]
NAC/prednisolone/
azathioprine, n= 77 Placebo, n= 78
Age, years 68.8 (7.3) 67.9 (8.1)
Male/female (%) 59/18 (77/23) 57/21 (73/27)
Race or ethnic group, n (%)a
White 75 (97) 75 (96)
Black 1 (1) 0
Hispanic 1 (1) 5 (6)
History of smoking, n (%)
Current 3 (4) 4 (5)
Former 51 (66) 54 (69)
Never 23 (30) 20 (26)
Time since diagnosis, years 0.9 (1.1) 1.1 (1.0)
Coexisting illness, n (%)
Coronary artery disease 13 (17) 17 (22)
Diabetes 11 (14) 14 (18)
Gastro-oesophageal reflux
disease
48 (62) 45 (58)
FVC, % 69.3 (15.1) 72.1 (14.1)
DLCO corrected for haemoglobin,
% predicted
42.1 (10.2) 45.3 (12.4)
PaO2 while breathing air, mmHg 79.6 (9.7) 78.8 (12.6)
CPIb 53.7 (11.7) 49.8 (13.5)
6MWT distance, m 362.0 (113.0) 368.9 (117.3)
SBQ (UCSD)c score 30.1 (20.1) 29.1 (19.4)
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Participant characteristics
[mean (SD) unless stated]
NAC/prednisolone/
azathioprine, n= 77 Placebo, n= 78
SGRQ total scored 38.7 (17.4) 39.4 (17.4)
SGRQ symptoms scored 49.4 (21.1) 45.6 (21.8)
SGRQ activity scored 51.1 (19.0) 52.7 (21.0)
SGRQ impacts scored 27.8 (19.2) 28.8 (17.3)
SF-36 aggregate physical scoree 40.3 (9.8) 40.6 (9.3)
SF-36 aggregate mental scoree 53.9 (9.6) 55.7 (7.4)
EQ-5D score 0.8 (0.2) 0.8 (0.2)
EQ-5D thermometer response 76.8 (15.5) 78.1 (15.4)
HRCT definite IPF 66 (86%) 61 (78%)
Diagnosis based on surgical lung
biopsy
38 (49%) 37 (47%)
CPI
Results [assumed by
reviewer as mean (95% CI)]
NAC/prednisolone/
azathioprine, n= 77 Placebo, n= 78
Difference, (95% CI);
p-value
FVC change, l –0.24 (–0.33 to –0.15) –0.23 (–0.32 to –0.14) –0.01 (–0.14 to 0.11);
0.85
Comments: FVC at 60 weeks could not be assessed because the study stopped early. Data above were at the time of the
interim analysis
All-cause mortality, n (%) 8 (10) 1 (1) 0.01
Respiratory mortality 7 (9) 1 (1) 0.02
Estimated any-cause mortality at
60 weeks, %
19.8 (9.9 to 37.2) 2.0 (0.3 to 13.6) HR 9.26 (1.16 to 74.1);
0.01
Estimated any-cause mortality or
hospitalisation
43.6 (30.7 to 59.0) 16.9 (8.7 to 31.5) HR 3.74 (1.68 to 8.34);
< 0.001
Estimated any-cause mortality or
≥ 10% decline in FVC
36.3 (23.7 to 53.0) 32.4 (19.7 to 50.3) HR 1.46, (0.70 to 3.05);
0.30
Comments: provides timelines until respiratory death during the study period, for each participant according to study group
All-cause hospitalisations 23 (30) 7 (9) < 0.001
Comments
Time to death Data in figure Data in figure NR
Time to death or disease
progression
Data in figure Data in figure States NS
Comments: as defined by a composite outcome of death or a relative drop in FVC of > 10%
Time to death or hospitalisation 32% 3% HR 12.11 (2.83 to 51.85);
<0.001
Comments
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Results [assumed by
reviewer as mean (95% CI)]
NAC/prednisolone/
azathioprine, n= 77 Placebo, n= 78
Difference, (95% CI);
p-value
Acute exacerbation 5 (6%) 0 Not reported
Comments
DLCO corrected –1.72 (–2.73 to –0.71) –1.66 (–2.65 to –0.67) –0.06 (–1.48 to 1.35);
0.93
Comments
6MWT distance, m –93.0 (–142.0 to –44.1) –73.6 (–118.4 to –28.7) –19.5 (–85.9 to 46.9),
0.56
Comments: also reports 6MWT oxygen desaturation area under the curve, 6MWT distance to saturation < 80%, 6MWT
minutes walked. Not data extracted here
CPI 6.72 (3.61 to 9.83) 5.33 (2.37 to 8.29) 1.39 (–2.90 to 5.68);
0.52
Comments
USCDSBQ 10.6 (3.60 to 17.6) 8.01 (1.67 to 14.3) 2.57 (–6.87 to 12.0);
0.59
Comments
SGRQ
Total score 4.29 (–1.14 to 9.73) 7.50 (2.57 to 12.4) –3.20 (–10.5 to 4.13);
0.39
Symptoms score –4.42 (–11.9 to 3.1) 8.31 (1.47 to 15.2) –12.7 (–22.9 to –2.61);
0.014
Activity score 7.33 (1.05 to 13.6) 10.3 (4.66 to 16.0) –2.99 (–11.4 to 5.46);
0.49
Impacts score 5.23 (–0.80 to 11.3) 5.80 (0.34 to 11.27) –0.57 (–8.71 to 7.57);
0.89
Comments
SF-36 aggregate physical score –4.18 (–7.40 to –0.97) –2.96 (–5.90 to –0.02) –1.23 (–5.58 to 3.13);
0.58
Comments: range 0–100, with higher scores indicating better health
SF-36 aggregate mental score 0.96 (–2.51 to 4.44) –4.35 (–7.50 to -1.20) 5.31 (0.62 to 10.00);
0.027
Comments
EQ-5D score –0.07 (–0.14 to 0.00) –0.02 (–0.09 to 0.04) –0.05 (–0.14 to 0.05);
0.31
Comments
EQ-5D thermometer response –6.81 (–13.0 to –0.67) –6.66 (–12.4 to –0.94) –0.15 (–8.54 to 8.24);
0.93
Comments
Serious adverse event rate
Any 24 (31) 8 (10) 0.001
Respiratory system 12 (16) 4 (5) 0.03
Infectious 5 (6) 1 (1) 0.12
Gastrointestinal 1 (1) 3 (4) 0.62
Cardiac 3 (4) 0 0.12
General disorderf 3 (4) 0 0.12
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Results [assumed by
reviewer as mean (95% CI)]
NAC/prednisolone/
azathioprine, n= 77 Placebo, n= 78
Difference, (95% CI);
p-value
Neoplasm 2 (3) 0 0.25
Metabolism 1 (1) 0 0.50
Musculoskeletal system 0 1 (1) 1.00
Nervous system 1 (1) 0 0.50
Reproductive system 1 (1) 0 0.50
Adverse eventsg
Any 68 (88) 61 (78) 0.09
General disorder 34 (44) 21 (27) 0.03
Skin 13 (17) 4 (5) 0.02
Renal and urinary system 10 (13) 1 (1) 0.005
Non-serious adverse eventsh
Respiratory 35 (45.5) 34 (43.6) 0.82
Infections 37 (48.1) 28 (35.9) 0.13
Gastrointestinal 29 (37.7) 27 (34.6) 0.69
Investigations 20 (26.0) 19 (24.4) 0.81
Nervous system 18 (23.4) 12 (15.4) 0.21
Musculoskeletal 10 (13.0) 16 (20.5) 0.21
Metabolism 14 (18.2) 7 (9.0) 0.09
Psychiatric 6 (7.8) 7 (9.0) 0.79
Injury 6 (7.8) 4 (5.1) 0.53
Eye 6 (7.8) 3 (3.8) 0.33
Blood and lymphatic 5 (6.5) 2 (2.6) 0.28
Cardiac 4 (5.2) 3 (3.8) 0.72
Vascular 5 (6.5) 2 (2.6) 0.28
Ear 4 (5.2) 2 (2.6) 0.44
Immune 2 (2.6) 3 (3.8) 1.00
Neoplasms 4 (5.2) 1 (1.3) 0.21
Reproductive 2 (2.6) 3 (3.8) 1.00
Congenital or genetic 0 1 (1.3) 1.00
Endocrine 0 1 (1.3) 1.00
Social circumstances 1 (1.3) 0 0.50
Methodology
Allocation to treatment groups: A permuted-block randomisation with varying block sizes stratified according to clinical
centre was used. Participants were randomised in a 1 : 1 : 1 ratio through telephone contact with a central interactive
voice-response system
Blinding: states double blind and that placebo treatments were matched; no further details reported
Comparability of treatment groups: States the two groups were well matched with respect to demographic and clinical
characteristics
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Results [assumed by
reviewer as mean (95% CI)]
NAC/prednisolone/
azathioprine, n= 77 Placebo, n= 78
Difference, (95% CI);
p-value
Method of data analysis: all analyses based on ITT principle. A two-step process was used; if any difference between study groups
was statistically significant at 0.05 level, then each of the three pairwise comparisons would be tested at the 0.05 level. For
continuous outcomes, a mixed-model repeated-measures analysis was used to compare FVC in the three study groups. Variables
included in the regression model included study group, time, time according to treatment, age, sex, race and height. Dichotomous
outcomes were compared with two-sided Fisher’s exact tests. Time-to-event outcomes were analysed with a Cox proportional-
hazards regression model. Kaplan–Meier curves were used to display event rates. One interim analysis for efficacy was planned,
where a Bonferroni approximation was applied, with the critical value set to an alpha level of 0.00001. Predefined subgroups were
noted. At the planned interim analysis, the data and safety monitoring board recommended discontinuation of the three-drug
regimen because of an excess number of deaths, hospitalisations and serious adverse events compared with the placebo group
Sample size/power calculation: based on previous clinical trials, an estimate of a 0.20 l decline in FVC in the placebo group, and a
difference of 0.15 l from that in the placebo group as clinically meaningful, was used. After accounting for potential dropout and
imperfect compliance, 130 participants per group were determined as providing a power of 90% for the first step of the testing
procedure under most scenarios. The target sample size was expected to provide a power of approximately 93% to detect a
significant difference at the two-sided 0.05 level
Attrition/dropout: numbers and reasons provided
General comments
Generalisability: described as mild to moderate impairment in pulmonary function
Outcome measures: appear valid
Intercentre variability: not reported
Conflict of interests: disclosure forms provided by all authors (available online)
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Yes
3. Were the groups similar at the outset of the study in terms of prognostic factors Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Yes
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
Yes
Yes
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Yes
No
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
CPI, Composite Physiologic Index; JRS, Japanese Respiratory Society; LATA, Latin American Thoracic Association;
NHLBI, National Heart, Lung and Blood Institute.
a Participants could select more than one category.
b No official upper or lower limit, higher scores indicate more severe disease.
c Scores range from 0 to 120, with higher scores indicating worse function.
d Scores range from 0 to 100, with higher scores indicating better function.
e Scores range from 0 to 100, with higher scores indicating better function.
f Includes all serious adverse events that did not fall into another body-system category, including drug reactions and
drug fever.
g Specific adverse events with a significant between-group difference.
h All other adverse events recorded.
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Idiopathic Pulmonary Fibrosis Clinical Research Network 201072
Study details Participant details
Zisman et al. IPFCRN 201072
Country: USA
Design: RCT
Number of centres: 14
Funding: NHLBI grants; the Cowlin Fund at the
Chicago Community trust; Pfizer; Masimo
Number of participants: 180 randomised: sildenafil n= 89, placebo
n= 91
Sample attrition/dropout:
Sildenafil: eight participants dropped out of the study (four adverse
events, two deaths, two lost to follow-up); placebo: six dropped out
of the study (four adverse events, one death, one underwent lung
transplantation)
Dropout rates for open-label period also presented but not extracted
here
Sample crossovers: not stated but assume none. All placebo
participants received sildenafil after 12 weeks (data for this period
not extracted)
Inclusion criteria: diagnosis of IPF as defined by the 2000 ATS/ERS
consensus criteria, in an advanced stage (a DLCO of < 35% predicted)
Exclusion criteria: 6MWT distance of < 50m (164 ft); a difference of
> 15% in the 6MWT distance between two prerandomisation walks;
an extent of emphysema greater than the extent of fibrotic change
(by HRCT); treatment with medications containing nitrates; the
presence of aortic stenosis or idiopathic hypertrophic subaortic
stenosis; the initiation of pulmonary rehabilitation within 30 days
after screening; the initiation or change in the dose of any
investigational treatment for IPF within 30 days after screening;
treatments for pulmonary hypertension with prostaglandins,
endothelin-1 antagonists, or other phosphodiesterase inhibitors
within 30 days after screening; a resting oxygen saturation of < 92%
while breathing 6 l of supplemental oxygen; being listed on an active
waiting list for lung transplantation
Intervention details Outcomes
Intervention
1. Sildenafil
2. Placebo
Dose details: sildenafil, oral, 20mg, three times
daily
Dose modifications: not reported
Concurrent treatment: not reported
Duration of treatment: 12 weeks during a
double-blind placebo controlled; 12 weeks
open-label extension where all received sildenafil
Primary outcomes: presence or absence of an improvement of at
least 20% in the 6MWT distance at 12 weeks
Secondary outcomes: changes in the 6MWT distance, degree of
dyspnoea, QoL, FVC, DLCO, arterial partial pressure of oxygen and
arterial oxygen saturation, and the alveolar–arterial oxygen gradient
while breathing ambient air, adverse events, hospitalisations, death
Method of assessing outcomes: dyspnoea with the UCSDSBQ and
the Borg Dyspnoea Index. QoL was measured by the SGRQ, SF-36
and EQ-5D. Each suspected acute exacerbation was adjudicated by a
central committee in a blinded fashion. 6MWT was performed with
the use of a standardised protocol. Those with pulse O2 saturation of
≥ 88% at rest were tested breathing ambient air; those below this
received supplemental O2, titrated to an O2 saturation of at least
92% while at rest. Participants walked for 6 minutes or until their O2
saturation fell below 80% for 6 seconds. The distance walked at
that point was recorded. Subsequent tests were performed with the
use of the same amount of O2 used at screening. Those whose
resting O2 saturation on follow-up testing did not reach 88% during
administration of the baseline O2 were not retested and were
recorded as having walked 0 metres
Length of follow-up: 12 weeks for the randomised comparison
(28 for the open-label extension study)
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Participant characteristics
[mean (SD) unless stated] Sildenafil, n= 89 Placebo, n= 91
Age (years) 69.76 (8.71) 68.20 (9.25)
M/F, n (%) 75/14 (84/16) 75/16 (82/18)
Race, n (%)
White 78 (88) 85 (93)
Black 5 (6) 1 (1)
Other 6 (7) 5 (5)
History of smoking, n (%) 68 (76) 69 (76)
Time since diagnosis, years 2.03 (1.94) 1.87 (1.93)
Supplemental O2 during walk test, n (%) 28 (31) 24 (26)
6MWT distance, m
First test 246.93 (99.11) 267.71 (127.75)
Second test 246.39 (103.40) 269.55 (129.83)
Borg Dyspnoea Index after walk test
(range 0–10)
3.82 (1.95) 3.33 (1.73)
UCSDSBQ (range 0–120) 50.71 (22.00) 43.28 (20.18)
Total score on SGRQ (range 0–100) 54.55 (16.46) 51.72 (15.86)
Symptoms score on SGRQ (range 0–100) 58.20 (17.75) 53.99 (18.90)
Activity score on SGRQ (range 0–100) 71.20 (17.50) 68.02 (17.63)
Impacts score on SGRQ (range 0–100) 43.20 (19.26) 39.77 (18.81)
SF-36 (subset range 0–100)
Aggregate physical score 33.17 (9.19) 34.84 (8.69)
Aggregate mental score 49.53 (9.76) 50.58 (9.52)
Bodily pain score 50.55 (10.98) 49.72 (10.44)
General health score 36.99 (9.64) 37.66 (8.73)
Mental health score 51.22 (9.07) 50.95 (8.59)
Physical functioning score 29.20 (8.49) 31.18 (8.31)
Role emotional score 45.13 (12.14) 44.0 (13.60)
Role physical score 34.67 (11.39) 36.38 (11.44)
Social functioning score 42.33 (10.88) 43.06 (10.17)
Vitality score 44.08 (9.28) 45.30 (9.88)
EQ-5D
Self-report (range –0.59 to 100) 0.71 (0.24) 0.74 (0.19)
VAS (range 0–100) 66.49 (17.45) 67.66 (16.98)
FVC % predicted 54.89 (14.00) 58.73 (14.12)
DLCO % predicted 25.81 (6.03) 26.73 (6.16)
Partial pressure O2, mmHg 66.22 (12.22) 69.88 (12.85)
Arterial O2 saturation, %a 91.24 (4.22) 92.59 (3.75)
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Results Sildenafil, n= 89 Placebo, n= 91
Absolute difference
(95% CI); p-value
6MWT improvement in distance of ≥20% 9 (10%) 6 (7%) 0.39
Comments
Borg Dyspnoea Index after walk test, mean
change (95% CI)
0.04 (–0.30 to 0.37) 0.37 (0.04 to 0.70) –0.34 (–0.81 to 0.14);
0.16
The Borg Dyspnoea Index measures perceived breathlessness on a scale of 0 (none) to 10 (maximum) and has a minimally
important difference of 1 (reference provided)
UCSDSBQ mean change (95% CI) 0.22 (–3.10 to 3.54) 6.81 (3.53 to 10.08) –6.58 (–11.25 to –1.92);
0.006
UCSDSBQ: indicates severity of dyspnoea on a scale from 0 to 5 on 21 activities of daily living, along with three ratings on
limitations caused by dyspnoea or fear of dyspnoea, for a total score ranging from 0 to 120, with higher score indicating
more dyspnoea. The minimally important difference for this is reported to be 5 points (reference provided)
SGRQ mean change –4.08 (–7.30 to –0.86);
0.01
Total score –1.64 (–3.91 to 0.64) 2.45 (0.17 to 4.72)
Symptoms score –3.58 (–7.02 to –0.13) 2.15 (–1.30 to 5.61) –5.73 (–10.61 to –0.85);
0.02
Activity score –1.15 (–3.68 to 1.38) 2.49 (0.00 to 4.99) –3.64 (–7.20 to –0.09);
0.04
Impacts score (social function) –0.88 (–3.72 to 2.02) 2.82 (–0.03 to 5.67) –3.70 (–7.76 to 0.37);
0.07
SGRQ: asks how breathing problems impair their life and is scored from 0 (no impairment) to 100 (maximum impairment).
The minimally important difference for this is reported to be 5 to 8 points (reference provided)
SF-36 mean change –0.17 (–2.06 to 1.73);
0.86
Aggregate physical score –0.51 (–1.86 to 0.83) –0.35 (–1.68 to 0.99)
Aggregate mental score 1.30 (–0.59 to 3.18) 3.02 (1.15 to 4.89) –1.72 (–4.38 to 0.93);
0.20
Bodily pain score –0.21 (–2.13 to 1.71) 1.97 (0.08 to 3.85) –2.17 (–4.86 to 0.52);
0.11
General health score –1.04 (–2.52 to 0.44) –3.89 (–5.37 to –2.42) 2.86 (0.76 to 4.95);
0.008
Mental health score –0.16 (–1.81 to 1.49) –1.31 (–2.93 to 0.30) 1.15 (–1.15 to 3.46);
0.32
Physical functioning score –0.93 (–2.24 to 0.38) –1.46 (–2.76 to –0.17) 0.53 (–1.31 to 2.37);
0.57
Role emotional score –2.72 (–5.56 to 0.12) –4.82 (–7.63 to –2.01) 2.10 (–1.90 to 6.10);
0.30
Role physical score –0.87 (–2.85 to 1.10) –2.03 (–3.98 to –0.08) 1.16 (–1.62 to 3.93);
0.41
Social functioning score –0.72 (–3.01 to 1.57) –2.71 (–4.97 to –0.46) 1.99 (–1.22 to 5.21); 0.22
Vitality score 0.02 (–1.70 to 1.75) –2.01 (–3.70 to –0.31) 2.03 (–0.39 to 4.44); 0.10
The SF-36 measures functional health and well-being scores on eight scales that correlate with two aggregate scores. Each
score ranges from 0 to 100, with a higher score indicating better function. Scores are normalised to a mean (SD) of 50 (10).
In IPF the SF-36 has a minimally important difference of 2 to 4 points (reference provided)
EQ-5D mean change 0.02 (–0.04 to 0.08);
0.54
Self-report questionnaire –0.01 (–0.06 to 0.03) –0.03 (–0.08 to 0.01)
VAS 0.48 (–3.10 to 4.06) –1.81 (–5.34 to 1.73) 2.28 (–2.75 to 7.32);
0.37
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Results Sildenafil, n= 89 Placebo, n= 91
Absolute difference
(95% CI); p-value
The EQ-5D measures general QoL on a self-report questionnaire on a scale of –0.59 to 1.00 (higher score indicating better
QoL and a negative value indicating a health state worse than death) and on a VAS with a range of 0 to 100 (higher equals
better QoL). The reported minimally important difference is approximately 0.08 for the self-report questionnaire and 7
points for the VAS (reference provided)
FVC (% predicted), mean change –0.97 (–2.00 to 0.06) –1.29 (–2.30 to –0.28) 0.32 (–1.12 to 1.76);
0.66
DLCO (% predicted), mean change –0.33 (–1.36 to 0.71) –1.87 (–2.91 to –0.83) 1.55 (0.08 to 3.01);
0.04
Partial pressure O2 (mmHg), mean change –0.63 (–2.41 to 1.16) –3.64 (–5.41 to –1.87) 3.02 (0.50 to 5.53);
0.02
Partial pressure of CO2 (mmHg), mean change –0.01 (–0.75 to 0.73) –0.02 (–0.75 to 0.71) 0.01 (–1.03 to 1.05);
0.98
Alveolar-arterial gradient (mmHg), mean
change
0.41 (–1.54 to 2.37) 2.95 (0.99 to 4.92) –2.54 (–5.31 to 0.23);
0.07
Arterial O2 saturation (%), mean change –0.17 (–1.02 to 0.69) –1.38 (–2.23 to –0.52) 1.21 (0.00 to 2.42); 0.05
Death from any cause, n (%) 2 (2) 4 (4) 0.43
Acute exacerbation, n (%) 2 (2) 4 (4) 0.68
Serious adverse events, number (%) of participants with at least one serious adverse event involving each organ system,
number of events observed (assumed by reviewer)
Any 13 (15), 14 15 (16), 23 0.73
Respiratory, thoracic or mediastinal disorder 7 (8), 7 9 (10), 11 0.63
Worsening IPF 2 (2), 2 5 (5), 5 0.44
Worsening dyspnoea 2 (2), 2 1 (1), 1 0.62
Respiratory failure 1 (1), 1 2 (2), 2 0.99
COPD 0 1 (1), 1 0.99
Hypoxaemia 1 (1), 1 0 0.49
Pleural effusion 0 1 (1), 1 0.99
Pneumothorax 0 1 (1), 1 0.99
Pulmonary embolism 1 (1), 1 0 0.49
Infection or infestation 3 (3), 4 2 (2), 2 0.68
Pneumonia 2 (2), 2 1 (1), 1 0.62
Bronchitis 0 1 (1), 1 0.99
Influenza 1 (1), 1 0 0.49
Viral infection 1 (1), 1 0 0.49
Cardiac disorder 1 (1), 1 3 (3), 3 0.62
Atrial fibrillation 0 2 (2), 2 0.50
Congestive heart failure 1 (1), 1 0 0.49
Coronary artery disease 0 1 (1), 1 0.99
Gastrointestinal disorder 2 (2), 2 1 (1), 1 0.62
Ischaemic colitis 1 (1), 1 0 0.49
Intestinal obstruction 0 1 (1), 1 0.99
Peptic ulcer haemorrhage 1 (1), 1 0 0.49
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Results Sildenafil, n= 89 Placebo, n= 91
Absolute difference
(95% CI); p-value
Hepatobiliary disorders 0 1 (1), 1 0.99
Biliary colic 0 1 (1), 1 0.99
Injury, poisoning and procedural complications 0 1 (1), 3 0.99
Fall 0 1 (1), 1 0.99
Femur fracture 0 1 (1), 1 0.99
Joint injury 0 1 (1), 1 0.99
Neoplasms benign, malignant and unspecified 0 1 (1), 1 0.99
Neoplasms malignant 0 1 (1), 1 0.99
Nervous system disorders 0 1 (1), 1 0.99
Convulsion 0 1 (1), 1 0.99
Adverse events, number (%) with at least one adverse event, number of adverse events observedb
Any body system and event 80 (89.9), 442 79 (86.8), 453 0.52
Respiratory, thoracic and mediastinal
disorders
46 (51.7), 85 52 (57.1), 86 0.46
Infections or infestations 42 (47.2), 58 39 (42.9), 52 0.56
Nervous system disorders 35 (39.3), 56 35 (38.5), 58 0.91
Gastrointestinal disorders 32 (36.0), 45 27 (29.7), 43 0.37
General disorders and administration site
conditions
27 (30.3), 45 26 (28.6), 44 0.80
Musculoskeletal and connective tissue
disorders
25 (28.1), 34 20 (22.0), 33 0.34
Vascular disorders 15 (16.9), 19 13 (14.3), 16 0.64
Skin and subcutaneous tissue disorders 12 (13.5), 21 14 (15.4), 15 0.72
Cardiac disorders 11 (12.4), 15 13 (14.3), 15 0.70
Investigations 10 (11.2), 11 13 (14.3), 18 0.54
Psychiatric disorders 6 (6.7), 7 16 (17.6), 21 0.03
Eye disorders 12 (13.5), 17 9 (9.9), 10 0.45
Metabolism and nutritional disorders 5 (5.6), 5 11 (12.1), 16 0.13
Blood and lymphatic system disorders 7 (7.9), 7 2 (2.2), 2 0.10
Ear and labyrinth disorders 5 (5.6), 5 3 (3.3), 5 0.49
Injury, poisoning and procedural
complications
3 (3.4), 5 4 (4.4), 6 0.99
Renal and urinary disorders 3 (3.4), 3 4 (4.4), 5 0.99
Neoplasms benign, malignant and
unspecified
2 (2.2), 2 3 (3.3), 3 0.99
Hepatobiliary disorders 0 2 (2.2), 3 0.50
Reproductive system and breast
disorders
1 (1.1), 1 1 (1.1), 1 0.99
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Results Sildenafil, n= 89 Placebo, n= 91
Absolute difference
(95% CI); p-value
Methodology
Allocation to treatment groups: states participants were randomly assigned in a 1 : 1 ratio with the use of a permuted-block
design, with stratification according to clinical centre
Blinding: states double blind. For the primary outcome the tests were conducted by study personnel who were not directly
involved in study co-ordination. Placebo tablets described as identical. Acute exacerbations adjudicated by a central
committee in a blinded fashion. The 6MWTs were performed by personnel not directly involved in study co-ordination
Comparability of treatment groups: appear similar, authors make no reference to this, except in the table of baseline
characteristics it states arterial O2 saturation was significant (assume between groups)
Method of data analysis: on the primary outcome states participants who withdrew, died, or were unable to complete the
walk test for any reason were considered to have an improvement of < 20% (an ITT analysis). The primary test statistic was
based on a chi-squared test comparing the rates of improvement of ≥ 20% on testing of the 6MWT from baseline to
12 weeks in the two study groups. Analysis of continuous outcomes used a linear mixed model, with adjustment for
baseline measurements for age, sex, race, height, and DLCO. Survival estimates were constructed using the Kaplan–Meier
method, with statistical comparison based on the log-rank statistic. No adjustment to the value (0.05) considered to
indicate statistical significance was made for multiple comparisons
Sample size/power calculation: the study was powered to show an improvement of ≥ 20% on the 6MWT distance from
enrolment to 12 weeks. Based on available safety and efficacy data, a response rate of 30% was expected for sildenafil.
On the basis of an assumed placebo response rate of 10%, with an overall type 1 error rate of 0.05, 170 patients were
needed to provide a power of 90%
Attrition/dropout: numbers and reasons provided
General comments
Generalisability: the study inclusion criteria states that participants were in an advanced stage of IPF
Intercentre variability: not reported
Conflict of interests: Pfizer donated sildenafil and placebo tablets, states had no role in the study design, accrual or analyses
of data, or preparation of the manuscript. Conflicts of interests disclosed by authors
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Yes
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Yes
Yes
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
a States p< 0.05; assume this means between the two groups.
b Online supplement reports details of all adverse events, major category types only data extracted here.
89.8% in the sildenafil group and 85.7% in the placebo group reported that they missed no more than 1 day
of medication.
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Jastrezebski et al.61
Study details Participant details
Jastrzebski et al. 200861
Note that this publication is in Polish and limited details
have been translated and extracted
Country: Poland
Design: CCT
Number of centres: one
Funding: not translated
Number of participants: 30: inspiratory muscle training
n= 16, control n= 14
Sample attrition/dropout: 30 completed the study; four
eligible participants did not complete the study, two
withdrew despite no side effects, two were excluded due to
exacerbations
Sample crossovers: not translated
Inclusion criteria: IPF diagnosed by ATS/ERS criteria in
patients aged > 50 years, and by lung biopsy in patients
< 50 years. At least 2 years’ duration of disease. Patients
were in remission, i.e. no infection or disease exacerbation
requiring increased doses of corticosteroids in past month
Exclusion criteria: > 20mg prednisone per day, duration of
treatment > 2 years, use of home oxygen therapy
Intervention details Outcomes
Intervention
1. Inspiratory muscle training
2. Control
Description of interventions: not translated in full. Appears
that both groups received pulmonary rehabilitation,
described as general body conditioning exercises
Duration of treatment: 12 weeks (two 6-week cycles)
Primary outcomes: not specified as primary or secondary
outcomes. Dyspnoea (oxygen cost diagram, BDI). QoL
(SF-36), 6MWT (distance, dyspnoea in Borg’s scale), maximal
inspiratory pressure, lung function tests (IC, TLC, VC, FEV1,
DLCOSB, DLCO/VA)
Method of assessing outcome: assessed before, after
6 weeks and after 12 weeks
Length of follow-up: 12 weeks
Participant characteristics [mean (SD)]
Inspiratory muscle
training, n= 16 Control, n= 14
Sex (M/F), % 10/6 (63/37) 9/5 (64/36)
Mean (SD) age, years 56.5 (6.5) 56.2 (7.2)
Maximal inspiratory pressure, cmH2O 96.9 (33.5) 96.9 (25.0)
Inspiratory capacity, l 1.9 (0.7) 1.9 (0.7)
Inspiratory capacity, % predicted 67.9 (20.7) 66.1 (23.0)
TLC, l 3.76 (0.68) 3.75 (0.94)
TLC, % predicted 59.46 (9.61) 59.11 (12.87)
FVC, l 2.6 (0.6) 2.6 (0.6)
FVC, % predicted 67.3 (14.3) 69.2 (14.6)
FEV1, l 2.7 (0.6) 2.5 (0.6)
FEV1, % predicted 78.6 (14.3) 78.1 (14.5)
DLCOSB (single breath), ml/minute/mmHg 11.1 (4.9) 10.6 (4.9)
DLCOSB,% predicted 39.5 (15.9) 38.1 (18.9)
DLCO/VA, ml/minute/mmHg 3.4 (1.1) 3.3 (0.8)
DLCO/VA, % predicted 73.4 (22.1) 71.6 (12.8)
6MWT, m 487.4 (100.2) 485.6 (111.9)
Saturated O2, %, before 6MWT 95 (2) 95 (3)
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Participant characteristics [mean (SD)]
Inspiratory muscle
training, n= 16 Control, n= 14
Sat O2, %, after 6MWT 87 (4) 87 (5)
Dyspnoea in Borg Dyspnoea Index before 6MWT 1.7 (1.1) 1.9 (1.0)
Dyspnoea in Borg Dyspnoea Index after 6MWT 5.3 (2.2) 5.2 (2.3)
BDI-FI 2.0 (0.7) 2.2 (1.2)
BDI-MT 2.3 (0.9) 2.29 (0.6)
BDI-ME 2.2 (1.1) 2.07 (0.6)
BDI FI+MT+ME 6.1 (2.3) 6.07 (2.3)
OCD 69.7 (11.5) 68.9 (12.1)
SF-36 PF 54.4 (23.6) 54.3 (17.4)
SF-36 RP 42.8 (32.0) 44.6 (24.4)
SF-36 BP 68.9 (27.2) 66.8 (22.2)
SF-36 GH 37.8 (17.7) 37.4 (11.1)
SF-36 VT 54.4 (18.2) 52.5 (13.3)
SF-36 SF 58.9 (23.5) 58.0 (14.4)
SF-36 RE 68.8 (39.4) 69.0 (44.3)
SF-36 MH 64.2 (17.7) 65.1 (17.9)
SF-36 PCS 38.4 (8.2) 36.1 (9.1)
SF-36 MCS 46.6 (9.9) 46.5 (10.9)
Results [mean (SD)]
Inspiratory muscle
training, n= 16 Control, n= 14
Difference,
p-value
After 6 weeks:
MIP, cmH2O 108.4 (31.4) 98.8 (24.8)
6MWT, m 553.1 (85.3) 518.1 (101.7)
Dyspnoea in Borg Dyspnoea Index before 6MWT 1.5 (0.7) 1.6 (0.8)
Dyspnoea in Borg Dyspnoea Index after 6MWT 4.7 (2.4) 4.7 (2.2)
BDI-FI 2.5 (1.2) 2.4 (1.2)
BDI-MT 2.7 (1.2) 2.4 (0.6)
BDI-ME 2.6 (1.0) 2.1 (0.7)
MDI+MT+ME 7.4 (3.2) 5.7 (2.4)
OCD 79.1 (17.4) 75.0 (14.0)
After 12 weeks
MIP, cmH2O 115.4 (37.3) 98.9 (24.1)
6MWT, m 600.8 (93.7) 544.5 (121.5)
Dyspnoea in Borg Dyspnoea Index before 6MWT 1.2 (0.5) 1.6 (1.6)
Dyspnoea in Borg Dyspnoea Index after 6MWT 3.8 (2.3) 4.2 (2.1)
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Results [mean (SD)]
Inspiratory muscle
training, n= 16 Control, n= 14
Difference,
p-value
BDI-FI 2.7 (1.1) 2.1 (0.8)
BDI-MT 3.0 (0.9) 2.6 (0.8)
BDI-ME 2.9 (0.8) 2.5 (0.8)
MDI+MT+ME 7.9 (2.7) 6.4 (2.5)
OCD 75.6 (16.8) 71.8 (15.4)
After 6 weeks
SF-36 PF 69.7 (23.8) 63.2 (12.6)
SF-36 RP 57.8 (43.5) 53.6 (33.8)
SF-36 BP 71.7 (23.0) 64.0 (19.2)
SF-36 GH 48.1 (19.4) 40.2 (16.0)
SF-36 VIT 61.6 (14.6) 59.3 (17.3)
SF-36 SF 74.2 (33.1) 69.1 (20.8)
SF-36 RE 77.1 (35.9) 76.2 (27.5)
SF-36 MH 70.0 (17.2) 67.5 (20.3)
SF-36 PCS 42.9 (9.6) 37.8 (7.4)
SF-36 MCS 49.5 (9.4) 49.1 (12.9)
After 12 weeks
SF-36 PF 68.1 (22.3) 62.5 (14.5)
SF-36 RP 65.6 (31.5) 64.3 (30.6)
SF-36 BP 75.7 (20.7) 69.6 (17.8)
SF-36 GH 44.2 (22.4) 42.4 (13.6)
SF-36 VIT 60.0 (16.4) 57.1 (16.9)
SF-36 SF 75.8 (30.8) 68.7 (18.2)
SF-36 RE 70.8 (29.5) 78.6 (28.1)
SF-36 MH 68.7 (16.8) 66.3 (20.2)
SF-36 PCS 44.8 (6.0) 42.3 (5.8)
SF-36 MCS 47.8 (11.22) 47.8 (11.6)
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Methodology
Note that this publication is in Polish and limited details have been translated and extracted
l Allocation to treatment groups: unclear, appears not to be random from the abstract
l Blinding: unclear (assume none)
l Comparability of treatment groups: no statistically significant differences between groups
l Method of data analysis: not translated. However, no obvious between-group comparisons were made. Only changes
from baseline for each group were reported in the English abstract
l Sample size/power calculation: not translated
l Attrition/dropout: not translated
General comments
l Generalisability: not stated in abstract
l Outcome measures: appear valid
l Intercentre variability: not applicable
l Conflict of interests: does not appear to be reported
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? No
2. Was the allocation adequately concealed? No
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Unclear
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
Unclear
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Yes
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Unclear
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Unclear
BP, bodily pain; DLcOSB, diffusing capacity of the lung for carbon monoxide in single breath; DLCO/VA, diffusing capacity of
the lung for carbon monoxide/alveolar volume; FI, functional impairment; FI+MT+ME, summary score; GH, general health;
IC, inspiratory capacity; MCS, mental cumulative score; ME, magnitude of effort; MH, mental health; MT, magnitude of task;
OCD, oxygen cost diagram; PCS, physical cumulative score; PF, physical functioning; RE, role emotional; RP, role physical;
SF, social functioning; VIT, vitality.
p-value not stated for all baseline characteristics listed above.
p-values reported for change from baseline within groups only, not data extracted.
States that there were no significant changes in the results of lung function tests in either group after 12 weeks of
pulmonary rehabilitation (translated using Google Translate); no data were presented.
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Lindell et al.74
Study details Participant details
Lindell et al. 201074
Country: USA
Design: RCT
Number of centres: one
Funding: Fairbanks-Horix Foundation
Number of participants: 21 patients and 21 carers in total.
Intervention n= 10 pairs; control n= 11 pairs
Sample attrition/dropout: in the control group two patients
and three care partners did not complete the data collection.
Two pairs did not continue because the patient died or
received a lung transplant. The third care partner was lost to
follow-up
Sample crossovers: not reported
Inclusion criteria: aged > 21 years, be able to read and
understand English, to be diagnosed with IPF, to have a FVC
reflecting moderate IPF (FVC 55–70% predicted) or severe
IPF (< 55% predicted). Care partners were required to be
aged > 21 years, be able to read and understand English, to
live with or care for the patient with IPF
Diagnostic criteria for IPF not stated
Exclusion criteria: none stated
Intervention details Outcomes
Intervention
1. Program to Reduce IPF Symptoms and Improve
Management (PRISIM)
2. Usual care
Description of interventions: 6-weekly group sessions
attended by patients and care partners. The content for
the sessions was developed collaboratively by a pulmonary
clinical nurse specialist whose practice included patients
with IPF, a psychiatric clinical specialist with training as a
cognitive–behavioural therapist, and an advanced care
planning instructor. The sessions included:
What is IPF and how to live with it (causes,
pathophysiology, treatment)
Gaining control of your moods and feelings: you feel the
way you think (basic principles of cognitive–behavioural
techniques and cognitive distortions)
Gaining control of your moods and feelings: what can
you do about depression (concepts of stress and
depression and interrelationships with illness)
Putting your life in order: what do I do now? (Planning
for uncertainty, concerns related to terminal illness,
communicating with clinicians, coping and planning
one’s affairs)
Living with IPF (symptom management, energy
conservation, oxygen therapy, the importance
of exercise)
Wrap up and review (informal discussions and review)
Each session lasted approximately 2 hours
Primary outcomes: not specified as primary or secondary
outcomes. Dyspnoea (UCSDSBQ); anxiety (BAI); depression
(Beck Depression Inventory-II); stress (PSS); QoL (SF-36
version 2); pulmonary function tests
Secondary outcomes:
Method of assessing outcome: participants completed
questionnaires before and after completion of the
intervention. Self-report measures are reported to have
established reliability and validity. The battery of tests
required 1 hour to complete
PFTs were obtained at 3- to 6-month intervals or more
frequently, if indicated
Pairs randomised to the intervention group were interviewed
in their own homes at the end of the intervention. Each of
the pair was interviewed separately by one researcher. The
interviews were open-ended to collect data that reflected the
perspectives on their experience
Length of follow-up: unclear
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Intervention details Outcomes
Both groups received a copy of a book ‘Feeling Good:
The New Mood Therapy’. The control groups could read at
leisure, the treatment group were to use in group exercise
Usual care participants were seen by members of the
clinical care team (pulmonary clinical nurse specialist,
physicians) at interval of every 3–6 months. The nurse
specialist was also available by telephone to answer
questions, and conducted an optional monthly support
group. Psychological counselling was provided if indicated
but not offered on a routine basis
Concurrent treatment: not reported
Duration of treatment: 6 weeks
Participant characteristics
[mean (SD) unless stated] PRISIM, n= 10 Usual care control, n= 11 p-value
Age, years 65.2 (10.28) 67.09 (11.90)
Sex (M/F), % 7/3 (70/30) 9/2 (82/18) 0.6351
Caucasian, % 10 (100%) 10 (90%) 1.0
Diagnosis, %
Biopsy 3 (30)a 9 (81)a 0.03
HRCT 7 (70)a 2 (19)a
FVC, % predicted n= 10
> 55% 8 (80)a 6 (60)a 0.665
50–55% 1 (10)a 2 (20)a
< 50% 1 (10)a 2 (20)a
Prior or current depression, % 2 (20)a 2 (19)a 1.0
Comments: states the majority (58%) had scores indicating mild to severe anxiety. Four participants reported scores consistent
with mild depression (n= 2) or moderate depression (n= 2)
Also reports data for the care partners, not extracted here
Results PRISIM, n= 10 Usual care control, n= 9
Difference,
p-value
UCSDSBQ adjusted mean (SD) score 49.51 (22.64) 49.88 (22.64) 0.972
Comments: UCSDSBQ rate severity of shortness of breath on a 6-point scale (0= not at all, 5=maximal or unable to do)
during 21 activities of daily living associated with varying exertion. Scores were obtained by summing responses on a range
of items (range 0–120)
BAI adjusted mean (SD) 15.13 (6.92) 8.56 (6.95) 0.077
Comments: BAI uses a 21-item tool that uses a four-point scale (0= absent/not at all disturbing to 3= I could barely stand it).
Scores were obtained by summing the 21 items (range 0–63). A score of 0–7 indicated no anxiety; 8–15 mild anxiety;
16–25 moderate anxiety; >26 severe anxiety
BDI adjusted mean (SD) 9.71 (4.34) 9.44 (4.35) 0.894
Comments: the Beck Depression Inventory-II is a revised version of the 21-item instrument Beck Depression Inventory. A score
of 0–13 suggests minimal depression, 14–19 mild depression, 20–28 moderate depression, 29 to 63 severe depression
PSS adjusted mean (SD) 19.32 (3.64) 18.20 (3.65) 0.531
Comments: the PSS measures the degree to which participants find their lives unpredictable, uncontrollable and overloading.
Respondents are asked to indicate how they feel or thought in the last month using the option of 0 (never) to 4 (very often).
Total scores range from 0 to 40, with higher scores indicating more stress
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
222
Results PRISIM, n= 10 Usual care control, n= 9
Difference,
p-value
SF-36 physical adjusted mean (SD) 31.06 (4.61) 36.04 (4.63) 0.038
SF-36 mental adjusted mean (SD) 55.98 (2.71) 55.61 (2.71) 0.772
Comments: SF-36 scores range from 0 (maximum impairment) to 100 (no impairment). The eight domains can be grouped
into a physical score that includes physical functioning, role physical, bodily pain and general health, and a mental score
that includes vitality, social functioning, role emotional and mental health. The physical score and mental score were
normalised to responses from the general population (mean score= 50)
Methodology
Allocation to treatment groups: randomisation was undertaken after completion of the baseline questionnaires. Participants
were randomised using a permuted blocked design to ensure that equal numbers of patients with moderate IPF (FVC
55–70% predicted) and severe IPF (< 55% predicted) were assigned to each group
Blinding: not reported
Comparability of treatment groups: states no statistically significant differences between groups in regard to demographic
variables or FVC. Baseline scores for anxiety and physical HRQoL (SF-36) were stated to be different between groups
(data not reported)
Method of data analysis: analysed those remaining in the study (n= 37; PRISIM n= 20; control n= 17). ANCOVA used to
account for the differences identified in baseline for anxiety and physical HRQoL. Description of coding used for qualitative
data provided; however, not extracted here
Sample size/power calculation: states the study was designed to obtain pilot data for a future study and therefore the
sample size was not based on a power calculation
Attrition/dropout: numbers and reasons provided, unclear when dropouts occurred
General comments
Generalisability: severity of participants not stated; however, based on FVC % predicted at baseline at least 30% of
participants could be classed as severe IPF (FVC ≤ 50%)
Outcome measures: all self-report measures are validated measures. No validation in this participant group reported
Intercentre variability: not applicable
Conflict of interests: authors declare no conflict of interests
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors? No
4. Was the care provider blinded? No
5. Was the patient blinded? No
6. Were outcome assessors blinded to the treatment allocation? No
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
Yes
Yes
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Yes
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? No
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? No
PFT, pulmonary function test.
a Numbers and percentages calculated by reviewer based on the proportions presented for the total patient group.
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Nishiyama et al.73
Study details Participant details
Nishiyama et al. 200873
Country: Japan
Design: RCT
Number of centres: one
Funding: Japanese Ministry of Health, Labour and Welfare
Number of participants: 30 participants: pulmonary
rehabilitation n= 15; control n= 15
Sample attrition/dropout: two in the pulmonary
rehabilitation group refused to undergo treatment and did
not have initial evaluations undertaken
Sample crossovers: not reported
Inclusion criteria: age < 75 years, diagnosis of IPF, shortness
of breath on effort, stable condition with no infection or
exacerbations in the previous 3 months. The diagnosis of IPF
was made in accordance with the ATS/ERS statement 2002
using the major criteria: exclusion of other known causes of
ILD; abnormal pulmonary function with restriction and
impaired gas exchange; bibasilar reticular abnormalities on
HRCT; transbronchial lung biopsy or BAL showing no
features to support and alternative diagnosis. Minor criteria
included age > 50 years, insidious onset of otherwise
unexplained dyspnoea; duration of illness > 3 months;
bibasilar inspiratory crackles. All major and at least three
minor criteria had to be satisfied. For those with a surgical
lung biopsy showing UIP, only the major criteria were
required
Exclusion criteria: severe comorbid illnesses, collagen
vascular diseases, the need for long-term oxygen therapy
and previous treatment with corticosteroids or
immunosuppressives
Intervention details Outcomes
Intervention
1. PRP
2. Control
Description of intervention: the PRP was a general
programme, not specific to IPF. It involved a twice-weekly
outpatient programme of exercise training integrated with
peripheral muscle training. Week 1 was the baseline
measurements. From weeks 2–9, exercise training was
performed on a treadmill at 80% of the patient’s maximal
walking speed assessed at the baseline 6MWT. In those
who underwent baseline cycle ergometer test, exercise
intensity was also targeted at 80% of the initial maximum
workload. Supplemental oxygen was given to maintain
oxygen saturation above 90% if desaturation occurred.
Strength training for the limbs was conducted using elastic
bands; exercises included arm raising and knee extensions
for about 20 minutes. Some educational lectures were
also held (no details reported)
No detail of the control group reported
Concurrent treatment: no treatments with corticosteroids or
immunosuppressive agents during the study
Duration of treatment: 10-week programme
Primary outcomes: not specified as primary or secondary
Pulmonary function tests (FVC, FEV1, TLC, PaO2, PaCO2,);
DLCO; 6MWT; BDI; SGRQ
Method of assessing outcome: PFTs according to the
method described by the ATS; 6MWT according to ATS
statement. The test was undertaken twice at each
evaluation and the longer distance was used. BDI and SGRQ
have been validated in Japanese participants (reference
provided)
Length of follow-up: 10 weeks after the start of the
programme
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Participant characteristics
[all mean (SD) unless stated]
Pulmonary rehabilitation,
n= 13 Control, n= 15
Sex (M/F), n 12/1 9/6
Age (years) 68.1 (8.9) 64.5 (9.1)
BMI (kg/m2) 23.0 (3.8) 22.9 (2.8)
FVC, l 2.1 (0.4) 2.0 (0.8)
FVC % predicted 66.1 (13.2) 68.7 (19.5)
FEV1, l 1.6 (0.2) 1.7 (0.6)
FEV1, % predicted 73.3 (15.0) 78.3 (19.4)
FEV1/FVC (%) 78.8 (8.2) 85.2 (6.1)
TLC, l 3.2 (0.7) 3.1 (1.0)
TLC, % predicted 64.1 (13.1) 66.6 (16.1)
DLCO% 59.4 (16.7) 48.6 (16.7)
PaO2 mmHg 79.8 (11.5) 83.0 (12.3)
PaCO2 mmHg 33.6 (6.5)a 39.5 (6.0)
6MWT distance, m 385 (116) 476 (128)
BDI score 6.7 (1.4)b 8.4 (1.5)
SGRQ score
Symptoms 56.4 (22.3) 38.0 (25.8)
Activity 64.7 (17.1) 50.4 (26.2)
Impacts 39.7 (17.6) 29.9 (23.7)
Total 50.2 (16.3) 37.8 (22.7)
Results (absolute values
after programme)
Pulmonary rehabilitation,
n= 13 Control, n= 15
Difference in change from
baseline (95% CI); p-value
FVC, l 2.1 (0.4) 2.0 (0.8) 0.03 (–0.13 to 0.19); NS
Comments
FEV1, l 1.6 (0.2) 1.7 (0.6) 0.04 (–0.17 to 0.08); NS
Comments
TLC, l 3.3 (0.6) 3.3 (1.0) 0.03 (–0.18 to 0.24); NS
Comments
PaO2, mmHg 79.5 (9.7) 75.2 (5.4) 5.5 (–5.0 to 16.0); NS
Comments
PaCO2, mmHg 35.4 (5.6) 42.3 (2.9) –1.0 (–5.8 to 3.9); NS
Comments
6MWT distance, m 427 (84) 472 (130) 46.3 (8.3 to 84.4); < 0.01
Comments
BDI score 6.7 (1.3) 8.0 (2.2) 0.4 (–0.6 to 1.4); NS
Comments: BDI comprises three categories: functional impairment, magnitude of task and magnitude of effort. Each category
recognises five grades (0–4), and the total BDI score ranges from 0 to 12, with higher score denoting milder dyspnoea in daily living
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Results (absolute values
after programme)
Pulmonary rehabilitation,
n= 13 Control, n= 15
Difference in change from
baseline (95% CI); p-value
SGRQ score
Symptoms 53.4 (25.8) 40.6 (21.2) –5.7 (–18.7 to 7.2); NS
Activity 62.5 (16.9) 54.0 (22.6) –5.8 (–14.7 to 3.1); NS
Impacts 36.5 (17.5) 32.9 (23.5) –6.2 (–12.8 to 0.3); NS
Total 47.3 (17.4) 40.9 (20.7) –6.1 (–11.7 to 0.5); p< 0.05
Comments: SGRQ comprises three component scores (symptoms, activity, impacts), which sum to a total score.
Each component can range from 0 to 100, with a lower score denoting better HRQoL
Methodology
Allocation to treatment groups: participants were randomly assigned to groups using sealed envelopes that had been
prepared prior to the study
Blinding: not reported whether or not outcome assessors were blind to treatment allocation. Blinding of participants would
have been inappropriate
Comparability of treatment groups: The PaCO2 and BDI scores were lower in the PRP group. No other differences were observed
Method of data analysis: paired t-tests were used to test differences in the values for each participant before and after treatment.
Comparisons between groups were tested with ANCOVA to account for differences in baseline characteristics
Sample size/power calculation: not stated
Attrition/dropout: numbers and reasons provided
General comments
Generalisability: severity of participants not stated, baseline FVC suggests participants might have moderate IPF
Outcome measures: appear valid
Intercentre variability: not applicable
Conflict of interests: not stated
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Unclear
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors? No
4. Was the care provider blinded? No
5. Was the patient blinded? No
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
Yes
Yes
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? No
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? No
BAL, bronchoalveolar lavage; NS, not stated; PaCO2, partial pressure of carbon dioxide; PFT, pulmonary function test;
PRP, pulmonary rehabilitation programme.
a p< 0.05.
b p< 0.01.
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Noble et al.62 (Capacity study 004)
Study details Participant details
Noble et al. 201162
Capacity study 004
Country: Australia, Belgium, Canada, France, Germany,
Ireland, Italy, Mexico, Poland, Spain, Switzerland, UK, USA
Design: RCT
Number of centres: 110
Funding: InterMune
Number of participants: 435 randomised. (1) Pirfenidone
2403mg/day: n= 174; (2) pirfenidone 1197mg/day: n= 87;
(3) placebo: n= 174
Sample attrition/dropout: study discontinuations:
(1) Pirfenidone 2403mg/day: n= 13 [four withdrew consent,
eight adverse events, one other reasons (deportation)]
(2) Pirfenidone 1197mg/day: n= 5 (two withdrew consent,
three adverse events)
(3) Placebo: n=8 (five withdrew consent, three adverse events)
Discontinued treatment:
(1) Pirfenidone 2403mg/day: n=38 [21 adverse events, five
patient’s decision, three lung transplant, five deaths, four
other (unknown reaction to chemotherapy, deportation,
non-adherence, spontaneous discontinuation of study drug)]
(2) Pirfenidone 1197mg/day: n=17 (11 adverse events, two
patient’s decision, four deaths)
(3) Placebo: n=31 (14 adverse events, four patient’s decision,
four lung transplant, nine deaths)
Sample crossovers: not reported
Inclusion criteria: aged 40–80 years with a diagnosis of IPF in
the previous 48 months and no evidence of improvement in
measures of disease severity over the preceding year. Predicted
FVC of at least 50%, predicted DLCO of ≥35%, either
predicted FVC or DLCO ≤90% and 6MWT distance of at least
150m. Those younger than 50 years and those not meeting
the protocol criteria for definite IPF by HRCT were required to
have a lung biopsy sample showing UIP
Exclusion criteria: obstructive airway disease, connective tissue
disease, alternative explanation for ILD, and being on a waiting
list for a lung transplant
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Intervention details Outcomes
Intervention
1. Pirfenidone 2403mg/day (801mg× three daily doses)
2. Pirfenidone 1197mg/day (399mg× three daily doses)
3. Placebo
Dose details: 2403mg was derived from normalisation of
the dose used in previous Japanese trials (1800mg) to
account for different predicted body weights. The dose was
increased to the full dose over 2 weeks
Dose modifications: a protocol for dose modifications was
provided for expected adverse events
Concurrent treatment: concomitant treatments for IPF were
prohibited, with exceptions for short courses of
azathioprine, cyclophosphamide, corticosteroids, or
acetylcysteine for protocol defined acute exacerbations,
acute respiratory decompensation, or disease progression
Duration of treatment: 72 weeks
Primary outcomes: change in per cent predicted FVC
Secondary outcomes: categorical FVC (5-point scale), PFS,
worsening IPF, dyspnoea, 6MWT distance, worst peripheral
oxygen saturation (SpO2) during the 6MWT, per cent
predicted DLco, mortality
Method of assessing outcomes: PFS defined as time to
confirmed ≥ 10% decline in per cent predicted FVC, ≥ 15%
decline in per cent predicted DLCO, or death. Worsening IPF
defined as time to acute exacerbation, death, lung
transplantation, or admission to hospital for respiratory
problems. Dyspnoea (UCSDSBQ)
Length of follow-up: 72 weeks from the date the last
patient was enrolled
Participant characteristics
Pirfenidone
1197mg/day,
n= 87
Pirfenidone
2403mg/day,
n= 174 Placebo, n= 174
Mean age (SD), years 68.0 (7.6) 65.7 (8.2) 66.3 (7.5)
Male/female, % 65/22 (75/25%) 118/56 (68/32%) 128/46 (74/26%)
White, % 83 (95%) 168 (97%) 168 (97%)
Mean weight (SD), kg
Male 88.4 (13.5) 91.3 (15.9) 88.9 (16.1)
Female 72.8 (13.0) 77.0 (13.2) 77.0 (13.6)
Smoking status, n (%)
Never 27 (31) 56 (32) 51 (29)
Former 57 (66) 110 (63) 114 (66)
Current 3 (3) 8 (5) 9 (5)
HRCT diagnosis IPF, n (%) 83 (95) 159 (91) 164 (94)
Surgical lung biopsy, n (%) 32 (37) 86 (49) 85 (49)
Diagnosis IPF ≤ 1 year, n (%) 46 (53) 83 (48) 81 (47)
Per cent predicted FVC (SD) 76.4 (14.4) 74.5 (14.5) 76.2 (15.5)
Mean (SD) DLCO (per cent predicted) 47.2 (8.2) 46.4 (9.5) 46.1 (10.2)
A-a gradient (mmHg) 15.5 (10.4) 17.7 (10.6) 18.9 (14.7)
Mean (SD) 6MWT distance, m 417.5 (112.8) 411.1 (91.8) 410.0 (90.9)
Use of supplemental O2 (%) 15 (17) 29 (17) 25 (14)
Comments:
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Results [pirfenidone 1197mg/day results
were not compared (see below) and hence
data not extracted here]
Pirfenidone
2403mg/day,
n= 174 Placebo, n= 174
Difference (95% CI);
p-value
Mean change per cent predicted FVC at
72 weeks
–8.0% (SD 16.5) –12.4% (SD 18.5) 4.4% (0.7 to 9.1); 0.001
Comments: Figure 2a shows the mean change from baseline for weeks 12, 24, 26, 48, 60 and 72
Proportion with a decline in FVC ≥ 10% 35 (20%) 60 (35%) 14.4 (95% CI 7.4 to 21.3);
0.01a
Comments: subgroup analysis, unclear if stated a priori or powered
PFS 138/174 116/174 HR 0.64 (0.44 to 0.95);
0.023
Comments: data for PFS presented graphically
Mean change in 6MWT distance, m –60.4 –76.8 16.4 (–10.9 to 43.7);
0.171
Comments: presents a post hoc subgroup analysis of proportion of participant with a ≥ 50m decrement in the 6MWT.
Data not extracted
Mean change in DLCO,% predicted –7.9 –9.9 2.0 (–0.4 to 4.4); 0.145
Comments
Mean change in dyspnoea score (UCSDSBQ) 12.1 15.2 –3.1 (–8.5 to 2.3); 0.509
Comments: UCSDSBQ total score ranges from 0 to 120, with larger scores indicating greater shortness of breath
Mean change in worst SpO2 during 6MWT, % –1.5 –2.3 0.8 (–0.2 to 1.8); 0.087
Comments
Time to worsening in IPF HR 0.84 (0.50 to 1.42);
0.515
Comments
Adverse events
Any adverse event 171 (98%) 169 (97%)
Nausea 60 (35%) 32 (18%)
Fatigue 48 (28%) 36 (21%)
Diarrhoea 43 (25%) 30 (17%)
Rash 53 (31%) 18 (10%)
Dizziness 33 (19%) 17 (10%)
Dyspepsia 30 (17%) 16 (9%)
Gastro-oesophageal reflux 26 (15%) 14 (8%)
Vomiting 24 (14%) 7 (4%)
Insomnia 22 (13%) 12 (7%)
Arthralgia 20 (12%) 13 (8%)
Anorexia 19 (11%) 7 (4%)
Abdominal distension 15 (9%) 12 (7%)
Photosensitivity reaction 25 (14%) 2 (1%)
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Results [pirfenidone 1197mg/day results
were not compared (see below) and hence
data not extracted here]
Pirfenidone
2403mg/day,
n= 174 Placebo, n= 174
Difference (95% CI);
p-value
Urinary tract infection 19 (11%) 9 (5%)
Stevens–Johnson syndrome 0 0
Toxic epidermal necrosis 0 0
Comments: based on adverse events occurring in ≥ 10% of participants receiving pirfenidone and an incidence of ≥ 1.5
times placebo. Events were generally mild or moderate, without clinical consequences
Serious adverse events
IPF 13 (7.5%) 14 (8.0%)
Pneumonia 4 (2.3%) 6 (3.4%)
Respiratory failure 2 (1.1%) 2 (1.1%)
Bronchitis 2 (1.1%) 2 (1.1%)
Lobar pneumonia 2 (1.1%) 2 (1.1%)
Myocardial infarction 0 4 (2.3%)
Acute respiratory failure 2 (1.1%) 3 (1.7%)
Angina pectoris 2 (1.1%) 1 (0.6%)
Atrial fibrillation 1 (0.6%) 1 (0.6%)
Coronary artery disease 0 2 (1.1%)
Pneumothorax 3 (1.7%) 0
Pulmonary embolism 1 (0.6%) 1 (0.6%)
Syncope 3 (1.7%) 1 (0.6%)
Dyspnoea 0 3 (1.7%)
Non-cardiac chest pain 2 (1.1%) 2 (1.1%)
Prostate cancerb 0 2 (1.6%)
Aortic aneurysm 2 (1.1%) 0
Chest pain 3 (1.7%) 0
Hypoxia 1 (0.6%) 2 (1.1%)
Acute renal failure 1 (0.6%) 0
Bladder cancer 2 (1.1%) 0
Gastro-oesophageal reflux disease 2 (1.1%) 0
Comments: based on serious adverse events occurring in ≥ 2 participants in any treatment group
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Methodology
Allocation to treatment groups: participants were randomly assigned in a 2 : 1 : 2 ratio to pirfenidone 2403mg/day,
pirfenidone 1197mg/day or placebo. The randomisation code (permuted block design with five participants per block) was
computer generated, stratified by region, by an independent statistician. Study centres used an interactive voice response
system to assign study bottles to participants
Blinding: all personnel involved in the study were masked to treatment group assignment until after final database lock
Comparability of treatment groups: states that there were no pronounced baseline imbalances between groups; not tested
statistically
Method of data analysis: states analyses were ITT. A rank analysis of covariance model, stratified by region, with
standardised rank change in FVC as the outcome and standardised rank baseline per cent predicted FVC as a covariate,
evaluated against a final adjusted two-tailed p-value of 0.0498, was used. Data analyses compared pirfenidone 2403mg/day
with placebo. The group assigned to pirfenidone 1197mg/day were summarised descriptively (and hence not reported here)
Sample size/power calculation: not reported
Attrition/dropout: numbers and reasons provided
General comments
Generalisability: participants from predominantly European populations; majority were men. Severity of IPF stated as being
mild to moderate IPF in the discussion and, based on per cent predicted FVC at baseline, this appears correct. Diagnosis
was within 2 years
Outcome measures: mostly surrogate end points. Unclear if the definition of PFS is a standard one. No mortality data
presented
Intercentre variability: not discussed
Conflict of interests: states the sponsor participated in the study design, data collection, data analysis and writing the
report. After study completion, the sponsor analysed and maintained the data. Authors participated in design, conduct,
analysis and reporting; had full access to data; and no limits were placed on the content of the report
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Yes
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Yes
5. Was the patient blinded? Yes
6. Were outcome assessors blinded to the treatment allocation? Yes
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Yes
Yes
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
A-a gradient, alveolar–arterial oxygen gradient.
a p-value from an analysis of five categories: severe decline (≥ 20%), moderate decline (< 20% but ≥ 10%), mild decline
(< 10% but ≥ 0), mild improvement (> 0 but < 10%), moderate improvement (≥ 10%).
b Percentage based on number of males in each treatment group.
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Noble et al.62 (Capacity study 006)
Study details Participant details
Noble et al. 201162
Capacity study 006
Country: Australia, Belgium, Canada, France, Germany,
Ireland, Italy, Mexico, Poland, Spain, Switzerland, UK, USA
Design: RCT
Number of centres: 110
Funding: InterMune
Number of participants: 344 randomised: (1) pirfenidone:
n= 171; (2) placebo: n= 173
Sample attrition/dropout:
Study discontinuations:
(1) Pirfenidone: n= 13 [six withdrew consent, five adverse
events, one sponsor’s decision, one other reasons
(placement lung transplant list)]
(2) Placebo: n= 9 (five withdrew consent, four adverse
events)
Discontinued treatment:
(1) Pirfenidone: n= 34 [24 adverse events, three patient’s
decision, two lung transplant, one sponsor’s decision,
one death, three other (placement on lung transplant list,
prolonged QTc interval, unknown)]
(2) Placebo: n= 31 (14 adverse events, three patient’s
decision, three lung transplant, 11 deaths)
Sample crossovers: not reported
Inclusion criteria: aged 40–80 years with a diagnosis of IPF in
the previous 48 months and no evidence of improvement in
measures of disease severity over the preceding year.
Predicted FVC of ≥ 50%, predicted DLCO of ≥ 35%, either
predicted FVC or DLCO ≥ 90%, 6MWT distance of ≥ 150m.
Those younger than 50 years and those not meeting the
protocol criteria for definite IPF by HRCT were required to
have a lung biopsy sample showing UIP
Exclusion criteria: obstructive airway disease, connective
tissue disease, alternative explanation for ILD, and being on
a waiting list for a lung transplant
Intervention details Outcomes
Intervention
1. Pirfenidone 2403mg/day (801mg× 3 daily)
2. Placebo
Dose details: 2403mg was derived from normalisation of
the dose used in previous Japanese trials (1800mg) to
account for different predicted body weights
The dose was increased to the full dose over 2 weeks
Dose modifications: a protocol for dose modifications was
provided for expected adverse events
Concurrent treatment: concomitant treatments for IPF were
prohibited, with exceptions for short courses of
azathioprine, cyclophosphamide, corticosteroids, or
acetylcysteine for protocol defined acute exacerbations,
acute respiratory decompensation, or disease progression
Duration of treatment: 72 weeks
Primary outcomes: change in per cent predicted FVC
Secondary outcomes: categorical FVC (5-point scale), PFS,
worsening IPF, dyspnoea, 6MWT distance, worst SpO2
during the 6MWT, per cent predicted DLCO, fibrosis, mortality
Method of assessing outcomes: PFS defined as time to
confirmed ≥ 10% decline in per cent predicted FVC, ≥ 15%
decline in per cent predicted DLCO, or death. Worsening IPF
defined as time to acute exacerbation, death, lung
transplantation, or admission to hospital for respiratory
problems. Dyspnoea (UCSDSBQ). Fibrosis by the HRCT
Length of follow-up: 72 weeks from the date the last patient
was enrolled
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Participant characteristics
Pirfenidone,
n= 171 Placebo, n= 173
Mean age (SD), years 66.8 (7.9) 67.0 (7.8)
Male/female, % 123/48 (72/28) 124/49 (72/28)
White, % 169 (99%) 171 (99%)
Mean weight (SD), kg
Male 95.4 (17.4) 93.2 (15.1)
Female 76.6 (14.0) 77.5 (14.8)
Smoking status
Never 59 (35%) 64 (37%)
Former 112 (65%) 101 (58%)
Current 0 8 (5)
HRCT diagnosis IPF 149 (87%) 158 (91%)
Surgical lung biopsy 94 (55%) 94 (54%)
Diagnosis IPF ≤ 1 year 100 (58%) 107 (62%)
Per cent predicted FVC (SD) 74.9 (13.2) 73.1 (14.2)
Mean DLCO (per cent predicted) 47.8 (9.8) 47.4 (9.2)
A-a gradient (mmHg) 18.3 (11.1) 17.0 (10.4)
Mean 6MWT distance, m 378.0 (82.2) 399.1 (89.7)
Use of supplemental O2 48 (28%) 49 (28%)
Comments:
Results
Pirfenidone,
n= 171 Placebo, n= 173
Difference (95% CI);
p-value
Mean change per cent predicted FVC at
72 weeks
–9.0% (SD 19.6) –9.6% (SD 19.1) 0.6% (–3.5% to 4.7%);
0.501
Comments: Figure 2b shows the mean change from baseline for weeks 12, 24, 26, 48, 60 and 72
Proportion with a decline in FVC ≥ 10% 39 (23%) 46 (27%) 3.8 (95% CI –2.7 to 10.2);
0.440a
Comments: subgroup analysis, unclear if stated a priori or powered
DOI: 10.3310/hta19200 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 20
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
233
Results
Pirfenidone,
n= 171 Placebo, n= 173
Difference (95% CI);
p-value
PFS 126/171 123/171 HR 0.84 (0.58 to 1.22); 0.355
Comments: data for PFS time presented graphically
Mean change in 6MWT distance, m –45.1 –76.9 31.8 (3.2 to 60.4); 0.0009
Comments: presents a post hoc subgroup analysis of proportion of participant with a ≥ 50m decrement in the 6MWT.
Data not extracted
Mean change in DLCO (% predicted) –9.8 –9.2 –0.5 (–3.2 to 2.2); 0.996
Comments
Mean change in dyspnoea score (UCSDSBQ) 11.9 13.9 –2.0 (–7.6 to 3.6), 0.604
Comments: UCSDSBQ total score ranges from 0 to 120, with larger scores indicating greater shortness of breath
Mean change in worst SpO2 during 6MWT, % –1.9 –1.3 –0.5 (–1.7 to 0.7); 0.893
Comments
Time to worsening in IPF HR 0.73 (0.43 to 1.24); 0.248
Comments
Adverse events, n (%)
Any adverse event 169 (99) 170 (98)
Nausea 65 (38) 28 (16)
Fatigue 56 (33) 35 (20)
Diarrhoea 56 (33) 37 (21)
Rash 58 (34) 22 (13)
Dizziness 30 (18) 18 (10)
Dyspepsia 36 (21) 10 (6)
Gastro-oesophageal reflux 10 (6) 12 (7)
Vomiting 23 (14) 8 (5)
Insomnia 12 (7) 11 (6)
Arthralgia 16 (9) 11 (6)
Anorexia 18 (11) 6 (4)
Abdominal distension 18 (11) 8 (5)
Photosensitivity reaction 17 (10) 4 (2)
Urinary tract infection 16 (9) 20 (12)
Comments: based on adverse events occurring in ≥ 10% of participants receiving pirfenidone and an incidence of
≥ 1.5 times placebo. States these events were generally mild or moderate in severity and without clinical consequences
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Results
Pirfenidone,
n= 171 Placebo, n= 173
Difference (95% CI);
p-value
Serious adverse events, n (%)
IPF 13 (7.6) 17 (9.8)
Pneumonia 7 (4.1) 7 (4.0%)
Respiratory failure 4 (2.3) 6 (3.5)
Coronary artery disease 6 (3.5) 0
Acute respiratory failure 2 (1.2) 3 (1.7)
Bronchitis 0 5 (2.9)
Atrial fibrillation 2 (1.2) 1 (0.6)
Renal failure 2 (1.2) 2 (1.2)
Fall 2 (1.2) 1 (0.6)
Hypotension 2 (1.2) 1 (0.6)
Prostate cancerb 2 (1.6) 0
Colitis 2 (1.2) 0
Hip fracture 2 (1.2) 0
Hypertension 0 2 (1.2)
Hypoxia 0 2 (1.2)
Intervertebral disc protrusion 2 (1.6) 0
Liver function test abnormal 2 (1.2) 0
Nephrolithiasis 2 (1.2) 0
Sick sinus syndrome 2 (1.2) 0
Transitional cell carcinoma 0 2 (1.2)
Comments: based on serious adverse events occurring in ≥ 2 participants in any treatment group
Methodology
Allocation to treatment groups: participants were randomly assigned to oral pirfenidone or placebo in a 1 : 1 ratio. The
randomisation code (permuted block design with four participants per block) was computer generated, stratified by region,
by an independent statistician. Study centres used an interactive voice response system to assign study bottles to
participants
Blinding: all personnel involved in the study were masked to treatment group assignment until after final database lock
Comparability of treatment groups: states that there were no pronounced baseline imbalances between groups, not tested
statistically
Method of data analysis: states that analyses were intention to treat. A rank analysis of covariance model, stratified by
region, with standardised rank change in FVC as the outcome and standardised rank baseline per cent predicted FVC as a
covariate, evaluated against a final adjusted two-tailed p-value of 0.0498 was used
Sample size/power calculation: not reported
Attrition/dropout: numbers and reasons provided
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General comments
Generalisability: participants from predominantly European populations; majority were men. Severity of IPF stated as being
mild to moderate IPF in the discussion and based on per cent predicted FVC at baseline this appears correct. Diagnosis was
within 2 years
Outcome measures: mostly surrogate end points. Unclear if the definition of PFS is a standard one. No mortality data
presented
Intercentre variability: not discussed
Conflict of interests: states that the sponsor participated in the study design, data collection, data analysis and writing the
report. After study completion the sponsor analysed and maintained the data. Authors participated in design, conduct,
analysis, and reporting; had full access to data; and no limits were placed on the content of the report
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Yes
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Yes
5. Was the patient blinded? Yes
6. Were outcome assessors blinded to the treatment allocation? Yes
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes than they
reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Yes
Yes
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
A-a gradient, alveolar–arterial oxygen gradient.
a p-value from an analysis of five categories: severe decline (≥ 20%), moderate decline (< 20% but ≥ 10%), mild decline
(< 10% but ≥ 0%), mild improvement (> 0% but < 10%) and moderate improvement (≥ 10%).
b Percentage based on number of males in each treatment group.
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Raghu et al.70
Study details Participant details
Raghu et al. 199170
Country: USA
Design: RCT
Number of centres: two
Funding: grant from Virginia Mason Research Centre,
Seattle, WA, USA
Number of participants: 27: prednisone and placebo n= 13;
prednisolone and azathioprine n= 14
Sample attrition/dropout: four participants from each group
died before completion
Sample crossovers: three participants crossed over because
of clinical deterioration: two from placebo group (at 4 and
3 months) and one in prednisolone/azathioprine group
(at 6 months)
Inclusion criteria: a diagnosis of IPF was suspected in
patients with diffuse reticulonodular infiltrates on chest
roentgenogram, bibasilar crackles, finger clubbing, absence
of fever, decrease in FVC and DLCO and no evidence of
extrathoracic disease. Only those who were previously
untreated and available for routine follow-up were considered
candidates. The diagnosis was supported by lung biopsy in all
patients with the histological diagnosis based on typical
microscopic findings excluding infection, granuloma, vasculitis,
or malignancy, and examined by a pathologist who was
blinded to clinical details. A transbronchial lung biopsy was
accepted in patients with typical clinical, roentgenographic and
physiologic features of IPF who either refused to have open
lung biopsy or had documented family history of familial IPF.
All fulfilled criteria for progressive clinical disease (one or more
of (1) progressive dyspnoea from day of onset, (2) progressive
roentgenographic parenchymal abnormality, (3) ≥10%
decrease in FVC or TLC compared with previous values and
(4) ≥20% reduction in DLCO compared with previous values
Exclusion criteria: collagen vascular disease, hypersensitivity
pneumonitis, pneumoconiosis, drug-induced diffuse
pulmonary injury, or irradiation fibrosis
Intervention details Outcomes
Intervention
1. Prednisone and placebo
2. Prednisone and azathioprine
Dose details: prednisolone to both groups according to an
identical protocol: initially 1.5mg/kg/day (not to exceed
100mg/day) for 2 weeks, followed by a fortnightly decrease
of 20mg/day until a dose of 40mg/day was reached. Was
further decreased in 5- or 10-mg/day decrements every
2 weeks according to patient tolerance in order to maintain
a dose of ≤ 20mg/day
Azathioprine administered at 3mg/kg/day (not to exceed
200mg/day) to the nearest 25-mg dose increment for the
duration of the study
Similar numbers of placebo tablets were dispensed to those
in group 1
Dose modifications: participants crossed over to the other
treatment arm if any of the following occurred: (1) nausea,
vomiting, diarrhoea unresponsive to symptomatic
treatment, (2) white blood count < 3500/ml, (3) platelet
count < 80,000/ml, (4) respiratory failure requiring
mechanical ventilation, (5) coma, (6) abnormal liver function
tests, (7) rapid disease progression or (8) patient’s request
Primary outcomes: not stated as primary or secondary:
measurable change in lung function at 12 months; survival
Secondary outcomes: see above
Method of assessing outcome: improvement in lung
function defined as any one of (1) ≥ 10% improvement in
FVC, (2) ≥ 20% improvement in DLCO or (3) ≥ 10%
improvement in resting PA – aO2. Patients who ‘worsened’
had decrements of similar magnitude in one or more of
these tests. Lesser degrees of change were categorised as
unchanged. These were analysed separately to assess the
outcome as independent variables rather than overall
patient improvement
Length of follow-up: at least 12 months
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Intervention details Outcomes
Concurrent treatment: no use of cyclophosphamide,
d-penicillamine, non-steroid anti-inflammatory agents,
colchicine or any other agents that could potentially
influence the course of IPF
Duration of treatment: 12 months
Participant characteristics
[mean (SE) unless stated]
Prednisone and
placebo, n= 13
Prednisolone and
azathioprine, n= 14 p-value
Sex, M/F 7/6 5/9
Age, years 54 (3) 58 (2) 0.41
Duration of illness, months 23 (6) 26 (6) 0.87
FVC, % predicted 65 (4) 70 (4) 0.45
DLCO ml/minute/mmHg haemoglobin
corrected, % predicted
40 (4) 48 (5) 0.32
PA – aO2, mmHg, at rest 35 (4) 36 (3) 0.83
Severity of fibrosis on open lung biopsy 2.5 (0.3) 2.8 (0.4) 0.50
Comments
Results
Prednisone and
placebo, n= 9
Prednisolone and
azathioprine, n= 10 Difference, p-value
Change in FVC, % predicted 1.7 (7.4) 6.5 (5.3) 0.87
Comments
Change in DLCO, % predicted 0.9 (5.7) 7.3 (5.3) 0.70
Comments
Change in rest PA – aO2, mmHg –1.0 (2.0) –6.0 (4.0) 0.12
Comments
Prednisone and
placebo, n= 13
Prednisolone and
azathioprine, n= 14 p-value
FVC, % predicted (%)
Improved 3 (23.1) 5 (35.7) % improved, 0.68
Unchanged 3 (23.1) 3 (21.4)
Deteriorateda 7 (53.8) 6 (42.9)
DLCO,% predicted (%)
Improved 2 (15.4) 3 (21.4) % improved, 1.00
Unchanged 5 (38.5) 6 (42.9)
Deteriorateda 6 (46.2) 5 (35.7)
PA – aO2, mmHg (%)
Improved 3 (23.1) 7 (50) Improved, 0.24
Assume others not
significant as not stated
Unchanged 3 (23.1) 1 (7.1)
Deteriorateda 7 (53.8) 6 (42.9)
Comments
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HR (95% CI);
p-valueb [p-valuec]
Survival, all patients NA NA 0.48 (0.17 to 1.38);
0.16 [0.15]
Survival, all patients adjusted for age NA NA 0.26 (0.08 to 0.88);
0.02 [0.05]
Deaths during observation period 4 (3 respiratory failure,
1 myocardial infarction)
4 (3 respiratory failure,
1 myocardial infarction)
Alive at 12 months 9 10
Alive at last follow-up 3 8
Adverse events
Prednisone and
placebo, n= 13
Prednisolone and
azathioprine, n= 14 p-value
Any 25 28 Not reported
Subjective
Gastrointestinal 6 3 Not reported
Neuropsychiatric 4 1
Objective
Elevated liver enzymes 0 1 Not reported
Vertebral fractures 0 3
Acne 1 0
Cushingoid features 4 5
Hypertension 1 2
Diabetes treatment (oral) 3 2
Diabetes treatment (insulin) 0 2
Congestive heart failure 2 0
Myocardial infarction 1 1
Bacterial pneumonia 1 1
Herpes zoster 0 2
Urosepsis 0 1
Cataracts 1 1
Myopathy 1 2
Peptic ulcer disease 1 1
Pancytopenia 0 0
Comments
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Methodology
Allocation to treatment groups: participants were randomised by block randomisation (blocks of 10) by a research
pharmacist. No other details reported
Blinding: states double blinded; all medications were dispensed by the research pharmacist
Comparability of treatment groups: the two groups were comparable in age, clinical duration of disease, pulmonary
function testing and amount of fibrosis on open lung biopsy
Method of data analysis: ordinal and interval variables compared with Wilcoxon rank-sum test, proportions compared by
Fisher’s exact test. Those who died before 1 year were included in the analysis of change in lung function at 1 year by
assigning the worst possible change. States all analyses were done on an ITT basis. Kaplan–Meier survival plots and Cox
proportional hazards regression model were used to analyse survival time data
Sample size/power calculation: not reported
Attrition/dropout: states no loss to follow-up. Crossovers and deaths reported
General comments
Generalisability: patients were newly diagnosed, had no previous treatments, FVCs in the region of mild to moderate
disease
Outcome measures: appear valid
Intercentre variability: not reported
Conflict of interests: not reported
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Yes
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes than they
reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Yes
Yes
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Unclear
F, female; M, male; NA, not applicable; PA – aO2, alveolar – arterial oxygen partial pressure; SE, standard error.
a Includes those who died in the first year of treatment.
b p-value based on large sample approximation.
c p-value based on randomisation test.
Also presents data for survival based on subgroups according to three age categories (< 50 years, 50–59 years, > 60 years) –
not data extracted as not a predefined subgroup analysis.
Survival calculated based on observation period; duration not stated but assumed 9 years (reported in abstract and in the
figure and no discussion of any estimation of data).
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Richeldi et al.71
Study details Participant details
Richeldi et al. 201171
Country: 25 countries including Italy, Mexico,
Germany, USA, Republic of Korea, UK and France
Design: RCT (dose finding phase II study)
Number of centres: 92
Funding: supported by Boehringer Ingelheim
(sponsor)
Number of participants: 432 randomised, 428 treated: BIBF 1120
50mg/day n= 86; BIBF 1120 100mg/day n= 86; BIBF 1120
200mg/day n= 86; BIBF 1120 300mg/day n= 85; placebo n= 85
Sample attrition/dropout: four were randomised but did not
participate
112 discontinued study medication: BIBF 1120 50mg/day n= 24
(27.9%); BIBF 1120 100mg/day n= 18 (20.9%); BIBF 1120
200mg/day n= 14 (16.3%); BIBF 1120 300mg/day n= 32 (37.6%);
placebo n= 24 (28.2%). 96 of the total 112 discontinuations
(85.7%) were due to adverse events
Of the 32 in the BIBF 1120 300mg/day group, 11 had previously
had their dose reduced
The dose was reduced by one dose level in 5, 7, 11, 20 and
7 participants in the five group, respectively
Sample crossovers: none
Inclusion criteria: patients ≥ 40 years of age who had IPF that was
consistent with the ATS/ERS 2000 criteria and who had received
the diagnosis < 5 years before screening. Eligible patients had
undergone HRCT < 1 year before randomisation and had a FVC that
was ≥ 50% of their predicted value, a DLCO that was 30–79% of
predicted value, and a PaO2 when breathing ambient air that was
≥ 55mmHg at altitudes up to 1500m, or ≥ 50mmHg at altitudes
above 1500m. Diagnosis was confirmed by independent review of
HRCT scans by an expert chest radiologist and assessment of
surgical lung-biopsy specimens (if available) by an expert lung
pathologist
Exclusion criteria: medical conditions or concomitant medications that
might interfere with the performance of the study, other diseases
that might interfere with testing procedures (e.g. myocardial
infarction or unstable angina), continues (>15 hours per day) oxygen
supplementation at randomisation, known predisposition to bleeding
or thrombosis, concomitant anticoagulation medication, elevated
liver enzymes, likelihood of lung transplantation during the study
(investigator’s opinion), or life expectancy <2.5 years for a disease
other than IPF (investigator’s opinion)
Intervention details Outcomes
Intervention
1. BIBF 1120 50mg/day
2. BIBF 1120 50mg twice per day (100mg/day)
3. BIBF 1120 100mg twice per day (200mg/day)
4. BIBF 1120 150mg twice per day (300mg/day)
5. Placebo
Dose details: a group-wise dose escalation was
used initially, beginning with the lowest dose or
placebo, with stepwise increases in dose for
serial cohorts (states concealment of allocation
maintained). Each step to the next dose cohort was
reviewed by a data monitoring committee before
proceeding
Primary outcomes: annual rate of decline in FVC
Secondary outcomes: changes from baseline in % predicted FVC;
DLCO; change in oxygen saturation (measured by SpO2); TLC;
distance achieved on 6MWT, total score on SGRQ; decrease in FVC
of > 10% or > 200ml; SpO2 decrease of more than four percentage
points; incidence of acute exacerbations, survival (at 52 weeks);
death from a respiratory cause; adverse events
Method of assessing outcome: spirometry results were centrally
reviewed by an independent third party to meet ATS/ERS criteria
Overall survival referred to all randomised participants and
on-treatment survival based on the number of fatal adverse
events that began during the treatment or up to 14 days after
treatment ended
Death from a respiratory cause included all randomised participants.
All deaths were adjudicated for cause of death by an independent
committee unaware of treatment assignments
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Intervention details Outcomes
Dose modifications: for individual participants, the
investigator was permitted to interrupt treatment
and restart with the next lower dose during the trial
in the event of unacceptable side effects
Concurrent treatment: ≤ 15mg of predisone per
day or equivalent was permitted if the treatment
dose had been stable for at least 8 weeks before
screening
Duration of treatment: 52 weeks
Safety data collected up to 14 days after administration of the last
dose included in the analysis. Serious adverse events defined as
fatal, life-threatening, disabling, incapacitating, requiring
hospitalisation, or medically significant
Length of follow-up: 54 weeks
Participant characteristics
[mean (SD) unless stated]
50mg/day,
n= 86
100mg/day,
n= 86
200mg/day,
n= 86
300mg/day,
n= 85 Placebo, n= 85
Sex (M/F), n (%) 65/21
(75.6/24.4)
62/24
(72.1/27.9)
65/21
(75.6/24.4)
65/20
(76.5/23.5)
63/22
(74.1/25.9)
Age, years 65.3 (9.4) 64.9 (8.5) 65.1 (8.6) 65.4 (7.8) 64.8 (8.6)
Race, n (%) (self-reported)
White 68 (79.1) 72 (83.7) 72 (83.7) 61 (71.8) 65 (76.5)
Asian 18 (20.9) 14 (16.3) 14 (16.3) 24 (28.2) 20 (23.5)
Weight, kg 78.8 (13.4) 79.0 (16.2) 76.0 (14.5) 74.9 (14.6) 77.3 (13.3)
Time since diagnosis, years 1.4 (1.3) 1.1 (1.2) 1.2 (1.2) 1.0 (1.2) 1.4 (1.5)
Surgical lung biopsy, n (%) 25 (29.1) 27 (31.4) 20 (23.3) 29 (34.1) 19 (22.4)
IPF diagnosis, n (%)
Definite 27 (31.4) 26 (30.2) 31 (36.0) 33 (38.8) 24 (28.2)
Probable 49 (57.0) 53 (61.6) 54 (62.8) 52 (61.2) 57 (67.1)
Possiblea 9 (10.5) 7 (8.1) 1 (1.2) 0 4 (4.7)
Definitely nota 1 (1.2) 0 0 0 0
FVC % predicted
Mean (SD) 80.4 (17.8) 79.8 (15.8) 85.5 (19.2) 79.1 (18.5) 81.7 (17.6)
Median 79.8 80.4 83.0 78.1 77.6
FVC, l
Mean (SD) 2.8 (0.8) 2.7 (0.7) 2.9 (0.8) 2.7 (0.8) 2.8 (0.8)
Median 2.8 2.7 2.8 2.7 2.7
SpO2, %
Mean (SD) 95.0 (2.7) 95.4 (2.2) 95.3 (2.0) 95.6 (1.7) 95.3 (2.2)
Median 96.0 96.0 96.0 96.0 96.0
DLCO, mmol/minute/kPa
Mean (SD) 3.8 (1.3) 3.9 (1.4) 3.8 (1.2) 3.7 (1.0) 3.8 (1.1)
Median 3.5 3.6 3.7 3.5 3.7
PaO2, mmHg
Mean (SD) 76.5 (10.7) 80.4 (20.5) 80.6 (14.4) 79.6 (13.3) 76.5 (14.1)
Median 75.8 78.4 80.0 78.3 75.0
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Participant characteristics
[mean (SD) unless stated]
50mg/day,
n= 86
100mg/day,
n= 86
200mg/day,
n= 86
300mg/day,
n= 85 Placebo, n= 85
Concomitant therapy, n (%)b
Any glucocorticoid 47 (54.7) 42 (48.8) 45 (52.3) 33 (38.8) 43 (50.6)
Prednisone 19 (22.1) 14 (16.3) 17 (19.8) 18 (21.2) 21 (24.7)
SGRQ, total score 43.7 (17.5) 42.5 (17.0) 43.7 (16.6) 40.1 (18.3) 41.2 (17.9)
Symptoms 44.4 (21.5) 42.3 (21.2) 45.4 (20.0) 43.1 (25.2) 42.2 (21.6)
Activity 55.8 (19.0) 56.1 (18.4) 58.7 (18.4) 53.9 (21.6) 54.2 (22.2)
Impacts 36.2 (19.1) 34.3 (18.7) 34.1 (18.7) 30.8 (19.0) 33.1 (19.7)
Comments
Results [mean (SE)
(95% CI) unless stated]
50mg/day,
n= 86
100mg/day,
n= 86
200mg/day,
n= 86
300mg/day,
n= 85 Placebo, n= 85
Annual rate of decline in FVC, l –0.17 (0.04)
(–0.25 to –0.10)
–0.21 (0.04)
(–0.28 to –0.14)
–0.16 (0.04)
(–0.23 to –0.09)
0.06 (0.04)
(–0.14 to 0.02)c
0.19 (0.04)
(–0.26 to –0.12)
Absolute change in FVC, l –0.18 (0.04)
(–0.25 to –0.11)
–0.19 (0.04)
(–0.26 to –0.12)
–0.13 (0.04)d
(–0.20 to –0.06)
–0.06 (0.04)
(–0.13 to 0.01)e
–0.23 (0.04)
(–0.30 to –0.16)
Comments: includes those who took the therapy at least once during the treatment period
Absolute change in FVC, %
predicted
–4.58 (1.03)
(–6.60 to –2.55)
–4.90 (0.98)
(–6.84 to –2.97)
–3.15 (1.00)
(–5.12 to –1.17)f
–1.04 (0.99)
(–2.98 to 0.91)g
–6.00 (1.02)
(–8.01 to –4.00)
Participants with a reduction
in mean FVC of > 10% or
200ml, n (%)
35 (41.2) 41 (47.7) 30 (35.3) 20 (23.8)h 37 (44.0)
Comments: unclear if this was an a priori, powered, subgroup analysis
Absolute change in SpO2, % –0.86 (0.38)
(–1.60 to –0.11)
–0.97 (0.36)
(–1.67 to –0.27)
0.06 (0.36)
(–0.65 to 0.78)i
–0.18 (0.36)
(–0.89 to 0.53)j
–1.29 (0.37)
(–2.03 to –0.56)
Proportion of patients with
≥ 4% decrease in SpO2
Not reported Not reported Not reported 3.6%k 11.0%
Absolute change in TLC, l –0.22 (0.08)
(–0.38 to –0.06)
–0.10 (0.07)
(–0.24 to 0.04)
–0.08 (0.07)
(–0.22 to 0.06)
0.12 (0.08)
(–0.03 to 0.27)g
–0.24 (0.08)
(–0.39 to –0.09)
Change in DLCO NR NR NR NR NR
Change in 6MWT NR NR NR NR NR
Comments: data not reported (NR) in the text or supplement report. States no significant differences between any of the
groups and placebo
Numbers reported in table,
possible reporting error
n= 87 n= 86 n= 86 n= 85 n= 87
SGRQ total score (change
from baseline)
4.67 (1.78)
(1.17 to 8.16)
2.18 (1.65)
(–1.07 to 5.43)
1.48 (1.66)
(–1.78 to 4.75)
–0.66 (1.71)
(–4.02 to 2.71)l
5.46 (1.73)
(2.06 to 8.86)
SGRQ symptoms domain
(change from baseline)
3.39 (2.51)
(–1.55 to 8.34)
2.11 (2.34)
(–2.48 to 6.71)
2.33 (2.35)
(–2.28 to 6.94)
–3.14 (2.40)
(–7.86 to 1.58)m
6.45 (2.45)
(1.65 to 11.26)
SGRQ activity domain
(change from baseline)
7.39 (1.96)
(3.53 to 11.25)
3.54 (1.82)
(–0.05 to 7.13)
3.00 (1.83)
(–0.60 to 6.60)
0.32 (1.89)
(–3.39 to 4.03)h
7.48 (1.91)
(3.73 to 11.24)
SGRQ impacts domain
(change from baseline)
3.71 (2.04)
(–0.30 to 7.72)
1.73 (1.90)
(–2.00 to 5.46)
0.79 (1.91)
(–2.96 to 4.54)
–0.14 (1.97)
(–4.00 to 3.73)
4.21 (1.99)
(0.31 to 8.12)
SGRQ, % improving
≥ 4 points
23.5% 27% 32.6%l 29.1%k 16.1%
Comments: score range 0 to 100, with lower scores indicating better QoL; a minimally clinical important difference in total
score= 4 points (later estimated as 5–8 points)
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Results [mean (SE)
(95% CI) unless stated]
50mg/day,
n= 86
100mg/day,
n= 86
200mg/day,
n= 86
300mg/day,
n= 85 Placebo, n= 85
Incidence of acute
exacerbations, n per 100
patient-years
13 12.5 7.5 2.4n 15.7
Incidence of acute
exacerbations, RR (95% CI),
compared with placebo
0.83
(0.36 to 1.93)
0.80
(0.34 to 1.84)
0.48
(0.18 to 1.27)
0.16
(0.03 to 0.70)
NA
Deaths from respiratory
causes
9 3 2o 2p 8
Deaths from any cause 11 3 4 7 9
Comments: no statistically significant differences observed between any group and placebo
Adverse events (any), n (%) 78 (90.6) 78 (90.7) 82 (95.3) 80 (94.1) 77 (90.6)
Adverse events occurring in > 10% in any study arm, n (%)
Diarrhoea 9 (10.5) 17 (19.8) 32 (37.2) 47 (55.3) 13 (15.3)
Cough 11 (12.8) 17 (19.8) 20 (23.3) 8 (9.4) 17 (20.0)
Nausea 9 (10.5) 8 (9.3) 17 (19.8) 20 (23.5) 8 (9.4)
Bronchitis 11 (12.8) 16 (18.6) 7 (8.1) 9 (10.6) 11 (12.9)
Dyspnoea 7 (8.1) 14 (16.3) 13 (15.1) 6 (7.1) 11 (12.9)
Progression of IPF 11 (12.8) 7 (8.1) 9 (10.5) 4 (4.7) 11 (12.9)
Vomiting 1 (1.2) 6 (7.0) 11 (12.8) 11 (12.9) 4 (4.7)
Upper abdominal pain 6 (7.0) 10 (11.6) 2 (2.3) 10 (11.8) 3 (3.5)
Nasopharyngitis 11 (12.8) 8 (9.3) 15 (17.4) 6 (7.1) 11 (12.9)
URTI 7 (8.1) 10 (11.6) 13 (15.1) 7 (8.2) 13 (15.3)
Headache 7 (8.1) 9 (10.5) 8 (9.3) 11 (12.9) 5 (5.9)
Fatigue 4 (4.7) 5 (5.8) 8 (9.3) 9 (10.6) 7 (8.2)
Decreased appetite 3 (3.5) 4 (4.7) 4 (4.7) 13 (15.3) 0
Severe adverse events 21 (24.4) 17 (19.8) 19 (22.1) 19 (22.4) 20 (23.5)
Serious adverse events 26 (30.2) 23 (26.7) 18 (20.9) 23 (27.1) 26 (30.6)
Fatal adverse events 10 (11.6) 4 (4.7) 5 (5.8) 1 (1.2) 12 (14.1)
Adverse events requiring
hospitalisation
22 (25.6) 18 (20.9) 15 (17.4) 23 (27.1) 22 (25.9)
Drug-related adverse event 24 (27.9) 30 (34.9) 41 (47.7) 55 (64.7) 25 (29.4)
Adverse events leading to
discontinuation
20 (23.3) 14 (16.3) 12 (14.0) 26 (30.6) 22 (25.9)
Respiratory, thoracic and
mediastinal disorders
8 (9.3) 2 (2.3) 3 (3.5) 4 (4.7) 10 (11.8)
Gastrointestinal disorders
(see also below)
2 (2.3) 2 (2.3) 2 (2.3) 14 (16.5) 2 (2.4)
Infections and infestations 2 (2.3) 3 (3.5) 2 (2.3) 0 6 (7.1)
Cardiac disorders 2 (2.3) 2 (2.3) 1 (1.2) 0 6 (7.1)
Gastrointestinal adverse events, n (%)
Any 33 (38.4) 31 (36.0) 49 (57.0) 63 (74.1) 27 (31.8)
Severe diarrhoea 1 (1.2) 1 (1.2) 2 (2.3) 4 (4.7) 0
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Results [mean (SE)
(95% CI) unless stated]
50mg/day,
n= 86
100mg/day,
n= 86
200mg/day,
n= 86
300mg/day,
n= 85 Placebo, n= 85
Serious diarrhoea 0 0 0 3 (3.5) 0
Serious gastrointestinal Not reported Not reported Not reported 4.7% 0
Severe gastrointestinal Not reported Not reported Not reported 5.9% 0
Related to treatment
(any gastrointestinal)
16 (18.6) 19 (22.1) 29 (33.7) 48 (56.5) 11 (12.9)
Related to treatment
(diarrhoea)
5 (5.8) 8 (9.3) 36 (42.4) 5 (5.9)
Reduced dose due to
gastrointestinal adverse
event
2 (2.3) 5 (5.8) 4 (4.7) 9 (10.6) 0
Discontinuation due to any
gastrointestinal adverse
event
2 (2.3) 2 (2.3) 2 (2.3) 14 (16.5) 2 (2.4)
Discontinuation due to
diarrhoea
1 (1.2) 1 (1.2) 0 10 (11.8) 0
Mean number days with
diarrhoea
70.2 39.3 138.6 85.4 6.5
Discontinuation due to
nausea
Not reported Not reported Not reported 4.7% 0%
Discontinuation due to
vomiting
Not reported Not reported Not reported 2.4% 1.2%
Comments: also reports rates of mild and moderate diarrhoea, not extracted here
Also reports elevations in liver enzyme levels but not extracted here
Methodology
Allocation to treatment groups: an interactive voice-response system was used to perform randomisation. Patients,
investigators and the team from Boehringer Ingelheim were unaware of the treatment assignments throughout the study.
When the next dose was introduced to a cohort, additional patients underwent randomisation to the previous dose group
to maintain blinding between the groups
Blinding: see above regarding allocation concealment
Comparability of treatment groups: no significant differences between groups were observed
Method of data analysis: states that all efficacy analyses were based on an ITT basis. Participants were assessed within the
dose group to which they were randomly assigned at the start of the study. For secondary end points the LOCF approach
was used when data were not available for the entire 52-week period of assessment. A random coefficient mixed-model
repeated measure was used to calculate the annual decline in FVC, with all data taken into consideration. Analysis of
covariance was performed for other continuous end points, the log-rank test and Cox regression model for time to event
end points, ordinal logistic regression for ordered categorical end points, Cochran–Mantel–Haenszel test for responder end
points and negative binomial model for incidence rates. Safety by descriptive statistics only
Sample size/power calculation: sample size was calculated to achieve 80% power to detect a difference of 0.1 in the
annual decrease in FVC
Attrition/dropout: reports numbers, reasons only reported for the total cohort
General comments
Generalisability: not stated; participants within 5 years of diagnosis and baseline FVC are suggested likely to be in mild IPF.
States that population reflected the range of disease seen in clinical practice
Outcome measures: appear valid
Intercentre variability: not reported
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Results [mean (SE)
(95% CI) unless stated]
50mg/day,
n= 86
100mg/day,
n= 86
200mg/day,
n= 86
300mg/day,
n= 85 Placebo, n= 85
Conflict of interests: states that all authors designed the study and had access to the data, which were analysed by
statisticians at Boehringer Ingelheim and checked by an independent consultant. The manuscript was written by medical
writers, funded by the sponsor, and was reviewed, amended and edited by all authors
Quality assessment/risk of bias Yes/no/not reported/unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Yes
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Yes
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
Yes
Unclear
8. Is there any evidence to suggest that the authors measured more outcomes
than they reported?
Yes
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? Yes
Yes
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
F, female; M, male; SE, standard error; NA, not applicable.
a 21 patients with possible IPF underwent randomisation early in the study period; none was included in the later stages of
the trial. One patient who did not have IPF was erroneously enrolled in the study.
b Administered at least once during the treatment period.
c p= 0.06 between 300mg/day group and placebo using the closed-testing procedure for multiplicity, p= 0.01 with
hierarchical testing. States that this difference corresponds to a reduction of 68.4% in the annual rate of decline
in FVC.
Also presents results of a sensitivity analysis, undertaken to account for discontinuations, which included all FVC
assessments (baseline and all follow-up visits, including visits after discontinuation). Results are reported to be similar
despite the 300mg/day group having a higher number of discontinuations. Data not extracted here.
Data also analysed according to the final dose (rather than randomised dose) to account for dose reductions during the
trial. Results were also reported to be similar despite more participants in the 300 mg/day group undergoing dose
reductions. Data not extracted here.
d p< 0.01 vs. placebo.
e p= 0.001 vs. placebo.
f p< 0.05 vs. placebo.
g p< 0.001 vs. placebo.
h p= 0.004 vs. placebo.
i p= 0.005 vs. placebo.
j p= 0.02 vs. placebo.
k p= 0.03 vs. placebo.
l p= 0.007 vs. placebo.
m p= 0.003 vs. placebo.
n p= 0.02.
o p= 0.04.
p p= 0.06.
Italics indicate estimated by reviewer from a figure.
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Taniguchi et al.65
Study details Participant details
Taniguchi et al. 201065
Country: Japan
Design: RCT
Number of centres: 73
Funding: supported by grants from the Japanese Ministry of
Health, Labour and Welfare, and the Japanese Respiratory
Society’s committee for diffuse lung disease. Drug and
placebo were provided by Shionogi & Co. (manufacturer in
Japan)
Number of participants: 275 randomised: high-dose group,
110; low-dose group, 56; placebo group, 109
267 in full analysis set: high-dose group, 108; low-dose
group, 55; placebo group, 104
Sample attrition/dropout: eight participants were deemed
‘ineligible’ after randomisation because no post-baseline
data were available. Of the ‘full analysis set’: high-dose
group: 40 (37%) withdrew (15 adverse events, eight
disease progression, four acute exacerbation, 13 ‘other’);
low-dose group: 15 (27%) withdrew (nine adverse events,
two acute exacerbation, four ‘other’); placebo group 31
(30%) withdrew (15 disease progression, seven adverse
events, four acute exacerbation, five ‘other’)
Sample crossovers: not reported
Inclusion criteria: adults 20–75 years with IPF diagnosed using
ATS/ERS 2002 consensus statement and the fourth version of
the clinical diagnostic criteria guidelines for IIP in Japan. HRCT
scans were independently evaluated by two independent
radiologists, with disagreement being resolved with a third.
Probably UIP confirmed by surgical lung biopsy. Arterial oxygen
saturation criteria (by pulse oximetry, SpO2) of (1) oxygen
desaturation of ≥5% difference between resting SpO2 and the
lowest SpO2 during a 6MET; and (2) the lowest SpO2 during
the 6MET of ≥85% while breathing air
Exclusion criteria: a decrease in symptoms during the
preceding 6 months; use of immune-suppressants and/or oral
corticosteroids at a dose of >10mg/day-1 during the
preceding 3 months; clinical features of IIP other than IPF;
evidence of known coexisting pulmonary hypertension,
asthma, tuberculosis, bronchiectasis, aspergillosis or severe
respiratory infection
Intervention details Outcomes
Intervention
1. Pirfenidone high dose (1800mg/day)
2. Pirfenidone low dose (1200mg/day)
3. Placebo
Dose details: oral doses were increased in a stepwise
manner from one tablet per dose three times daily for the
first 2 weeks, then two tablets per dose for 2 weeks, then
three tablets three times a day for the remaining 48 weeks.
Therefore: high-dose group 600mg/day weeks 1–2,
1200mg/day weeks 3–4, 1800mg/day until week 52;
low-dose group 600mg/day weeks 1–2, 600mg/day
weeks 3–4, 1200mg/day until week 52
Dose modifications: not reported
Concurrent treatment: concomitant use of corticosteroid
≤ 10mg/day (prednisolone equivalent) was permitted.
Concomitant use of immunosuppressants and other
experimental agents under investigation not allowed
Duration of treatment: 52 weeks
Primary outcomes: change in VC to week 52
Secondary outcomes: PFS time, change in lowest SpO2 during
the 6MET. Also pulmonary function tests (PFTs, PaO2,
PA – aO2, TLC and DLCO), acute exacerbation, serum levels
of markers of interstitial pneumonias, subjective/objective
symptoms (cough, presence/absence of sputum and dyspnoea
in daily living assessed with Hugh-Jones classification)
Method of assessing outcome: disease progression was
defined as death and/or ≥10% decline in VC from baseline,
or, when VC data not obtainable due to worsening respiratory
symptoms, including acute exacerbation
Acute exacerbation defined according to previous reports and
revised criteria from Japan (references provided)
Length of follow-up: 52 weeks
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Participant characteristics
[mean (SD) unless stated]
High-dose (1800)
pirfenidone, n= 108
Low-dose (1200)
pirfenidone, n= 55 Placebo, n= 104 p-value
Sex (M/F), n (%) 85/23 (78.7/21.3) 47/8 (85.5/14.5) 81/23 (77.9/22.1) 0.53
Age, years 65.4 (6.2) 63.9 (7.5) 64.7 (7.3) 0.44
Smoking status (%)
Smoker 5 (4.6) 10 (18.2) 13 (12.5) 0.07a
Former 81 (75.0) 33 (60.0) 70 (67.3)
Never smoked 22 (20.4) 12 (21.8) 21 (20.2)
Time since diagnosis, years (%)
< 1 38 (35.2) 20 (36.4) 41 (39.4) 0.86
1–3 29 (26.9) 13 (23.6) 25 (24.0)
≥ 3 41 (38.0) 22 (40.0) 38 (36.5)
Prior treatment with steroids
No (%) 99 (91.7) 49 (89.1) 98 (94.2) 0.49
Yes (%) 9 (8.3) 6 (10.9) 6 (5.8)
Current steroid use (%) 8 (7.4) 6 (10.9) 5 (4.8)
Surgical lung biopsy (%) 26 (24.1) 16 (29.1) 28 (26.9) 0.78
VC, ml 2400.8 (638.4) 2437.8 (684.8) 2472.3 (698.9) 0.74
VC, % predicted 77.3 (16.8) 76.2 (18.7) 79.1 (17.4) 0.57
TLC, % predicted 73.2 (16.5) 72.4 (15.6) 75.2 (15.7) 0.50
DLCO,% predicted 52.1 (16.8) 53.6 (19.1) 55.2 (18.2) 0.44
PaO2 at rest, mmHg 79.8 (10.2) 81.6 (8.4) 81.0 (9.5) 0.48
PA – aO2, mmHg 18.4 (11.3) 16.9 (9.6) 17.4 (9.7) 0.64
Lowest SpO2, % 89.0 (2.3) 88.8 (2.4) 89.0 (2.2) 0.86
< 88% saturation 6MET (%) 34 (31.5) 19 (34.5) 24 (23.1)
Comments: states that VC, TLC, DLCO, PaO2 and PA – aO2 were measured for 106 participants in the high-dose group, and
TLC and DLCO for 103 participants in the placebo group
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Results
High-dose
pirfenidone,
n= 108
Low-dose
pirfenidone,
n= 55
Placebo,
n= 104
Difference, p-value high
dose/low dose vs. placebo
Adjusted (LOCF) mean
change in VC, l (SE)
n= 104
–0.09 (0.02)
n= 54
–0.08 (0.03)
n= 103
–0.16 (0.02)
High dose: 0.07 (0.03);
p= 0.0416
Low dose: 0.09 (0.04);
p= 0.0394
Comments: states no significant differences were shown between high-dose and low-dose groups
Unadjusted mean change in
VC, l (SE)
n= 67
2.36 (0.73)
n= 38
2.34 (0.71)
n= 72
2.42 (0.75)
Not tested
Comments
PFS 45/106 26/55 40/104 High dose: p= 0.0280
Low dose: p= 0.0655
Comments: data reported in figure high dose vs. low dose, p= 0.9106
Change in lowest SpO2
during the 6MET (SE)
n= 99
–1.70 (0.35)
n= 53
–0.84 (0.48)
n= 100
–1.53 (0.35)
High dose: –0.17 (0.50);
p= 0.7393
Low dose: 0.69 (0.59);
p= 0.2485
Comments
Acute exacerbation rate 6 (5.6%) 3 (5.5%) 5 (4.8%) NS
Comments: calculated as during the study or within 28 days of the termination of the study
Change in TLC n= 99
–0.16
n= 52
–0.06
n= 99
–0.20
High dose: p= 0.5344
Low dose: p= 0.0408
Comments: high dose vs. low dose, p= 0.1250
Change in DLCO n= 96
–0.88
n= 51
–0.51
n= 98
–1.36
High dose: p= 0.2317
Low dose: p= 0.0768
Comments: high dose vs. low dose, p= 0.4379
Change in PaO2 n= 98
–2.09
n= 54
–3.39
n= 103
–3.85
High dose: p= 0.2433
Low dose: p= 0.7996
Comments: high dose vs. low dose, p= 0.4710
Change in AaDO2b n= 98
2.14
n= 54
3.16
n= 103
3.59
High dose: p= 0.3325
Low dose: p= 0.8081
Comments: b is PA – aO2 ≥ (alveolar – arterial oxygen tension difference); high dose vs. low dose, p= 0.5709
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Adverse events ≥ 5% n (%)
High-dose
pirfenidone n= 109
Low-dose
pirfenidone n= 55
Placebo,
n= 107
Difference, p-value high
dose/low dose vs. placebo
Any 109 (100) 54 (98.2) 106 (99.1) High dose: p= 0.50
Low dose: p= 1.00
High dose vs. low dose, p= 0.34
Photosensitivity 56 (51.4) 29 (52.7) 24 (22.4) High dose: p< 0.01
Low dose: p< 0.01
High dose vs. low dose, p= 1.00
Eczema asteatotic 0 3 (5.5) 0 Low dose: p= 0.04
High dose vs. low dose, p= 0.04
Anorexia 18 (16.5) 6 (10.9) 3 (2.8) High dose: p< 0.01
Low dose: p= 0.06
High dose vs. low dose, p= 0.48
Abdominal discomfort 3 (2.8) 4 (7.3) 0 High dose: p= 0.25
Low dose: p= 0.01
High dose vs. low dose, p= 0.23
Dizziness 8 (7.3) 0 1 (0.9) High dose: p= 0.04
Low dose: p= 1.00
High dose vs. low dose, p= 0.05
Nasopharyngitis 54 (49.5) 30 (54.5) 70 (65.4) High dose: p= 0.02
Low dose: p= 0.23
High dose vs. low dose, p= 0.62
URTI 1 (0.9) 3 (5.5) 9 (8.4) High dose: p< 0.01
Low dose: p= 0.75
High dose vs. low dose, p= 0.11
γ-GTP elevation 25 (22.9) 12 (21.8) 10 (9.3) High dose: p< 0.01
Low dose: p= 0.05
High dose vs. low dose, p= 1.00
WBC decrease 4 (3.7) 3 (5.5) 0 High dose: p= 0.12
Low dose: p= 0.04
High dose vs. low dose, p= 0.69
Comments: specific adverse events leading to discontinuations for each treatment group also reported but not data
extracted. Total numbers are as extracted above under ‘sample attrition/dropout’. No one particular adverse event appears
to have been more common reason for discontinuation
Methodology
Allocation to treatment groups: states that eligible patients were allocated to the three groups in a ratio of 2 : 1 : 2 with a
modified minimisation method, including some random allocation based on biased coin design to balance baseline SpO2
Blinding: states placebo was matched, and described as double blind. No further details
Comparability of treatment groups: no significant differences seen in the distribution of the demographic and baseline
characteristics except for smoking history (lower proportion of smokers in the high-dose group)
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Adverse events ≥ 5% n (%)
High-dose
pirfenidone n= 109
Low-dose
pirfenidone n= 55
Placebo,
n= 107
Difference, p-value high
dose/low dose vs. placebo
Method of data analysis: the main analysis was between the high-dose and placebo groups. The low dose was intended to
assess benefit-risk profiles of pirfenidone at a tapered dose. For the change in VC and lowest SpO2 analyses an ANCOVA
was used, with the respective baseline measurements as covariates. Other outcomes analysed with the least significant
difference method based on one-way ANOVA. The LOCF was adopted to impute missing values if patient data were
available for ≥ 4 weeks after the baseline. A mixed-model approach using available repeated measures of changes in VC
was performed using a sensitivity analysis. Cumulative PFS rates were estimated using the Kaplan–Meier method and
compared using a log-rank test. Incidences were compared with Fisher’s exact test
Sample size/power calculation: initially the primary outcome was the lowest SpO2 during the 6MET test; however, this was
changed by the independent Data and Safety Monitoring Board before the randomisation code was broken, based on
evolved knowledge of assessment with objective measurements in IPF, as well as the lack of validation in the 6MET study
and difficulty in reproducibility of the SpO2 measurement during the 6MWT. The planned sample size was 250, with 100,
50, and 100 patients in the high-dose, low-dose and placebo groups, respectively. The sizes for high dose and placebo
were determined on the basis of simulations that would provide a statistical power of 0.8 to detect assumed difference of
the mean changes in the lowest SpO2 from baseline to week 52 between the two groups at a significance level of 0.1.
States that the power calculated on the basis of change in VC was the same
Attrition/dropout: numbers and reasons provided for those withdrawing during treatment; however, eight were excluded
after randomisation to groups (two high dose; one low dose, five placebo) because no post-baseline data were available
General comments
Generalisability: paper states that participants were assumed to have relatively mild functional impairment based on
pulmonary function tests
Outcome measures: appear appropriate. Primary outcome initially intended to be the lowest SpO2 during the 6MET but was
changed following recommendation by the independent Data and Safety Monitoring Board and before the (randomisation)
code was broken
Intercentre variability: not reported
Conflict of interests: statements of interests for each author are declared online (link not working)
Quality assessment/risk of bias
Yes/no/not reported/
unclear
1. Was the method used to generate random allocations adequate? Yes
2. Was the allocation adequately concealed? Unclear
3. Were the groups similar at the outset of the study in terms of prognostic factors? Yes
4. Was the care provider blinded? Unclear
5. Was the patient blinded? Unclear
6. Were outcome assessors blinded to the treatment allocation? Unclear
7. (i) Were there any unexpected imbalances in dropouts between groups?
(ii) If so, were they explained or adjusted for?
No
8. Is there any evidence to suggest that the authors measured more outcomes than they
reported?
Unclear
9. (i) Did the analysis include an ITT analysis? (ii) If so, was this defined? No
10. (i) Did the analysis account for missing data? (ii) If so, were the methods appropriate? Yes
Yes
γ-GTP, glutamyl-transpeptidase; 6MET, 6-minute exercise test; ANCOVA, analysis of covarience; ANOVA, analysis of
vanerice; PA – aO2, alveolar – arterial oxygen partial pressure; PFT, pulmonary function test; SE, standard error; WBC, white
blood cell.
a States p< 0.15; unclear what this refers to.
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Appendix 6 Model code network meta-analysis
W inBUGs code (adapted from Decision Support Unit report 2) (Dias et al.83).
# Fixed effects model for two-arm trials
model{ # *** PROGRAM STARTS
for(ii in 1:ns) { # LOOP THROUGH 2-ARM STUDIES
y[ii,2] ∼ dnorm(md[ii,2],prec[ii,2]) # normal likelihood for 2-arm trials
var[ii,2] <- pow(se[ii,2],2) # calculate variances
prec[ii,2] <- 1/var[ii,2] # set precisions
dev[ii,2] <- (y[ii,2]-md[i,2])*(y[ii,2]-md[ii,2])*prec[ii,2] #Deviance contribution
md[ii,2] <- d[t[ii,1]] - d[t[ii,2]] # mean of treat effects distributions
}
totresdev <- sum(dev[,2]) #Total Residual Deviance
d[1]<-0 # treatment effect is zero for reference treatment
for (kk in 2:nt){ d[kk] ∼ dnorm(0,.0001) } # vague priors for treatment effects
} # *** PROGRAM ENDS
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# Data (IPF – trial-level data: standardised treatment differences)
list(ns=10, nt=8)
t[,1] t[,2] y[,2] se[,2]
2 1 0.234793937 0.461455736 #Raghu 1991
3 1 0.457405244 0.155432826 #Richeldi 2011
4 5 0.343971125 0.170963162 #Demedts 2005
4 1 –0.02487725 0.160653585 #IPFCRN 2012
6 1 0.232946081 0.230234875 #Homma 2012
7 1 0.471090122 0.208655219 #Azuma 2005
7 1 0.250474568 0.107635613 #Capacity 004
7 1 0.030939458 0.107841122 #Capacity 006
7 1 0.348717949 0.140084088 #Taniguchi 2010
8 1 0.065705107 0.149121516 #IPFCRN 2010
END
# 1=placebo
# 2= Azathioprine
# 3=BIBF 1120
# 4=NAC triple therapy
# 5=Azathioprine+placebo
# 6=Inhaled NAC
# 7=Pirfenidone
# 8=Sildenafil
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# Initial Values
#chain 1
list(d=c(NA, 0,0,0,0, 0,0,0))
#chain 2
list(d=c(NA, 1,1,1,1, 1,1,1))
DOI: 10.3310/hta19200 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 20
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
255

Appendix 7 Validation code for the network
meta-analysis
The NMA OpenBUGS code was validated using an alternative software package, SAS 9.3 (SAS InstituteInc., Cary, NC, USA). The standardised mean difference data were recreated at the arm level, and then
fixed- and random-effects models were conducted using proc genmod and proc mcmc, respectively. Both
SAS models produced comparable estimates to the OpenBUGS code: within ± 0.01 for the fixed effects
and ± 0.012 for the random effects.
TABLE 89 Validated results using SAS: standardised mean differences
Treatment Comparator
Fixed effects Random effects
Estimate SE Estimate SE
Azathioprine Placebo 0.2449 0.2091 0.1534 0.3619
Inhaled NAC Placebo –0.2330 0.2302 –0.5213 0.3605
NAC triple Placebo –0.03326 0.1527 –0.0810 0.3062
Nintedanib Placebo –0.5338 0.1562 –0.2278 0.4132
Pirfenidone Placebo –0.2151 0.06379 –0.2430 0.1858
Sildenafil Placebo –0.06571 0.1491 –0.0765 0.3638
reSD 0.2433 0.2286
reSD, random-effects standard deviation; SE, standard error.
DOI: 10.3310/hta19200 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 20
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
257
SAS code
/* load data */
data ipf;
input study trt y SE;
datalines;
1 1 0 0.317595619
1 2 -0.23479 0.334775177
2 1 0 0.110424628
2 3 -0.53375 0.110424628
3 2 0 0.119577535
3 4 -0.34397 0.122186807
4 1 0 0.113965099
4 4 0.02488 0.113232197
5 1 0 0.162800641
5 5 -0.23295 0.162800641
6 1 0 0.119335975
6 6 -0.47109 0.171160526
7 1 0 0.076109872
7 6 -0.25047 0.076109872
8 1 0 0.076476539
8 6 -0.03094 0.076476539
9 1 0 0.098814857
9 6 -0.34872 0.099293382
10 1 0 0.106029022
10 7 -0.06571 0.104857394
;
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/* data manipulation */
data ipf;
set ipf;
length Treatment $ 18;
if trt=1 then treatment=“Placebo”;
if trt=2 then treatment=“Azathioprine”;
if trt=3 then treatment=“Nintedanib”;
if trt=4 then treatment=“NAC triple”;
if trt=5 then treatment=“Inhaled NAC”;
if trt=6 then treatment=“Pirfenidone”;
if trt=7 then treatment=“Sildenafil”;
Var=SE**2;
Weight=1/Var;
run;
* Fixed effects;
Title1 “Fixed effects model”;
procgenmod data=ipf ;
class Study Treatment;
model Y= Study Treatment /dist=normal noscale;
weight Weight;
lsmeans Treatment / diff=control(“Placebo”);
run;
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* Random effects, Bayesian;
title1 “Random effects model”;
proc mcmc data=ipf nmc=1000000 nthin=20 seed=246810
monitor=(mysd);
random Studyeffect ∼general(0) subject=Study init=(0) ;
random Treat ∼general(0) subject=Treatment init=(0) zero=first
monitor=(Treat);
parms logsd 0;
prior logsd ∼ general(logsd, upper=log(5));
mysd=exp(logsd);
random RE ∼normal(0,sd=mysd/sqrt(2)) subject=_OBS_ init=(0);
Mu= Studyeffect + Treat +RE;
model Y ∼ normal(mean=Mu, sd=SE);
run;
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Appendix 9 Data extraction from systematic
review of cost-effectiveness
Study characteristics
Reference
Hagaman 2010.99
Health technology
TPMT testing genotypic assay to identify IPF patients at risk for developing leukopenia with azathioprine.
Interventions and comparators
What interventions/strategies were included?
Azathioprine, NAC and steroids (prednisolone) with TPMT testing.
Azathioprine, NAC and steroids (prednisolone) without TPMT testing.
Conservative therapy.
Was a no treatment/supportive care strategy included?
Yes – conservative therapy which consisted of no specific pharmacologic treatment for IPF and utilised only
supportive measures.
Describe interventions/strategies
In the testing strategy, TPMT activity was assessed before initiating therapy and defined as normal, intermediate
or low ‘according to convention’ (references provided in paper). Patients with normal activity were started on
azathioprine, prednisolone and NAC at standard doses. Those with intermediate activity were started on
azathioprine at a reduced dose along with prednisolone and NAC, consistent with previous recommendations
(references provided in paper). In patients with absent TPMT activity, patients were started on conservative
therapy. Actual dosages are not stated.
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Research question
What are the stated objectives of the evaluation?
To determine whether or not TPMT testing before initiation of azathioprine, NAC and steroids is a cost-effective
treatment in IPF when compared with no TMPT testing or conservative therapy.
Study type
Cost–utility.
Study population
What definition was used for [condition]? What are the characteristics of the baseline cohort for
the evaluation?
No definitions of IPF or leukopenia are given. References given for classification of TPMT activity into normal,
intermediate and absent, although actual basis is not outline in the report itself. Baseline cohort includes
patients with IPF who are considered appropriate for treatment with azathioprine, NAC and prednisolone or
conservative therapy. No other details are provided.
Institutional setting
Where is/are the intervention(s) being evaluated usually provided?
Not stated; however, TPMT and treatment regimens will usually be provided in secondary care.
Country/currency
Has a country setting been provided for the evaluation? What currency are costs expressed in and does the
publication give the base year to which those costs relate?
Costs expressed in 2007 US$.
Funding source
None stated.
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Analytical perspective
What is the perspective adopted for the evaluation [health service, health and personal social services, third
party payer, societal (i.e. including costs borne by individuals and lost productivity)]?
Not stated; however, costs included focus on health service costs.
Effectiveness
Were the effectiveness data derived from a single study, a review/synthesis of previous studies or expert
opinion? Give the definition of treatment effect used in the evaluation. Give the size of the treatment
effect used in the evaluation.
No systematic review was undertaken. Two studies on patients with inflammatory bowel disease were used to
provide the risk of developing leukopenia by TPMT status and their estimates were combined by weighted average.
These estimates showed that 5% of patients who had normal TMPT activity, 21.4% intermediate activity and
100% no activity developed leukopenia. Risk of developing leukopenia for intermediate TPMT status assumed to
be halved at reduced dose of azathioprine (10%), based on two studies. Efficacy of interventions were obtained
from the Infigenia RCT, with 37% of those receiving azathioprine, NAC and prednisolone incurring disease
progression at 12 months compared with 51% in those receiving azathioprine and prednisolone.
Intervention costs
Were the cost data derived from a single (observational) study, a review/synthesis of previous studies or
expert opinion? Were the methods for deriving these data adequately described (give sources if using data
from other published studies)? List the direct intervention costs and other direct costs used in the
evaluation – include resource estimates (and sources for these estimates, if appropriate) as well as sources
for unit costs used.
No systematic review was undertaken. Costs tended to originate from routinely available sources. Drug costs
obtained from an online resource (www.drugstore.com). Average Medicare reimbursement for Current
Procedural Terminology or Diagnosis-Related-Group was used as a proxy for the cost of procedures, office visits
and hospitalizations. Source of cost of TPMT assay was not made clear. The basis for resources use was
not stated.
Direct intervention costs included:
l cost of TMPT assay: US$300
l cost of azathioprine, NAC and steroids (per month): US$297
l cost of azathioprine at reduced dose, NAC and steroids (per month): US$240
l cost of conservative therapy (per month): US$66
l complicated leukopenia: US$10,136
l complicated leukopenia leading to death: US$14,666
l uncomplicated leukopenia: US$423
l cost of IPF disease progression: US$14,773.
Detailed description of microcosting is provided.
Indicate the source for individual cost values (if appropriate).
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Indirect costs (costs due to lost productivity, unpaid inputs to patient care)
Were indirect costs included?
Indirect costs were not included.
Health state valuations/utilities (if study uses quality of life adjustments
to outcomes)
Were the utility data derived from a single (observational) study, a review/synthesis of previous studies or
expert opinion. Were the methods for deriving these data adequately described (give sources if using data
from other published studies)?
QoL for ‘progression of IPF’ state derived from single study. QoL in leukopenia and complicated leukopenia
states derived from three studies; derivation not discussed in text.
List the utility values used in the evaluation.
Utility values used for the base case (range for sensitivity analysis):
l progression of IPF: 0.63 (0.5 to 0.9)
l leukopenia: 0.95 (0.92 to 0.98)
l complicated leukopenia: 0.76 (0.66 to 0.86).
Sources of the data are provided, although there is no discussion as to the nature of the data (e.g.
patient group).
Indicate the source for individual cost values (if appropriate).
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Modelling
If a model was used, describe the type of model used (e.g. Markov state transition model, discrete event
simulation). Was this a newly developed model or was it adapted from a previously reported model? If an
adaptation, give the source of the original. What was the purpose of the model (i.e. why was a model
required in this evaluation)? What are the main components of the model (e.g. health states within a
Markov model)? Are sources for assumptions over model structure (e.g. allowable transitions)
reported – list them if reported.
A newly developed decision tree model was used to assess cost–utility of the addition of TPMT screening prior
to the treatment of IPF patients with azathioprine, NAC and prednisolone compared with not screening and a
conservative therapy.
Decision node:
l whether to screen, not screen, or opt for conservative therapy.
Chance nodes
l TPMT status (normal, intermediate or absent activity)
l leukopenia or no leukopenia
l complicated leukopenia or no complications form leukopenia
l death from leukopenia or survive leukopenia and change to conservative therapy
l progression of IPF to either death or alive with either progression or no progression.
The rationale for the model and its assumptions are not discussed or referenced.
Extract transition probabilities for [natural history/disease progression] model and show sources (or refer to
table in text).
Prevalence of TPMT activity [base case (range for sensitivity analysis)]:
l normal (high) 87.6% (85.6% to 90%)
l intermediate 11.9% (7.8% to 13.5%)
l low (absent) 0.5% (0 to 3%).
1-year cumulative probabilities of developing leukopenia with standard azathioprine dosing:
l normal TPMT activity 1% (0.5% to 1.5%)
l intermediate TMPT activity 21.4% (16.8% to 26%)
l absent TMPT activity 100% (not tested).
1-year cumulative probabilities of developing leukopenia with reduced azathioprine dosing:
l normal TPMT activity 1% (0.5% to 5%)
l intermediate TMPT activity 10% (5.4% to 14.6%)
l absent TMPT activity – not applicable.
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1-year cumulative probabilities of miscellaneous complications on azathioprine: 2.5% (1% to 4%) in patients
with leukopenia:
l probability of complicated leukopenia 16% (10% to 22%)
l probability of death 8% (2% to 16%).
1-year cumulative probability of disease progression
l azathoprine, NAC, steroids 37% (31.6% to 42.4%)
l conservative therapy 51% (30% to 65%).
Excess mortality due to IPF per year: 9% (5% to 20%).
Life expectancy with IPF after diagnosis: 3 years (3 to 10 years).
Sources of the data are provided, with some limited discussion as to the rationale for their use.
What is the model time horizon?
1 year, with all events modelled occurring at an average of 0.5 years (including treatment-related adverse
events, disease progression and death).
What, if any, discount rates have been applied in the model? Same rate for costs and outcomes?
Not stated.
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Results/analysis
What measure(s) of benefit were reported in the evaluation?
Marginal QALYs.
Provide a summary of the clinical outcome/benefits estimated for each intervention/strategy assessed in
the evaluation.
Conservative therapy – 2.50 QALYs.
Azathioprine without TPMT testing – 2.61 QALYs.
Azathioprine with TPMT testing – 2.62 QALYs.
Provide a summary of the costs estimated for each intervention/strategy assessed in the evaluation.
Conservative therapy $9691.
Azathioprine without testing $15,802.
Azathioprine with testing $15,818.
Synthesis of costs and benefits – are the costs and outcomes reported together (e.g. as cost-effectiveness
ratios)? If so, provide a summary of the results.
Outcomes were reported as ICERs.
Marginal cost-effectiveness ratio with extended dominance ($/QALY gained)
l azathioprine, NAC and steroids with TPMT testing vs. conservative therapy: $49,245
l azathioprine, NAC and steroids without TPMT testing is extendedly dominated by azathioprine, NAC and
steroids with TPMT testing.
Marginal cost-effectiveness ratio without extended dominance ($/QALY gained)
l azathioprine, NAC and steroids without TPMT testing vs. conservative therapy: $49,245.
l azathioprine, NAC and steroids with TPMT testing vs. azathioprine, NAC and steroids without TPMT
testing: $29,663.
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Give results of any statistical analysis of the results of the evaluation.
Not applicable.
Was any sensitivity analysis performed – if yes, what type(s) (i.e. deterministic (one-way, two-way, etc.)
or probabilistic)?
Sensitivity analyses were performed on all parameters. Although it is not specified whether analyses were
deterministic or probabilistic, selective results of one-way and two-way analyses are presented.
What scenarios were tested in the sensitivity analysis? How do these relate to structural uncertainty (testing
assumptions over model structure such as relationships between health states), methodological uncertainty
(such as choices of discount rate or inclusion of indirect costs) or parameter uncertainty (assumptions over
values of parameters in the model, such as costs, QoL or disease progression rates)?
There is limited discussion concerning the sensitivity analyses, with only three scenarios assessing parameter
uncertainty that had the greatest impact (not defined) discussed, including:
l frequency of abnormal TPMT alleles
l probability of developing leukopenia as a consequence of treatment with reduced dose of azathioprine,
patients with intermediate TPMT status
l treatment efficacy.
Give a summary of the results of the sensitivity analysis – did they differ substantially from the base-case
analysis? If so, what were the suggested causes?
ICER of testing vs. no testing increases dramatically when the frequency of abnormal alleles is < 12%.
As the probability of leukopenia increases above the base case value of 10%, TPMT testing becomes
increasingly expensive. Above a probability of 12% testing is no longer ‘cost-effective’.
As the rate of disease progression in 1 year on conservative therapy increases, TPMT testing is favoured at
increasingly higher rates of disease progression on azathioprine, NAC and steroids.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
TPMT testing before starting a regimen of azathioprine in combination with NAC and steroids is cost-effective
in patients with IPF.
What are the implications of the evaluation for practice?
Little implication for practice, as TPMT screening before initiating azathioprine is already common.
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Southampton Health Technology Assessments
Centre commentary
Selection of comparators:
Appropriate.
Validity of estimate of measure of benefit:
Given that the focus of the evaluation is the benefit of the addition of TMPT testing prior to treatment with
azathioprine in combination with NAC and steroids (rather than the effectiveness of the treatment itself), QoL
appears appropriate. Utilities associated with various disease states are presented but not discussed in the
paper. It is not clear how valid the specific utilities used are.
Validity of estimate of costs:
Although the estimates for costs appear reasonable and detailed descriptions of microcosts have been
provided, there is limited discussion regarding the resources used.
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Appendix 10 Excluded studies: systematic review
of health-related quality of life
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Appendix 11 Data extractions from systematic
review of health-related quality of life
Reference
Baddini Martinez 2002.111
Study characteristics
Research question
What are the stated objectives of the study?
To investigate how some commonly used dyspnoea scales correlate with measurements of HRQoL in
IPF patients.
Describe the type of study and study design.
Cross-sectional study/single-cohort study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Diagnosed by surgical lung biopsy or HRCT.
What are the characteristics of the baseline cohort for the evaluation?
Age 58.6
Sex, M/F 18/12
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample size) n= 30
FVC per cent predicted 61.9% (standard error of the mean 3.24)
QoL instrument SF-36
Utility values, Y/N N
Treatment effect, if reported Not applicable
DOI: 10.3310/hta19200 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 20
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Loveman et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
275
Country/setting
What is the country and setting for the evaluation?
Brazil, outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL data obtained in this single study.
Results
Summarise the results.
All dyspnoea scales showed significant correlations with both physical and mental HRQoL domains. The highest
Spearman correlation coefficients were obtained using the BDI
SF-36 scores Mean SEM
Physical function 40.83 4.41
Role physical 44.17 8.86
Pain index 78.57 4.40
General health 53.07 4.33
Vitality 50.50 5.10
Social function 60.83 7.26
Role emotional 64.44 8.74
Mental health 59.47 4.15
SEM, standard error of the mean.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
Dyspnoea ratings correlate with HRQoL in IPF patients and can be used as a measure of HRQoL in
special circumstances.
What are the implications of the study for the model?
Model might possibly use dyspnoea measurements as a proxy for HRQoL in patients with IPF. Baseline SF-36
may be useful in the absence of utility data as may be able to map this to the EQ-5D. Limited by the small
sample size.
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Reference
De Vries 2000.117
Study characteristics
Research question
What are the stated objectives of the study?
To identify aspects of QoL that are relevant to this population and to establish which measure is preferable to
assess these aspects.
Describe the type of study and study design.
Three focus groups/cross-sectional survey.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) From three hospitals, uncertain diagnostic criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 61.1
Sex, M/F 4/6
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample size) n= 10
FVC % predicted not reported
QoL instrument SGRQ and WHOQoL-100 (translated to Dutch)
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
The Netherlands; university hospital setting assumed by reviewers.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, expert opinion?
QoL derived in this single observational study, prior to focus groups.
Results
Summarise the results
Results indicate aspects relevant to IPF patients QoL – mobility, working capacity, energy, etc.
SGRQ scores Mean SD
Activity 56.0 20.2
Impact 38.7 22.7
Symptoms 46.1 20.8
Total 44.5 17.8
WHOQOL-100 overall 12.5 2.3
Also reports data from six domains and 24 facets of the WHOQOL but not data extracted as not per inclusion
criteria
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
WHOQOL-100, with additional social support questionnaire, was preferred to the SGRQ, as it mentioned all
aspects of QoL mentioned by the IPF patients.
What are the implications of the study for the model?
SGRQ is not a detailed instrument for capturing IPF QoL. May provide useful data if no utility data identified,
although small numbers limit the reliability and uncertainty over the diagnosis of IPF as not reported.
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Reference
Horton and colleagues 2012,55 and Lechtzin and colleagues 2013.121
Study characteristics
Research question
What are the stated objectives of the study?
To assess the effect of thalidomide on cough in patients with IPF/to validate the CQLQ.
Describe the type of study and study design.
RCT, crossover design.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Patients with IPF diagnosed with IPF by HRCT or lung biopsy, and a symptom duration of between 3 months
and 5 years and chronic cough (more than 8 weeks’ duration) and aged over 50 years.
What are the characteristics of the baseline cohort for the evaluation?
Age 67.6 years
Sex, M/F 18/5
Race (if appropriate) White: 91.2%
Black: 4.4%
Hispanic: 4.4%
Indication/disease IPF
Other characteristics (sample size) Number randomised: 23
FVC per cent predicted: 70.4% (SD 13.7)
QoL instrument SGRQ
Utility values, Y/N N
Treatment effect, if reported CQLQ
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Country/setting
What is the country and setting for the evaluation?
USA; university setting.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
Single study.
Results
Summarise the results.
Results from the combined thalidomide and placebo group at baseline only data extracted as no baseline data for
the placebo group alone were presented:
SGRQ Mean SD
Total 57.4 18.8
Symptom 67.7 19.7
Impact 48.1 20.7
Activity 64.3 22.7
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
Overall QoL measured by the SGRQ is significantly improved with thalidomide.
What are the implications of the study for the model?
SGRQ data could be mapped to EQ-5D if no relevant data were available.
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Reference
Jastrzebski 2005.112
Study characteristics
Research question
What are the stated objectives of the study?
To compare changes in the QoL in patients with IPF at point of meeting qualification criteria for lung transplant
and 12 months later.
Describe the type of study and study design.
Cohort study with reference group (emphysema) controls.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Patients with disease of interest who also received lung transplant, diagnosed by ATS/ERS criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 48.3
Sex, M/F 11/5
Race (if appropriate) Not reported
Indication/disease IPF, eligible for lung transplantation (reference group patients with
emphysema)
Other characteristics (sample
size)
n= 16
FVC per cent predicted reported (44.0%, SD 15.3)
QoL instrument SF-36
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Poland; hospital.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
Single study.
Results
Summarise the results.
A year after the qualification for lung transplantation the results of the SF-36 questionnaire were not different in the
IPF patients, compared with their baseline scores.
SF-36 mean Baseline 12 months
Physical function 45 47
Role physical 43 25
Bodily pain 62 64
General health 28 28
Vitality 38 42
Social function 58 63
Role emotional 65 68
Mental health 50 56
Physical overall 35 33
Mental overall 42 45
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
SF-36 is a sensitive tool to assess the QoL in IPF patients qualified for lung transplantation.
What are the implications of the study for the model?
Data may be useful if no utility data identified as may be able to be mapped onto the EQ-5D, population with
severe IPF based on FVC per cent predicted. Limited by small numbers and no measure of variance provided.
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Reference
Jastrzebski 2006.62
Study characteristics
Research question
What are the stated objectives of the study?
To examine the effects of pulmonary rehabilitation in patients suffering from IPF on QoL and dyspnoea.
Describe the type of study and study design.
Cohort study, pre and post design.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(iv) Patients with the disease of interest and other patients treated for ILD; diagnostic criteria for IPF
not provided.
What are the characteristics of the baseline cohort for the evaluation?
Age 48.7
Sex, M/F 19/12
Race (if appropriate)
Indication/disease 13 patients had IPF
Other characteristics (sample size) 31 patients finished rehabilitation programme (n= 38 qualified)
FVC % predicted not reported
QoL instrument SF-36 and SGRQ (Polish versions)
Utility values, Y/N N
Treatment effect, if reported Change in dyspnoea severity before and after rehabilitation
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Country/setting
What is the country and setting for the evaluation?
Poland; hospital outpatients.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL obtained from this study, before and after the 6-week pulmonary rehabilitation program.
Results
Summarise the results.
Rehabilitation caused the scores of all SF-36 components to increase, most significantly (p< 0.05). Two SGRQ
domains showed significant improvement. Data reported in figures only and not extracted given other ILD
participants constitute the majority of cases in this study.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis
The rehabilitation programme improved the QoL of included patients.
What are the implications of the study for the model?
Not entirely relevant to model as it appears that very few patients had IPF and data in figures only.
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Reference
Kozu 2011.114
Study characteristics
Research question
What are the stated objectives of the study?
1. To evaluate the effects of pulmonary rehabilitation on dyspnoea, exercise capacity and health status in
subjects with IPF with health limitations.
2. To compare the responses in subjects with IPF with the changes seen in a control group of COPD subjects.
Describe the type of study and study design.
Prospective non-randomised pre- and post-cohort study with COPD controls.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Diagnosis based on ATS/ERS criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 67.5
Sex, M/F 37/8
Race (if appropriate) Asian (assumed)
Indication/disease IPF
Other characteristics (sample size) n= 45
FVC per cent predicted reported (68.6%, SD 16)
QoL instrument SF-36
Utility values, Y/N N
Treatment effect, if reported Change in SF-36 score, 6 MWD, muscle force, etc.
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Country/setting
What is the country and setting for the evaluation?
Japan/outpatient programme.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL obtained from this study – taken at baseline, immediately following rehabilitation programme (≈8 weeks) and
at 6 months thereafter
Mean (SD) scores SF-36 at baseline
Mean SD
Physical function 35.7 18.7
Role physical 33.9 21.7
Bodily pain 62.4 30.3
General health 34.7 19.9
Vitality 38.3 21.3
Social function 48.3 23.7
Role emotional 36.5 30.1
Mental health 50.0 18.7
Also reports SF-36 for participants who completed the programme at baseline, at 8 weeks (n= 36) and 6 months
(n= 30) following pulmonary rehabilitation. Not extracted here
Results
Summarise the results.
No changes in SF-36 scores in IPF patients although other improvements seen (muscle force, dyspnoea, etc.).
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
Pulmonary rehab in IPF does not improve health status as measured by SF-36; a pulmonary rehab program
specifically tailored to the needs of IPF should be investigated in future.
What are the implications of the study for the model?
The baseline measurements of the SF-36 may be useful if no utility data are identified as these can be mapped
to the EQ-5D if required. The population were approximately moderate disease severity. Small sample size limit
the reliability of the data.
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Reference
Kozu 2011.113
Study characteristics
Research question
What are the stated objectives of the study?
To investigate differences in response to pulmonary rehabilitation in subjects with IPF who were grouped
according to their level of disability, as categorised by MRC dyspnoea scale.
Describe the type of study and study design.
Prospective non-randomised and uncontrolled, pre- and post-cohort study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Patients with a diagnosis of IPF (based on the International Consensus statement) who were referred for
pulmonary rehabilitation.
What are the characteristics of the baseline cohort for the evaluation?
Age 67.5
Sex M/F 46/19
Race (if appropriate) Asian (assumed)
Indication/disease IPF and referred for pulmonary rehabilitation
Other characteristics (sample size) n= 65
FVC per cent predicted reported by dyspnoea grade, ranged 51–83%
QoL instrument SF-36
Utility values, Y/N N
Treatment effect, if reported Change in 6 MWD, %
Change in SF-36
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Country/setting
What is the country and setting for the evaluation?
Japan/hospital outpatients.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
SF-36 obtained from this study – completed at baseline and immediately following the 8-week rehabilitation
programme. Baseline scores reported by dyspnoea grade.
Results
Summarise the results.
Baseline characteristics
MRC dyspnoea grade 2, n= 16 3, n= 17 4, n= 17 5, n= 15
FVC per cent predicted,
mean (SD)
83 (11) 67 (13) 60 (16) 51 (11)
SF-36, mean (SD)
Physical function 55.3 (7.2) 34.1 (18.4) 20.3 (7.0) 16.0 (9.1)
Role physical 55.9 (15.9) 22.4 (17.3) 23.2 (13.4) 19.6 (10.3)
Bodily pain 66.5 (25.1) 57.2 (29.0) 65.6 (29.1) 65.6 (28.4)
General health 50.9 (11.0) 35.8 (21.5) 24.1 (16.8) 19.1 (10.7)
Vitality 54.7 (11.7) 37.9 (21.5) 26.5 (18.0) 19.6 (15.3)
Social function 62.5 (18.8) 42.6 (27.6) 36.0 (15.2) 30.0 (14.8)
Role emotional 66.7 (15.2) 47.1 (28.2) 30.9 (21.4) 19.4 (15.3)
Mental health 61.6 (14.3) 42.9 (20.8) 41.8 (17.2) 35.0 (12.0)
Differential improvement in SF-36 by disability level in response to rehabilitation programme (data not extracted)
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
Disability level has an effect on response to pulmonary rehabilitation in patients with IPF, when response is
measured in terms of 6MWD and SF-36.
What are the implications of the study for the model?
Overall response to treatment will vary by mix of disability levels in IPF population. Scores may be of value to
the model if no utility data are identified.
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Reference
Lutogniewska et al. 2010.127
Study characteristics
Research question
What are the stated objectives of the study?
To determine the correlation between QoL and dyspnoea in patients awaiting lung transplantation.
Describe the type of study and study design.
Single-cohort study with subgroup data.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Included patients fulfilling the criteria for lung transplant with IPF, COPD or IIP. Subgroup data for IPF
patients reported here.
What are the characteristics of the baseline cohort for the evaluation?
Age Not reported
Sex, M/F Not reported
Race (if appropriate) Not reported
Indication/disease IPF, no definition of the diagnostic criteria used provided
Other characteristics (sample size) n= 30
FVC per cent predicted not reported
QoL instrument SGRQ, SF-36
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Poland.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
Single study.
Results
Summarise the results.
Mean SD
SGRQ
Total score 64.0 19.0
Symptoms 58.7 20.3
Activity 70.4 20.1
Impact 65.4 24.8
SF-36
Physical function 19.1 17.0
Role physical 20.7 23.2
Bodily pain 47.3 25.9
General health 28.5 10.7
Vitality 38.7 19.8
Social function 33.4 26.0
Role emotional 40.3 36.9
Mental health 49.2 22.8
Physical component score 25.9 7.8
Mental component score 42.4 14.2
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Provides a reference for the methodological details (is an included study).
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
The SF-36 and SGRQ are sensitive tools in the assessment of the QoL of patients referred for lung transplant.
What are the implications of the study for the model?
If no utility data available these results could be mapped.
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Reference
Martinez 2000.109
Study characteristics
Research question
What are the stated objectives of the study?
To validate the use of the SF-36 questionnaire in patients with IPF and no comorbidity.
Describe the type of study and study design.
Cross sectional with matched healthy controls, matched for sex and age.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) With no significant comorbidity, diagnosis by lung biopsy or HRCT, and healthy controls.
What are the characteristics of the baseline cohort for the evaluation?
Age 58.29
Sex M/F 20/14
Race (if appropriate) Not reported
Indication/disease IPF no comorbidity
Other characteristics (sample size) n= 34
FVC per cent predicted reported (62.41%, SD 2.96)
QoL instrument SF-36 validated for Portuguese language
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Brazil; outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL obtained from this study only.
Results
Summarise the results.
Patients with IPF scored significantly worse than control subjects for most of the SF-36 components apart from pain
index
SF-36 Mean SEM
Physical function 42.79 4.40
Role physical 44.12 8.11
Bodily pain 76.91 4.16
General health 53.50 3.90
Vitality 50.44 4.88
Social function 60.29 6.69
Role emotional 60.78 8.26
Mental health 57.33 4.07
SEM, standard error of the mean.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
Patients with IPF have significant impairment of HRQoL in both physical and psychological functioning.
Dyspnoea is the most important factor in influencing QoL.
What are the implications of the study for the model?
SF-36 is a valid instrument to measure HRQoL in IPF patients, limited by small numbers; however, may be useful
if no utility data are identified. Moderate severity cases.
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Reference
Mermigkis et al. 2013.116
Study characteristics
Research question
What are the stated objectives of the study?
To assess the results of effective continuous positive airway pressure (CPAP) therapy in terms of sleep quality
and overall QoL in IPF patients with moderate to severe obstructive sleep apnoea.
Describe the type of study and study design.
Single cohort study, before and after.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Newly diagnosed, histologically proven IPF or fulfilled consensus criteria for IPF and had features compatible
with moderate to severe obstructive sleep apnoea.
What are the characteristics of the baseline cohort for the evaluation?
Age 67.1 (SD 7.2) years
Sex, M/F 10/2
Race (if appropriate) Not reported
Indication/disease IPF and moderate to severe obstructive sleep apnoea
Other characteristics (sample
size)
n= 12 (also present characteristics of 11 others who had IPF but did not fulfil
the criteria for obstructive sleep apnoea)
FVC per cent predicted: 77.1% (SD 18.1)
QoL instrument SF-36
Utility values, Y/N N
Treatment effect, if reported Various sleep rating scales used to assess the effectiveness of CPAP
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Country/setting
What is the country and setting for the evaluation?
Greece.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
A single study.
Results
Summarise the results.
SF-36 overall score only presented. At baseline this was 63.2 (SD 13.9).
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
CPAP can lead to improvements in sleep and overall QoL.
What are the implications of the study for the model?
Minimal SF-36 data presented.
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Reference
Nishiyama et al. 2012.122
Study characteristics
Research question
What are the stated objectives of the study?
To determine the prognostic significance of HRQL (HRQoL) scores in IPF assessed with the SGRQ.
Describe the type of study and study design.
Retrospective cohort study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) With diagnosis by ATS/ERS criteria, and newly diagnosed having not received any other treatments.
What are the characteristics of the baseline cohort for the evaluation?
Age 66.3 years
Sex, M/F 77/10
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample size) n= 87
FVC per cent predicted: 75.0 (SD 19.2)
QoL instrument SGRQ
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Japan.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
A single study.
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Results
Summarise the results.
SGRQ at baseline
Mean SD
Symptoms 45.0 23.3
Activity 48.0 24.7
Impact 31.6 20.7
Total 39.0 20.2
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
No details of SGRQ; states that it is standard practice for this to be completed by IPF patients at diagnosis.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
No significant relationship between HRQoL evaluated by the SGRQ and subsequent mortality in IPF
was demonstrated.
What are the implications of the study for the model?
Data could be mapped if no EQ-5D data available.
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Reference
Nishiyama 2005.119
Study characteristics
Research question
What are the stated objectives of the study?
To identify factors significantly contributing to HRQoL in IPF patients using the SGRQ, and to examine
hypotheses that dyspnoea and exercise capacity affect HRQoL.
Describe the type of study and study design.
Cross-sectional/single-cohort study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Diagnosed by surgical lung biopsy or HRCT in accordance with ATS/ERS consensus criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 64
Sex, M/F 35/6
Race (if appropriate) Asian (assumed)
Indication/disease IPF
Other characteristics (sample size) n= 41
FVC per cent predicted not reported, only VC (76.6%, SD 16.8)
QoL instrument SGRQ (Japanese version)
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Japan; hospital outpatients.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies or expert opinion?
QoL data obtained in this single observational study.
Results
Summarise the results.
The BDI score showed the most significant correlation with each SGRQ score
SGRQ score Mean SD
Symptoms 40.1 24.6
Activity 44.5 26.7
Impacts 28.9 19.8
Total 35.7 20.6
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
308
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
Dyspnoea was most important factor determining HRQoL in IPF. The types of other variables that correlated
with HRQoL were different from those in COPD.
What are the implications of the study for the model?
SGRQ would be reasonably valid instrument to use for utility scores based on correlations with physiological
variables and may be useful if no utility data are identified.
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Reference
Nishiyama 2008.73
Study characteristics
Research question
What are the stated objectives of the study?
To evaluate effects of pulmonary rehabilitation in patients with IPF, compared with control.
Describe the type of study and study design.
RCT (included in clinical effectiveness systematic review).
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Consecutive patients referred to outpatient clinic with IPF, diagnosed using ATS/ERS consensus criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 68.1 for treated group, 66.3 for total group
Sex, M/F 21/7
Race (if appropriate) Asian (assumed)
Indication/disease IPF
Other characteristics (sample size) n= 28
FVC per cent predicted reported (67.4%)
QoL instrument SGRQ
Utility values, Y/N N
Treatment effect, if reported FVC
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Country/setting
What is the country and setting for the evaluation?
Japan; outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
Single study (RCT).
Results
Summarise the results.
Significant improvements were seen in 6MWD and HRQoL as a result of rehabilitation programme
SGRQ scores baseline Control, mean (SD) Treated, mean (SD)
Symptoms 38.0 (25.8) 56.4 (22.3)
Activity 50.4 (26.2) 64.7 (17.1)
Impacts 29.9 (23.7) 39.7 (17.6)
Total 37.8 (22.7) 50.2 (16.3)
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis
Pulmonary rehab improves both exercise capacity and HRQoL in patients with IPF.
What are the implications of the study for the model?
May be useful if no valid utility data identified. Limited by small numbers. Participants mostly moderate
severity IPF.
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Reference
Ozalevli 2009.110
Study characteristics
Research question
What are the stated objectives of the study?
To investigate the effects of a home-based pulmonary rehab programme on functional outcome parameters in
patients with IPF.
Describe the type of study and study design.
Prospective cohort pre and post study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Diagnosed by ATS/ERS consensus criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 62.8
Sex, M/F 10/5
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample size) n= 15
FVC per cent predicted reported (71.6%, SD 8.2)
QoL instrument SF-36
Utility values, Y/N N
Treatment effect, if reported Pulmonary function tests
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Country/setting
What is the country and setting for the evaluation?
Turkey; home.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
Single study.
Results
Summarise the results.
Baseline results:
SF-36 scores baseline Mean SD
Physical function 56.0 5.7
Role physical 25.0 1.7
Bodily pain 67.3 2.6
General health 57.0 4.6
Vitality 52.0 4.9
Social function 75.8 2.7
Role emotional 29.0 1.3
Mental health 49.9 6.7
A significant increase in general HRQoL was seen after the programme
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
Home-based pulmonary rehab may improve HRQoL in patients with IPF.
What are the implications of the study for the model?
Data may be useful if no utility data are identified as may be mapped onto EQ-5D. Limited by small sample size.
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Reference
Peng 2008.118
Study characteristics
Research question
What are the stated objectives of the study?
To confirm the cross-sectional and longitudinal construct validity of the SGRQ for the measurement of HRQoL
in patients with IPF.
Describe the type of study and study design.
Observational, cross-sectional and longitudinal.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Diagnosed by surgical lung biopsy or HRCT.
What are the characteristics of the baseline cohort for the evaluation?
Age 64
Sex, M/F 54/14
Race (if appropriate) Asian (assumed)
Indication/disease IPF
Other characteristics (sample size) n= 68
FVC per cent predicted reported (66%)
QoL instrument SGRQ (Chinese version)
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
China; outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
From this single observational study.
Results
Summarise the results.
SGRQ score at baseline Mean SD
Symptoms 65 16
Activity 56 15
Impact 49 19
Total 54 15
HRQoL substantially impaired in IPF patients, especially in symptom and activity domains. SGRQ was correlated with
lung function and exercise function. Over time, n= 45, SGRQ scores reduced (not significantly) in two domains
(symptoms/impact) and improved on one (activity) and total score significantly
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
SGRQ has good longitudinal and construct validity in patients with IPF; however, further assessment of
reliability and responsiveness is needed.
What are the implications of the study for the model?
SGRQ would be a reasonable instrument to map to utility if no data available. Limitation using longer-term
data owing to dropout rates. Population mostly moderate in severity.
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Reference
Raghu 2010.125
Study characteristics
Research question
What are the stated objectives of the study?
To examine longitudinal changes in HRQoL and dyspnoea in IPF patients.
Describe the type of study and study design.
Randomised, placebo-controlled trial of bosentan.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Well-defined diagnosis of IPF based on ATS/ERS consensus criteria (BUILD-1) (excluded from the clinical
effectiveness systematic review).
What are the characteristics of the baseline cohort for the evaluation?
Age 65.2
Sex, M/F 112/42
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample
size)
158 randomised (154 analysed)
FVC per cent predicted not reported in this publication, was 67.7% in another
publication128
QoL instrument SGRQ and SF-36
Utility values, Y/N N
Treatment effect, if reported Mitigation of impairment of HRQoL
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Country/setting
What is the country and setting for the evaluation?
29 centres in Europe (Germany, France, Italy, Switzerland and the UK), the USA, Canada and Israel.128
Outpatient setting.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL from this study.
Results
Summarise the results.
No differences in HRQoL between treatment groups at baseline or at 12 months
Bosentan Placebo
Baseline SGRQ, median (95% CI)
Symptoms 51.2 (44.7 to 56.0) 54.8 (47.9 to 59.1)
Activity 59.5 (53.6 to 66.1) 59.5 (56.0 to 65.6)
Impacts 32.9 (25.0 to 40.3) 30.5 (25.7 to 38.4)
Total 43.9 (36.6 to 52.1) 44.3 (40.2 to 50.0)
Baseline SF-36, median (95% CI)
Physical function 55.0 (40.0 to 65.0) 47.5 (35.0 to 55.0)
Role physical 25.0 (25.0 to 50.0) 25.0 (25.0 to 50.0)
Bodily pain 74.0 (64.0 to 100.0) 64.0 (61.0 to 74.0)
General health 47.0 (37.0 to 57.0) 46.0 (40.0 to 52.0)
Vitality 50.0 (40.0 to 55.0) 50.0 (40.0 to 55.0)
Social function 75.0 (75.0 to 87.5) 81.3 (62.5 to 87.5)
Role emotional 100.0 (66.7 to 100.0) 100.0 (66.7 to 100.0)
Mental health 80.0 (68.0 to 84.0) 76.0 (68.0 to 80.0)
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
HRQoL changed minimally as a result of treatment with bosentan, although exploratory analysis suggested a
QoL benefit among those diagnosed by surgical lung biopsy.
What are the implications of the study for the model
Bosentan treatment does not appear to give rise to changes in QoL for IPF patients. Baseline data may be of
use to the model if no utility data are identified, although median not mean scores reported.
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Reference
Swigris 2010.126
Study characteristics
Research question
What are the stated objectives of the study?
To examine the validity of the SF-36 and SGRQ in IPF and to determine scores from each that would constitute
a minimum important difference.
Describe the type of study and study design.
Retrospective analysis of BUILD-l trial data (BUILD-1 was a randomised placebo-controlled trial of bosentan).
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) With IPF defined according to consensus guidelines (ATS/ERS).
What are the characteristics of the baseline cohort for the evaluation?
Age 65.12
Sex, M/F 73/27
Race (if appropriate) 92% Caucasian
Indication/disease IPF
Other characteristics (sample size) n= 100. 158 in original sample and for baseline measurement
FVC per cent predicted reported (66.97%)
QoL instrument SF-36 and SGRQ
Utility values, Y/N N
Treatment effect, if reported Not applicable
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
322
Country/setting
What is the country and setting for the evaluation?
BUILD-1 trial was performed in 29 centres in Europe (Germany, France, Italy, Switzerland and the UK), the USA,
Canada and Israel.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
SF-36 and SGRQ data obtained from BUILD-1 trial for two time points – baseline and 6 months.
Results
Summarise the results.
SF-36 and SGRQ are valid instruments in longitudinal studies of IPF
Baseline Mean SD
SRGQ
Symptoms 50.1 21.9
Activity 60.6 22.8
Impact 33.7 20.6
Total 44.8 19.5
SF-36
Physical function 35.4 10.3
Role physical 37.8 11.6
Bodily pain 47.6 10.7
General health 37.8 9.4
Vitality 43.1 9.2
Social function 44.6 12.3
Role emotional 42.7 14.2
Mental health 48.2 10.1
Physical summary 37 10
Mental summary 44.2 10.84
NB: 95% CI data available but not extracted
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
For SF-36 used scoring algorithms to generate linear t-score transformations.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
SF-36 and SGRQ possess reasonable validity for differentiating subjects whose disease severity changes
over time.
What are the implications of the study for the model?
Either SF-36 or SGRQ would be OK to use for utilities if no data available. Patients were mostly
moderate severity.
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Reference
Tomioka 2007.115
Study characteristics
Research question
What are the stated objectives of the study?
To validate the cross-sectional and longitudinal use of SF-36 for measuring HRQoL in patients with IPF.
Describe the type of study and study design.
Cross-sectional and longitudinal study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Diagnosed on basis of lung biopsy or HRCT as defined by ATS/ERS consensus criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 69.9
Sex, M/F 32/14
Race (if appropriate) Asian (assumed)
Indication/disease IPF
Other characteristics (sample size) n= 46
FVC per cent predicted not reported, VC only (71.0%, SD 17.5)
QoL instrument SF-36
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Japan/outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from: a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL from this study (baseline and > 1 year later).
Results
Summarise the results.
Patients with IPF had significantly lower scores across all eight domains of the SF-36 than the general
population. Presented as deviation values against national reference values; no actual data presented in the
publication. Also showed decline over time from 32 participants but this was no statistically significant in six of
the eight domains. Data in a figure only.
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
IPF patients have significantly impaired HRQoL and this is reflected in their SF-36 scores. SF-36 scores also
measure dimensions not fully estimated by clinical assessment.
What are the implications of the study for the model?
SF-36 scores would be a reasonable choice for model utilities in the absence of data. However, data are
not presented.
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Reference
Tzanakis 2005.120
Study characteristics
Research question
What are the stated objectives of the study?
To test whether existing instruments for obstructive airway disease could be applied to patients with IPF.
Describe the type of study and study design.
Cross-sectional/matched control study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Plus healthy control group. Diagnosis clinically and histologically consistent with IPF by ATS/ERS
consensus criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 66
Sex, M/F 21/4
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample size) n= 25
FVC per cent predicted reported (68.8%, SD 16)
QoL instrument SGRQ
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Greece; hospital (outpatients).
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
Single study.
Results
Summarise the results.
Lung volumes (FVC and TLC) correlated significantly with the SGRQ. IPF patient scores were significantly different
from scores in the control group
SGRQ domain Mean SD
Symptoms 55.9 25.3
Activity 36.2 21.4
Impact 29.6 21
Total 37.7 18.9
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
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Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
SGRQ is sensitive to HRQoL in IPF patients.
What are the implications of the study for the model?
May be useful if no utility data are identified, limited by the small sample size. Participants were approximately
of moderate IPF severity.
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Reference
Verma 2011.123
Study characteristics
Research question
What are the stated objectives of the study?
To determine whether or not an association between SF-36 and SGRQ scores and other markers of disease
severity exists, and to identify which physiological and functional variables are independently associated
with HRQoL.
Describe the type of study and study design.
Cross-sectional study/single-cohort study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) With diagnosis based on ATS/ERS criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 59.4
Sex, M/F 90/47
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample size) n= 137
FVC per cent predicted reported (61.7%, SD 19.8)
QoL instrument SF-36 and SGRQ
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Canada. Web-based versions of SGRQ and SF-36 were administered. Clinical assessment at hospital clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL data from this study
Mean 95% CI
Score SF-36
Physical function 25.6 21.9 to 29.4
Role physical 31.0 26.9 to 35.1
Bodily pain 68.0 63.4 to 72.7
General health 35.5 31.9 to 39.0
Vitality 39.3 35.8 to 42.9
Social function 59.2 54.05 to 64.38
Role emotional 74.5 69.6 to 79.3
Mental health 71.2 67.9 to 74.6
Physical summary 29.4 27.9 to 30.9
Mental summary 49.7 47.6 to 51.7
Score SGRQ
Symptoms 59.8 56.2 to 63.4
Activity 81.6 78.7 to 84.4
Impacts 54.1 50.6 to 57.6
Total 63.4 60.4 to 66.3
Results
Summarise the results.
6MWD was the only functional measure of disease severity significantly associated with all domain scores of
the SGRQ and SF-36.
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Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
SF-36 component summary scores were normalised.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis
6MWD is an important predictor of HQoL in patients with IPF.
What are the implications of the study for the model?
6MWD might be used as proxy for HRQoL. Scores of SGRQ or SF-36 may be useful if no utility data are
identified and if they can be mapped to the EQ-5D. Population mostly moderate in severity.
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Reference
Zimmermann 2007.124
Study characteristics
Research question
What are the stated objectives of the study?
To determine if there is a HRQoL instrument that best represents functional capacity in IPF patients.
Describe the type of study and study design.
Cross-sectional/single-cohort study.
Was the sample from (i) the general population, (ii) patients with the disease of interest, (iii) individuals
with knowledge of the disease or (iv) other?
(ii) Identified through clinical records, diagnosis based on ATS/ERS consensus criteria.
What are the characteristics of the baseline cohort for the evaluation?
Age 61.4
Sex, M/F 12/8
Race (if appropriate) Not reported
Indication/disease IPF
Other characteristics (sample size) n= 20
FVC per cent predicted reported (70.4%, SD 19.4)
QoL instrument SF-36 and SGRQ
Utility values, Y/N N
Treatment effect, if reported Not applicable
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Country/setting
What is the country and setting for the evaluation?
Brazil; outpatient clinic.
Data sources
Effectiveness
Were the QoL data derived from a single (observational) study, a review/synthesis or combination of
previous studies, or expert opinion?
QoL obtained in this study.
Results
Summarise the results.
Almost all of the SGRQ domains were strongly correlated with functional status, but only physical function and
vitality from SF-36 had a strong correlation with functional status
Mean SD
SGRQ scores
Symptoms 46.4 20.3
Activity 62.4 19
Impact 43.6 20.9
Total 48.4 17.9
SF-36
Physical function 46 18.3
Role physical 57.5 39.8
Bodily pain 60.6 31.9
General health 53.7 24.1
Vitality 49.2 24.3
Social function 56.9 32.2
Role emotional 46.6 39.5
Mental health 66.8 17
Were the methods for deriving these data adequately described (give sources if using data from other
published studies)?
Yes.
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Mapping
If a model was used, describe the type of model (e.g. regression) or other conversion algorithm.
Not applicable.
Conclusions/implications
Give a brief summary of the authors’ conclusions from their analysis.
A specific rather than a generic instrument is more appropriate for HRQoL evaluation in IPF.
What are the implications of the study for the model?
SGRQ is to be preferred to SF-36 for providing utilities (if correlation to functional status does indeed suggest
that it is a more ‘valid’ instrument). May be useful if no utility data identified, limited by small sample size.
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